U.S. patent application number 13/310661 was filed with the patent office on 2012-04-05 for myostatin binding agents.
This patent application is currently assigned to AMGEN INC.. Invention is credited to THOMAS CHARLES BOONE, HQ HAN, HOSUNG MIN.
Application Number | 20120083442 13/310661 |
Document ID | / |
Family ID | 32682298 |
Filed Date | 2012-04-05 |
United States Patent
Application |
20120083442 |
Kind Code |
A1 |
HAN; HQ ; et al. |
April 5, 2012 |
MYOSTATIN BINDING AGENTS
Abstract
The present invention provides binding agents comprising
peptides capable of binding myostatin and inhibiting its activity.
In one embodiment the binding agent comprises at least one
myostatin-binding peptide attached directly or indirectly to at
least one vehicle such as a polymer or an Fc domain. The binding
agents of the present invention produced increased lean muscle mass
when administered to animals and decreased fat to muscle ratios.
Therapeutic compositions containing the binding agents of the
present invention are useful for treating muscle-wasting disorders
and metabolic disorders including diabetes and obesity.
Inventors: |
HAN; HQ; (THOUSAND OAKS,
CA) ; MIN; HOSUNG; (SUNGNAM-SI, KR) ; BOONE;
THOMAS CHARLES; (NEWBURY PARK, CA) |
Assignee: |
AMGEN INC.
THOUSAND OAKS
CA
|
Family ID: |
32682298 |
Appl. No.: |
13/310661 |
Filed: |
December 2, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12806880 |
Aug 23, 2010 |
8071538 |
|
|
13310661 |
|
|
|
|
12322369 |
Jan 30, 2009 |
7803923 |
|
|
12806880 |
|
|
|
|
10742379 |
Dec 19, 2003 |
7511012 |
|
|
12322369 |
|
|
|
|
60435923 |
Dec 20, 2002 |
|
|
|
Current U.S.
Class: |
514/4.8 ;
435/252.3; 435/252.33; 435/254.2; 435/320.1; 435/325; 435/348;
435/350; 435/352; 435/353; 435/357; 435/358; 435/364; 435/365;
435/367; 435/369; 435/370; 435/371; 435/419; 435/69.1; 435/7.21;
436/501; 506/9; 514/15.4; 514/16.4; 514/16.5; 514/16.6; 514/16.7;
514/19.3; 514/21.3; 514/21.4; 514/21.5; 514/21.6; 514/6.9; 530/300;
530/328; 530/329; 530/387.3; 536/23.1; 536/23.4 |
Current CPC
Class: |
A61K 2039/505 20130101;
C07K 14/00 20130101; C12N 2710/14143 20130101; A61P 31/10 20180101;
C07K 16/22 20130101; A61P 19/08 20180101; A61P 31/12 20180101; A61P
3/10 20180101; A61P 13/12 20180101; A61P 21/00 20180101; A61K 38/00
20130101; G01N 33/74 20130101; A61P 3/04 20180101; A61P 19/10
20180101; A61P 37/00 20180101; C07K 14/475 20130101; A61P 43/00
20180101; A61P 11/00 20180101; A61P 35/00 20180101; A61P 19/02
20180101; C07K 2317/21 20130101; G01N 2333/475 20130101; A61P 29/00
20180101; C07K 2317/94 20130101; C07K 2319/00 20130101; A61P 13/02
20180101; A61P 21/04 20180101; A61P 9/00 20180101; A61P 21/06
20180101; G01N 33/567 20130101; A61P 3/02 20180101; A61P 9/04
20180101; C07K 2319/30 20130101; C07K 2319/35 20130101; A61P 3/00
20180101; A61P 7/00 20180101; A61P 31/18 20180101 |
Class at
Publication: |
514/4.8 ;
530/300; 530/328; 530/329; 530/387.3; 514/21.6; 514/21.5; 514/21.4;
514/21.3; 536/23.1; 536/23.4; 435/320.1; 435/252.3; 435/254.2;
435/348; 435/419; 435/325; 435/252.33; 435/364; 435/367; 435/358;
435/365; 435/352; 435/350; 435/357; 435/369; 435/353; 435/370;
435/371; 435/69.1; 514/16.5; 514/16.4; 514/16.7; 514/16.6;
514/19.3; 514/15.4; 514/6.9; 436/501; 435/7.21; 506/9 |
International
Class: |
A61K 38/16 20060101
A61K038/16; C07K 14/00 20060101 C07K014/00; C07K 7/06 20060101
C07K007/06; C07K 19/00 20060101 C07K019/00; A61K 38/03 20060101
A61K038/03; A61K 38/08 20060101 A61K038/08; C12N 15/11 20060101
C12N015/11; C12N 15/62 20060101 C12N015/62; C12N 15/63 20060101
C12N015/63; C12N 1/21 20060101 C12N001/21; C12N 1/19 20060101
C12N001/19; C12N 5/10 20060101 C12N005/10; C12P 21/02 20060101
C12P021/02; G01N 33/566 20060101 G01N033/566; C40B 30/04 20060101
C40B030/04; A61P 3/04 20060101 A61P003/04; A61P 3/00 20060101
A61P003/00; A61P 3/10 20060101 A61P003/10; A61P 19/08 20060101
A61P019/08; A61P 21/00 20060101 A61P021/00; A61P 11/00 20060101
A61P011/00; A61P 9/04 20060101 A61P009/04; A61P 35/00 20060101
A61P035/00; A61P 19/02 20060101 A61P019/02; C07K 4/00 20060101
C07K004/00 |
Claims
1. A binding agent comprising at least one peptide capable of
binding myostatin, wherein the peptide comprises the amino acid
sequence Ca.sub.1a.sub.2Wa.sub.3WMCPP (SEQ ID NO: 352), wherein
a.sub.1, a.sub.2 and a.sub.3 are selected from a neutral
hydrophobic, neutral polar, or basic amino acid, and wherein the
peptide is between 10 and 50 amino acids in length, and
physiologically acceptable salts thereof.
2. A binding agent comprising at least one peptide capable of
binding myostatin, wherein the peptide comprises the sequence
Cb.sub.1b.sub.2Wb.sub.3WMCPP (SEQ ID NO: 353), wherein b.sub.1 is
selected from any one of the amino acids T, I, or R; b.sub.2 is
selected from any one of R, S, Q; b.sub.3 is selected from any one
of P, R and Q, and wherein the peptide is between 10 and 50 amino
acids in length, and physiologically acceptable salts thereof.
3. A binding agent comprising at least one peptide capable of
binding myostatin, wherein the peptide is selected from the group
consisting of: (a) a peptide comprising the amino acid sequence
WYe.sub.1e.sub.2Ye.sub.3G, (SEQ ID NO: 356), wherein e.sub.1 is P,
S or Y, e.sub.2 is C or Q, and e.sub.3 is G or H; (b) a peptide
comprising the amino acid sequence
f.sub.1EMLf.sub.2SLf.sub.3f.sub.4LL, (SEQ ID NO: 455), wherein
f.sub.1 is M or I, f.sub.2 is any amino acid, f.sub.3 is L or F,
and f.sub.4 is E, Q or D; (c) a peptide comprising the amino acid
sequence Lg.sub.1g.sub.2LLg.sub.3g.sub.4L, (SEQ ID NO: 456),
wherein g.sub.1 is Q, D or E, g.sub.2 is S, Q, D or E, g.sub.3 is
any amino acid, and g.sub.4 is L, W, F, or Y; and (d) a peptide
comprising the amino acid sequence
h.sub.1h.sub.2h.sub.3h.sub.4h.sub.5h.sub.6h.sub.7h.sub.8h.sub.6
(SEQ ID NO: 457), wherein h.sub.1 is R or D, h.sub.2 is any amino
acid, h.sub.3 is A, T S or Q, h.sub.4 is L or M, h.sub.5 is L or S,
h.sub.6 is any amino acid, h.sub.7 is F or E, h.sub.8 is W, F or C,
and h.sub.9 is L, F, M or K, and physiologically acceptable salts
thereof.
4. A binding agent wherein said agent has the structure:
(X.sup.1).sub.a--F.sup.1--(X.sup.2).sub.b, or multimers thereof;
wherein F.sup.1 is a vehicle; and X.sup.1 and X.sup.2 are each
independently selected from -(L.sup.1).sub.c-P.sup.1;
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2;
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3;
and
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.su-
p.3-(L.sup.4).sub.f-P.sup.4; wherein P.sup.1, P.sup.2, P.sup.3, and
P.sup.4 are peptides capable of binding myostatin, wherein L.sup.1,
L.sup.2, L.sup.3, and L.sup.4 are each linkers; and a, b, c, d, e,
and f are each independently 0 or 1, provided that at least one of
a and b is 1, and physiologically acceptable salts thereof.
5. The binding agent of claim 4 wherein one or more of the
myostatin binding peptides comprise the amino acid sequence
Ca.sub.1a.sub.2Wa.sub.3WMCPP (SEQ ID NO: 352), wherein a.sub.1,
a.sub.2 and a.sub.3 are selected from a neutral hydrophobic,
neutral polar, or basic amino acid, and wherein the peptide is
between 10 and 50 amino acids in length, and physiologically
acceptable salts thereof.
6. The binding agent of claim 4, wherein one or more of the
myostatin binding peptides comprise the amino acid sequence
Cb.sub.1b.sub.2Wb.sub.3WMCPP (SEQ ID NO: 353), wherein b.sub.1 is
selected from any one of the amino acids T, I, or R; b.sub.2 is
selected from any one of R, S, Q; b.sub.3 is selected from any one
of P, R and Q, and wherein the peptide is between 10 and 50 amino
acids in length, and physiologically acceptable salts thereof.
7. The binding agent of claim 4, wherein the myostatin binding
peptides P.sup.1, P.sup.2, P.sup.3, and P.sup.4 are selected from
the group consisting of: (a) a peptide comprising the amino acid
sequence WYe.sub.1e.sub.2Ye.sub.3G, (SEQ ID NO: 356), wherein
e.sub.1 is P, S or Y, e.sub.2 is C or Q, and e.sub.3 is G or H; (b)
a peptide comprising the amino acid sequence
f.sub.1EMLf.sub.2SLf.sub.3f.sub.4LL, (SEQ ID NO: 455), wherein
f.sub.1 is M or I, f.sub.2 is any amino acid, f.sub.3 is L or F,
and f.sub.4 is E, Q or D; (c) a peptide comprising the amino acid
sequence Lg.sub.1g.sub.2LLg.sub.3g.sub.4L, (SEQ ID NO: 456),
wherein g.sub.1 is Q, D or E, g.sub.2 is S, Q, D or E, g.sub.3 is
any amino acid, and g.sub.4 is L, W, F, or Y; and (d) a peptide
comprising the amino acid sequence
h.sub.1h.sub.2h.sub.3h.sub.4h.sub.5h.sub.6h.sub.7h.sub.8h.sub.9
(SEQ ID NO: 457), wherein h.sub.1 is R or D, h.sub.2 is any amino
acid, h.sub.3 is A, T S or Q, h.sub.4 is L or M, h.sub.5 is L or S,
h.sub.6 is any amino acid, h.sub.7 is F or E, h.sub.8 is W, F or C,
and h.sub.9 is L, F, M or K; wherein the peptide is between 9 and
50 amino acids in length, wherein L.sup.1, L.sup.2, L.sup.3, and
L.sup.4 are each linkers; and a, b, c, d, e, and f are each
independently 0 or 1, provided that at least one of a and b is 1,
and physiologically acceptable salts thereof
8. A binding agent wherein said agent has the structure:
(X.sup.1).sub.a--F.sup.1--(X.sup.2).sub.b, or multimers thereof
wherein F.sup.1 is a vehicle; and X.sup.1 and X.sup.2 are each
independently selected from -(L.sup.1).sub.c-P.sup.1;
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2;
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3;
and
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.su-
p.3-(L.sup.4).sub.f-P.sup.4; wherein P.sup.1, P.sup.2, P.sup.3, and
P.sup.4 are peptides capable of binding myostatin, and are
independently selected from SEQ ID NO: 305 through 351 and SEQ ID
NO: 357 through 454; wherein L.sup.1, L.sup.2, L.sup.3, and L.sup.4
are each linkers; and a, b, c, d, e, and f are each independently 0
or 1, provided that at least one of a and b is 1, and
physiologically acceptable salts thereof.
9. The binding agent of claim 8, wherein the binding agent has the
structure F.sup.1-(L.sup.1).sub.c-P.sup.1 or
F.sup.1-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2.
10. The binding agent of claim 9, wherein the peptide is selected
from any one of SEQ ID NO: 305-308, 310-313, 315-331, 333, 335-346,
wherein F.sup.1 is an Fc domain.
11. A binding agent capable of binding myostatin comprising the
structure F.sup.1-(L.sup.1)-P.sup.1, wherein F.sup.1 is a human IgG
Fc, wherein L.sup.1 is (Gly).sub.5, wherein the binding agent
further comprises AQ and wherein P.sup.1 is selected from SEQ ID
NO: 311, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 336, SEQ ID NO:
337, and SEQ ID NO: 345.
12. A pharmaceutical composition comprising a therapeutically
effective amount of the binding agent of claim 6 in admixture with
a pharmaceutically acceptable carrier thereof.
13. An isolated nucleic acid molecule comprising a polynucleotide
encoding the binding agent of any one of claim 6 or 8.
14. The nucleic acid molecule of claim 13, wherein the
polynucleotide selected from any one of SEQ ID NO: 573 through 614,
and 616, 618, 620, 622, 624, 626, 628, 630, 632.
15. An expression vector comprising the polynucleotide of claim
13.
16. A host cell comprising the expression vector of claim 15.
17. A method of making a myostatin binding agent comprising
culturing the host cell of claim 16 under conditions suitable for
expressing the binding agent, and purifying the binding agent.
18. A method of inhibiting myostatin activity in a subject
comprising administering an effective amount of the composition of
claim 12 to the subject.
19. A method of increasing lean muscle mass in a subject comprising
administering the composition of claim 12 to the subject.
20. A method of increasing the ratio of lean muscle mass to fat in
a subject comprising administering a therapeutically effective
amount of the composition of claim 12 to the subject.
21. A method of treating a muscle-wasting disease in a subject
comprising administering a therapeutically effective amount of the
composition of claim 12 to the subject.
22. The method of claim 21, wherein the disease is selected from
muscular dystrophy, amyotrophic lateral sclerosis, congestive
obstructive pulmonary disease, chronic heart failure, cancer, AIDs,
renal failure, uremia, rheumatoid arthritis, age-related
sarcopenia, and muscle-wasting due to prolonged bedrest, spinal
chord injury, stroke, bone fracture, and aging.
23. A method of treating a myostatin-related metabolic disorder in
a subject comprising administering a therapeutically effective
amount of the composition of claim 12 to the subject.
24. The method of claim 23 wherein the metabolic disorder is
selected from diabetes, obesity, hyperglycemia, and bone loss.
25. A method of detecting or measuring myostatin in a sample
comprising contacting the sample with a binding agent of claim 1
and detecting or measuring the bound complex.
Description
[0001] This application is a divisional of U.S. patent application
Ser. No. 12/806,880, filed Aug. 23, 2010, which is a divisional of
U.S. patent application Ser. No. 12/322,369, filed Jan. 30, 2009,
now U.S. Pat. No. 7,803,923, which is a divisional of U.S. patent
application Ser. No. 10/742,379, filed Dec. 19, 2003, now U.S. Pat.
No. 7,511,012, which hereby claims benefit of U.S. provisional
application Ser. No. 60/435,923, filed Dec. 20, 2002, the entire
disclosure of each of the above applications is relied upon and
incorporated by reference herein.
[0002] The present application is being filed along with a Sequence
Listing in electronic format. The Sequence Listing is provided as a
file entitled A-828-US-DIV3.txt created Oct. 20, 2011, which is 190
KB in size. The information in the electronic format of the
Sequence Listing is incorporated herein by reference in its
entirety.
[0003] Throughout this application various publications are
referenced within parentheses or brackets. The disclosures of these
publications in their entireties are hereby incorporated by
reference in this application in order to more fully describe the
state of the art to which this invention pertains.
FIELD OF THE INVENTION
[0004] The invention relates to growth factors and in particular to
the growth factor myostatin and agents which bind myostatin and
inhibit its activity.
BACKGROUND
[0005] Myostatin, also known as growth/differentiation factor 8
(GDF-8), is a transforming growth factor-.beta. (TGF-.beta.) family
member known to be involved in regulation of skeletal muscle mass.
Most members of the TGF-.beta.-GDF family are expressed
non-specifically in many tissue types and exert a variety of
pleitrophic actions. However, myostatin is largely expressed in the
cells of developing and adult skeletal muscle tissue and plays an
essential role in negatively controlling skeletal muscle growth
(McPherron et al. Nature (London) 387, 83-90 (1997)). Recent
studies, however, indicate that low levels of myostatin expression
can be measured in cardiac, adipose and pre-adipose tissues.
[0006] The myostatin protein has been highly conserved
evolutionarily (McPherron et al. PNAS USA 94:12457-12461 (1997)).
The biologically active C-terminal region of myostatin has 100
percent sequence identity between human, mouse, rat, cow, chicken,
and turkey sequences. The function of myostatin also appears to be
conserved across species as well. This is evident from the
phenotypes of animals having a mutation in the myostatin gene. Two
breeds of cattle, the Belgian Blue (Hanset R., Muscle Hypertrophy
of Genetic Origin and its Use to Improve Beef Production, eds,
King, J. W. G. & Menissier, F. (Nijhoff, The Hague, The
Netherlands) pp. 437-449) and the Piedmontese (Masoero, G. &
Poujardieu, B, Muscle Hypertrophy of Genetic Origin and its Use to
Improve Beef Production., eds, King, J. W. G. & Menissier, F.
(Nijhoff, The Hague, The Netherlands) pp. 450-459) are
characterized by a "double muscling" phenotype and increase in
muscle mass. These breeds were shown to contain mutations in the
coding region of the myostatin gene (McPherron et al. (1997)
supra). In addition, mice containing a targeted deletion of the
gene encoding myostatin (Mstn) demonstrate a dramatic increase in
muscle mass without a corresponding increase in fat. Individual
muscles of Mstn.sup.-/- mice weigh approximately 100 to 200 percent
more than those of control animals as a result of muscle fiber
hypertrophy and hyperplasia (Zimmers et al. Science 296, 1486
(2002)).
[0007] Administration of myostatin to certain strains of mice has
been shown to create a condition similar to muscle wasting
disorders found associated with cancer, AIDS, and muscular
dystrophy, for example. Myostatin administered as
myostatin-producing CHO cells to athymic nude mice resulted in a
wasting effect with a high degree of weight loss, a decrease of as
much as 50% of skeletal muscle mass in addition to fat wasting, and
severe hypoglycemia (Zimmers et al. supra).
[0008] Loss of myostatin appears to result in the retention of
muscle mass and reduction in fat accumulation with aging. It has
been shown that age-related increases in adipose tissue mass and
decrease in muscle mass were proportional to myostatin levels, as
determined by a comparison of fat and muscle mass in Mstn.sup.+/+
when compared with Mstn.sup.-/- adult knockout mice (McFerron et
al. J. Clin. Invest 109, 595 (2002)). Mstn.sup.-/- mice showed
decreased fat accumulation with age compared with Mstn.sup.+/+
mice.
[0009] In addition myostatin may play a role in maintaining blood
glucose levels and may influence the development of diabetes in
certain cases. It is known that, for example, skeletal muscle
resistance to insulin-stimulated glucose uptake is the earliest
known manifestation of non-insulin-dependent (type 2) diabetes
mellitus (Corregan et al. Endocrinology 128:1682 (1991)). It has
now been shown that the lack of myostatin partially attenuates the
obese and diabetes phenotypes of two mouse models, the agouti
lethal yellow (A.sup.y) (Yen et al. FASEB J. 8:479 (1994)), and
obese (Lep.sup.ob/ob). Fat accumulation and total body weight of
the A.sup.y/a, Mstn.sup.-/- double mutant mouse was dramatically
reduced compared with the A.sup.y/a Mstn.sup.+/+ mouse (McFerron et
al., (2002) supra). In addition, blood glucose levels in the
A.sup.y/a, Mstn.sup.-/- mice was dramatically lower than in
A.sup.y/a Mstn.sup.+/+ mice following exogenous glucose load,
indicating that the lack of myostatin improved glucose metabolism.
Similarly Lep.sup.ob/ob Mstn.sup.-/- mice showed decreased fat
accumulation when compared with the Lep.sup.ob/ob Mstn.sup.+/+
phenotype.
[0010] Therefore, there is considerable evidence from the
phenotypes of over-expressing and knockout animals that myostatin
may play a role in contributing to a number of metabolic disorders
including disorders resulting in muscle wasting, diabetes, obesity
and hyperglycemia.
SUMMARY OF THE INVENTION
[0011] The present invention is directed to binding agents which
bind myostatin and inhibit its activity. The binding agents
comprise at least one peptide capable of binding myostatin. The
myostatin-binding peptides are preferably between about 5 and about
50 amino acids in length, more preferably between about 10 and 30
amino acids in length, and most preferably between about 10 and 25
amino acids in length. In one embodiment the myostatin-binding
peptide comprises the amino acid sequence WMCPP (SEQ ID NO: 633).
In another embodiment the myostatin binding peptides comprise the
amino acid sequence Ca.sub.1a.sub.2Wa.sub.3WMCPP (SEQ ID NO: 352),
wherein a.sub.1, a.sub.2 and a.sub.3 are selected from a neutral
hydrophobic, neutral polar, or basic amino acid. In another
embodiment the myostatin binding peptide comprises the sequence
Cb.sub.1b.sub.2Wb.sub.3WMCPP (SEQ ID NO: 353), wherein b.sub.1 is
selected from any one of the amino acids T, I, or R; b.sub.2 is
selected from any one of R, S, Q; b.sub.3 is selected from any one
of P, R and Q, and wherein the peptide is between 10 and 50 amino
acids in length, and physiologically acceptable salts thereof. In
another embodiment, the myostatin binding peptide comprises the
formula:
c.sub.1c.sub.2c.sub.3c.sub.4c.sub.5c.sub.6Cc.sub.7c.sub.8Wc.sub.9WMCPPc.-
sub.10c.sub.11c.sub.12c.sub.13(SEQ ID NO: 354),
[0012] wherein:
[0013] c.sub.1 is absent or any amino acid;
[0014] c.sub.2 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0015] c.sub.3 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0016] c.sub.4 is absent or any amino acid;
[0017] c.sub.5 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0018] c.sub.6 is absent or a neutral hydrophobic, neutral polar,
or basic amino acid;
[0019] c.sub.7 is a neutral hydrophobic, neutral polar, or basic
amino acid;
[0020] c.sub.8 is a neutral hydrophobic, neutral polar, or basic
amino acid;
[0021] c.sub.9 is a neutral hydrophobic, neutral polar or basic
amino acid; and
[0022] c.sub.10 to c.sub.13 is any amino acid; and wherein the
peptide is between 20 and 50 amino acids in length, and
physiologically acceptable salts thereof.
[0023] A related embodiment the myostatin binding peptide comprises
the formula:
d.sub.1d.sub.2d.sub.3d.sub.4d.sub.5d.sub.6Cd.sub.7d.sub.8Wd.sub.9WMCPPd.-
sub.10d.sub.11d.sub.12d.sub.13(SEQ ID NO: 355),
[0024] wherein
[0025] d.sub.1 is absent or any amino acid;
[0026] d.sub.2 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0027] d.sub.3 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0028] d.sub.4 is absent or any amino acid;
[0029] d.sub.5 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0030] d.sub.6 is absent or a neutral hydrophobic, neutral polar,
or basic amino acid;
[0031] d.sub.7 is selected from any one of the amino acids T, I, or
R;
[0032] d.sub.8 is selected from any one of R, S, Q;
[0033] d.sub.9 is selected from any one of P, R and Q, and
[0034] d.sub.10 to d.sub.13 is selected from any amino acid,
[0035] and wherein the peptide is between 20 and 50 amino acids in
length, and physiologically acceptable salts thereof.
[0036] Additional embodiments of binding agents comprise at least
one of the following peptides:
[0037] (1) a peptide capable of binding myostatin, wherein the
peptide comprises the sequence WYe.sub.1e.sub.2Ye.sub.3G, (SEQ ID
NO: 356),
[0038] wherein e.sub.1 is P, S or Y,
[0039] e.sub.2 is C or Q, and
[0040] e.sub.3 is G or H, wherein the peptide is between 7 and 50
amino acids in length, and physiologically acceptable salts
thereof;
[0041] (2) a peptide capable of binding myostatin, wherein the
peptide comprises the sequence f.sub.1EMLf.sub.2SLf.sub.3f.sub.4LL,
(SEQ ID NO: 455),
[0042] wherein f.sub.1 is M or I,
[0043] f.sub.2 is any amino acid,
[0044] f.sub.3 is L or F,
[0045] f.sub.4 is E, Q or D;
[0046] and wherein the peptide is between 7 and 50 amino acids in
length, and physiologically acceptable salts thereof;
[0047] (3) a peptide capable of binding myostatin wherein the
peptide comprises the sequence Lg.sub.1g.sub.2LLg.sub.3g.sub.4L,
(SEQ ID NO: 456), wherein
[0048] g.sub.1 is Q, D or E,
[0049] g.sub.2 is S, Q, D or E,
[0050] g.sub.3 is any amino acid,
[0051] g.sub.4 is L, W, F, or Y, and wherein the peptide is between
8 and 50 amino acids in length, and physiologically acceptable
salts thereof;
[0052] (4) a peptide capable of binding myostatin, wherein the
peptide comprises the sequence
h.sub.1h.sub.2h.sub.3h.sub.4h.sub.5h.sub.6h.sub.7h.sub.8h.sub.9
(SEQ ID NO: 457), wherein
[0053] h.sub.1 is R or D,
[0054] h.sub.2 is any amino acid,
[0055] h.sub.3 is A, T S or Q,
[0056] h.sub.4 is L or M,
[0057] h.sub.5 is L or S,
[0058] h.sub.6 is any amino acid,
[0059] h.sub.7 is F or E,
[0060] h.sub.8 is W, F or C,
[0061] h.sub.9 is L, F, M or K, and wherein the peptide is between
9 and 50 amino acids in length, and physiologically acceptable
salts thereof.
[0062] In one embodiment, the binding agents of the present
invention further comprise at least one vehicle such as a polymer
or an Fc domain, and may further comprise at least one linker
sequence. In this embodiment, the binding agents of the present
invention are constructed so that at least one myostatin-binding
peptide is attached to at least one vehicle. The peptide or
peptides are attached directly or indirectly through a linker
sequence, to the vehicle at the N-terminal, C-terminal or an amino
acid sidechain of the peptide. In this embodiment, the binding
agents of the present invention have the following generalized
structure:
[0063] (X.sup.1).sub.a--F.sup.1--(X.sup.2).sub.b, or multimers
thereof;
wherein F.sup.1 is a vehicle; and X.sup.1 and X.sup.2 are each
independently selected from [0064] -(L.sup.1).sub.c-P.sup.1; [0065]
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2; [0066]
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3;
[0067] and
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3--
(L.sup.4).sub.f-P.sup.4; [0068] wherein P.sup.1, P.sup.2, P.sup.3,
and P.sup.4 are peptides capable of binding myostatin; and [0069]
L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are each linkers; and a, b,
c, d, e, and f are each independently 0 or 1, provided that at
least one of a and b is 1, and physiologically acceptable salts
thereof.
[0070] In various embodiments of binding agents having this
generalized structure, the peptides P.sup.1, P.sup.2, P.sup.3, and
P.sup.4 can be independently selected from one or more of any of
the peptides comprising the sequences provided above. P.sup.1,
P.sup.2, P.sup.3, and P.sup.4 are independently selected from one
or more peptides comprising any of the following sequences: SEQ ID
NO: 633, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO:
355, SEQ ID NO: 356, SEQ ID NO: 455, SEQ ID NO: 456, or SEQ ID NO:
457.
[0071] In a further embodiment, the binding agents comprise
peptides fused to an Fc domain, either directly or indirectly,
thereby providing peptibodies. The peptibodies of the present
invention display a high binding affinity for myostatin and can
inhibit the activity of myostatin as demonstrated both in vitro
using cell based assays and in animals.
[0072] The present invention also provides nucleic acid molecules
comprising polynucleotides encoding the peptides, peptibodies, and
peptide and peptibody variants and derivatives of the present
invention.
[0073] The present invention provides pharmaceutically acceptable
compositions comprising one or more binding agents of the present
invention.
[0074] The binding agents of the present invention inhibit
myostatin activity in vitro and in vivo. The binding agents of the
present invention increase lean muscle mass in a treated animal and
decreases fat mass as a percentage of body weight of the animal.
The myostatin binding agents of the present invention increase
muscular strength in treated animal models.
[0075] The present invention provides methods of inhibiting
myostatin activity in animals including humans by administering an
effective dosage of one or more binding agents to the subject. The
present invention provides methods of increasing lean muscle mass
in animals including humans by administering an effective dosage of
one or more binding agents. The present invention further provides
methods of treating myostatin-related disorders by administering a
therapeutically effective dosage of one or more myostatin binding
agents in a pharmaceutically acceptable composition to a subject.
The present invention provides methods of treating muscle wasting
disorders including muscular dystrophy, muscle wasting due to
cancer, AIDS, rheumatoid arthritis, renal failure, uremia, chronic
heart failure, age-related sarcopenia, prolonged bed-rest, spinal
chord injury, stroke, bone fracture. The present invention also
provides methods of treating metabolic disorders including obesity,
diabetes, hyperglycemia, and bone loss.
[0076] The present invention also provides a method of increasing
muscle mass in food animals by administering an effective dosage of
one or more myostatin binding agents to the animal.
[0077] The present invention provides assays utilizing one or more
myostatin binding agents to identify and quantitate myostatin in a
sample. The assays may be diagnotic assays for measuring or
monitoring myostatin levels in individuals with a myostatin related
disorder or disease.
BRIEF DESCRIPTION OF THE FIGURES
[0078] FIG. 1 shows myostatin activity as measured by expressed
luciferase activity (y-axis) vs. concentration (x-axis) for the
TN8-19 peptide QGHCTRWPWMCPPY (Seq ID No: 32) and the TN8-19
peptibody (pb) to determine the IC.sub.50 for each using the C2C12
pMARE luciferase assay described in the Examples below. The
peptibody has a lower IC.sub.50 value compared with the
peptide.
[0079] FIG. 2 is a graph showing the increase in total body weight
for CD1 nu/nu mice treated with increasing dosages of the
1.times.mTN8-19-21 peptibody over a fourteen day period compared
with mice treated with a huFc control, as described in Example
8.
[0080] FIG. 3A shows the increase in the mass of the gastrocnemius
muscle mass at necropsy of the mice treated in FIG. 2 (Example 8).
FIG. 3B shows the increase in lean mass as determined by NMR on day
0 compared with day 13 of the experiment described in Example
8.
[0081] FIG. 4 shows the increase in lean body mass as for CD1 nu/nu
mice treated with biweekly injections of increasing dosages of
1.times.mTN8-19-32 peptibody as determined by NMR on day 0 and day
13 of the experiment described in Example 8.
[0082] FIG. 5A shows the increase in body weight for CD1 nu/nu mice
treated with biweekly injections of 1.times.mTN8-19-7 compared with
2.times.mTN8-19-7 and the control animal for 35 days as described
in Example 8. FIG. 5B shows the increase in lean carcass weight at
necropsy for the 1.times. and 2.times. versions at 1 mg/kg and 3
mg/kg compared with the animals receiving the vehicle (huFc)
(controls).
[0083] FIG. 6A shows the increase in lean muscle mass vs. body
weight for aged mdx mice treated with either affinity matured
1.times.mTN8-19-33 peptibody or huFc vehicle at 10 mg/kg
subcutaneously every other day for three months. FIG. 6B shows the
change in fat mass compared to body weight as determined by NMR for
the same mice after 3 months of treatment.
DETAILED DESCRIPTION OF THE INVENTION
[0084] The present invention provides binding agents capable of
binding myostatin and inhibiting its activity. The myostatin
binding agents can be used in assays, to identify, quantitate, or
monitor the level of myostatin in an animal. The myostatin binding
agents of the present invention reduce myostatin activity. The
myostatin binding agents of the present invention increase lean
muscle mass in animals, decrease fat mass as a percentage of body
weight, and increase muscle strength. The myostatin binding agents
of the present invention can be used to treat a variety of
metabolic disorders in which myostatin plays a role, including
muscle wasting disorders such as muscular dystrophies, muscle
wasting due to cancer, AIDS, rheumatoid arthritis, renal failure,
uremia, chronic heart failure, prolonged bed-rest, spinal chord
injury, stroke, and age-related sarcopenia as well as other
metabolic disorders including diabetes, obesity, hyperglycemia, and
bone loss, by administering a therapeutic dosage of one or more
binding agents in a pharmaceutically acceptable composition to a
subject.
Myostatin
[0085] Myostatin, a growth factor also known as GDF-8, is known to
be a negative regulator of skeletal muscle tissue. Myostatin is
synthesized as an inactive preproprotein which is activated by
proteolyic cleavage (Zimmers et al., supra (2002)). The precurser
protein is cleaved to produce an NH.sub.2-terminal inactive
prodomain and an approximately 109 amino acid COOH-terminal protein
in the form of a homodimer of about 25 kDa, which is the mature,
active form (Zimmers et al, supra (2002)). It is now believed that
the mature dimer circulates in the blood as an inactive latent
complex bound to the propeptide (Zimmers et al, supra (2002).
[0086] As used herein the term "full-length myostatin" refers to
the full-length human preproprotein sequence described in McPherron
et al. supra (1997), as well as related full-length polypeptides
including allelic variants and interspecies homologs which are also
described in McPherron et al. (1997). As used herein, the term
"prodomain" or "propeptide" refers to the inactive
NH.sub.2-terminal protein which is cleaved off to release the
active COOH-terminal protein. As used herein the term "myostatin"
or "mature myostatin" refers to the mature, biologically active
COOH-terminal polypeptide, in monomer, dimer, multimeric form or
other form. "Myostatin" or "mature myostatin" also refers to
fragments of the biologically active mature myostatin, as well as
related polypeptides including allelic variants, splice variants,
and fusion peptides and polypeptides. The mature myostatin
COOH-terminal protein has been reported to have 100% sequence
identity among many species including human, mouse, chicken,
porcine, turkey, and rat (Lee et al., PNAS 98, 9306 (2001)).
Myostatin may or may not include additional terminal residues such
as targeting sequences, or methionine and lysine residues and/or
tag or fusion protein sequences, depending on how it is
prepared.
[0087] As used herein the term "capable of binding to myostatin" or
"having a binding affinity for myostatin" refers to a binding agent
or peptide which binds to myostatin as demonstrated by as the phage
ELISA assay, the BIAcore.RTM. or KinExA.TM. assays described in the
Examples below.
[0088] As used herein, the term "capable of modifying myostatin
activity" refers to the action of an agent as either an agonist or
an antagonist with respect to at least one biological activity of
myostatin. As used herein, "agonist" or "mimetic" activity refers
an agent having biological activity comparable to a protein that
interacts with the protein of interest, as described, for example,
in International application WO 01/83525, filed May 2, 2001, which
is incorporated herein by reference.
[0089] As used herein, the term "inhibiting myostatin activity" or
"having antagonist activity" refers to the ability of a peptide or
binding agent to reduce or block myostatin activity or signaling as
demonstrated or in vitro assays such as, for example, the pMARE
C2C12 cell-based myostatin activity assay or by in vivo animal
testing as described below.
Structure of Myostatin Binding Agents
[0090] In one embodiment, the binding agents of the present
invention comprise at least one myostatin binding peptide
covalently attached to at least one vehicle such as a polymer or an
Fc domain. The attachment of the myostatin-binding peptides to at
least one vehicle is intended to increase the effectiveness of the
binding agent as a therapeutic by increasing the biological
activity of the agent and/or decreasing degradation in vivo,
increasing half-life in vivo, reducing toxicity or immunogenicity
in vivo. The binding agents of the present invention may further
comprise a linker sequence connecting the peptide and the vehicle.
The peptide or peptides are attached directly or indirectly through
a linker sequence to the vehicle at the N-terminal, C-terminal or
an amino acid sidechain of the peptide. In this embodiment, the
binding agents of the present invention have the following
structure: [0091] (X.sup.1).sub.a--F.sup.1--(X.sup.2).sub.b, or
multimers thereof; [0092] wherein F.sup.1 is a vehicle; and X.sup.1
and X.sup.2 are each independently selected from [0093]
-(L.sup.1).sub.c-P.sup.1; [0094]
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2; [0095]
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3;
[0096] and
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3--
(L.sup.4).sub.f-P.sup.4; [0097] wherein P.sup.1, P.sup.2, P.sup.3,
and P.sup.4 are peptides capable of binding myostatin; and [0098]
L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are each linkers; and a, b,
c, d, e, and f are each independently 0 or 1, provided that at
least one of a and b is 1.
[0099] Any peptide containing a cysteinyl residue may be
cross-linked with another Cys-containing peptide, either or both of
which may be linked to a vehicle. Any peptide having more than one
Cys residue may form an intrapeptide disulfide bond, as well.
[0100] In one embodiment, the vehicle is an Fc domain, defined
below. This embodiment is referred to as a "peptibody". As used
herein, the term "peptibody" refers to a molecule comprising an
antibody Fc domain attached to at least one peptide. The production
of peptibodies is generally described in PCT publication WO
00/24782, published May 4, 2000, which is herein incorporated by
reference. Exemplary peptibodies are provided as 1.times. and
2.times. configurations with one copy and two copies of the peptide
(attached in tandem) respectively, as described in the Examples
below.
Peptides
[0101] As used herein the term "peptide" refers to molecules of
about 5 to about 90 amino acids linked by peptide bonds. The
peptides of the present invention are preferably between about 5 to
about 50 amino acids in length, more preferably between about 10
and 30 amino acids in length, and most preferably between about 10
and 25 amino acids in length, and are capable of binding to the
myostatin protein.
[0102] The peptides of the present invention may comprise part of a
sequence of naturally occurring proteins, may be randomized
sequences derived from naturally occurring proteins, or may be
entirely randomized sequences. The peptides of the present
invention may be generated by any methods known in the art
including chemical synthesis, digestion of proteins, or recombinant
technology. Phage display and RNA-peptide screening, and other
affinity screening techniques are particularly useful for
generating peptides capable of binding myostatin.
[0103] Phage display technology is described, for example, in Scott
et al. Science 249: 386 (1990); Devlin et al., Science 249: 404
(1990); U.S. Pat. No. 5,223,409, issued Jun. 29, 1993; U.S. Pat.
No. 5,733,731, issued Mar. 31, 1998; U.S. Pat. No. 5,498,530,
issued Mar. 12, 1996; U.S. Pat. No. 5,432,018, issued Jul. 11,
1995; U.S. Pat. No. 5,338,665, issued Aug. 16, 1994; U.S. Pat. No.
5,922,545, issued Jul. 13, 1999; WO 96/40987, published Dec. 19,
1996; and WO 98/15833, published Apr. 16, 1998, each of which is
incorporated herein by reference. Using phage libraries, random
peptide sequences are displayed by fusion with coat proteins of
filamentous phage. Typically, the displayed peptides are
affinity-eluted either specifically or non-specifically against the
target molecule. The retained phages may be enriched by successive
rounds of affinity purification and repropagation. The best binding
peptides are selected for further analysis, for example, by using
phage ELISA, described below, and then sequenced. Optionally,
mutagenesis libraries may be created and screened to further
optimize the sequence of the best binders (Lowman, Ann Rev Biophys
Biomol Struct 26:401-24 (1997)).
[0104] Other methods of generating the myostatin binding peptides
include additional affinity selection techniques known in the art.
A peptide library can be fused in the carboxyl terminus of the lac
repressor and expressed in E. coli. Another E. coli-based method
allows display on the cell's outer membrane by fusion with a
peptidoglycan-associated lipoprotein (PAL). Hereinafter, these and
related methods are collectively referred to as "E. coli display."
In another method, translation of random RNA is halted prior to
ribosome release, resulting in a library of polypeptides with their
associated RNA still attached. Hereinafter, this and related
methods are collectively referred to as "ribosome display." Other
methods employ chemical linkage of peptides to RNA. See, for
example, Roberts and Szostak, Proc Natl Acad Sci USA, 94: 12297-303
(1997). Hereinafter, this and related methods are collectively
referred to as "RNA-peptide screening." Yeast two-hybrid screening
methods also may be used to identify peptides of the invention that
bind to myostatin. In addition, chemically derived peptide
libraries have been developed in which peptides are immobilized on
stable, non-biological materials, such as polyethylene rods or
solvent-permeable resins. Another chemically derived peptide
library uses photolithography to scan peptides immobilized on glass
slides. Hereinafter, these and related methods are collectively
referred to as "chemical-peptide screening." Chemical-peptide
screening may be advantageous in that it allows use of D-amino
acids and other analogues, as well as non-peptide elements. Both
biological and chemical methods are reviewed in Wells and Lowman,
Curr Opin Biotechnol 3: 355-62 (1992).
[0105] Additionally, selected peptides capable of binding myostatin
can be further improved through the use of "rational design". In
this approach, stepwise changes are made to a peptide sequence and
the effect of the substitution on the binding affinity or
specificity of the peptide or some other property of the peptide is
observed in an appropriate assay. One example of this technique is
substituting a single residue at a time with alanine, referred to
as an "alanine walk" or an "alanine scan". When two residues are
replaced, it is referred to as a "double alanine walk". The
resultant peptide containing amino acid substitutions are tested
for enhanced activity or some additional advantageous property.
[0106] In addition, analysis of the structure of a protein-protein
interaction may also be used to suggest peptides that mimic the
interaction of a larger protein. In such an analysis, the crystal
structure of a protein may suggest the identity and relative
orientation of critical residues of the protein, from which a
peptide may be designed. See, for example, Takasaki et al., Nature
Biotech 15:1266 (1977). These methods may also be used to
investigate the interaction between a targeted protein and peptides
selected by phage display or other affinity selection processes,
thereby suggesting further modifications of peptides to increase
binding affinity and the ability of the peptide to inhibit the
activity of the protein.
[0107] In one embodiment, the peptides of the present invention are
generated as families of related peptides. Exemplary peptides are
represented by SEQ ID NO: 1 through 132. These exemplary peptides
were derived through a selection process in which the best binders
generated by phage display technology were further analyzed by
phage ELISA to obtain candidate peptides by an affinity selection
technique such as phage display technology as described herein.
However, the peptides of the present invention may be produced by
any number of known methods including chemical synthesis as
described below.
[0108] The peptides of the present invention can be further
improved by the process of "affinity maturation". This procedure is
directed to increasing the affinity or the activity of the peptides
and peptibodies of the present invention using phage display or
other selection technologies. Based on a consensus sequence,
directed secondary phage display libraries, for example, can be
generated in which the "core" amino acids (determined from the
consensus sequence) are held constant or are biased in frequency of
occurrence. Alternatively, an individual peptide sequence can be
used to generate a biased, directed phage display library. Panning
of such libraries under more stringent conditions can yield
peptides with enhanced binding to myostatin, selective binding to
myostatin, or with some additional desired property. However,
peptides having the affinity matured sequences may then be produced
by any number of known methods including chemical synthesis or
recombinantly. These peptides are used to generate binding agents
such as peptibodies of various configurations which exhibit greater
inhibitory activity in cell-based assays and in vivo assays.
[0109] Example 6 below describes affinity maturation of the "first
round" peptides described above to produce affinity matured
peptides. Exemplary affinity matured peptibodies are presented in
Tables IV and V. The resultant 1.times. and 2.times. peptibodies
made from these peptides were then further characterized for
binding affinity, ability to neutralize myostatin activity,
specificity to myostatin as opposed to other TNF.beta. family
members, and for additional in vitro and in vivo activity, as
described below. Affinity-matured peptides and peptibodies are
referred to by the prefix "m" before their family name to
distinguish them from first round peptides of the same family.
[0110] Exemplary first round peptides chosen for further affinity
maturation according to the present invention included the
following peptides: TN8-19 QGHCTRWPWMCPPY (SEQ ID NO: 33), and the
linear peptides Linear-2 MEMLDSLFELLKDMVPISKA (SEQ ID NO: 104),
Linear-15 HHGWNYLRKGSAPQWFEAWV (SEQ ID NO: 117), Linear-17,
RATLLKDFWQLVEGYGDN (SEQ ID NO: 119), Linear-20 YREMSMLEGLLDVLERLQHY
(SEQ ID NO: 122), Linear-21 HNSSQMLLSELIMLVGSMMQ (SEQ ID NO: 123),
Linear-24 EFFHWLHNHRSEVNHWLDMN (SEQ ID NO: 126). The affinity
matured families of each of these is presented below in Tables IV
and V.
[0111] The peptides of the present invention also encompass
variants and derivatives of the selected peptides which are capable
of binding myostatin. As used herein the term "variant" refers to
peptides having one or more amino acids inserted, deleted, or
substituted into the original amino acid sequence, and which are
still capable of binding to myostatin. Insertional and
substitutional variants may contain natural amino acids as well as
non-naturally occurring amino acids. As used herein the term
"variant" includes fragments of the peptides which still retain the
ability to bind to myostatin. As used herein, the term "derivative"
refers to peptides which have been modified chemically in some
manner distinct from insertion, deletion, and substitution
variants. Variants and derivatives of the peptides and peptibodies
of the present invention are described more fully below.
Vehicles
[0112] As used herein the term "vehicle" refers to a molecule that
may be attached to one or more peptides of the present invention.
Preferably, vehicles confer at least one desired property on the
binding agents of the present invention. Peptides alone are likely
to be removed in vivo either by renal filtration, by cellular
clearance mechanisms in the reticuloendothelial system, or by
proteolytic degradation. Attachment to a vehicle improves the
therapeutic value of a binding agent by reducing degradation of the
binding agent and/or increasing half-life, reducing toxicity,
reducing immunogenicity, and/or increasing the biological activity
of the binding agent.
[0113] Exemplary vehicles include Fc domains; linear polymers such
as polyethylene glycol (PEG), polylysine, dextran; a branched chain
polymer (see for example U.S. Pat. No. 4,289,872 to Denkenwalter et
al., issued Sep. 15, 1981; U.S. Pat. No. 5,229,490 to Tam, issued
Jul. 20, 1993; WO 93/21259 by Frechet et al., published 28 Oct.
1993); a lipid; a cholesterol group (such as a steroid); a
carbohydrate or oligosaccharide; or any natural or synthetic
protein, polypeptide or peptide that binds to a salvage
receptor.
[0114] In one embodiment, the myostatin binding agents of the
present invention have at least one peptide attached to at least
one vehicle (F.sup.1, F.sup.2) through the N-terminus, C-terminus
or a side chain of one of the amino acid residues of the
peptide(s). Multiple vehicles may also be used; such as an Fc
domain at each terminus or an Fc domain at a terminus and a PEG
group at the other terminus or a side chain.
[0115] An Fc domain is one preferred vehicle. As used herein, the
term "Fc domain" encompasses native Fc and Fc variant molecules and
sequences as defined below. As used herein the term "native Fc"
refers to a non-antigen binding fragment of an antibody or the
amino acid sequence of that fragment which is produced by
recombinant DNA techniques or by enzymatic or chemical cleavage of
intact antibodies. A preferred Fc is a fully human Fc and may
originate from any of the immunoglobulins, such as IgG1 and IgG2.
However, Fc molecules that are partially human, or originate from
non-human species are also included herein. Native Fc molecules are
made up of monomeric polypeptides that may be linked into dimeric
or multimeric forms by covalent (i.e., disulfide bonds) and
non-covalent association. The number of intermolecular disulfide
bonds between monomeric subunits of native Fc molecules ranges from
1 to 4 depending on class (e.g., IgG, IgA, IgE) or subclass (e.g.,
IgG1, IgG2, IgG3, IgA1, IgGA2). One example of a native Fc is a
disulfide-bonded dimer resulting from papain digestion of an IgG
(see Ellison et al. (1982), Nucl Acids Res 10: 4071-9). The term
"native Fc" as used herein is used to refer to the monomeric,
dimeric, and multimeric forms.
[0116] As used herein, the term "Fc variant" refers to a modified
form of a native Fc sequence provided that binding to the salvage
receptor is maintained, as described, for example, in WO 97/34631
and WO 96/32478, both of which are incorporated herein by
reference. Fc variants may be constructed for example, by
substituting or deleting residues, inserting residues or truncating
portions containing the site. The inserted or substituted residues
may also be altered amino acids, such as peptidomimetics or D-amino
acids. Fc variants may be desirable for a number of reasons,
several of which are described below. Exemplary Fc variants include
molecules and sequences in which:
[0117] 1. Sites involved in disulfide bond formation are removed.
Such removal may avoid reaction with other cysteine-containing
proteins present in the host cell used to produce the molecules of
the invention. For this purpose, the cysteine-containing segment at
the N-terminus may be truncated or cysteine residues may be deleted
or substituted with other amino acids (e.g., alanyl, seryl). Even
when cysteine residues are removed, the single chain Fc domains can
still form a dimeric Fc domain that is held together
non-covalently.
[0118] 2. A native Fc is modified to make it more compatible with a
selected host cell. For example, one may remove the PA sequence
near the N-terminus of a typical native Fc, which may be recognized
by a digestive enzyme in E. coli such as proline iminopeptidase.
One may also add an N-terminal methionyl residue, especially when
the molecule is expressed recombinantly in a bacterial cell such as
E. coli.
[0119] 3. A portion of the N-terminus of a native Fc is removed to
prevent N-terminal heterogeneity when expressed in a selected host
cell. For this purpose, one may delete any of the first 20 amino
acid residues at the N-terminus, particularly those at positions 1,
2, 3, 4 and 5.
[0120] 4. One or more glycosylation sites are removed. Residues
that are typically glycosylated (e.g., asparagine) may confer
cytolytic response. Such residues may be deleted or substituted
with unglycosylated residues (e.g., alanine).
[0121] 5. Sites involved in interaction with complement, such as
the C1q binding site, are removed. For example, one may delete or
substitute the EKK sequence of human IgG1. Complement recruitment
may not be advantageous for the molecules of this invention and so
may be avoided with such an Fc variant.
[0122] 6. Sites are removed that affect binding to Fc receptors
other than a salvage receptor. A native Fc may have sites for
interaction with certain white blood cells that are not required
for the fusion molecules of the present invention and so may be
removed.
[0123] 7. The ADCC site is removed. ADCC sites are known in the
art. See, for example, Molec Immunol 29 (5):633-9 (1992) with
regard to ADCC sites in IgG1. These sites, as well, are not
required for the fusion molecules of the present invention and so
may be removed.
[0124] 8. When the native Fc is derived from a non-human antibody,
the native Fc may be humanized. Typically, to humanize a native Fc,
one will substitute selected residues in the non-human native Fc
with residues that are normally found in human native Fc.
Techniques for antibody humanization are well known in the art.
[0125] The term "Fc domain" includes molecules in monomeric or
multimeric form, whether digested from whole antibody or produced
by other means. As used herein the term "multimer" as applied to Fc
domains or molecules comprising Fc domains refers to molecules
having two or more polypeptide chains associated covalently,
noncovalently, or by both covalent and non-covalent interactions.
IgG molecules typically form dimers; IgM, pentamers; IgD, dimers;
and IgA, monomers, dimers, trimers, or tetramers. Multimers may be
formed by exploiting the sequence and resulting activity of the
native Ig source of the Fc or by derivatizing such a native Fc. The
term "dimer" as applied to Fc domains or molecules comprising Fc
domains refers to molecules having two polypeptide chains
associated covalently or non-covalently.
[0126] Additionally, an alternative vehicle according to the
present invention is a non-Fc domain protein, polypeptide, peptide,
antibody, antibody fragment, or small molecule (e.g., a
peptidomimetic compound) capable of binding to a salvage receptor.
For example, one could use as a vehicle a polypeptide as described
in U.S. Pat. No. 5,739,277, issued Apr. 14, 1998 to Presta et al.
Peptides could also be selected by phage display for binding to the
FcRn salvage receptor. Such salvage receptor-binding compounds are
also included within the meaning of "vehicle", and are within the
scope of this invention. Such vehicles should be selected for
increased half-life (e.g., by avoiding sequences recognized by
proteases) and decreased immunogenicity (e.g., by favoring
non-immunogenic sequences, as discovered in antibody
humanization).
[0127] In addition, polymer vehicles may also be used to construct
the binding agents of the present invention. Various means for
attaching chemical moieties useful as vehicles are currently
available, see, e.g., Patent Cooperation Treaty ("PCT")
International Publication No. WO 96/11953, entitled "N-Terminally
Chemically Modified Protein Compositions and Methods," herein
incorporated by reference in its entirety. This PCT publication
discloses, among other things, the selective attachment of water
soluble polymers to the N-terminus of proteins.
[0128] A preferred polymer vehicle is polyethylene glycol (PEG).
The PEG group may be of any convenient molecular weight and may be
linear or branched. The average molecular weight of the PEG will
preferably range from about 2 kDa to about 100 kDa, more preferably
from about 5 kDa to about 50 kDa, most preferably from about 5 kDa
to about 10 kDa. The PEG groups will generally be attached to the
compounds of the invention via acylation or reductive alkylation
through a reactive group on the PEG moiety (e.g., an aldehyde,
amino, thiol, or ester group) to a reactive group on the inventive
compound (e.g., an aldehyde, amino, or ester group). A useful
strategy for the PEGylation of synthetic peptides consists of
combining, through forming a conjugate linkage in solution, a
peptide and a PEG moiety, each bearing a special functionality that
is mutually reactive toward the other. The peptides can be easily
prepared with conventional solid phase synthesis as known in the
art. The peptides are "preactivated" with an appropriate functional
group at a specific site. The precursors are purified and fully
characterized prior to reacting with the PEG moiety. Ligation of
the peptide with PEG usually takes place in aqueous phase and can
be easily monitored by reverse phase analytical HPLC. The PEGylated
peptides can be easily purified by preparative HPLC and
characterized by analytical HPLC, amino acid analysis and laser
desorption mass spectrometry.
[0129] Polysaccharide polymers are another type of water soluble
polymer which may be used for protein modification. Dextrans are
polysaccharide polymers comprised of individual subunits of glucose
predominantly linked by a1-6 linkages. The dextran itself is
available in many molecular weight ranges, and is readily available
in molecular weights from about 1 kDa to about 70 kDa. Dextran is a
suitable water-soluble polymer for use in the present invention as
a vehicle by itself or in combination with another vehicle (e.g.,
Fc). See, for example, WO 96/11953 and WO 96/05309. The use of
dextran conjugated to therapeutic or diagnostic immunoglobulins has
been reported; see, for example, European Patent Publication No. 0
315 456, which is hereby incorporated by reference. Dextran of
about 1 kDa to about 20 kDa is preferred when dextran is used as a
vehicle in accordance with the present invention.
Linkers
[0130] The binding agents of the present invention may optionally
further comprise a "linker" group. Linkers serve primarily as a
spacer between a peptide and a vehicle or between two peptides of
the binding agents of the present invention. In one embodiment, the
linker is made up of amino acids linked together by peptide bonds,
preferably from 1 to 20 amino acids linked by peptide bonds,
wherein the amino acids are selected from the 20 naturally
occurring amino acids. One or more of these amino acids may be
glycosylated, as is understood by those in the art. In one
embodiment, the 1 to 20 amino acids are selected from glycine,
alanine, proline, asparagine, glutamine, and lysine. Preferably, a
linker is made up of a majority of amino acids that are sterically
unhindered, such as glycine and alanine. Thus, exemplary linkers
are polyglycines (particularly (Gly).sub.5, (Gly).sub.8),
poly(Gly-Ala), and polyalanines. As used herein, the designation
"g" refers to a glycine homopeptide linkers. As shown in Table II,
"gn" refers to a 5.times.gly linker at the N terminus, while "gc"
refers to 5.times.gly linker at the C terminus. Combinations of Gly
and Ala are also preferred. One exemplary linker sequence useful
for constructing the binding agents of the present invention is the
following: gsgsatggsgstassgsgsatg (Seq ID No: 305). This linker
sequence is referred to as the "k" or 1k sequence. The designations
"kc", as found in Table II, refers to the k linker at the
C-terminus, while the designation "kn", refers to the k linker at
the N-terminus.
[0131] The linkers of the present invention may also be non-peptide
linkers. For example, alkyl linkers such as
--NH--(CH.sub.2)s-C(O)--, wherein s=2-20 can be used. These alkyl
linkers may further be substituted by any non-sterically hindering
group such as lower alkyl (e.g., C.sub.1-C.sub.6) lower acyl,
halogen (e.g., Cl, Br), CN, NH.sub.2, phenyl, etc. An exemplary
non-peptide linker is a PEG linker, and has a molecular weight of
100 to 5000 kDa, preferably 100 to 500 kDa. The peptide linkers may
be altered to form derivatives in the same manner as above.
Exemplary Binding Agents
[0132] The binding agents of the present invention comprise at
least one peptide capable of binding myostatin. In one embodiment,
the myostatin binding peptide is between about 5 and about 50 amino
acids in length, in another, between about 10 and 30 amino acids in
length, and in another, between about 10 and 25 amino acids in
length. In one embodiment the myostatin binding peptide comprises
the amino acid sequence WMCPP (SEQ ID NO: 633). In other
embodiment, the myostatin binding peptide comprises the amino acid
sequence Ca.sub.1a.sub.2Wa.sub.3WMCPP (SEQ ID NO: 352), wherein
a.sub.1, a.sub.2 and a.sub.3 are selected from a neutral
hydrophobic, neutral polar, or basic amino acid. In another
embodiment the myostatin binding peptide comprises the amino acid
sequence Cb.sub.1b.sub.2Wb.sub.3WMCPP (SEQ ID NO: 353), wherein
b.sub.1 is selected from any one of the amino acids T, I, or R;
b.sub.2 is selected from any one of R, S, Q; b.sub.3 is selected
from any one of P, R and Q, and wherein the peptide is between 10
and 50 amino acids in length, and physiologically acceptable salts
thereof.
[0133] In another embodiment, the myostatin binding peptide
comprises the formula:
c.sub.1c.sub.2c.sub.3c.sub.4c.sub.5c.sub.6Cc.sub.7c.sub.8Wc.sub.9WMCPPc.-
sub.10c.sub.11c.sub.12c.sub.13(SEQ ID NO: 354),
[0134] wherein:
[0135] c.sub.1 is absent or any amino acid;
[0136] c.sub.2 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0137] c.sub.3 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0138] c.sub.4 is absent or any amino acid;
[0139] c.sub.5 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0140] c.sub.6 is absent or a neutral hydrophobic, neutral polar,
or basic amino acid;
[0141] c.sub.7 is a neutral hydrophobic, neutral polar, or basic
amino acid;
[0142] c.sub.8 is a neutral hydrophobic, neutral polar, or basic
amino acid;
[0143] c.sub.9 is a neutral hydrophobic, neutral polar or basic
amino acid; and
[0144] c.sub.10 to c.sub.13 is any amino acid; and wherein the
peptide is between 20 and 50 amino acids in length, and
physiologically acceptable salts thereof.
[0145] A related embodiment the myostatin binding peptide comprises
the formula:
d.sub.1d.sub.2d.sub.3d.sub.4d.sub.5d.sub.6Cd.sub.7d.sub.8Wd.sub.9WMCPPd.-
sub.10d.sub.11d.sub.12d.sub.13(SEQ ID NO: 355),
[0146] wherein
[0147] d.sub.1 is absent or any amino acid;
[0148] d.sub.2 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0149] d.sub.3 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0150] d.sub.4 is absent or any amino acid;
[0151] d.sub.5 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0152] d.sub.6 is absent or a neutral hydrophobic, neutral polar,
or basic amino acid;
[0153] d.sub.7 is selected from any one of the amino acids T, I, or
R;
[0154] d.sub.8 is selected from any one of R, S, Q;
[0155] d.sub.9 is selected from any one of P, R and Q, and
[0156] d.sub.10 to d.sub.13 is selected from any amino acid,
[0157] and wherein the peptide is between 20 and 50 amino acids in
length, and physiologically acceptable salts thereof.
[0158] Additional embodiments of binding agents comprise at least
one of the following peptides:
[0159] (1) a peptide capable of binding myostatin, wherein the
peptide comprises the sequence WYe.sub.1e.sub.2Ye.sub.3G, (SEQ ID
NO: 356),
[0160] wherein e.sub.1 is P, S or Y,
[0161] e.sub.2 is C or Q, and
[0162] e.sub.3 is G or H, wherein the peptide is between 7 and 50
amino acids in length, and physiologically acceptable salts
thereof;
[0163] (2) a peptide capable of binding myostatin, wherein the
peptide comprises the sequence f.sub.1EMLf.sub.2SLf.sub.3f.sub.4LL,
(SEQ ID NO: 455),
[0164] wherein f.sub.1 is M or I,
[0165] f.sub.2 is any amino acid,
[0166] f.sub.3 is L or F,
[0167] f.sub.4 is E, Q or D;
[0168] and wherein the peptide is between 7 and 50 amino acids in
length, and physiologically acceptable salts thereof;
[0169] (3) a peptide capable of binding myostatin wherein the
peptide comprises the sequence Lg.sub.1g.sub.2LLg.sub.3g.sub.4L,
(SEQ ID NO: 456), wherein
[0170] g.sub.1 is Q, D or E,
[0171] g.sub.2 is S, Q, D or E,
[0172] g.sub.3 is any amino acid,
[0173] g.sub.4 is L, W, F, or Y, and wherein the peptide is between
8 and 50 amino acids in length, and physiologically acceptable
salts thereof;
[0174] (4) a peptide capable of binding myostatin, wherein the
peptide comprises the sequence
h.sub.1h.sub.2h.sub.3h.sub.4h.sub.5h.sub.6h.sub.7h.sub.8h.sub.9
(SEQ ID NO: 457), wherein
[0175] h.sub.1 is R or D,
[0176] h.sub.2 is any amino acid,
[0177] h.sub.3 is A, T S or Q,
[0178] h.sub.4 is L or M,
[0179] h.sub.5 is L or S,
[0180] h.sub.6 is any amino acid,
[0181] h.sub.7 is F or E,
[0182] h.sub.8 is W, F or C,
[0183] h.sub.9 is L, F, M or K, and wherein the peptide is between
9 and 50 amino acids in length, and physiologically acceptable
salts thereof.
[0184] In one embodiment, the binding agents of the present
invention further comprise at least one vehicle such as a polymer
or an Fc domain, and may further comprise at least one linker
sequence. In this embodiment, the binding agents of the present
invention are constructed so that at least one myostatin-binding
peptide is covalently attached to at least one vehicle. The peptide
or peptides are attached directly or indirectly through a linker
sequence, to the vehicle at the N-terminal, C-terminal or an amino
acid sidechain of the peptide. In this embodiment, the binding
agents of the present invention have the following generalized
structure:
[0185] (X.sup.1).sub.a--F.sup.1--(X.sup.2).sub.b, or multimers
thereof;
wherein F.sup.1 is a vehicle; and X.sup.1 and X.sup.2 are each
independently selected from [0186] -(L.sup.1).sub.c-P.sup.1; [0187]
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2; [0188]
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.c-P.sup.3;
[0189] and
-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3--
(L.sup.4).sub.f-P.sup.4; [0190] wherein P.sup.1, P.sup.2, P.sup.3,
and P.sup.4 are peptides capable of binding myostatin; and [0191]
L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are each linkers; and a, b,
c, d, e, and f are each independently 0 or 1, provided that at
least one of a and b is 1.
[0192] In one embodiment of the binding agents having this
generalized structure, the peptides P.sup.1, P.sup.2, P.sup.3, and
P.sup.4 can be selected from one or more of any of the peptides
comprising the sequences provided above. Peptides P.sup.1, P.sup.2,
P.sup.3, and P.sup.4 can be selected from one or more peptides
comprising any of the following sequences: SEQ ID NO: 633, SEQ ID
NO: 352, SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO:
356, SEQ ID NO: 455, SEQ ID NO: 456, or SEQ ID NO: 457.
[0193] In a further embodiment, the vehicles of binding agents
having the general formula above are Fc domains. The peptides are
therefore fused to an Fc domain, either directly or indirectly,
thereby providing peptibodies. The peptibodies of the present
invention display a high binding affinity for myostatin and can
inhibit the activity of myostatin as demonstrated by in vitro
assays and in vivo testing in animals provided herein.
[0194] The present invention also provides nucleic acid molecules
comprising polynucleotides encoding the peptides, peptibodies, and
peptide and peptibody variants and derivatives of the present
invention. Exemplary nucleotides sequences are given below.
Variants and Derivatives of Peptides and Peptibodies
[0195] The binding agents of the present invention also encompass
variants and derivatives of the peptides and peptibodies described
herein. Since both the peptides and peptibodies of the present
invention can be described in terms of their amino acid sequence,
the terms "variants" and "derivatives" can be said to apply to a
peptide alone, or a peptide as a component of a peptibody. As used
herein, the term "peptide variants" refers to peptides or
peptibodies having one or more amino acid residues inserted,
deleted or substituted into the original amino acid sequence and
which retain the ability to bind to myostatin and modify its
activity. As used herein, fragments of the peptides or peptibodies
are included within the definition of "variants".
[0196] It is understood that any given peptide or peptibody may
contain one or two or all three types of variants. Insertional and
substitutional variants may contain natural amino acids, as well as
non-naturally occurring amino acids or both.
[0197] Peptide and peptibody variants also include mature peptides
and peptibodies wherein leader or signal sequences are removed, and
the resulting proteins having additional amino terminal residues,
which amino acids may be natural or non-natural. Peptibodies with
an additional methionyl residue at amino acid position -1 (Met
1-peptibody) are contemplated, as are peptibodies with additional
methionine and lysine residues at positions -2 and -1
(Met.sup.-2-Lys.sup.-1-). Variants having additional Met, Met-Lys,
Lys residues (or one or more basic residues, in general) are
particularly useful for enhanced recombinant protein production in
bacterial host cells.
[0198] Peptide or peptibody variants of the present invention also
includes peptides having additional amino acid residues that arise
from use of specific expression systems. For example, use of
commercially available vectors that express a desired polypeptide
as part of glutathione-S-transferase (GST) fusion product provides
the desired polypeptide having an additional glycine residue at
amino acid position-1 after cleavage of the GST component from the
desired polypeptide. Variants which result from expression in other
vector systems are also contemplated, including those wherein
histidine tags are incorporated into the amino acid sequence,
generally at the carboxy and/or amino terminus of the sequence.
[0199] In one example, insertional variants are provided wherein
one or more amino acid residues, either naturally occurring or
non-naturally occurring amino acids, are added to a peptide amino
acid sequence. Insertions may be located at either or both termini
of the protein, or may be positioned within internal regions of the
peptibody amino acid sequence. Insertional variants with additional
residues at either or both termini can include, for example, fusion
proteins and proteins including amino acid tags or labels.
Insertional variants include peptides in which one or more amino
acid residues are added to the peptide amino acid sequence or
fragment thereof.
[0200] Insertional variants also include fusion proteins wherein
the amino and/or carboxy termini of the peptide or peptibody is
fused to another polypeptide, a fragment thereof or amino acids
which are not generally recognized to be part of any specific
protein sequence. Examples of such fusion proteins are immunogenic
polypeptides, proteins with long circulating half lives, such as
immunoglobulin constant regions, marker proteins, proteins or
polypeptides that facilitate purification of the desired peptide or
peptibody, and polypeptide sequences that promote formation of
multimeric proteins (such as leucine zipper motifs that are useful
in dimer formation/stability).
[0201] This type of insertional variant generally has all or a
substantial portion of the native molecule, linked at the N- or
C-terminus, to all or a portion of a second polypeptide. For
example, fusion proteins typically employ leader sequences from
other species to permit the recombinant expression of a protein in
a heterologous host. Another useful fusion protein includes the
addition of an immunologically active domain, such as an antibody
epitope, to facilitate purification of the fusion protein.
Inclusion of a cleavage site at or near the fusion junction will
facilitate removal of the extraneous polypeptide after
purification. Other useful fusions include linking of functional
domains, such as active sites from enzymes, glycosylation domains,
cellular targeting signals or transmembrane regions.
[0202] There are various commercially available fusion protein
expression systems that may be used in the present invention.
Particularly useful systems include but are not limited to the
glutathione-S-transferase (GST) system (Pharmacia), the maltose
binding protein system (NEB, Beverley, Mass.), the FLAG system
(IBI, New Haven, Conn.), and the 6.times.His system (Qiagen,
Chatsworth, Calif.). These systems are capable of producing
recombinant peptides and/or peptibodies bearing only a small number
of additional amino acids, which are unlikely to significantly
affect the activity of the peptide or peptibody. For example, both
the FLAG system and the 6.times.His system add only short
sequences, both of which are known to be poorly antigenic and which
do not adversely affect folding of a polypeptide to its native
conformation. Another N-terminal fusion that is contemplated to be
useful is the fusion of a Met-Lys dipeptide at the N-terminal
region of the protein or peptides. Such a fusion may produce
beneficial increases in protein expression or activity.
[0203] Other fusion systems produce polypeptide hybrids where it is
desirable to excise the fusion partner from the desired peptide or
peptibody. In one embodiment, the fusion partner is linked to the
recombinant peptibody by a peptide sequence containing a specific
recognition sequence for a protease. Examples of suitable sequences
are those recognized by the Tobacco Etch Virus protease (Life
Technologies, Gaithersburg, Md.) or Factor Xa (New England Biolabs,
Beverley, Mass.).
[0204] The invention also provides fusion polypeptides which
comprise all or part of a peptide or peptibody of the present
invention, in combination with truncated tissue factor (tTF). tTF
is a vascular targeting agent consisting of a truncated form of a
human coagulation-inducing protein that acts as a tumor blood
vessel clotting agent, as described U.S. Pat. Nos. 5,877,289;
6,004,555; 6,132,729; 6,132,730; 6,156,321; and European Patent No.
EP 0988056. The fusion of tTF to the anti-myostatin peptibody or
peptide, or fragments thereof facilitates the delivery of
anti-myostatin antagonists to target cells, for example, skeletal
muscle cells, cardiac muscle cells, fibroblasts, pre-adipocytes,
and possibly adipocytes.
[0205] In another aspect, the invention provides deletion variants
wherein one or more amino acid residues in a peptide or peptibody
are removed. Deletions can be effected at one or both termini of
the peptibody, or from removal of one or more residues within the
peptibody amino acid sequence. Deletion variants necessarily
include all fragments of a peptide or peptibody.
[0206] In still another aspect, the invention provides substitution
variants of peptides and peptibodies of the invention. Substitution
variants include those peptides and peptibodies wherein one or more
amino acid residues are removed and replaced with one or more
alternative amino acids, which amino acids may be naturally
occurring or non-naturally occurring. Substitutional variants
generate peptides or peptibodies that are "similar" to the original
peptide or peptibody, in that the two molecules have a certain
percentage of amino acids that are identical. Substitution variants
include substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, and 20
amino acids within a peptide or peptibody, wherein the number of
substitutions may be up to ten percent of the amino acids of the
peptide or peptibody. In one aspect, the substitutions are
conservative in nature, however, the invention embraces
substitutions that are also non-conservative and also includes
unconventional amino acids.
[0207] Identity and similarity of related peptides and peptibodies
can be readily calculated by known methods. Such methods include,
but are not limited to, those described in Computational Molecular
Biology, Lesk, A. M., ed., Oxford University Press, New York
(1988); Biocomputing: Informatics and Genome Projects, Smith, D.
W., ed., Academic Press, New York (1993); Computer Analysis of
Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds.,
Humana Press, New Jersey (1994); Sequence Analysis in Molecular
Biology, von Heinje, G., Academic Press (1987); Sequence Analysis
Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New
York (1991); and Carillo et al., SIAM J. Applied Math., 48:1073
(1988).
[0208] Preferred methods to determine the relatedness or percent
identity of two peptides or polypeptides, or a polypeptide and a
peptide, are designed to give the largest match between the
sequences tested. Methods to determine identity are described in
publicly available computer programs. Preferred computer program
methods to determine identity between two sequences include, but
are not limited to, the GCG program package, including GAP
(Devereux et al., Nucl. Acid. Res., 12:387 (1984); Genetics
Computer Group, University of Wisconsin, Madison, Wis., BLASTP,
BLASTN, and FASTA (Altschul et al., J. Mol. Biol., 215:403-410
(1990)). The BLASTX program is publicly available from the National
Center for Biotechnology Information (NCBI) and other sources
(BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894;
Altschul et al., supra (1990)). The well-known Smith Waterman
algorithm may also be used to determine identity.
[0209] Certain alignment schemes for aligning two amino acid
sequences may result in the matching of only a short region of the
two sequences, and this small aligned region may have very high
sequence identity even though there is no significant relationship
between the two full-length sequences. Accordingly, in certain
embodiments, the selected alignment method will result in an
alignment that spans at least ten percent of the full length of the
target polypeptide being compared, i.e., at least 40 contiguous
amino acids where sequences of at least 400 amino acids are being
compared, 30 contiguous amino acids where sequences of at least 300
to about 400 amino acids are being compared, at least 20 contiguous
amino acids where sequences of 200 to about 300 amino acids are
being compared, and at least 10 contiguous amino acids where
sequences of about 100 to 200 amino acids are being compared. For
example, using the computer algorithm GAP (Genetics Computer Group,
University of Wisconsin, Madison, Wis.), two polypeptides for which
the percent sequence identity is to be determined are aligned for
optimal matching of their respective amino acids (the "matched
span", as determined by the algorithm). In certain embodiments, a
gap opening penalty (which is typically calculated as 3.times. the
average diagonal; the "average diagonal" is the average of the
diagonal of the comparison matrix being used; the "diagonal" is the
score or number assigned to each perfect amino acid match by the
particular comparison matrix) and a gap extension penalty (which is
usually 1/10 times the gap opening penalty), as well as a
comparison matrix such as PAM 250 or BLOSUM 62 are used in
conjunction with the algorithm. In certain embodiments, a standard
comparison matrix (see Dayhoff et al., Atlas of Protein Sequence
and Structure, 5(3)(1978) for the PAM 250 comparison matrix;
Henikoff et al., Proc. Natl. Acad. Sci. USA, 89:10915-10919 (1992)
for the BLOSUM 62 comparison matrix) is also used by the
algorithm.
[0210] In certain embodiments, for example, the parameters for a
polypeptide sequence comparison can be made with the following:
Algorithm: Needleman et al., J. Mol. Biol., 48:443-453 (1970);
Comparison matrix: BLOSUM 62 from Henikoff et al., supra (1992);
Gap Penalty: 12; Gap Length Penalty: 4; Threshold of Similarity: 0,
along with no penalty for end gaps.
[0211] In certain embodiments, the parameters for polynucleotide
molecule sequence (as opposed to an amino acid sequence)
comparisons can be made with the following: Algorithm: Needleman et
al., supra (1970); Comparison matrix: matches=+10, mismatch=0; Gap
Penalty: 50: Gap Length Penalty: 3
[0212] Other exemplary algorithms, gap opening penalties, gap
extension penalties, comparison matrices, thresholds of similarity,
etc. may be used, including those set forth in the Program Manual,
Wisconsin Package, Version 9, September, 1997. The particular
choices to be made will be apparent to those of skill in the art
and will depend on the specific comparison to be made, such as
DNA-to-DNA, protein-to-protein, protein-to-DNA; and additionally,
whether the comparison is between given pairs of sequences (in
which case GAP or BestFit are generally preferred) or between one
sequence and a large database of sequences (in which case FASTA or
BLASTA are preferred).
[0213] Stereoisomers (e.g., D-amino acids) of the twenty
conventional (naturally occurring) amino acids, non-naturally
occurring amino acids such as .alpha.-, .alpha.-disubstituted amino
acids, N-alkyl amino acids, lactic acid, and other unconventional
amino acids may also be suitable components for peptides of the
present invention. Examples of non-naturally occurring amino acids
include, for example: aminoadipic acid, beta-alanine,
beta-aminopropionic acid, aminobutyric acid, piperidinic acid,
aminocaprioic acid, aminoheptanoic acid, aminoisobutyric acid,
aminopimelic acid, diaminobutyric acid, desmosine, diaminopimelic
acid, diaminopropionic acid, N-ethylglycine, N-ethylasparagine,
hyroxylysine, all0-hydroxylysine, hydroxyproline, isodesmosine,
allo-isoleucine, N-methylglycine, sarcosine, N-methylisoleucine,
N-methylvaline, norvaline, norleucine, orithine, 4-hydroxyproline,
.gamma.-carboxyglutamate, .epsilon.-N,N,N-trimethyllysine,
.epsilon.-N-acetyllysine, O-phosphoserine, N-acetylserine,
N-formylmethionine, 3-methylhistidine, 5-hydroxylysine,
.sigma.-N-methylarginine, and other similar amino acids and amino
acids (e.g., 4-hydroxyproline).
[0214] Naturally occurring residues may be divided into
(overlapping) classes based on common side chain properties:
[0215] 1) neutral hydrophobic: Met, Ala, Val, Leu, Ile, Pro, Trp,
Met, Phe;
[0216] 2) neutral polar: Cys, Ser, Thr, Asn, Gln, Tyr, Gly;
[0217] 3) acidic: Asp, Glu;
[0218] 4) basic: His, Lys, Arg;
[0219] 5) residues that influence chain orientation: Gly, Pro;
and
[0220] 6) aromatic: Trp, Tyr, Phe.
[0221] Substitutions of amino acids may be conservative, which
produces peptides having functional and chemical characteristics
similar to those of the original peptide. Conservative amino acid
substitutions involve exchanging a member of one of the above
classes for another member of the same class. Conservative changes
may encompass unconventional amino acid residues, which are
typically incorporated by chemical peptide synthesis rather than by
synthesis in biological systems. These include peptidomimetics and
other reversed or inverted forms of amino acid moieties.
[0222] Non-conservative substitutions may involve the exchange of a
member of one of these classes for a member from another class.
These changes can result in substantial modification in the
functional and/or chemical characteristics of the peptides. In
making such changes, according to certain embodiments, the
hydropathic index of amino acids may be considered. Each amino acid
has been assigned a hydropathic index on the basis of its
hydrophobicity and charge characteristics. They are: isoleucine
(+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8);
cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine
(-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9);
tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate
(-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5);
lysine (-3.9); and arginine (-4.5).
[0223] The importance of the hydropathic amino acid index in
conferring interactive biological function on a protein is
understood in the art. Kyte et al., J. Mol. Biol., 157:105-131
(1982). It is known that certain amino acids may be substituted for
other amino acids having a similar hydropathic index or score and
still retain a similar biological activity. In making changes based
upon the hydropathic index, in certain embodiments, the
substitution of amino acids whose hydropathic indices are within
.+-.2 is included. In certain embodiments, those which are within
.+-.1 are included, and in certain embodiments, those within
.+-.0.5 are included.
[0224] It is also understood in the art that the substitution of
like amino acids can be made effectively on the basis of
hydrophilicity, particularly where the biologically functional
peptibody or peptide thereby created is intended for use in
immunological embodiments, as in the present case. In certain
embodiments, the greatest local average hydrophilicity of a
protein, as governed by the hydrophilicity of its adjacent amino
acids, correlates with its immunogenicity and antigenicity, i.e.,
with a biological property of the protein.
[0225] The following hydrophilicity values have been assigned to
these amino acid residues: arginine (+3.0); lysine (+3.0);
aspartate (+3.0.+-.1); glutamate (+3.0.+-.1); serine (+0.3);
asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4);
proline (-0.5.+-.1); alanine (-0.5); histidine (-0.5); cysteine
(-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8);
isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5) and
tryptophan (-3.4). In making changes based upon similar
hydrophilicity values, in certain embodiments, the substitution of
amino acids whose hydrophilicity values are within .+-.2 is
included, in certain embodiments, those which are within .+-.1 are
included, and in certain embodiments, those within .+-.0.5 are
included. One may also identify epitopes from primary amino acid
sequences on the basis of hydrophilicity. These regions are also
referred to as "epitopic core regions."
[0226] Exemplary amino acid substitutions are set forth in Table 1
below.
TABLE-US-00001 Amino Acid Substitutions Original Preferred Residues
Exemplary Substitutions Substitutions Ala Val, Leu, Ile Val Arg
Lys, Gln, Asn Lys Asn Gln, Glu, Asp Gln Asp Glu, Gln, Asp Glu Cys
Ser, Ala Ser Gln Asn, Glu, Asp Asn Glu Asp, Gln, Asn Asp Gly Pro,
Ala Ala His Asn, Gln, Lys, Arg Arg Ile Leu, Val, Met, Ala, Phe,
Norleucine Leu Leu Norleucine, Ile, Val, Met, Ala, Phe Ile Lys Arg,
1,4 Diamino-butyric Acid, Gln, Asn Arg Met Leu, Phe, Ile Leu Phe
Leu, Val, Ile, Ala, Tyr Leu Pro Ala Gly Ser Thr, Ala, Cys Thr Thr
Ser Ser Trp Tyr, Phe Tyr Tyr Trp, Phe, Thr, Ser Phe Val Ile, Met,
Leu, Phe, Ala, Norleucine Leu
[0227] One skilled in the art will be able to produce variants of
the peptides and peptibodies of the present invention by random
substitution, for example, and testing the resulting peptide or
peptibody for binding activity using the assays described
herein.
[0228] Additionally, one skilled in the art can review
structure-function studies or three-dimensional structural analysis
in order to identify residues in similar polypeptides that are
important for activity or structure. In view of such a comparison,
one can predict the importance of amino acid residues in a protein
that correspond to amino acid residues which are important for
activity or structure in similar proteins. One skilled in the art
may opt for chemically similar amino acid substitutions for such
predicted important amino acid residues. The variants can then be
screened using activity assays as described herein.
[0229] A number of scientific publications have been devoted to the
prediction of secondary structure. See Moult J., Curr. Op. in
Biotech., 7(4):422-427 (1996), Chou et al., Biochemistry,
13(2):222-245 (1974); Chou et al., Biochemistry, 113(2):211-222
(1974); Chou et al., Adv. Enzymol. Relat. Areas Mol. Biol.,
47:45-148 (1978); Chou et al., Ann. Rev. Biochem., 47:251-276 and
Chou et al., Biophys. J., 26:367-384 (1979). Moreover, computer
programs are currently available to assist with predicting
secondary structure. One method of predicting secondary structure
is based upon homology modeling. For example, two polypeptides or
proteins which have a sequence identity of greater than 30%, or
similarity greater than 40% often have similar structural
topologies. The recent growth of the protein structural database
(PDB) has provided enhanced predictability of secondary structure,
including the potential number of folds within a protein's
structure. See Holm et al., Nucl. Acid. Res., 27(1):244-247 (1999).
It has been suggested (Brenner et al., Curr. Op. Struct. Biol.,
7(3):369-376 (1997)) that there are a limited number of folds in a
given protein and that once a critical number of structures have
been resolved, structural prediction will become dramatically more
accurate.
[0230] Additional methods of predicting secondary structure include
"threading" (Jones, D., Curr. Opin. Struct. Biol., 7(3):377-87
(1997); Sippl et al., Structure, 4(1):15-19 (1996)), "profile
analysis" (Bowie et al., Science, 253:164-170 (1991); Gribskov et
al., Meth. Enzym., 183:146-159 (1990); Gribskov et al., Proc. Nat.
Acad. Sci., 84(13):4355-4358 (1987)), and "evolutionary linkage"
(See Holm, supra (1999), and Brenner, supra (1997)).
[0231] In certain embodiments, peptide or peptibody variants
include glycosylation variants wherein one or more glycosylation
sites such as a N-linked glycosylation site, has been added to the
peptibody. An N-linked glycosylation site is characterized by the
sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue
designated as X may be any amino acid residue except proline. The
substitution or addition of amino acid residues to create this
sequence provides a potential new site for the addition of an
N-linked carbohydrate chain. Alternatively, substitutions which
eliminate this sequence will remove an existing N-linked
carbohydrate chain. Also provided is a rearrangement of N-linked
carbohydrate chains wherein one or more N-linked glycosylation
sites (typically those that are naturally occurring) are eliminated
and one or more new N-linked sites are created.
[0232] The invention also provides "derivatives" of the peptides or
peptibodies of the present invention. As used herein the term
"derivative" refers to modifications other than, or in addition to,
insertions, deletions, or substitutions of amino acid residues
which retain the ability to bind to myostatin.
[0233] Preferably, the modifications made to the peptides of the
present invention to produce derivatives are covalent in nature,
and include for example, chemical bonding with polymers, lipids,
other organic, and inorganic moieties. Derivatives of the invention
may be prepared to increase circulating half-life of a peptibody,
or may be designed to improve targeting capacity for the peptibody
to desired cells, tissues, or organs.
[0234] The invention further embraces derivative binding agents
covalently modified to include one or more water soluble polymer
attachments, such as polyethylene glycol, polyoxyethylene glycol,
or polypropylene glycol, as described U.S. Pat. Nos. 4,640,835;
4,496,689; 4,301,144; 4,670,417; 4,791,192; and 4,179,337. Still
other useful polymers known in the art include
monomethoxy-polyethylene glycol, dextran, cellulose, or other
carbohydrate based polymers, poly-(N-vinyl
pyrrolidone)-polyethylene glycol, propylene glycol homopolymers, a
polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated
polyols (e.g., glycerol) and polyvinyl alcohol, as well as mixtures
of these polymers. Particularly preferred are peptibodies
covalently modified with polyethylene glycol (PEG) subunits.
Water-soluble polymers may be bonded at specific positions, for
example at the amino terminus of the peptibodies, or randomly
attached to one or more side chains of the polypeptide. The use of
PEG for improving the therapeutic capacity for binding agents, e.g.
peptibodies, and for humanized antibodies in particular, is
described in U.S. Pat. No. 6,133,426 to Gonzales et al., issued
Oct. 17, 2000.
[0235] The invention also contemplates derivatizing the peptide
and/or vehicle portion of the myostatin binding agents. Such
derivatives may improve the solubility, absorption, biological
half-life, and the like of the compounds. The moieties may
alternatively eliminate or attenuate any undesirable side-effect of
the compounds and the like. Exemplary derivatives include compounds
in which:
[0236] 1. The derivative or some portion thereof is cyclic. For
example, the peptide portion may be modified to contain two or more
Cys residues (e.g., in the linker), which could cyclize by
disulfide bond formation.
[0237] 2. The derivative is cross-linked or is rendered capable of
cross-linking between molecules. For example, the peptide portion
may be modified to contain one Cys residue and thereby be able to
form an intermolecular disulfide bond with a like molecule. The
derivative may also be cross-linked through its C-terminus.
[0238] 3. One or more peptidyl [--C(O)NR--] linkages (bonds) is
replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages
are --CH.sub.2-carbamate [--CH.sub.2--OC(O)NR--], phosphonate,
--CH.sub.2-sulfonamide [--CH.sub.2--S(O).sub.2NR--], urea
[--NHC(O)NH--], --CH.sub.2-secondary amine, and alkylated peptide
[--C(O)NR.sub.6-- wherein R.sub.6 is lower alkyl].
[0239] 4. The N-terminus is derivatized. Typically, the N-terminus
may be acylated or modified to a substituted amine. Exemplary
N-terminal derivative groups include --NRR.sub.1 (other than
--NH.sub.2), --NRC(O)R.sub.1, --NRC(O)OR.sub.1,
--NRS(O).sub.2R.sub.1, --NHC(O)NHR.sub.1, succinimide, or
benzyloxycarbonyl-NH-- (CBZ--NH--), wherein R and R1 are each
independently hydrogen or lower alkyl and wherein the phenyl ring
may be substituted with 1 to 3 substituents selected from the group
consisting of C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
chloro, and bromo.
[0240] 5. The free C-terminus is derivatized. Typically, the
C-terminus is esterified or amidated. For example, one may use
methods described in the art to add
(NH--CH.sub.2--CH.sub.2--NH.sub.2).sub.2 to compounds of this
invention at the C-terminus. Likewise, one may use methods
described in the art to add --NH.sub.2, (or "capping" with an
--NH.sub.2 group) to compounds of this invention at the C-terminus.
Exemplary C-terminal derivative groups include, for example,
--C(O)R.sub.2 wherein R.sub.2 is lower alkoxy or --NR.sub.3R.sub.4
wherein R.sub.3 and R.sub.4 are independently hydrogen or
C.sub.1-C.sub.8 alkyl (preferably C.sub.1-C.sub.4 alkyl).
[0241] 6. A disulfide bond is replaced with another, preferably
more stable, cross-linking moiety (e.g., an alkylene). See, e.g.,
Bhatnagar et al., J Med Chem 39: 3814-9 (1996), Alberts et al.,
Thirteenth Am Pep Symp, 357-9 (1993).
[0242] 7. One or more individual amino acid residues is modified.
Various derivatizing agents are known to react specifically with
selected side chains or terminal residues, as described in detail
below.
[0243] Lysinyl residues and amino terminal residues may be reacted
with succinic or other carboxylic acid anhydrides, which reverse
the charge of the lysinyl residues. Other suitable reagents for
derivatizing alpha-amino-containing residues include imidoesters
such as methyl picolinimidate; pyridoxal phosphate; pyridoxal;
chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea;
2,4 pentanedione; and transaminase-catalyzed reaction with
glyoxylate.
[0244] Arginyl residues may be modified by reaction with any one or
combination of several conventional reagents, including
phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and
ninhydrin. Derivatization of arginyl residues requires that the
reaction be performed in alkaline conditions because of the high
pKa of the guanidine functional group. Furthermore, these reagents
may react with the groups of lysine as well as the arginine
epsilon-amino group.
[0245] Specific modification of tyrosyl residues has been studied
extensively, with particular interest in introducing spectral
labels into tyrosyl residues by reaction with aromatic diazonium
compounds or tetranitromethane. Most commonly, N-acetylimidizole
and tetranitromethane are used to form O-acetyl tyrosyl species and
3-nitro derivatives, respectively.
[0246] Carboxyl side chain groups (aspartyl or glutamyl) may be
selectively modified by reaction with carbodiimides
(R'--N.dbd.C.dbd.N--R') such as
1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or
1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore,
aspartyl and glutamyl residues may be converted to asparaginyl and
glutaminyl residues by reaction with ammonium ions.
[0247] Glutaminyl and asparaginyl residues may be deamidated to the
corresponding glutamyl and aspartyl residues. Alternatively, these
residues are deamidated under mildly acidic conditions. Either form
of these residues falls within the scope of this invention.
[0248] Cysteinyl residues can be replaced by amino acid residues or
other moieties either to eliminate disulfide bonding or,
conversely, to stabilize cross-linking. See, e.g., Bhatnagar et
al., (supra).
[0249] Derivatization with bifunctional agents is useful for
cross-linking the peptides or their functional derivatives to a
water-insoluble support matrix or to other macromolecular vehicles.
Commonly used cross-linking agents include, e.g.,
1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde,
N-hydroxysuccinimide esters, for example, esters with
4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides
such as bis-N-maleimido-1,8-octane. Derivatizing agents such as
methyl-3-[(p-azidophenyl)dithio]propioimidate yield
photoactivatable intermediates that are capable of forming
crosslinks in the presence of light. Alternatively, reactive
water-insoluble matrices such as cyanogen bromide-activated
carbohydrates and the reactive substrates described in U.S. Pat.
Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and
4,330,440 are employed for protein immobilization.
[0250] Carbohydrate (oligosaccharide) groups may conveniently be
attached to sites that are known to be glycosylation sites in
proteins. Generally, O-linked oligosaccharides are attached to
serine (Ser) or threonine (Thr) residues while N-linked
oligosaccharides are attached to asparagine (Asn) residues when
they are part of the sequence Asn-X-Ser/Thr, where X can be any
amino acid except proline. X is preferably one of the 19 naturally
occurring amino acids other than proline. The structures of
N-linked and O-linked oligosaccharides and the sugar residues found
in each type are different. One type of sugar that is commonly
found on both is N-acetylneuraminic acid (referred to as sialic
acid). Sialic acid is usually the terminal residue of both N-linked
and O-linked oligosaccharides and, by virtue of its negative
charge, may confer acidic properties to the glycosylated compound.
Such site(s) may be incorporated in the linker of the compounds of
this invention and are preferably glycosylated by a cell during
recombinant production of the polypeptide compounds (e.g., in
mammalian cells such as CHO, BHK, COS). However, such sites may
further be glycosylated by synthetic or semi-synthetic procedures
known in the art.
[0251] Other possible modifications include hydroxylation of
proline and lysine, phosphorylation of hydroxyl groups of seryl or
threonyl residues, oxidation of the sulfur atom in Cys, methylation
of the alpha-amino groups of lysine, arginine, and histidine side
chains [see, for example, Creighton, Proteins: Structure and
Molecule Properties (W. H. Freeman & Co., San Francisco), pp.
79-86 (1983)].
[0252] Compounds of the present invention may be changed at the DNA
level, as well. The DNA sequence of any portion of the compound may
be changed to codons more compatible with the chosen host cell. For
E. coli, which is the preferred host cell, optimized codons are
known in the art. Codons may be substituted to eliminate
restriction sites or to include silent restriction sites, which may
aid in processing of the DNA in the selected host cell. The
vehicle, linker and peptide DNA sequences may be modified to
include any of the foregoing sequence changes.
[0253] Additional derivatives include non-peptide analogs that
provide a stabilized structure or lessened biodegradation, are also
contemplated. Peptide mimetic analogs can be prepared based on a
selected inhibitory peptide by replacement of one or more residues
by nonpeptide moieties. Preferably, the nonpeptide moieties permit
the peptide to retain its natural confirmation, or stabilize a
preferred, e.g., bioactive, confirmation which retains the ability
to recognize and bind myostatin. In one aspect, the resulting
analog/mimetic exhibits increased binding affinity for myostatin.
One example of methods for preparation of nonpeptide mimetic
analogs from peptides is described in Nachman et al., Regul Pept
57:359-370 (1995). If desired, the peptides of the invention can be
modified, for instance, by glycosylation, amidation, carboxylation,
or phosphorylation, or by the creation of acid addition salts,
amides, esters, in particular C-terminal esters, and N-acyl
derivatives of the peptides of the invention. The peptibodies also
can be modified to create peptide derivatives by forming covalent
or noncovalent complexes with other moieties. Covalently-bound
complexes can be prepared by linking the chemical moieties to
functional groups on the side chains of amino acids comprising the
peptibodies, or at the N- or C-terminus.
[0254] In particular, it is anticipated that the peptides can be
conjugated to a reporter group, including, but not limited to a
radiolabel, a fluorescent label, an enzyme (e.g., that catalyzes a
colorimetric or fluorometric reaction), a substrate, a solid
matrix, or a carrier (e.g., biotin or avidin). The invention
accordingly provides a molecule comprising a peptibody molecule,
wherein the molecule preferably further comprises a reporter group
selected from the group consisting of a radiolabel, a fluorescent
label, an enzyme, a substrate, a solid matrix, and a carrier. Such
labels are well known to those of skill in the art, e.g., biotin
labels are particularly contemplated. The use of such labels is
well known to those of skill in the art and is described in, e.g.,
U.S. Pat. Nos. 3,817,837; 3,850,752; 3,996,345; and 4,277,437.
Other labels that will be useful include but are not limited to
radioactive labels, fluorescent labels and chemiluminescent labels.
U.S. patents concerning use of such labels include, for example,
U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; and 3,996,345. Any
of the peptibodies of the present invention may comprise one, two,
or more of any of these labels.
Methods of Making Peptides and Peptibodies
[0255] The peptides of the present invention can be generated using
a wide variety of techniques known in the art. For example, such
peptides can be synthesized in solution or on a solid support in
accordance with conventional techniques. Various automatic
synthesizers are commercially available and can be used in
accordance with known protocols. See, for example, Stewart and
Young (supra); Tam et al., J Am Chem Soc, 105:6442, (1983);
Merrifield, Science 232:341-347 (1986); Barany and Merrifield, The
Peptides, Gross and Meienhofer, eds, Academic Press, New York,
1-284; Barany et al., Int J Pep Protein Res, 30:705-739 (1987); and
U.S. Pat. No. 5,424,398, each incorporated herein by reference.
[0256] Solid phase peptide synthesis methods use a
copoly(styrene-divinylbenzene) containing 0.1-1.0 mM amines/g
polymer. These methods for peptide synthesis use butyloxycarbonyl
(t-BOC) or 9-fluorenylmethyloxy-carbonyl(FMOC) protection of
alpha-amino groups. Both methods involve stepwise syntheses whereby
a single amino acid is added at each step starting from the
C-terminus of the peptide (See, Coligan et al., Curr Prot Immunol,
Wiley Interscience, 1991, Unit 9). On completion of chemical
synthesis, the synthetic peptide can be deprotected to remove the
t-BOC or FMOC amino acid blocking groups and cleaved from the
polymer by treatment with acid at reduced temperature (e.g., liquid
HF-10% anisole for about 0.25 to about 1 hours at 0.degree. C.).
After evaporation of the reagents, the peptides are extracted from
the polymer with 1% acetic acid solution that is then lyophilized
to yield the crude material. This can normally be purified by such
techniques as gel filtration on Sephadex G-15 using 5% acetic acid
as a solvent. Lyophilization of appropriate fractions of the column
will yield the homogeneous peptides or peptide derivatives, which
can then be characterized by such standard techniques as amino acid
analysis, thin layer chromatography, high performance liquid
chromatography, ultraviolet absorption spectroscopy, molar
rotation, solubility, and quantitated by the solid phase Edman
degradation.
[0257] Phage display techniques can be particularly effective in
identifying the peptides of the present invention as described
above. Briefly, a phage library is prepared (using e.g. ml 13, fd,
or lambda phage), displaying inserts from 4 to about 80 amino acid
residues. The inserts may represent, for example, a completely
degenerate or biased array. Phage-bearing inserts that bind to the
desired antigen are selected and this process repeated through
several cycles of reselection of phage that bind to the desired
antigen. DNA sequencing is conducted to identify the sequences of
the expressed peptides. The minimal linear portion of the sequence
that binds to the desired antigen can be determined in this way.
The procedure can be repeated using a biased library containing
inserts containing part or all of the minimal linear portion plus
one or more additional degenerate residues upstream or downstream
thereof. These techniques may identify peptides of the invention
with still greater binding affinity for myostatin than agents
already identified herein.
[0258] Regardless of the manner in which the peptides are prepared,
a nucleic acid molecule encoding each such peptide can be generated
using standard recombinant DNA procedures. The nucleotide sequence
of such molecules can be manipulated as appropriate without
changing the amino acid sequence they encode to account for the
degeneracy of the nucleic acid code as well as to account for codon
preference in particular host cells.
[0259] The present invention also provides nucleic acid molecules
comprising polynucleotide sequences encoding the peptides and
peptibodies of the present invention. These nucleic acid molecules
include vectors and constructs containing polynucleotides encoding
the peptides and peptibodies of the present invention, as well as
peptide and peptibody variants and derivatives. Exemplary nucleic
acid molecules are provided in the Examples below.
[0260] Recombinant DNA techniques also provide a convenient method
for preparing full length peptibodies and other large polypeptide
binding agents of the present invention, or fragments thereof. A
polynucleotide encoding the peptibody or fragment may be inserted
into an expression vector, which can in turn be inserted into a
host cell for production of the binding agents of the present
invention. Preparation of exemplary peptibodies of the present
invention are described in Example 2 below.
[0261] A variety of expression vector/host systems may be utilized
to express the peptides and peptibodies of the invention. These
systems include but are not limited to microorganisms such as
bacteria transformed with recombinant bacteriophage, plasmid or
cosmid DNA expression vectors; yeast transformed with yeast
expression vectors; insect cell systems infected with virus
expression vectors (e.g., baculovirus); plant cell systems
transfected with virus expression vectors (e.g., cauliflower mosaic
virus, CaMV; tobacco mosaic virus, TMV) or transformed with
bacterial expression vectors (e.g., Ti or pBR322 plasmid); or
animal cell systems. One preferred host cell line is E. coli strain
2596 (ATCC #202174), used for expression of peptibodies as
described below in Example 2. Mammalian cells that are useful in
recombinant protein productions include but are not limited to VERO
cells, HeLa cells, Chinese hamster ovary (CHO) cell lines, COS
cells (such as COS-7), W138, BHK, HepG2, 3T3, RIN, MDCK, A549,
PC12, K562 and 293 cells.
[0262] The term "expression vector" refers to a plasmid, phage,
virus or vector, for expressing a polypeptide from a polynucleotide
sequence. An expression vector can comprise a transcriptional unit
comprising an assembly of (1) a genetic element or elements having
a regulatory role in gene expression, for example, promoters or
enhancers, (2) a structural or sequence that encodes the binding
agent which is transcribed into mRNA and translated into protein,
and (3) appropriate transcription initiation and termination
sequences. Structural units intended for use in yeast or eukaryotic
expression systems preferably include a leader sequence enabling
extracellular secretion of translated protein by a host cell.
Alternatively, where recombinant protein is expressed without a
leader or transport sequence, it may include an amino terminal
methionyl residue. This residue may or may not be subsequently
cleaved from the expressed recombinant protein to provide a final
peptide product.
[0263] For example, the peptides and peptibodies may be
recombinantly expressed in yeast using a commercially available
expression system, e.g., the Pichia Expression System (Invitrogen,
San Diego, Calif.), following the manufacturer's instructions. This
system also relies on the pre-pro-alpha sequence to direct
secretion, but transcription of the insert is driven by the alcohol
oxidase (AOX1) promoter upon induction by methanol. The secreted
peptide is purified from the yeast growth medium using the methods
used to purify the peptide from bacterial and mammalian cell
supernatants.
[0264] Alternatively, the cDNA encoding the peptide and peptibodies
may be cloned into the baculovirus expression vector pVL1393
(PharMingen, San Diego, Calif.). This vector can be used according
to the manufacturer's directions (PharMingen) to infect Spodoptera
frugiperda cells in sF9 protein-free media and to produce
recombinant protein. The recombinant protein can be purified and
concentrated from the media using a heparin-Sepharose column
(Pharmacia).
[0265] Alternatively, the peptide or peptibody may be expressed in
an insect system. Insect systems for protein expression are well
known to those of skill in the art. In one such system, Autographa
californica nuclear polyhedrosis virus (AcNPV) can be used as a
vector to express foreign genes in Spodoptera frugiperda cells or
in Trichoplusia larvae. The peptide coding sequence can be cloned
into a nonessential region of the virus, such as the polyhedrin
gene, and placed under control of the polyhedrin promoter.
Successful insertion of the peptide will render the polyhedrin gene
inactive and produce recombinant virus lacking coat protein coat.
The recombinant viruses can be used to infect S. frugiperda cells
or Trichoplusia larvae in which the peptide is expressed (Smith et
al., J Virol 46: 584 (1983); Engelhard et al., Proc Nat Acad Sci
(USA) 91: 3224-7 (1994)).
[0266] In another example, the DNA sequence encoding the peptide
can be amplified by PCR and cloned into an appropriate vector for
example, pGEX-3.times. (Pharmacia). The pGEX vector is designed to
produce a fusion protein comprising glutathione-S-transferase
(GST), encoded by the vector, and a protein encoded by a DNA
fragment inserted into the vector's cloning site. The primers for
PCR can be generated to include for example, an appropriate
cleavage site. Where the fusion moiety is used solely to facilitate
expression or is otherwise not desirable as an attachment to the
peptide of interest, the recombinant fusion protein may then be
cleaved from the GST portion of the fusion protein. The
pGEX-3.times./specific binding agent peptide construct is
transformed into E. coli XL-1 Blue cells (Stratagene, La Jolla
Calif.), and individual transformants isolated and grown. Plasmid
DNA from individual transformants can be purified and partially
sequenced using an automated sequencer to confirm the presence of
the desired specific binding agent encoding nucleic acid insert in
the proper orientation.
[0267] The fusion protein, which may be produced as an insoluble
inclusion body in the bacteria, can be purified as follows. Host
cells are collected by centrifugation; washed in 0.15 M NaCl, 10 mM
Tris, pH 8, 1 mM EDTA; and treated with 0.1 mg/ml lysozyme (Sigma,
St. Louis, Mo.) for 15 minutes at room temperature. The lysate can
be cleared by sonication, and cell debris can be pelleted by
centrifugation for 10 minutes at 12,000.times.g. The fusion
protein-containing pellet can be resuspended in 50 mM Tris, pH 8,
and 10 mM EDTA, layered over 50% glycerol, and centrifuged for 30
min. at 6000.times.g. The pellet can be resuspended in standard
phosphate buffered saline solution (PBS) free of Mg++ and Ca++. The
fusion protein can be further purified by fractionating the
resuspended pellet in a denaturing SDS-PAGE (Sambrook et al.,
supra). The gel can be soaked in 0.4 M KCl to visualize the
protein, which can be excised and electroeluted in gel-running
buffer lacking SDS. If the GST/fusion protein is produced in
bacteria as a soluble protein, it can be purified using the GST
Purification Module (Pharmacia).
[0268] The fusion protein may be subjected to digestion to cleave
the GST from the peptide of the invention. The digestion reaction
(20-40 mg fusion protein, 20-30 units human thrombin (4000 U/mg,
Sigma) in 0.5 ml PBS can be incubated 16-48 hrs at room temperature
and loaded on a denaturing SDS-PAGE gel to fractionate the reaction
products. The gel can be soaked in 0.4 M KCl to visualize the
protein bands. The identity of the protein band corresponding to
the expected molecular weight of the peptide can be confirmed by
amino acid sequence analysis using an automated sequencer (Applied
Biosystems Model 473A, Foster City, Calif.). Alternatively, the
identity can be confirmed by performing HPLC and/or mass
spectometry of the peptides.
[0269] Alternatively, a DNA sequence encoding the peptide can be
cloned into a plasmid containing a desired promoter and,
optionally, a leader sequence (Better et al., Science 240:1041-43
(1988)). The sequence of this construct can be confirmed by
automated sequencing. The plasmid can then be transformed into E.
coli strain MC1061 using standard procedures employing CaCl2
incubation and heat shock treatment of the bacteria (Sambrook et
al., supra). The transformed bacteria can be grown in LB medium
supplemented with carbenicillin, and production of the expressed
protein can be induced by growth in a suitable medium. If present,
the leader sequence can effect secretion of the peptide and be
cleaved during secretion.
[0270] Mammalian host systems for the expression of recombinant
peptides and peptibodies are well known to those of skill in the
art. Host cell strains can be chosen for a particular ability to
process the expressed protein or produce certain post-translation
modifications that will be useful in providing protein activity.
Such modifications of the protein include, but are not limited to,
acetylation, carboxylation, glycosylation, phosphorylation,
lipidation and acylation. Different host cells such as CHO, HeLa,
MDCK, 293, WI38, and the like have specific cellular machinery and
characteristic mechanisms for such post-translational activities
and can be chosen to ensure the correct modification and processing
of the introduced, foreign protein.
[0271] It is preferable that transformed cells be used for
long-term, high-yield protein production. Once such cells are
transformed with vectors that contain selectable markers as well as
the desired expression cassette, the cells can be allowed to grow
for 1-2 days in an enriched media before they are switched to
selective media. The selectable marker is designed to allow growth
and recovery of cells that successfully express the introduced
sequences. Resistant clumps of stably transformed cells can be
proliferated using tissue culture techniques appropriate to the
cell line employed.
[0272] A number of selection systems can be used to recover the
cells that have been transformed for recombinant protein
production. Such selection systems include, but are not limited to,
HSV thymidine kinase, hypoxanthine-guanine
phosphoribosyltransferase and adenine phosphoribosyltransferase
genes, in tk-, hgprt- or aprt-cells, respectively. Also,
anti-metabolite resistance can be used as the basis of selection
for dhfr which confers resistance to methotrexate; gpt which
confers resistance to mycophenolic acid; neo which confers
resistance to the aminoglycoside G418 and confers resistance to
chlorsulfuron; and hygro which confers resistance to hygromycin.
Additional selectable genes that may be useful include trpB, which
allows cells to utilize indole in place of tryptophan, or hisD,
which allows cells to utilize histinol in place of histidine.
Markers that give a visual indication for identification of
transformants include anthocyanins, .beta.-glucuronidase and its
substrate, GUS, and luciferase and its substrate, luciferin.
Purification and Refolding of Binding Agents
[0273] In some cases, the binding agents such as the peptides
and/or peptibodies of this invention may need to be "refolded" and
oxidized into a proper tertiary structure and disulfide linkages
generated in order to be biologically active. Refolding can be
accomplished using a number of procedures well known in the art.
Such methods include, for example, exposing the solubilized
polypeptide agent to a pH usually above 7 in the presence of a
chaotropic agent. The selection of chaotrope is similar to the
choices used for inclusion body solubilization, however a chaotrope
is typically used at a lower concentration. Exemplary chaotropic
agents are guanidine and urea. In most cases, the
refolding/oxidation solution will also contain a reducing agent
plus its oxidized form in a specific ratio to generate a particular
redox potential which allows for disulfide shuffling to occur for
the formation of cysteine bridges. Some commonly used redox couples
include cysteine/cystamine, glutathione/dithiobisGSH, cupric
chloride, dithiothreitol DTT/dithiane DTT, and 2-mercaptoethanol
(bME)/dithio-bME. In many instances, a co-solvent may be used to
increase the efficiency of the refolding. Commonly used cosolvents
include glycerol, polyethylene glycol of various molecular weights,
and arginine.
[0274] It may be desirable to purify the peptides and peptibodies
of the present invention. Protein purification techniques are well
known to those of skill in the art. These techniques involve, at
one level, the crude fractionation of the proteinaceous and
non-proteinaceous fractions. Having separated the peptide and/or
peptibody from other proteins, the peptide or polypeptide of
interest can be further purified using chromatographic and
electrophoretic techniques to achieve partial or complete
purification (or purification to homogeneity). Analytical methods
particularly suited to the preparation of peptibodies and peptides
or the present invention are ion-exchange chromatography, exclusion
chromatography; polyacrylamide gel electrophoresis; isoelectric
focusing. A particularly efficient method of purifying peptides is
fast protein liquid chromatography or even HPLC.
[0275] Certain aspects of the present invention concern the
purification, and in particular embodiments, the substantial
purification, of a peptibody or peptide of the present invention.
The term "purified peptibody or peptide" as used herein, is
intended to refer to a composition, isolatable from other
components, wherein the peptibody or peptide is purified to any
degree relative to its naturally-obtainable state. A purified
peptide or peptibody therefore also refers to a peptibody or
peptide that is free from the environment in which it may naturally
occur.
[0276] Generally, "purified" will refer to a peptide or peptibody
composition that has been subjected to fractionation to remove
various other components, and which composition substantially
retains its expressed biological activity. Where the term
"substantially purified" is used, this designation will refer to a
peptide or peptibody composition in which the peptibody or peptide
forms the major component of the composition, such as constituting
about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or
more of the proteins in the composition.
[0277] Various methods for quantifying the degree of purification
of the peptide or peptibody will be known to those of skill in the
art in light of the present disclosure. These include, for example,
determining the specific binding activity of an active fraction, or
assessing the amount of peptide or peptibody within a fraction by
SDS/PAGE analysis. A preferred method for assessing the purity of a
peptide or peptibody fraction is to calculate the binding activity
of the fraction, to compare it to the binding activity of the
initial extract, and to thus calculate the degree of purification,
herein assessed by a "-fold purification number." The actual units
used to represent the amount of binding activity will, of course,
be dependent upon the particular assay technique chosen to follow
the purification and whether or not the peptibody or peptide
exhibits a detectable binding activity.
[0278] Various techniques suitable for use in purification will be
well known to those of skill in the art. These include, for
example, precipitation with ammonium sulphate, PEG, antibodies
(immunoprecipitation) and the like or by heat denaturation,
followed by centrifugation; chromatography steps such as affinity
chromatography (e.g., Protein-A-Sepharose), ion exchange, gel
filtration, reverse phase, hydroxylapatite and affinity
chromatography; isoelectric focusing; gel electrophoresis; and
combinations of such and other techniques. As is generally known in
the art, it is believed that the order of conducting the various
purification steps may be changed, or that certain steps may be
omitted, and still result in a suitable method for the preparation
of a substantially purified binding agent.
[0279] There is no general requirement that the binding agents of
the present invention always be provided in their most purified
state. Indeed, it is contemplated that less substantially purified
binding agent products will have utility in certain embodiments.
Partial purification may be accomplished by using fewer
purification steps in combination, or by utilizing different forms
of the same general purification scheme. For example, it is
appreciated that a cation-exchange column chromatography performed
utilizing an HPLC apparatus will generally result in a greater
"-fold" purification than the same technique utilizing a
low-pressure chromatography system. Methods exhibiting a lower
degree of relative purification may have advantages in total
recovery of the peptide or peptibody, or in maintaining binding
activity of the peptide or peptibody.
[0280] It is known that the migration of a peptide or polypeptide
can vary, sometimes significantly, with different conditions of
SDS/PAGE (Capaldi et al., Biochem Biophys Res Comm, 76: 425
(1977)). It will therefore be appreciated that under differing
electrophoresis conditions, the apparent molecular weights of
purified or partially purified binding agent expression products
may vary.
Activity of Myostatin Binding Agents
[0281] After the construction of the binding agents of the present
invention, they are tested for their ability to bind myostatin and
inhibit or block myostatin activity. Any number of assays or animal
tests may be used to determine the ability of the agent to inhibit
or block myostatin activity. Several assays used for characterizing
the peptides and peptibodies of the present invention are described
in the Examples below. One assay is the C2C12 pMARE-luc assay which
makes use of a myostatin-responsive cell line (C2C12 myoblasts)
transfected with a luciferase reporter vector containing
myostatin/activin response elements (MARE). Exemplary peptibodies
are assayed by pre-incubating a series of peptibody dilutions with
myostatin, and then exposing the cells to the incubation mixture.
The resulting luciferase activity is determined, and a titration
curve is generated from the series of peptibody dilutions. The
IC.sub.50 (the concentration of peptibody to achieve 50% inhibition
of myostatin activity as measured by luciferase activity) was then
determined A second assay described below is a BIAcore.RTM. assay
to determine the kinetic parameters k.sub.a (association rate
constant), k.sub.d (dissociation rate constant), and K.sub.D
(dissociation equilibrium constant) for the myostatin binding
agents. Lower dissociation equilibrium constants (K.sub.D,
expressed in nM) indicated a greater affinity of the peptibody for
myostatin. Additional assays include blocking assays, to determine
whether a binding agent such as a peptibody is neutralizing
(prevents binding of myostatin to its receptor), or
non-neutralizing (does not prevent binding of myostatin to its
receptor); selectivity assays, which determine if the binding
agents of the present invention bind selectively to myostatin and
not to other TGF.beta. family members; and KinEx A.TM. assays or
solution-based equilibrium assays, which also determine K.sub.D and
are considered to be more sensitive in some circumstances. These
assays are described in Example 3.
[0282] FIG. 1 shows the IC.sub.50 of a peptide compared with the
IC.sub.50 of the peptibody form of the peptide. This demonstrates
that the peptibody is significantly more effective at inhibiting
myostatin activity than the peptide alone. In addition,
affinity-matured peptibodies generally exhibit improved IC.sub.50
and K.sub.D values compared with the parent peptides and
peptibodies. The IC.sub.50 values for a number of exemplary
affinity matured peptibodies are shown in Table VII, Example 7
below. Additionally, in some instances, making a 2.times. version
of a peptibody, where two peptides are attached in tandem, increase
the activity of the peptibody both in vitro and in vivo.
[0283] In vivo activities are demonstrated in the Examples below.
The activities of the binding agents include anabolic activity
increasing lean muscle mass in animal models, as well as decreasing
the fat mass with respect to total body weight in treated animal
models, and increasing muscular strength in animal models.
Uses of the Myostatin Binding Agents
[0284] The myostatin binding agents of the present invention bind
to myostatin and block or inhibit myostatin signaling within
targeted cells. The present invention provides methods and reagents
for reducing the amount or activity of myostatin in an animal by
administering an effective dosage of one or more myostatin binding
agents to the animal. In one aspect, the present invention provides
methods and reagents for treating myostatin-related disorders in an
animal comprising administering an effective dosage of one or more
binding agents to the animal. These myostatin-related disorders
include but are not limited to various forms of muscle wasting, as
well as metabolic disorders such as diabetes and related disorders,
and bone degenerative diseases such as osteoporosis.
[0285] As shown in the Example 8 below, exemplary peptibodies of
the present invention dramatically increases lean muscle mass in
the CD1 nu/nu mouse model. This in vivo activity correlates to the
in vitro binding and inhibitory activity described below for the
same peptibodies.
[0286] Muscle wasting disorders include dystrophies such as
Duchenne's muscular dystrophy, progressive muscular dystrophy,
Becker's type muscular dystrophy, Dejerine-Landouzy muscular
dystrophy, Erb's muscular dystrophy, and infantile neuroaxonal
muscular dystrophy. For example, blocking myostatin through use of
antibodies in vivo improved the dystrophic phenotype of the mdx
mouse model of Duchenne muscular dystrophy (Bogdanovich et al,
Nature 420, 28 (2002)). The peptibodies of the present invention
increase lean muscle mass as a percentage of body weight and
decrease fat mass as percentage of body weight when administered to
an aged mdx mouse model.
[0287] Additional muscle wasting disorders arise from chronic
disease such as amyotrophic lateral sclerosis, congestive
obstructive pulmonary disease, cancer, AIDS, renal failure, and
rheumatoid arthritis. For example, cachexia or muscle wasting and
loss of body weight was induced in athymic nude mice by a
systemically administered myostatin (Zimmers et al., supra). In
another example, serum and intramuscular concentrations of
myostatin-immunoreactive protein was found to be increased in men
exhibiting AIDS-related muscle wasting and was inversely related to
fat-free mass (Gonzalez-Cadavid et al., PNAS USA 95: 14938-14943
(1998)). Additional conditions resulting in muscle wasting may
arise from inactivity due to disability such as confinement in a
wheelchair, prolonged bedrest due to stroke, illness, spinal chord
injury, bone fracture or trauma, and muscular atrophy in a
microgravity environment (space flight). For example, plasma
myostatin immunoreactive protein was found to increase after
prolonged bedrest (Zachwieja et al. J Gravit Physiol. 6(2):11
(1999). It was also found that the muscles of rats exposed to a
microgravity environment during a space shuttle flight expressed an
increased amount of myostatin compared with the muscles of rats
which were not exposed (Lalani et al., J. Endocrin 167 (3):417-28
(2000)).
[0288] In addition, age-related increases in fat to muscle ratios,
and age-related muscular atrophy appear to be related to myostatin.
For example, the average serum myostatin-immunoreactive protein
increased with age in groups of young (19-35 yr old), middle-aged
(36-75 yr old), and elderly (76-92 yr old) men and women, while the
average muscle mass and fat-free mass declined with age in these
groups (Yarasheski et al. J Nutr Aging 6(5):343-8 (2002)). It has
also been shown that myostatin gene knockout in mice increased
myogenesis and decreased adipogenesis (Lin et al., Biochem Biophys
Res Commun 291(3):701-6 (2002), resulting in adults with increased
muscle mass and decreased fat accumulation and leptin secretion.
Exemplary peptibodies improve the lean muscle mass to fat ratio in
aged mdx mice as shown below.
[0289] In addition, myostatin has now been found to be expressed at
low levels in heart muscle and expression is upregulated in
cardiomyocytes after infarct (Sharma et al., J Cell Physiol. 180
(1):1-9 (1999)). Therefore, reducing myostatin levels in the heart
muscle may improve recovery of heart muscle after infarct.
[0290] Myostatin also appears to influence metabolic disorders
including type 2 diabetes, noninsulin-dependent diabetes mellitus,
hyperglycemia, and obesity. For example, lack of myostatin has been
shown to improve the obese and diabetic phenotypes of two mouse
models (Yen et al. supra). It has been demonstrated in the Examples
below that decreasing myostatin activity by administering the
inhibitors of the present invention will decrease the fat to muscle
ratio in an animal, including aged animal models. Therefore,
decreasing fat composition by administering the inhibitors of the
present invention will improve diabetes, obesity, and hyperglycemic
conditions in animals.
[0291] In addition, increasing muscle mass by reducing myostatin
levels may improve bone strength and reduce osteoporosis and other
degenerative bone diseases. It has been found, for example, that
myostatin-deficient mice showed increased mineral content and
density of the mouse humerus and increased mineral content of both
trabecular and cortical bone at the regions where the muscles
attach, as well as increased muscle mass (Hamrick et al. Calcif
Tissue Int 71(1):63-8 (2002)).
[0292] The present invention also provides methods and reagents for
increasing muscle mass in food animals by administering an
effective dosage of the myostatin binding agent to the animal.
Since the mature C-terminal myostatin polypeptide is identical in
all species tested, myostatin binding agents would be expected to
be effective for increasing muscle mass and reducing fat in any
agriculturally important species including cattle, chicken,
turkeys, and pigs.
[0293] The binding agents of the present invention may be used
alone or in combination with other therapeutic agents to enhance
their therapeutic effects or decrease potential side effects. The
binding agents of the present invention possess one or more
desirable but unexpected combination of properties to improve the
therapeutic value of the agents. These properties include increased
activity, increased solubility, reduced degradation, increased
half-life, reduced toxicity, and reduced immunogenicity. Thus the
binding agents of the present invention are useful for extended
treatment regimes. In addition, the properties of hydrophilicity
and hydrophobicity of the compounds of the invention are well
balanced, thereby enhancing their utility for both in vitro and
especially in vivo uses. Specifically, compounds of the invention
have an appropriate degree of solubility in aqueous media that
permits absorption and bioavailability in the body, while also
having a degree of solubility in lipids that permits the compounds
to traverse the cell membrane to a putative site of action, such as
a particular muscle mass.
[0294] The binding agents of the present invention are useful for
treating a "subject" or any animal, including humans, when
administered in an effective dosage in a suitable composition.
[0295] In addition, the mystatin binding agents of the present
invention are useful for detecting and quantitating myostatin in a
number of assays. These assays are described in more detail
below.
[0296] In general, the binding agents of the present invention are
useful as capture agents to bind and immobilize myostatin in a
variety of assays, similar to those described, for example, in
Asai, ed., Methods in Cell Biology, 37, Antibodies in Cell Biology,
Academic Press, Inc., New York (1993). The binding agent may be
labeled in some manner or may react with a third molecule such as
an anti-binding agent antibody which is labeled to enable myostatin
to be detected and quantitated. For example, a binding agent or a
third molecule can be modified with a detectable moiety, such as
biotin, which can then be bound by a fourth molecule, such as
enzyme-labeled streptavidin, or other proteins. (Akerstrom, J
Immunol 135:2589 (1985); Chaubert, Mod Pathol 10:585 (1997)).
[0297] Throughout any particular assay, incubation and/or washing
steps may be required after each combination of reagents.
Incubation steps can vary from about 5 seconds to several hours,
preferably from about 5 minutes to about 24 hours. However, the
incubation time will depend upon the assay format, volume of
solution, concentrations, and the like. Usually, the assays will be
carried out at ambient temperature, although they can be conducted
over a range of temperatures.
Non-Competitive Binding Assays:
[0298] Binding assays can be of the non-competitive type in which
the amount of captured myostatin is directly measured. For example,
in one preferred "sandwich" assay, the binding agent can be bound
directly to a solid substrate where it is immobilized. These
immobilized agents then bind to myostatin present in the test
sample. The immobilized myostatin is then bound with a labeling
agent, such as a labeled antibody against myostatin, which can be
detected. In another preferred "sandwich" assay, a second agent
specific for the binding agent can be added which contains a
detectable moiety, such as biotin, to which a third labeled
molecule can specifically bind, such as streptavidin. (See, Harlow
and Lane, Antibodies, A Laboratory Manual, Ch 14, Cold Spring
Harbor Laboratory, NY (1988), which is incorporated herein by
reference).
Competitive Binding Assays:
[0299] Binding assays can be of the competitive type. The amount of
myostatin present in the sample is measured indirectly by measuring
the amount of myostatin displaced, or competed away, from a binding
agent by the myostatin present in the sample. In one preferred
competitive binding assay, a known amount of myostatin, usually
labeled, is added to the sample and the sample is then contacted
with the binding agent. The amount of labeled myostatin bound to
the binding agent is inversely proportional to the concentration of
myostatin present in the sample, (following the protocols found in,
for example Harlow and Lane, Antibodies, A Laboratory Manual, Ch
14, pp. 579-583, supra).
[0300] In another preferred competitive binding assay, the binding
agent is immobilized on a solid substrate. The amount of myostastin
bound to the binding agent may be determined either by measuring
the amount of myostatin present in a myostatin/binding agent
complex, or alternatively by measuring the amount of remaining
uncomplexed myostatin.
Other Binding Assays
[0301] The present invention also provides Western blot methods to
detect or quantify the presence of myostatin in a sample. The
technique generally comprises separating sample proteins by gel
electrophoresis on the basis of molecular weight and transferring
the proteins to a suitable solid support, such as nitrocellulose
filter, a nylon filter, or derivatized nylon filter. The sample is
incubated with the binding agents or fragments thereof that bind
myostatin and the resulting complex is detected. These binding
agents may be directly labeled or alternatively may be subsequently
detected using labeled antibodies that specifically bind to the
binding agent.
Diagnostic Assays
[0302] The binding agents or fragments thereof of the present
invention may be useful for the diagnosis of conditions or diseases
characterized by increased amounts of myostatin. Diagnostic assays
for high levels of myostatin include methods utilizing a binding
agent and a label to detect myostatin in human body fluids,
extracts of cells or specific tissue extracts. For example, serum
levels of myostatin may be measured in an individual over time to
determine the onset of muscle wasting associated with aging or
inactivity, as described, for example, in Yarasheski et al., supra.
Increased myostatin levels were shown to correlate with average
decreased muscle mass and fat-free mass in groups of men and women
of increasing ages (Yarasheski et al., supra). The binding agents
of the present invention may be useful for monitoring increases or
decreases in the levels of myostatin with a given individual over
time, for example. The binding agents can be used in such assays
with or without modification. In a preferred diagnostic assay, the
binding agents will be labeled by attaching, e.g., a label or a
reporter molecule. A wide variety of labels and reporter molecules
are known, some of which have been already described herein. In
particular, the present invention is useful for diagnosis of human
disease.
[0303] A variety of protocols for measuring myostatin proteins
using binding agents of myostatin are known in the art. Examples
include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay
(RIA) and fluorescence activated cell sorting (FACS).
[0304] For diagnostic applications, in certain embodiments the
binding agents of the present invention typically will be labeled
with a detectable moiety. The detectable moiety can be any one that
is capable of producing, either directly or indirectly, a
detectable signal. For example, the detectable moiety may be a
radioisotope, such as .sup.3H, .sup.14C, .sup.35S, or .sup.125I, a
fluorescent or chemiluminescent compound, such as fluorescein
isothiocyanate, rhodamine, or luciferin; or an enzyme, such as
alkaline phosphatase, .beta.galactosidase, or horseradish
peroxidase (Bayer et al., Meth Enz, 184: 138 (1990)).
Pharmaceutical Compositions
[0305] Pharmaceutical compositions of myostatin binding agents such
as peptibodies described herein are within the scope of the present
invention. Such compositions comprise a therapeutically or
prophylactically effective amount of a myostatin binding agent,
fragment, variant, or derivative thereof as described herein, in
admixture with a pharmaceutically acceptable agent. In a preferred
embodiment, pharmaceutical compositions comprise antagonist binding
agents that inhibit myostatin partially or completely in admixture
with a pharmaceutically acceptable agent. Typically, the myostatin
binding agents will be sufficiently purified for administration to
an animal.
[0306] The pharmaceutical composition may contain formulation
materials for modifying, maintaining or preserving, for example,
the pH, osmolarity, viscosity, clarity, color, isotonicity, odor,
sterility, stability, rate of dissolution or release, adsorption or
penetration of the composition. Suitable formulation materials
include, but are not limited to, amino acids (such as glycine,
glutamine, asparagine, arginine or lysine); antimicrobials;
antioxidants (such as ascorbic acid, sodium sulfite or sodium
hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl,
citrates, phosphates, other organic acids); bulking agents (such as
mannitol or glycine), chelating agents (such as ethylenediamine
tetraacetic acid (EDTA)); complexing agents (such as caffeine,
polyvinylpyrrolidone, beta-cyclodextrin or
hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides;
disaccharides and other carbohydrates (such as glucose, mannose, or
dextrins); proteins (such as serum albumin, gelatin or
immunoglobulins); coloring; flavoring and diluting agents;
emulsifying agents; hydrophilic polymers (such as
polyvinylpyrrolidone); low molecular weight polypeptides;
salt-forming counterions (such as sodium); preservatives (such as
benzalkonium chloride, benzoic acid, salicylic acid, thimerosal,
phenethyl alcohol, methylparaben, propylparaben, chlorhexidine,
sorbic acid or hydrogen peroxide); solvents (such as glycerin,
propylene glycol or polyethylene glycol); sugar alcohols (such as
mannitol or sorbitol); suspending agents; surfactants or wetting
agents (such as pluronics, PEG, sorbitan esters, polysorbates such
as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin,
cholesterol, tyloxapal); stability enhancing agents (sucrose or
sorbitol); tonicity enhancing agents (such as alkali metal halides
(preferably sodium or potassium chloride, mannitol sorbitol);
delivery vehicles; diluents; excipients and/or pharmaceutical
adjuvants. (Remington's Pharmaceutical Sciences, 18.sup.th Edition,
A. R. Gennaro, ed., Mack Publishing Company, 1990).
[0307] The optimal pharmaceutical composition will be determined by
one skilled in the art depending upon, for example, the intended
route of administration, delivery format, and desired dosage. See
for example, Remington's Pharmaceutical Sciences, supra. Such
compositions may influence the physical state, stability, rate of
in vivo release, and rate of in vivo clearance of the binding
agent.
[0308] The primary vehicle or carrier in a pharmaceutical
composition may be either aqueous or non-aqueous in nature. For
example, a suitable vehicle or carrier may be water for injection,
physiological saline solution or artificial cerebrospinal fluid,
possibly supplemented with other materials common in compositions
for parenteral administration. Neutral buffered saline or saline
mixed with serum albumin are further exemplary vehicles. Other
exemplary pharmaceutical compositions comprise Tris buffer of about
pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may
further include sorbitol or a suitable substitute therefore. In one
embodiment of the present invention, binding agent compositions may
be prepared for storage by mixing the selected composition having
the desired degree of purity with optional formulation agents
(Remington's Pharmaceutical Sciences, supra) in the form of a
lyophilized cake or an aqueous solution. Further, the binding agent
product may be formulated as a lyophilizate using appropriate
excipients such as sucrose.
[0309] The pharmaceutical compositions can be selected for
parenteral delivery. Alternatively, the compositions may be
selected for inhalation or for enteral delivery such as orally,
aurally, opthalmically, rectally, or vaginally. The preparation of
such pharmaceutically acceptable compositions is within the skill
of the art.
[0310] The formulation components are present in concentrations
that are acceptable to the site of administration. For example,
buffers are used to maintain the composition at physiological pH or
at slightly lower pH, typically within a pH range of from about 5
to about 8.
[0311] When parenteral administration is contemplated, the
therapeutic compositions for use in this invention may be in the
form of a pyrogen-free, parenterally acceptable aqueous solution
comprising the desired binding agent in a pharmaceutically
acceptable vehicle. A particularly suitable vehicle for parenteral
injection is sterile distilled water in which a binding agent is
formulated as a sterile, isotonic solution, properly preserved. Yet
another preparation can involve the formulation of the desired
molecule with an agent, such as injectable microspheres,
bio-erodible particles, polymeric compounds (polylactic acid,
polyglycolic acid), beads, or liposomes, that provides for the
controlled or sustained release of the product which may then be
delivered via a depot injection. Hyaluronic acid may also be used,
and this may have the effect of promoting sustained duration in the
circulation. Other suitable means for the introduction of the
desired molecule include implantable drug delivery devices.
[0312] In another aspect, pharmaceutical formulations suitable for
parenteral administration may be formulated in aqueous solutions,
preferably in physiologically compatible buffers such as Hanks'
solution, ringer's solution, or physiologically buffered saline.
Aqueous injection suspensions may contain substances that increase
the viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Additionally, suspensions of the
active compounds may be prepared as appropriate oily injection
suspensions. Suitable lipophilic solvents or vehicles include fatty
oils, such as sesame oil, or synthetic fatty acid esters, such as
ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic
amino polymers may also be used for delivery. Optionally, the
suspension may also contain suitable stabilizers or agents to
increase the solubility of the compounds and allow for the
preparation of highly concentrated solutions. In another
embodiment, a pharmaceutical composition may be formulated for
inhalation. For example, a binding agent may be formulated as a dry
powder for inhalation. Polypeptide or nucleic acid molecule
inhalation solutions may also be formulated with a propellant for
aerosol delivery. In yet another embodiment, solutions may be
nebulized. Pulmonary administration is further described in PCT
Application No. PCT/US94/001875, which describes pulmonary delivery
of chemically modified proteins.
[0313] It is also contemplated that certain formulations may be
administered orally. In one embodiment of the present invention,
binding agent molecules that are administered in this fashion can
be formulated with or without those carriers customarily used in
the compounding of solid dosage forms such as tablets and capsules.
For example, a capsule may be designed to release the active
portion of the formulation at the point in the gastrointestinal
tract when bioavailability is maximized and pre-systemic
degradation is minimized. Additional agents can be included to
facilitate absorption of the binding agent molecule. Diluents,
flavorings, low melting point waxes, vegetable oils, lubricants,
suspending agents, tablet disintegrating agents, and binders may
also be employed.
[0314] Pharmaceutical compositions for oral administration can also
be formulated using pharmaceutically acceptable carriers well known
in the art in dosages suitable for oral administration. Such
carriers enable the pharmaceutical compositions to be formulated as
tablets, pills, dragees, capsules, liquids, gels, syrups, slurries,
suspensions, and the like, for ingestion by the patient.
[0315] Pharmaceutical preparations for oral use can be obtained
through combining active compounds with solid excipient and
processing the resultant mixture of granules (optionally, after
grinding) to obtain tablets or dragee cores. Suitable auxiliaries
can be added, if desired. Suitable excipients include carbohydrate
or protein fillers, such as sugars, including lactose, sucrose,
mannitol, and sorbitol; starch from corn, wheat, rice, potato, or
other plants; cellulose, such as methyl cellulose,
hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose;
gums, including arabic and tragacanth; and proteins, such as
gelatin and collagen. If desired, disintegrating or solubilizing
agents may be added, such as the cross-linked polyvinyl
pyrrolidone, agar, and alginic acid or a salt thereof, such as
sodium alginate.
[0316] Dragee cores may be used in conjunction with suitable
coatings, such as concentrated sugar solutions, which may also
contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel,
polyethylene glycol, and/or titanium dioxide, lacquer solutions,
and suitable organic solvents or solvent mixtures. Dyestuffs or
pigments may be added to the tablets or dragee coatings for product
identification or to characterize the quantity of active compound,
i.e., dosage.
[0317] Pharmaceutical preparations that can be used orally also
include push-fit capsules made of gelatin, as well as soft, sealed
capsules made of gelatin and a coating, such as glycerol or
sorbitol. Push-fit capsules can contain active ingredients mixed
with fillers or binders, such as lactose or starches, lubricants,
such as talc or magnesium stearate, and, optionally, stabilizers.
In soft capsules, the active compounds may be dissolved or
suspended in suitable liquids, such as fatty oils, liquid, or
liquid polyethylene glycol with or without stabilizers.
[0318] Another pharmaceutical composition may involve an effective
quantity of binding agent in a mixture with non-toxic excipients
that are suitable for the manufacture of tablets. By dissolving the
tablets in sterile water, or other appropriate vehicle, solutions
can be prepared in unit dose form. Suitable excipients include, but
are not limited to, inert diluents, such as calcium carbonate,
sodium carbonate or bicarbonate, lactose, or calcium phosphate; or
binding agents, such as starch, gelatin, or acacia; or lubricating
agents such as magnesium stearate, stearic acid, or talc.
[0319] Additional pharmaceutical compositions will be evident to
those skilled in the art, including formulations involving binding
agent molecules in sustained- or controlled-delivery formulations.
Techniques for formulating a variety of other sustained- or
controlled-delivery means, such as liposome carriers, bio-erodible
microparticles or porous beads and depot injections, are also known
to those skilled in the art. See for example, PCT/US93/00829 that
describes controlled release of porous polymeric microparticles for
the delivery of pharmaceutical compositions. Additional examples of
sustained-release preparations include semipermeable polymer
matrices in the form of shaped articles, e.g. films, or
microcapsules. Sustained release matrices may include polyesters,
hydrogels, polylactides (U.S. Pat. No. 3,773,919, EP 58,481),
copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman
et al., Biopolymers, 22:547-556 (1983),
poly(2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater.
Res., 15:167-277, (1981); Langer et al., Chem. Tech., 12:98-105
(1982)), ethylene vinyl acetate (Langer et al., supra) or
poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release
compositions also include liposomes, which can be prepared by any
of several methods known in the art. See e.g., Eppstein et al.,
PNAS (USA), 82:3688 (1985); EP 36,676; EP 88,046; EP 143,949.
[0320] The pharmaceutical composition to be used for in vivo
administration typically must be sterile. This may be accomplished
by filtration through sterile filtration membranes. Where the
composition is lyophilized, sterilization using this method may be
conducted either prior to or following lyophilization and
reconstitution. The composition for parenteral administration may
be stored in lyophilized form or in solution. In addition,
parenteral compositions generally are placed into a container
having a sterile access port, for example, an intravenous solution
bag or vial having a stopper pierceable by a hypodermic injection
needle.
[0321] Once the pharmaceutical composition has been formulated, it
may be stored in sterile vials as a solution, suspension, gel,
emulsion, solid, or a dehydrated or lyophilized powder. Such
formulations may be stored either in a ready-to-use form or in a
form (e.g., lyophilized) requiring reconstitution prior to
administration.
[0322] In a specific embodiment, the present invention is directed
to kits for producing a single-dose administration unit. The kits
may each contain both a first container having a dried protein and
a second container having an aqueous formulation. Also included
within the scope of this invention are kits containing single and
multi-chambered pre-filled syringes (e.g., liquid syringes and
lyosyringes).
[0323] An effective amount of a pharmaceutical composition to be
employed therapeutically will depend, for example, upon the
therapeutic context and objectives. One skilled in the art will
appreciate that the appropriate dosage levels for treatment will
thus vary depending, in part, upon the molecule delivered, the
indication for which the binding agent molecule is being used, the
route of administration, and the size (body weight, body surface or
organ size) and condition (the age and general health) of the
patient. Accordingly, the clinician may titer the dosage and modify
the route of administration to obtain the optimal therapeutic
effect. A typical dosage may range from about 0.1 mg/kg to up to
about 100 mg/kg or more, depending on the factors mentioned above.
In other embodiments, the dosage may range from 0.1 mg/kg up to
about 100 mg/kg; or 1 mg/kg up to about 100 mg/kg; or 5 mg/kg up to
about 100 mg/kg.
[0324] For any compound, the therapeutically effective dose can be
estimated initially either in cell culture assays or in animal
models such as mice, rats, rabbits, dogs, pigs, or monkeys. An
animal model may also be used to determine the appropriate
concentration range and route of administration. Such information
can then be used to determine useful doses and routes for
administration in humans.
[0325] The exact dosage will be determined in light of factors
related to the subject requiring treatment. Dosage and
administration are adjusted to provide sufficient levels of the
active compound or to maintain the desired effect. Factors that may
be taken into account include the severity of the disease state,
the general health of the subject, the age, weight, and gender of
the subject, time and frequency of administration, drug
combination(s), reaction sensitivities, and response to therapy.
Long-acting pharmaceutical compositions may be administered every 3
to 4 days, every week, or biweekly depending on the half-life and
clearance rate of the particular formulation.
[0326] The frequency of dosing will depend upon the pharmacokinetic
parameters of the binding agent molecule in the formulation used.
Typically, a composition is administered until a dosage is reached
that achieves the desired effect. The composition may therefore be
administered as a single dose, or as multiple doses (at the same or
different concentrations/dosages) over time, or as a continuous
infusion. Further refinement of the appropriate dosage is routinely
made. Appropriate dosages may be ascertained through use of
appropriate dose-response data.
[0327] The route of administration of the pharmaceutical
composition is in accord with known methods, e.g. orally, through
injection by intravenous, intraperitoneal, intracerebral
(intra-parenchymal), intracerebroventricular, intramuscular,
intra-ocular, intraarterial, intraportal, intralesional routes,
intramedullary, intrathecal, intraventricular, transdermal,
subcutaneous, intraperitoneal, intranasal, enteral, topical,
sublingual, urethral, vaginal, or rectal means, by sustained
release systems or by implantation devices. Where desired, the
compositions may be administered by bolus injection or continuously
by infusion, or by implantation device.
[0328] Alternatively or additionally, the composition may be
administered locally via implantation of a membrane, sponge, or
another appropriate material on to which the desired molecule has
been absorbed or encapsulated. Where an implantation device is
used, the device may be implanted into any suitable tissue or
organ, and delivery of the desired molecule may be via diffusion,
timed-release bolus, or continuous administration.
[0329] In some cases, it may be desirable to use pharmaceutical
compositions in an ex vivo manner. In such instances, cells,
tissues, or organs that have been removed from the patient are
exposed to the pharmaceutical compositions after which the cells,
tissues and/or organs are subsequently implanted back into the
patient.
[0330] In other cases, a binding agent of the present invention
such as a peptibody can be delivered by implanting certain cells
that have been genetically engineered, using methods such as those
described herein, to express and secrete the polypeptide. Such
cells may be animal or human cells, and may be autologous,
heterologous, or xenogeneic. Optionally, the cells may be
immortalized. In order to decrease the chance of an immunological
response, the cells may be encapsulated to avoid infiltration of
surrounding tissues. The encapsulation materials are typically
biocompatible, semi-permeable polymeric enclosures or membranes
that allow the release of the protein product(s) but prevent the
destruction of the cells by the patient's immune system or by other
detrimental factors from the surrounding tissues.
[0331] Pharmaceutical compositions containing the binding agents of
the present invention are administered to a subject to treat any
myostatin-related disorders. These include muscle-wasting disorders
including but not limited to muscular dystrophy, muscle wasting in
cancer, AIDS, muscle atrophy, rheumatoid arthritis, renal
failure/uremia, chronic heart failure, prolonged bed-rest, spinal
chord injury, stroke, and aging related sarcopenia. In addition
these compositions are administed to treat obesity, diabetes,
hyperglycemia, and increase bone density,
[0332] The invention having been described, the following examples
are offered by way of illustration, and not limitation.
Example 1
Identification of Myostatin-Binding Peptides
[0333] Three filamentous phage libraries, TN8-IX (5.times.10.sup.9
independent transformants), TN12-I (1.4.times.10.sup.9 independent
transformants), and linear (2.3.times.10.sup.9 independent
transformants) (Dyax Corp.) were used to select for myostatin
binding phage. Each library was incubated on myostatin-coated
surfaces and subjected to different panning conditions:
non-specific elution, and specific elution using recombinant human
activin receptor IIB/Fc chimera (R&D Systems, Inc.,
Minneapolis, Minn.), or myostatin propeptide elution as described
below. For all three libraries, the phages were eluted in a
non-specific manner for the first round of selection, while the
receptor and promyostatin was used in the second and third rounds
of selection. The selection procedures were carried out as
described below.
Preparation of Myostatin
[0334] Myostatin protein was produced recombinantly in the E. coli
K-12 strain 2596 (ATCC #202174) as follows. Polynucleotides
encoding the human promyostatin molecule were cloned into the
pAMG21 expression vector (ATCC No. 98113), which was derived from
expression vector pCFM1656 (ATCC No. 69576) and the expression
vector system described in U.S. Pat. No. 4,710,473, by following
the procedure described in published International Patent
Application WO 00/24782. The polynucleotides encoding promyostatin
were obtained from a mammalian expression vector. The coding region
was amplified using a standard PCR method and the following PCR
primers to introduce the restriction site for NdeI and BamHI.
TABLE-US-00002 5' primer: (Seq ID No: 292)
5'-GAGAGAGAGCATATGAATGAGAACAGTGAGCAAAAAG-3' 3'primer: (Seq ID No:
293) 5'-AGAGAGGGATCCATTATGAGCACCCACAGCGGTC-3'
[0335] The PCR product and vector were digested with both enzymes,
mixed and ligated. The product of the ligation was transformed into
E. coli strain #2596. Single colonies were checked microscopically
for recombinant protein expression in the form of inclusion bodies.
The plasmid was isolated and sequenced through the coding region of
the recombinant gene to verify genetic fidelity.
[0336] Bacterial paste was generated from a 10 L fermentation using
a batch method at 37.degree. C. The culture was induced with HSL at
a cell density of 9.6 OD.sub.600 and harvested six hours later at a
density of 104 OD.sub.600. The paste was stored at -80.degree. C.
E. coli paste expressing promyostatin was lysed in a microfluidizer
at 16,000 psi, centrifuged to isolate the insoluble inclusion body
fraction. Inclusion bodies were resuspended in guanidine
hydrochloride containing dithiothreitol and solubilized at room
temperature. This was then diluted 30 fold in an aqueous buffer.
The refolded promyostatin was then concentrated and buffer
exchanged into 20 mM Tris pH 8.0, and applied to an anion exchange
column. The anion exchange column was eluted with an increasing
sodium chloride gradient. The fractions containing promyostatin
were pooled. The promyostatin produced in E. coli is missing the
first 23 amino acids and begins with a methionine before the
residue 24 asparagine. To produce mature myostatin, the pooled
promyostatin was enzymatically cleaved between the propeptide and
mature myostatin C terminal. The resulting mixture was then applied
to a C4-rpHPLC column using a increasing gradient of acetonitrile
containing 0.1% trifluoroacetic acid. Fractions containing mature
myostatin were pooled and dried in a speed-vac.
[0337] The recombinant mature myostatin produced from E. coli was
tested in the myoblast C2C12 based assay described below and found
to be fully active when compared with recombinant murine myostatin
commercially produced in a mammalian cell system (R&D Systems,
Inc., Minneapolis, Minn.). The E. coli-produced mature myostatin
was used in the phage-display and screening assays described
below.
Preparation of Myostatin-Coated Tubes
[0338] Myostatin was immobilized on 5 ml Immuno.TM. Tubes (NUNC) at
a concentration of 8 ug of myostatin protein in 1 ml of 0.1M sodium
carbonate buffer (pH 9.6). The myostatin-coated Immuno.TM. Tube was
incubated with orbital shaking for 1 hour at room temperature.
Myostatin-coated Immuno.TM. Tube was then blocked by adding 5 ml of
2% milk-PBS and incubating at room temperature for 1 hour with
rotation. The resulting myostatin-coated Immuno.TM. Tube was then
washed three times with PBS before being subjected to the selection
procedures. Additional Immuno.TM. Tubes were also prepared for
negative selections (no myostatin). For each panning condition,
five to ten Immuno.TM. Tubes were subjected to the above procedure
except that the Immuno.TM. Tubes were coated with 1 ml of 2%
BSA-PBS instead of myostatin protein.
Negative Selection
[0339] For each panning condition, about 100 random library
equivalents for TN8-IX and TN12-I libraries (5.times.10.sup.11 pfu
for TN8-IX, and 1.4.times.10.sup.11 pfu for TN12-I) and about 10
random library equivalents for the linear library
(2.3.times.10.sup.10 pfu) were aliquoted from the library stock and
diluted to 1 ml with PBST (PBS with 0.05% Tween-20). The 1 ml of
diluted library stock was added to an Immuno.TM. Tube prepared for
the negative selection, and incubated for 10 minutes at room
temperature with orbital shaking. The phage supernatant was drawn
out and added to the second Immuno.TM. Tube for another negative
selection step. In this way, five to ten negative selection steps
were performed.
Selection for Myostatin Binding
[0340] After the last negative selection step above, the phage
supernatant was added to the prepared myostatin coated Immuno.TM.
Tubes. The Immuno.TM. Tube was incubated with orbital shaking for
one hour at room temperature, allowing specific phage to bind to
myostatin. After the supernatant was discarded, the Immuno.TM. Tube
was washed about 15 times with 2% milk-PBS, 10 times with PBST and
twice with PBS for the three rounds of selection with all three
libraries (TN8-IX, TN12-I, and Linear libraries) except that for
the second round of selections with TN8-1.times. and TN12-I
libraries, the Immuno.TM. Tube was washed about 14 times with 2%
milk-PBS, twice with 2% BSA-PBS, 10 times with PBST and once with
PBS.
Non-Specific Elution
[0341] After the last washing step, the bound phages were eluted
from the Immuno.TM. Tube by adding 1 ml of 100 mM triethylamine
solution (Sigma, St. Louis, Mo.) with 10-minute incubation with
orbital shaking. The pH of the phage containing solution was then
neutralized with 0.5 ml of 1 M Tris-HCl (pH 7.5).
Receptor (Human Activin Receptor) Elution of Bound Phage
[0342] For round 2 and 3, after the last washing step, the bound
phages were eluted from the Immuno.TM. Tube by adding 1 ml of 1
.mu.M of receptor protein (recombinant human activin receptor
IIB/Fc chimera, R&D Systems, Inc., Minneapolis, Minn.) with a
1-hour incubation for each condition.
Propeptide Elution of Bound Phage
[0343] For round 2 and 3, after the last washing step, the bound
phages were eluted from the Immuno.TM. Tube by adding 1 ml of 1
.mu.M propeptide protein (made as described above) with a 1-hour
incubation for each condition.
Phage Amplification
[0344] Fresh E. coli. (XL-1 Blue MRF') culture was grown to
OD.sub.600=0.5 in LB media containing 12.5 ug/ml tetracycline. For
each panning condition, 20 ml of this culture was chilled on ice
and centrifuged. The bacteria pellet was resuspended in 1 ml of the
min A salts solution.
[0345] Each mixture from different elution methods was added to a
concentrated bacteria sample and incubated at 37.degree. C. for 15
minutes. 2 ml of NZCYM media (2.times.NZCYM, 50 ug/ml Ampicillin)
was added to each mixture and incubated at 37.degree. C. for 15
minutes. The resulting 4 ml solution was plated on a large NZCYM
agar plate containing 50 ug/ml ampicillin and incubated overnight
at 37.degree. C.
[0346] Each of the bacteria/phage mixture that was grown overnight
on a large NZCYM agar plate was scraped off in 35 ml of LB media,
and the agar plate was further rinsed with additional 35 ml of LB
media. The resulting bacteria/phage mixture in LB media was
centrifuged to pellet the bacteria away. 50 ul of the phage
supernatant was transferred to a fresh tube, and 12.5 ml of PEG
solution (20% PEG8000, 3.5M ammonium acetate) was added and
incubated on ice for 2 hours to precipitate phages. The
precipitated phages were centrifuged down and resuspended in 6 ml
of the phage resuspension buffer (250 mM NaCl, 100 mM Tris pH8, 1
mM EDTA). This phage solution was further purified by centrifuging
away the remaining bacteria and precipitating the phage for the
second time by adding 1.5 ml of the PEG solution. After a
centrifugation step, the phage pellet was resuspended in 400 ul of
PBS. This solution was subjected to a final centrifugation to rid
of remaining bacteria debris. The resulting phage preparation was
titered by a standard plaque formation assay (Molecular Cloning,
Maniatis et al., 3.sup.rd Edition).
Additional Rounds of Selection and Amplification
[0347] In the second round, the amplified phage (10.sup.11 pfu)
from the first round was used as the input phage to perform the
selection and amplification steps. The amplified phage (10.sup.11
pfu) from the second round in turn was used as the input phage to
perform third round of selection and amplification. After the
elution steps of the third round, a small fraction of the eluted
phage was plated out as in the plaque formation assay above.
Individual plaques were picked and placed into 96 well microtiter
plates containing 100 ul of TE buffer in each well. These master
plates were incubated at 4.degree. C. overnight to allow phages to
elute into the TE buffer.
Clonal Analysis
Phage ELISA
[0348] The phage clones were subjected to phage ELISA and then
sequenced. The sequences were ranked as discussed below.
[0349] Phage ELISA was performed as follows. An E. Coli XL-1 Blue
MRF' culture was grown until OD.sub.600 reached 0.5. 30 ul of this
culture was aliquoted into each well of a 96 well microtiter plate.
10 ul of eluted phage was added to each well and allowed to infect
bacteria for 15 min at room temperature. About 120 ul of LB media
containing 12.5 ug/ml of tetracycline and 50 ug/ml of ampicillin
were added to each well. The microtiter plate was then incubated
with shaking overnight at 37.degree. C. Myostatin protein (2 ug/ml
in 0.1M sodium carbonate buffer, pH 9.6) was allowed to coat onto a
96 well Maxisorp.TM. plates (NUNC) overnight at 4.degree. C. As a
control, a separate Maxisorp.TM. plate was coated with 2% BSA
prepared in PBS.
[0350] On the following day, liquid in the protein coated
Maxisorp.TM. plates was discarded, washed three times with PBS and
each well was blocked with 300 ul of 2% milk solution at room
temperature for 1 hour. The milk solution was discarded, and the
wells were washed three times with the PBS solution. After the last
washing step, about 50 ul of PBST-4% milk was added to each well of
the protein-coated Maxisorp.TM. plates. About 50 ul of overnight
cultures from each well in the 96 well microtiter plate was
transferred to the corresponding wells of the myostatin coated
plates as well as the control 2% BSA coated plates. The 100 ul
mixture in the two kinds of plates were incubated for 1 hour at
room temperature. The liquid was discarded from the Maxisorp.TM.
plates, and the wells were washed about three times with PBST
followed by two times with PBS. The HRP-conjugated anti-M13
antibody (Amersham Pharmacia Biotech) was diluted to about 1:7,500,
and 100 ul .quadrature. of the diluted solution was added to each
well of the Maxisorp.TM. plates for 1 hour incubation at room
temperature. The liquid was again discarded and the wells were
washed about three times with PBST followed by two time with PBS.
100 ul of LumiGlo.TM. Chemiluminescent substrate (KPL) was added to
each well of the Maxisorp.TM. plates and incubated for about 5
minutes for reaction to occur. The chemiluminescent unit of the
Maxisorp.TM. plates was read on a plate reader (Lab System).
Sequencing of the Phage Clones
[0351] For each phage clone, the sequencing template was prepared
by a PCR method. The following oligonucleotide pair was used to
amplify a 500 nucleotide fragment: primer #1:
5'-CGGCGCAACTATCGGTATCAAGCTG-3' (Seq ID No: 294) and primer #2:
5'-CATGTACCGTAACACTGAGTTTCGTC-3'(Seq ID No: 295). The following
mixture was prepared for each clone.
TABLE-US-00003 Reagents Volume (.mu.L)/tube distilled H.sub.2O
26.25 50% glycerol 10 10X PCR Buffer (w/o MgCl.sub.2) 5 25 mM
MgCl.sub.2 4 10 mM dNTP mix 1 100 .mu.M primer 1 0.25 100 .mu.M
primer 2 0.25 Taq polymerase 0.25 Phage in TE (section 4) 3 Final
reaction volume 50
[0352] A thermocycler (GeneAmp PCR System 9700, Applied Biosystem)
was used to run the following program: [94.degree. C. for 5 min;
94.degree. C. for 30 sec, 55.degree. C. for 30 sec, 72.degree. C.
for 45 sec.].times.30 cycles; 72.degree. C. for 7 min; cool to
4.degree. C. The PCR product from each reaction was cleaned up
using the QIAquick Multiwell PCR Purification kit (Qiagen),
following the manufacturer's protocol. The PCR cleaned up product
was checked by running 10 ul of each PCR reaction mixed with 1 ul
of dye (10.times.BBXS agarose gel loading dye) on a 1% agarose gel.
The remaining product was then sequenced using the ABI 377
Sequencer (Perkin Elmer) following the manufacturer recommended
protocol.
Sequence Ranking and Analysis
[0353] The peptide sequences that were translated from the
nucleotide sequences were correlated to ELISA data. The clones that
showed high chemiluminescent units in the myostatin-coated wells
and low chemiluminescent units in the 2% BSA-coated wells were
identified. The sequences that occurred multiple times were
identified. Candidate sequences chosen based on these criteria were
subjected to further analysis as peptibodies. Approximately 1200
individual clones were analyzed. Of these approximately 132
peptides were chosen for generating the peptibodies of the present
invention. These are shown in Table I below. The peptides having
SEQ ID NO: 1 to 129 were used to generate peptibodies of the same
name. The peptides having SEQ ID NO: 130 to 141 shown in Table 1
comprise two or more peptides from SEQ ID NO: 1 to 132 attached by
a linker sequence. SEQ ID NO: 130 to 141 were also used to generate
peptibodies of the same name.
[0354] Consensus sequences were determined for the TN-8 derived
group of peptides. These are as follows:
TABLE-US-00004 KDXCXXWHWMCKPX (Seq ID No: 142) WXXCXXXGFWCXNX (Seq
ID No: 143) IXGCXWWDXXCYXX (Seq ID No: 144) XXWCVSPXWFCXXX (Seq ID
No: 145) XXXCPWFAXXCVDW (Seq ID No: 146)
For all of the above consensus sequences, the underlined "core
sequences" from each consensus sequence are the amino acid which
always occur at that position. "X" refers to any naturally
occurring or modified amino acid. The two cysteines contained with
the core sequences were fixed amino acids in the TN8-IX
library.
TABLE-US-00005 TABLE I SEQ. PEPTIDE PEPTIBODY NAME ID No SEQUENCE
Myostatin-TN8-Con1 1 KDKCKMWHWMCKPP Myostatin-TN8-Con2 2
KDLCAMWHWMCKPP Myostatin-TN8-Con3 3 KDLCKMWKWMCKPP
Myostatin-TN8-Con4 4 KDLCKMWHWMCKPK Myostatin-TN8-Con5 5
WYPCYEFHFWCYDL Myostatin-TN8-Con6 6 WYPCYEGHFWCYDL
Myostatin-TN8-Con7 7 IFGCKWWDVQCYQF Myostatin-TN8-Con8 8
IFGCKWWDVDCYQF Myostatin-TN8-Con9 9 ADWCVSPNWFCMVM
Myostatin-TN8-Con10 10 HKFCPWWALFCWDF Myostatin-TN8-1 11
KDLCKMWHWMCKPP Myostatin-TN8-2 12 IDKCAIWGWMCPPL Myostatin-TN8-3 13
WYPCGEFGMWCLNV Myostatin-TN8-4 14 WFTCLWNCDNE Myostatin-TN8-5 15
HTPCPWFAPLCVEW Myostatin-TN8-6 16 KEWCWRWKWMCKPE Myostatin-TN8-7 17
FETCPSWAYFCLDI Myostatin-TN8-8 18 AYKCEANDWGCWWL Myostatin-TN8-9 19
NSWCEDQWHRCWWL Myostatin-TN8-10 20 WSACYAGHFWCYDL Myostatin-TN8-11
21 ANWCVSPNWFCMVM Myostatin-TN8-12 22 WTECYQQEFWCWNL
Myostatin-TN8-13 23 ENTCERWKWMCPPK Myostatin-TN8-14 24
WLPCHQEGFWCMNF Myostatin-TN8-15 25 STMCSQWHWMCNPF Myostatin-TN8-16
26 IFGCHWWDVDCYQF Myostatin-TN8-17 27 IYGCKWWDIQCYDI
Myostatin-TN8-18 28 PDWCIDPDWWCKFW Myostatin-TN8-19 29
QGHCTRWPWMCPPY Myostatin-TN8-20 30 WQECYREGFWCLQT Myostatin-TN8-21
31 WFDCYGPGFKCWSP Myostatin-TN8-22 32 GVRCPKGHLWCLYP
Myostatin-TN8-23 33 HWACGYWPWSCKWV Myostatin-TN8-24 34
GPACHSPWWWCVFG Myostatin-TN8-25 35 TTWCISPMWFCSQQ Myostatin-TN8-26
36 HKFCPPWAIFCWDF Myostatin-TN8-27 37 PDWCVSPRWYCNMW
Myostatin-TN8-28 38 VWKCHWFGMDCEPT Myostatin-TN8-29 39
KKHCQIWTWMCAPK Myostatin-TN8-30 40 WFQCGSTLFWCYNL Myostatin-TN8-31
41 WSPCYDHYFYCYTI Myostatin-TN8-32 42 SWMCGFFKEVCMWV
Myostatin-TN8-33 43 EMLCMIHPVFCNPH Myostatin-TN8-34 44
LKTCNLWPWMCPPL Myostatin-TN8-35 45 VVGCKWYEAWCYNK Myostatin-TN8-36
46 PIHCTQWAWMCPPT Myostatin-TN8-37 47 DSNCPWYFLSCVIF
Myostatin-TN8-38 48 HIWCNLAMMKCVEM Myostatin-TN8-39 49
NLQCIYFLGKCIYF Myostatin-TN8-40 50 AWRCMWFSDVCTPG Myostatin-TN8-41
51 WFRCFLDADWCTSV Myostatin-TN8-42 52 EKICQMWSWMCAPP
Myostatin-TN8-43 53 WFYCHLNKSECTEP Myostatin-TN8-44 54
FWRCAIGIDKCKRV Myostatin-TN8-45 55 NLGCKWYEVWCFTY Myostatin-TN8-46
56 IDLCNMWDGMCYPP Myostatin-TN8-47 57 EMPCNIWGWMCPPV
Myostatin-TN12-1 58 WFRCVLTGIVDWSECFGL Myostatin-TN12-2 59
GFSCTFGLDEFYVDCSPF Myostatin-TN12-3 60 LPWCHDQVNADWGFCMLW
Myostatin-TN12-4 61 YPTCSEKFWIYGQTCVLW Myostatin-TN12-5 62
LGPCPIHHGPWPQYCVYW Myostatin-TN12-6 63 PFPCETHQISWLGHCLSF
Myostatin-TN12-7 64 HWGCEDLMWSWHPLCRRP Myostatin-TN12-8 65
LPLCDADMMPTIGFCVAY Myostatin-TN12-9 66 SHWCETTFWMNYAKCVHA
Myostatin-TN12-10 67 LPKCTHVPFDQGGFCLWY Myostatin-TN12-11 68
FSSCWSPVSRQDMFCVFY Myostatin-TN12-13 69 SHKCEYSGWLQPLCYRP
Myostatin-TN12-14 70 PWWCQDNYVQHMLHCDSP Myostatin-TN12-15 71
WFRCMLMNSFDAFQCVSY Myostatin-TN12-16 72 PDACRDQPWYMFMGCMLG
Myostatin-TN12-17 73 FLACFVEFELCFDS Myostatin-TN12-18 74
SAYCIITESDPYVLCVPL Myostatin-TN12-19 75 PSICESYSTMWLPMCQHN
Myostatin-TN12-20 76 WLDCHDDSWAWTKMCRSH Myostatin-TN12-21 77
YLNCVMMNTSPFVECVFN Myostatin-TN12-22 78 YPWCDGFMIQQGITCMFY
Myostatin-TN12-23 79 FDYCTWLNGFKDWKCWSR Myostatin-TN12-24 80
LPLCNLKEISHVQACVLF Myostatin-TN12-25 81 SPECAFARWLGIEQCQRD
Myostatin-TN12-26 82 YPQCFNLHLLEWTECDWF Myostatin-TN12-27 83
RWRCEIYDSEFLPKCWFF Myostatin-TN12-28 84 LVGCDNVWHRCKLF
Myostatin-TN12-29 85 AGWCHVWGEMFGMGCSAL Myostatin-TN12-30 86
HHECEWMARWMSLDCVGL Myostatin-TN12-31 87 FPMCGIAGMKDFDFCVWY
Myostatin-TN12-32 88 RDDCTFWPEWLWKLCERP Myostatin-TN12-33 89
YNFCSYLFGVSKEACQLP Myostatin-TN12-34 90 AHWCEQGPWRYGNICMAY
Myostatin-TN12-35 91 NLVCGKISAWGDEACARA Myostatin-TN12-36 92
HNVCTIMGPSMKWFCWND Myostatin-TN12-37 93 NDLCAMWGWRNTIWCQNS
Myostatin-TN12-38 94 PPFCQNDNDMLQSLCKLL Myostatin-TN12-39 95
WYDCNVPNELLSGLCRLF Myostatin-TN12-40 96 YGDCDQNHWMWPFTCLSL
Myostatin-TN12-41 97 GWMCHFDLHDWGATCQPD Myostatin-TN12-42 98
YFHCMFGGHEFEVHCESF Myostatin-TN12-43 99 AYWCWHGQCVRF
Myostatin-Linear-1 100 SEHWTFTDWDGNEWWVRPF Myostatin-Linear-2 101
MEMLDSLFELLKDMVPISKA Myostatin-Linear-3 102 SPPEEALMEWLGWQYGKFT
Myostatin-Linear-4 103 SPENLLNDLYILMTKQEWYG Myostatin-Linear-5 104
FHWEEGIPFHVVTPYSYDRM Myostatin-Linear-6 105 KRLLEQFMNDLAELVSGHS
Myostatin-Linear-7 106 DTRDALFQEFYEFVRSRLVI Myostatin-Linear-8 107
RMSAAPRPLTYRDIMDQYWH Myostatin-Linear-9 108 NDKAHFFEMFMFDVHNFVES
Myostatin-Linear-10 109 QTQAQKIDGLWELLQSIRNQ Myostatin-Linear-11
110 MLSEFEEFLGNLVHRQEA Myostatin-Linear-12 111 YTPKMGSEWTSFWHNRIHYL
Myostatin-Linear-13 112 LNDTLLRELKMVLNSLSDMK Myostatin-Linear-14
113 FDVERDLMRWLEGFMQSAAT Myostatin-Linear-15 114
HHGWNYLRKGSAPQWFEAWV Myostatin-Linear-16 115 VESLHQLQMWLDQKLASGPH
Myostatin-Linear-17 116 RATLLKDFWQLVEGYGDN Myostatin-Linear-18 117
EELLREFYRFVSAFDY Myostatin-Linear-19 118 GLLDEFSHFIAEQFYQMPGG
Myostatin-Linear-20 119 YREMSMLEGLLDVLERLQHY Myostatin-Linear-21
120 HNSSQMLLSELIMLVGSMMQ Myostatin-Linear-22 121
WREHFLNSDYIRDKLIAIDG Myostatin-Linear-23 122
QFPFYVFDDLPAQLEYWIA
Myostatin-Linear-24 123 EFFHWLHNHRSEVNHWLDMN Myostatin-Linear-25
124 EALFQNFFRDVLTLSEREY Myostatin-Linear-26 125
QYWEQQWMTYFRENGLHVQY Myostatin-Linear-27 126 NQRMMLEDLWRIMTPMFGRS
Myostatin-Linear-29 127 FLDELKAELSRHYALDDLDE Myostatin-Linear-30
128 GKLIEGLLNELMQLETFMPD Myostatin-Linear-31 129 ILLLDEYKKDWKSWF
Myostatin-2xTN8-19 kc 130 QGHCTRWPWMCPPYGSGSAT GGSGSTASSGSGSATGQGHC
TRWPWMCPPY Myostatin-2xTN8-con6 131 WYPCYEGHFWCYDLGSGSTA
SSGSGSATGWYPCYEGHFWC YDL Myostatin-2xTN8-5 kc 132
HTPCPWFAPLCVEWGSGSAT GGSGSTASSGSGSATGHTPC PWFAPLCVEW
Myostatin-2xTN8-18 kc 133 PDWCIDPDWWCKFWGSGSAT GGSGSTASSGSGSATGPDWC
IDPDWWCKFW Myostatin-2xTN8-11 kc 134 ANWCVSPNWFCMVMGSGSAT
GGSGSTASSGSGSATGANWC VSPNWFCMVM Myostatin-2xTN8-25 kc 135
PDWCIDPDWWCKFWGSGSAT GGSGSTASSGSGSATGPDWC IDPDWWCKFW
Myostatin-2xTN8-23 kc 136 HWACGYWPWSCKWVGSGSAT GGSGSTASSGSGSATGHWAC
GYWPWSCKWV Myostatin-TN8-29-19 kc 137 KKHCQIWTWMCAPKGSGSAT
GGSGSTASSGSGSATGQGHC TRWPWMCPPY Myostatin-TN8-19-29 kc 138
QGHCTRWPWMCPPYGSGSAT GGSGSTASSGSGSATGKKHC QIWTWMCAPK
Myostatin-TN8-29-19 kn 139 KKHCQIWTWMCAPKGSGSAT
GGSGSTASSGSGSATGQGHC TRWPWMCPPY Myostatin-TN8-29-19-8g 140
KKHCQIWTWMCAPKGGGGGG GGQGHCTRWPWMCPPY Myostatin-TN8-19-29-6gc 141
QGHCTRWPWMCPPYGGGGGG KKHCQIWTWMCAPK
Example 2
Generating Peptibodies
Construction of DNA Encoding Peptide-Fc Fusion Proteins
[0355] Peptides capable of binding myostatin were used alone or in
combination with each other to construct fusion proteins in which a
peptide was fused to the Fc domain of human IgG1. The amino acid
sequence of the Fc portion of each peptibody is as follows (from
amino terminus to carboxyl terminus):
TABLE-US-00006 (Seq ID No: 296)
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK
[0356] The peptide was fused in the N configuration (peptide was
attached to the N-terminus of the Fc region), the C configuration
(peptide was attached to the C-terminus of the Fc region), or the
N,C configuration (peptide attached both at the N and C terminus of
the Fc region). Separate vectors were used to express N-terminal
fusions and C-terminal fusions. Each peptibody was constructed by
annealing pairs of oligonucleotides ("oligos") to the selected
phage nucleic acid to generate a double stranded nucleotide
sequence encoding the peptide. These polynucleotide molecules were
constructed as ApaL to XhoI fragments. The fragments were ligated
into either the pAMG21-Fc N-terminal vector for the N-terminal
orientation, or the pAMG21-Fc-C-terminal vector for the C-terminal
orientation which had been previously digested with ApaLI and XhoI.
The resulting ligation mixtures were transformed by electroporation
into E. coli strain 2596 or 4167 cells (a hsdR-variant of strain
2596 cells) using standard procedures. Clones were screened for the
ability to produce the recombinant protein product and to possess
the gene fusion having a correct nucleotide sequence. A single such
clone was selected for each of the modified peptides.
[0357] Many of constructs were created using an alternative vector
designated pAMG21-2xBs-N(ZeoR) Fc. This vector is similar to the
above-described vector except that the vector digestion was
performed with BsmBI. Some constructs fused peptide sequences at
both ends of the Fc. In those cases the vector was a composite of
pAMG21-2xBs-N(ZeoR) Fc and pAMG21-2xBs-C-Fc.
Construction of pAMG21
[0358] Expression plasmid pAMG21 (ATCC No. 98113) is derived from
expression vector pCFM1656 (ATCC No. 69576) and the expression
vector system described in U.S. Pat. No. 4,710,473, by following
the procedure described in published International Patent
Application WO 00/24782, all of which are incorporated herein by
reference.
Fc N-Terminal Vector
[0359] The Fc N-terminal vector was constructed using the pAMG21
Fc_Gly5_Tpo vector as a template. A 5' PCR primer (below) was
designed to remove the Tpo peptide sequence in pAMG Tpo Gly5 and
replace it with a polylinker containing ApaLI and XhoI sites. Using
this vector as a template, PCR was performed with Expand Long
Polymerase, using the following 5' primer and a universal 3'
primer:
TABLE-US-00007 5'primer: (Seq ID No: 297)
5'-ACAAACAAACATATGGGTGCACAGAAAGCGGCCGCAAAAAAA
CTCGAGGGTGGAGGCGGTGGGGACA-3' 3' primer: (Seq ID No: 298)
5'-GGTCATTACTGGACCGGATC-3'
[0360] The resulting PCR product was gel purified and digested with
restriction enzymes NdeI and BsrGI. Both the plasmid and the
polynucleotide encoding the peptide of interest together with its
linker were gel purified using Qiagen (Chatsworth, Calif.) gel
purification spin columns. The plasmid and insert were then ligated
using standard ligation procedures, and the resulting ligation
mixture was transformed into E. coli cells (strain 2596). Single
clones were selected and DNA sequencing was performed. A correct
clone was identified and this was used as a vector source for the
modified peptides described herein.
Construction of Fc C-terminal Vector
[0361] The Fc C-terminal vector was constructed using pAMG21
Fc_Gly5_Tpo vector as a template. A 3' PCR primer was designed to
remove the Tpo peptide sequence and to replace it with a polylinker
containing ApaLI and XhoI sites. PCR was performed with Expand Long
Polymerase using a universal 5' primer and the 3' primer.
TABLE-US-00008 5' Primer: (Seq ID No: 299)
5'-CGTACAGGTTTACGCAAGAAAATGG-3' 3' Primer: (Seq ID No: 300)
5'-TTTGTTGGATCCATTACTCGAGTTTTTTTGCGGCCGCT
TTCTGTGCACCACCACCTCCACCTTTAC-3'
[0362] The resulting PCR product was gel purified and digested with
restriction enzymes BsrGI and BamHI. Both the plasmid and the
polynucleotide encoding each peptides of interest with its linker
were gel purified via Qiagen gel purification spin columns. The
plasmid and insert were then ligated using standard ligation
procedures, and the resulting ligation mixture was transformed into
E. coli (strain 2596) cells. Strain 2596 (ATCC #202174) is a strain
of E. coli K-12 modified to contain the lux promoter and two lambda
temperature sensitive repressors, the cI857s7 and the lac I.sup.Q
repressor. Single clones were selected and DNA sequencing was
performed. A correct clone was identified and used as a source of
each peptibody described herein.
Expression in E. coli.
[0363] Cultures of each of the pAMG21-Fc fusion constructs in E.
coli strain 2596 were grown at 37.degree. C. in Terrific Broth
medium (See Tartof and Hobbs, "Improved media for growing plasmid
and cosmid clones", Bethesda Research Labs Focus, Volume 9, page
12, 1987, cited in aforementioned Sambrook et al. reference).
Induction of gene product expression from the luxPR promoter was
achieved following the addition of the synthetic autoinducer,
N-(3-oxohexanoyl)-DL-homoserine lactone, to the culture medium to a
final concentration of 20 nanograms per milliliter (ng/ml).
Cultures were incubated at 37.degree. C. for an additional six
hours. The bacterial cultures were then examined by microscopy for
the presence of inclusion bodies and collected by centrifugation.
Retractile inclusion bodies were observed in induced cultures,
indicating that the Fc-fusions were most likely produced in the
insoluble fraction in E. coli. Cell pellets were lysed directly by
resuspension in Laemmli sample buffer containing 10%
.beta.-mercaptoethanol and then analyzed by SDS-PAGE. In most
cases, an intense coomassie-stained band of the appropriate
molecular weight was observed on an SDS-PAGE gel.
Folding and Purifying Peptibodies
[0364] Cells were broken in water ( 1/10 volume per volume) by high
pressure homogenization (3 passes at 15,000 PSI) and inclusion
bodies were harvested by centrifugation (4000 RPM in J-6B for 30
minutes). Inclusion bodies were solubilized in 6 M guanidine, 50 mM
Tris, 8 mM DTT, pH 8.0 for 1 hour at a 1/10 ratio at ambient
temperature. The solubilized mixture was diluted 25 times into 4 M
urea, 20% glycerol, 50 mM Tris, 160 mM arginine, 3 mM cysteine, 1
mM cystamine, pH 8.5. The mixture was incubated overnight in the
cold. The mixture was then dialyzed against 10 mM Tris pH 8.5, 50
mM NaCl, 1.5 M urea. After an overnight dialysis the pH of the
dialysate was adjusted to pH 5 with acetic acid. The precipitate
was removed by centrifugation and the supernatant was loaded onto a
SP-Sepharose Fast Flow column equilibrated in 10 mM NaAc, 50 mM
NaCl, pH 5, 4.degree. C.). After loading the column was washed to
baseline with 10 mM NaAc, 50 mM NaCl, pH 5.2. The column was
developed with a 20 column volume gradient from 50 mM-500 mM NaCl
in the acetate buffer. Alternatively, after the wash to baseline,
the column was washed with 5 column volumes of 10 mM sodium
phosphate pH 7.0 and the column developed with a 15 column volume
gradient from 0-400 mM NaCl in phosphate buffer. Column fractions
were analyzed by SDS-PAGE. Fractions containing dimeric peptibody
were pooled. Fractions were also analyzed by gel filtration to
determine if any aggregate was present.
[0365] A number of peptibodies were prepared from the peptides of
Table I. The peptides were attached to the human IgG1 Fc molecule
to form the peptibodies in Table II. Regarding the peptibodies in
Table II, the C configuration indicates that the peptide named was
attached at the C-termini of the Fc. The N configuration indicates
that the peptide named was attached at the N-termini of the Fc. The
N,C configuration indicates that one peptide was attached at the
N-termini and one at the C-termini of each Fc molecule. The
2.times. designation indicates that the two peptides named were
attached in tandem to each other and also attached at the N or the
C termini, or both the N,C of the Fc, separated by the linker
indicated. Two peptides attached in tandem separated by a linker,
are indicated, for example, as Myostatin-TN8-29-19-8g, which
indicates that TN8-29 peptide is attached via a (gly).sub.8 linker
to TN8-19 peptide. The peptide(s) were attached to the Fc via a
(gly).sub.5 linker sequence unless otherwise specified. In some
instances the peptide(s) were attached via a k linker. The linker
designated k or 1k refers to the gsgsatggsgstassgsgsatg (Seq ID No:
301) linker sequence, with kc referring to the linker attached to
the C-terminus of the Fc, and kn referring to the linker attached
to the N-terminus of the Fc. In Table II below, column 4 refers to
the linker sequence connecting the Fc to the first peptide and the
fifth column refers to the configuration N or C or both.
[0366] Since the Fc molecule dimerizes in solution, a peptibody
constructed so as to have one peptide will actually be a dimer with
two copies of the peptide and two Fc molecules, and the 2.times.
version having two peptides in tandem will actually be a dimer with
four copies of the peptide and two Fc molecules.
[0367] Since the peptibodies given in Table II are expressed in E.
coli, the first amino acid residue is Met (M). Therefore, the
peptibodies in the N configuration are Met-peptide-linker-Fc, or
Met-peptide-linker-peptide-linker-Fc, for example. Peptibodies in
the C configuration are arranged as Met-Fc-linker-peptide or
Met-Fc-linker-peptide-linker-peptide, for example. Peptibodies in
the C,N configuration are a combination of both, for example,
Met-peptide-linker-Fc-linker-peptide.
[0368] Nucleotide sequences encoding exemplary peptibodies are
provided below in Table II. The polynucleotide sequences encoding
an exemplary peptibody of the present invention includes a
nucleotide sequence encoding the Fc polypeptide sequence such as
the following:
TABLE-US-00009 (Seq ID No: 301)
5'-GACAAAACTCACACATGTCCACCTTGCCCAGCACCTGAACTCCTGGG
GGGACCGTCAGTTTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGA
TCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA
GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGG
TCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCAT
CTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC
CATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCT
CCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAG
GGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA
CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA-3'
[0369] In addition, the polynucleotides encoding the (Gly).sub.5
linker such as the following are included:
TABLE-US-00010 5'-GGTGGAGGTGGTGGT-3'. (Seq ID No: 302)
[0370] The polynucleotide encoding the peptibody also includes the
codon encoding the methionine ATG and a stop codon such as TAA.
[0371] Therefore, the structure of the first peptibody in Table II
is TN8-Con1 with a C configuration and a (gly).sub.5 linker is as
follows: M-Fc-GGGGG-KDKCKMWHWMCKPP (Seq ID No: 303). Exemplary
polynucleotides encoding this peptibody would be:
TABLE-US-00011 (Seq ID No: 304)
5'-ATGGACAAAACTCACACATGTCCACCTTGCCCAGCACCTGAACTCCT
GGGGGGACCGTCAGTTTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA
TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCAC
GAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA
TAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG
TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAAC
CATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGC
CCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTG
GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG
GCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
GCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAG
CAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA
CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAGGTGGAGGTGGTG
GTAAGACAAATGCAAAATGTGGCACTGGATGTGCAAACCGCCG-3'
TABLE-US-00012 TABLE II Peptibody Name Peptide Nucleotide Sequence
(SEQ ID NO) L Myostatin-TN8-con1 KDKCKMWHWMCKPP
AAAGACAAATGCAAAATGTGGCACTG 5 gly C (SEQ ID NO: 1) GATGTGCAAACCGCCG
(SEQ. ID NO: 147) Myostatin-TN8-con2 KDLCAMWHWMCKPP
AAAGACCTGTGCGCTATGTGGCACTG 5 gly C (SEQ ID NO: 2) GATGTGCAAACCGCCG
(SEQ. ID NO: 148) Myostatin-TN8-con3 KDLCKMWKWMCKPP
AAAGACCTGTGCAAAATGTGGAAATG 5 gly C (SEQ ID NO: 3) GATGTGCAAACCGCCG
(SEQ ID NO: 149) Myostatin-TN8-con4 KDLCKMWHWMCKPK
AAAGACCTGTGCAAAATGTGGCACTG 5 gly C (SEQ ID NO: 4) GATGTGCAAACCGAAA
(SEQ ID NO: 150) Myostatin-TN8-con5 WYPCYEFHFWCYDL
TGGTACCCGTGCTACGAATTCCACTTC 5 gly C (SEQ ID NO: 5) TGGTGCTACGACCTG
(SEQ ID NO: 151) Myostatin-TN8-con5 WYPCYEFHFWCYDL
TGGTACCCGTGCTACGAATTCCACTTC 5 gly N (SEQ ID NO: 5) TGGTGCTACGACCTG
(SEQ ID NO: 152) Myostatin-TN8-con6 WYPCYEGHFWCYDL
TGGTACCCGTGCTACGAAGGTCACTT 5 gly C (SEQ ID NO: 6) CTGGTGCTACGACCTG
(SEQ ID NO: 153) Myostatin-TN8-con6 WYPCYEGHFWCYDL
TGGTACCCGTGCTACGAAGGTCACTT 5 gly N (SEQ ID NO: 6) CTGGTGCTACGACCTG
(SEQ ID NO: 154) Myostatin-TN8-con7 IFGCKWWDVQCYQF
ATCTTCGGTTGCAAATGGTGGGACGT 5 gly C (SEQ ID NO: 7) TCAGTGCTACCAGTTC
(SEQ. ID NO: 155) Myostatin-TN8-con8 IFGCKWWDVDCYQF
ATCTTCGGTTGCAAATGGTGGGACGT 5 gly C (SEQ ID NO: 8) TGACTGCTACCAGTTC
(SEQ ID NO: 156) Myostatin-TN8-con8 IFGCKWWDVDCYQF
ATCTTCGGTTGCAAATGGTGGGACGT 5 gly N (SEQ ID NO: 8) TGACTGCTACCAGTTC
(SEQ ID NO: 157) Myostatin-TN8-con9 ADWCVSPNWFCMVM
GCTGACTGGTGCGTTTCCCCGAACTG 5 gly C (SEQ ID NO: 9) GTTCTGCATGGTTATG
(SEQ ID NO: 158) Myostatin-TN8- HKFCPWWALFCWDF
CACAAATTCTGCCCGTGGTGGGCTCT 5 gly C con10 (SEQ ID NO: 10)
GTTCTGCTGGGACTTC (SEQ ID NO: 159) Myostatin-TN8-1 KDLCKMWHWMCKPP
AAAGACCTGTGCAAAATGTGGCACTG 5 gly C (SEQ. ID NO: 11)
GATGTGCAAACCGCCG (SEQ ID NO: 160) Myostatin-TN8-2 IDKCAIWGWMCPPL
ATCGACAAATGCGCTATCTGGGGTTG 5 gly C (SEQ ID NO: 12) GATGTGCCCGCCGCTG
(SEQ ID NO: 161) Myostatin-TN8-3 WYPCGEFGMWCLNV
TGGTACCCGTGCGGTGAATTCGGTAT 5 gly C (SEQ ID NO: 13) GTGGTGCCTGAACGTT
(SEQ ID NO: 162) Myostatin-TN8-4 WFTCLWNCDNE (SEQ
TGGTTCACCTGCCTGTGGAACTGCGA 5 gly C ID NO: 14) CAACGAA (SEQ ID NO:
163) Myostatin-TN8-5 HTPCPWFAPLCVEW CACACCCCGTGCCCGTGGTTCGCTCC 5
gly C (SEQ ID NO: 15) GCTGTGCGTTGAATGG (SEQ ID NO: 164)
Myostatin-TN8-6 KEWCWRWKWMCKPE AAAGAATGGTGCTGGCGTTGGAAATG 5 gly C
(SEQ ID NO: 16) GATGTGCAAACCGGAA (SEQ ID NO: 165) Myostatin-TN8-7
FETCPSWAYFCLDI TTCGAAACCTGCCCGTCCTGGGCTTA 5 gly C (SEQ ID NO: 17)
CTTCTGCCTGGACATC (SEQ ID NO: 166) Myostatin-TN8-7 FETCPSWAYFCLDI
TTCGAAACCTGCCCGTCCTGGGCTTA 5 gly N (SEQ ID NO: 17) CTTCTGCCTGGACATC
(SEQ ID NO: 167) Myostatin-TN8-8 AYKCEANDWGCWWL
GCTTACAAATGCGAAGCTAACGACTG 5 gly C (SEQ ID NO: 18) GGGTTGCTGGTGGCTG
(SEQ ID NO: 168) Myostatin-TN8-9 NSWCEDQWHRCWWL
AACTCCTGGTGCGAAGACCAGTGGCA 5 gly C (SEQ ID NO: 19) CCGTTGCTGGTGGCTG
(SEQ ID NO: 169) Myostatin-TN8-10 WSACYAGHFWCYDL
TGGTCCGCTTGCTACGCTGGTCACTTC 5 gly C (SEQ ID NO: 20) TGGTGCTACGACCTG
(SEQ ID NO: 170) Myostatin-TN8-11 ANWCVSPNWFCMVM
GCTAACTGGTGCGTTTCCCCGAACTG 5 gly C (SEQ ID NO: 21) GTTCTGCATGGTTATG
(SEQ ID NO: 171) Myostatin-TN8-12 WTECYQQEFWCWNL
TGGACCGAATGCTACCAGCAGGAATT 5 gly C (SEQ ID NO: 22) CTGGTGCTGGAACCTG
(SEQ ID NO: 172) Myostatin-TN8-13 ENTCERWKWMCPPK
GAAAACACCTGCGAACGTTGGAAATG 5 gly C (SEQ ID NO: 23) GATGTGCCCGCCGAAA
(SEQ ID NO: 173) Myostatin-TN8-14 WLPCHQEGFWCMNF
TGGCTGCCGTGCCACCAGGAAGGTTT 5 gly C (SEQ ID NO: 24) CTGGTGCATGAACTTC
(SEQ ID NO: 174) Myostatin-TN8-15 STMCSQWHWMCNPF
TCCACCATGTGCTCCCAGTGGCACTG 5 gly C (SEQ ID NO: 25) GATGTGCAACCCGTTC
(SEQ ID NO: 175) Myostatin-TN8-16 IFGCHWWDVDCYQF
ATCTTCGGTTGCCACTGGTGGGACGT 5 gly C (SEQ ID NO: 26) TGACTGCTACCAGTTC
(SEQ ID NO: 176) Myostatin-TN8-17 IYGCKWWDIQCYDI
ATCTACGGTTGCAAATGGTGGGACAT 5 gly C (SEQ ID NO: 27) CCAGTGCTACGACATC
(SEQ ID NO: 177) Myostatin-TN8-18 PDWCIDPDWWCKFW
CCGGACTGGTGCATCGATCCGGACTG 5 gly C (SEQ ID NO: 28) GTGGTGCAAATTCTGG
(SEQ ID NO: 178) Myostatin-TN8-19 QGHCTRWPWMCPPY
CAGGGTCACTGCACCCGTTGGCCGTG 5 gly C (SEQ ID NO: 29) GATGTGCCCGCCGTAC
(SEQ ID NO: 179) Myostatin-TN8-20 WQECYREGFWCLQT
TGGCAGGAATGCTACCGTGAAGGTTT 5 gly C (SEQ ID NO: 30) CTGGTGCCTGCAGACC
(SEQ ID NO: 180) Myostatin-TN8-21 WFDCYGPGFKCWSP
TGGTTCGACTGCTACGGTCCGGGTTTC 5 gly C (SEQ ID NO: 31) AAATGCTGGTCCCCG
(SEQ ID NO: 181) Myostatin-TN8-22 GVRCPKGHLWCLYP
GGTGTTCGTTGCCCGAAAGGTCACCT 5 gly C (SEQ ID NO: 32) GTGGTGCCTGTACCCG
(SEQ ID NO: 182) Myostatin-TN8-23 HWACGYWPWSCKWV
CACTGGGCTTGCGGTTACTGGCCGTG 5 gly C (SEQ ID NO: 33) GTCCTGCAAATGGGTT
(SEQ ID NO: 183) Myostatin-TN8-24 GPACHSPWWWCVFG
GGTCCGGCTTGCCACTCCCCGTGGTG 5 gly C (SEQ ID NO: 34) GTGGTGCGTTTTCGGT
(SEQ ID NO: 184) Myostatin-TN8-25 TTWCISPMWFCSQQ
ACCACCTGGTGCATCTCCCCGATGTG 5 gly C (SEQ ID NO: 35) GTTCTGCTCCCAGCAG
(SEQ ID NO: 185) Myostatin-TN8-26 HKFCPPWAIFCWDF
CACAAATTCTGCCCGCCGTGGGCTAT 5 gly N (SEQ ID NO: 36) CTTCTGCTGGGACTTC
(SEQ ID NO: 186) Myostatin-TN8-27 PDWCVSPRWYCNMW
CCGGACTGGTGCGTTTCCCCGCGTTG 5 gly N (SEQ ID NO: 37) GTACTGCAACATGTGG
(SEQ ID NO: 187) Myostatin-TN8-28 VWKCHWFGMDCEPT
GTTTGGAAATGCCACTGGTTCGGTAT 5 gly N (SEQ ID NO: 38) GGACTGCGAACCGACC
(SEQ ID NO: 188) Myostatin-TN8-29 KKHCQIWTWMCAPK
AAAAAACACTGCCAGATCTGGACCTG 5 gly N (SEQ ID NO: 39) GATGTGCGCTCCGAAA
(SEQ ID NO: 189) Myostatin-TN8-30 WFQCGSTLFWCYNL
TGGTTCCAGTGCGGTTCCACCCTGTTC 5 gly N (SEQ ID NO: 40) TGGTGCTACAACCTG
(SEQ ID NO: 190) Myostatin-TN8-31 WSPCYDHYFYCYTI
TGGTCCCCGTGCTACGACCACTACTTC 5 gly N (SEQ ID NO: 41) TACTGCTACACCATC
(SEQ ID NO: 191) Myostatin-TN8-32 SWMCGFFKEVCMWV
TCCTGGATGTGCGGTTTCTTCAAAGA 5 gly N (SEQ ID NO: 42) AGTTTGCATGTGGGTT
(SEQ ID NO: 192) Myostatin-TN8-33 EMLCMIHPVFCNPH
GAAATGCTGTGCATGATCCACCCGGT 5 gly N (SEQ ID NO: 43) TTTCTGCAACCCGCAC
(SEQ ID NO: 193) Myostatin-TN8-34 LKTCNLWPWMCPPL
CTGAAAACCTGCAACCTGTGGCCGTG 5 gly N (SEQ ID NO: 44) GATGTGCCCGCCGCTG
(SEQ ID NO: 194) Myostatin-TN8-35 VVGCKWYEAWCYNK
GTTGTTGGTTGCAAATGGTACGAAGC 5 gly N (SEQ ID NO: 45) TTGGTGCTACAACAAA
(SEQ ID NO: 195) Myostatin-TN8-36 PIHCTQWAWMCPPT
CCGATCCACTGCACCCAGTGGGCTTG 5 gly N (SEQ ID NO: 46) GATGTGCCCGCCGACC
(SEQ ID NO: 196) Myostatin-TN8-37 DSNCPWYFLSCVIF
GACTCCAACTGCCCGTGGTACTTCCT 5 gly N (SEQ ID NO: 47) GTCCTGCGTTATCTTC
(SEQ ID NO: 197) Myostatin-TN8-38 HIWCNLAMMKCVEM
CACATCTGGTGCAACCTGGCTATGAT 5 gly N (SEQ ID NO: 48) GAAATGCGTTGAAATG
(SEQ ID NO: 198) Myostatin-TN8-39 NLQCIYFLGKCIYF
AACCTGCAGTGCATCTACTTCCTGGG 5 gly N (SEQ ID NO: 49) TAAATGCATCTACTTC
(SEQ ID NO: 199) Myostatin-TN8-40 AWRCMWFSDVCTPG
GCTTGGCGTTGCATGTGGTTCTCCGAC 5 gly N (SEQ ID NO: 50) GTTTGCACCCCGGGT
(SEQ ID NO: 200) Myostatin-TN8-41 WFRCFLDADWCTSV
TGGTTTCGTTGTTTTCTTGATGCTGAT 5 gly N (SEQ ID NO: 51) TGGTGTACTTCTGTT
(SEQ ID NO: 201) Myostatin-TN8-42 EKICQMWSWMCAPP
GAAAAAATTTGTCAAATGTGGTCTTG 5 gly N (SEQ ID NO: 52) GATGTGTGCTCCACCA
(SEQ ID NO: 202) Myostatin-TN8-43 WFYCHLNKSECTEP
TGGTTTTATTGTCATCTTAATAAATCT 5 gly N (SEQ ID NO: 53) GAATGTACTGAACCA
(SEQ ID NO: 203) Myostatin-TN8-44 FWRCAIGIDKCKRV
TTTTGGCGTTGTGCTATTGGTATTGAT 5 gly N (SEQ ID NO: 54) AAATGTAAACGTGTT
(SEQ ID NO: 204) Myostatin-TN8-45 NLGCKWYEVWCFTY
AATCTTGGTTGTAAATGGTATGAAGT 5 gly N (SEQ ID NO: 55) TTGGTGTTTTACTTAT
(SEQ ID NO: 205) Myostatin-TN8-46 IDLCNMWDGMCYPP
ATTGATCTTTGTAATATGTGGGATGGT 5 gly N (SEQ ID NO: 56) ATGTGTTATCCACCA
(SEQ ID NO: 206) Myostatin-TN8-47 EMPCNIWGWMCPPV
GAAATGCCATGTAATATTTGGGGTTG 5 gly N (SEQ ID NO: 57) GATGTGTCCACCAGTT
(SEQ ID NO: 207) Myostatin-TN12-1 WFRCVLTGIVDWSECF
TGGTTCCGTTGCGTTCTGACCGGTATC 5 gly N GL (SEQ ID NO: 58)
GTTGACTGGTCCGAATGCTTCGGTCT G (SEQ ID NO: 208) Myostatin-TN12-2
GFSCTFGLDEFYVDCSP GGTTTCTCCTGCACCTTCGGTCTGGAC 5 gly N F (SEQ ID NO:
59) GAATTCTACGTTGACTGCTCCCCGTTC (SEQ ID NO: 209)
Myostatin-TN12-3 LPWCHDQVNADWGFC CTGCCGTGGTGCCACGACCAGGTTAA 5 gly N
MLW (SEQ ID NO: 60) CGCTGACTGGGGTTTCTGCATGCTGT GG (SEQ ID NO: 210)
Myostatin-TN12-4 YPTCSEKFWIYGQTCV TACCCGACCTGCTCCGAAAAATTCTG 5 gly
N LW (SEQ ID NO: 61) GATCTACGGTCAGACCTGCGTTCTGT GG (SEQ ID NO: 211)
Myostatin-TN12-5 LGPCPIHHGPWPQYCV CTGGGTCCGTGCCCGATCCACCACGG 5 gly
N YW (SEQ ID NO: 62) TCCGTGGCCGCAGTACTGCGTTTACT GG (SEQ ID NO: 212)
Myostatin-TN12-6 PFPCETHQISWLGHCLS CCGTTCCCGTGCGAAACCCACCAGAT 5 gly
N F (SEQ ID NO: 63) CTCCTGGCTGGGTCACTGCCTGTCCTT C (SEQ ID NO: 213)
Myostatin-TN12-7 HWGCEDLMWSWHPLC CACTGGGGTTGCGAAGACCTGATGTG 5 gly N
RRP (SEQ ID NO: 64) GTCCTGGCACCCGCTGTGCCGTCGTC CG (SEQ ID NO: 214)
Myostatin-TN12-8 LPLCDADMMPTIGFCV CTGCCGCTGTGCGACGCTGACATGAT 5 gly
N AY (SEQ ID NO: 65) GCCGACCATCGGTTTCTGCGTTGCTTA C (SEQ ID NO: 215)
Myostatin-TN12-9 SHWCETTFWMNYAKC TCCCACTGGTGCGAAACCACCTTCTG 5 gly N
VHA (SEQ ID NO: 66) GATGAACTACGCTAAATGCGTTCACG CT (SEQ ID NO: 216)
Myostatin-TN12-10 LPKCTHVPFDQGGFCL CTGCCGAAATGCACCCACGTTCCGTT 5 gly
N WY (SEQ ID NO: 67) CGACCAGGGTGGTTTCTGCCTGTGGT AC (SEQ ID NO: 217)
Myostatin-TN12-11 FSSCWSPVSRQDMFCV TTCTCCTCCTGCTGGTCCCCGGTTTCC 5
gly N FY (SEQ ID NO: 68) CGTCAGGACATGTTCTGCGTTTTCTAC (SEQ ID NO:
218) Myostatin-TN12-13 SHKCEYSGWLQPLCYR TCCCACAAATGCGAATACTCCGGTTG
5 gly N P (SEQ ID NO: 69) GCTGCAGCCGCTGTGCTACCGTCCG (SEQ ID NO:
219) Myostatin-TN12-14 PWWCQDNYVQHMLH CCGTGGTGGTGCCAGGACAACTACGT 5
gly N CDSP (SEQ ID NO: 70) TCAGCACATGCTGCACTGCGACTCCC CG (SEQ ID
NO: 220) Myostatin-TN12-15 WFRCMLMNSFDAFQC
TGGTTCCGTTGCATGCTGATGAACTCC 5 gly N VSY (SEQ ID NO: 71)
TTCGACGCTTTCCAGTGCGTTTCCTAC (SEQ ID NO: 221) Myostatin-TN12-16
PDACRDQPWYMFMGC CCGGACGCTTGCCGTGACCAGCCGTG 5 gly N MLG (SEQ ID NO:
72) GTACATGTTCATGGGTTGCATGCTGG GT (SEQ ID NO: 222)
Myostatin-TN12-17 FLACFVEFELCFDS TTCCTGGCTTGCTTCGTTGAATTCGAA 5 gly
N (SEQ ID NO: 73) CTGTGCTTCGACTCC (SEQ ID NO: 223)
Myostatin-TN12-18 SAYCIITESDPYVLCVP TCCGCTTACTGCATCATCACCGAATCC 5
gly N L (SEQ ID NO: 74) GACCCGTACGTTCTGTGCGTTCCGCTG (SEQ ID NO:
224) Myostatin-TN12-19 PSICESYSTMWLPMCQ CCGTCCATCTGCGAATCCTACTCCACC
5 gly N HN (SEQ ID NO: 75) ATGTGGCTGCCGATGTGCCAGCACAA C (SEQ ID NO:
225) Myostatin-TN12-20 WLDCHDDSWAWTKM TGGCTGGACTGCCACGACGACTCCTG 5
gly N CRSH (SEQ ID NO: 76) GGCTTGGACCAAAATGTGCCGTTCCC AC (SEQ ID
NO: 226) Myostatin-TN12-21 YLNCVMMNTSPFVEC
TACCTGAACTGCGTTATGATGAACAC 5 gly N VFN (SEQ ID NO: 77)
CTCCCCGTTCGTTGAATGCGTTTTCAA C (SEQ ID NO: 227) Myostatin-TN12-22
YPWCDGFMIQQGITCM TACCCGTGGTGCGACGGTTTCATGAT 5 gly N FY (SEQ ID NO:
78) CCAGCAGGGTATCACCTGCATGTTCT AC (SEQ ID NO: 228)
Myostatin-TN12-23 FDYCTWLNGFKDWKC TTCGACTACTGCACCTGGCTGAACGG 5 gly
N WSR (SEQ ID NO: 79) TTTCAAAGACTGGAAATGCTGGTCCC GT (SEQ ID NO:
229) Myostatin-TN12-24 LPLCNLKEISHVQACVL CTGCCGCTGTGCAACCTGAAAGAAAT
5 gly N F (SEQ ID NO: 80) CTCCCACGTTCAGGCTTGCGTTCTGTT C (SEQ ID NO:
230) Myostatin-TN12-25 SPECAFARWLGIEQCQ TCCCCGGAATGCGCTTTCGCTCGTTGG
5 gly N RD (SEQ ID NO: 81) CTGGGTATCGAACAGTGCCAGCGTGA C (SEQ ID NO:
231) Myostatin-TN12-26 YPQCFNLHLLEWTECD TACCCGCAGTGCTTCAACCTGCACCT
5 gly N WF (SEQ ID NO: 82) GCTGGAATGGACCGAATGCGACTGGT TC (SEQ ID
NO: 232) Myostatin-TN12-27 RWRCEIYDSEFLPKCW
CGTTGGCGTTGCGAAATCTACGACTC 5 gly N FF (SEQ ID NO: 83)
CGAATTCCTGCCGAAATGCTGGTTCTT C (SEQ ID NO: 233) Myostatin-TN12-28
LVGCDNVWHRCKLF CTGGTTGGTTGCGACAACGTTTGGCA 5 gly N (SEQ ID NO: 84)
CCGTTGCAAACTGTTC (SEQ ID NO: 234) Myostatin-TN12-29 AGWCHVWGEMFGMG
GCTGGTTGGTGCCACGTTTGGGGTGA 5 gly N CSAL (SEQ ID NO: 85)
AATGTTCGGTATGGGTTGCTCCGCTCT G (SEQ ID NO: 235) Myostatin-TN12-30
HHECEWMARWMSLD CACCACGAATGCGAATGGATGGCTCG 5 gly N CVGL (SEQ ID NO:
86) TTGGATGTCCCTGGACTGCGTTGGTCT G (SEQ ID NO: 236)
Myostatin-TN12-31 FPMCGIAGMKDFDFCV TTCCCGATGTGCGGTATCGCTGGTAT 5 gly
N WY (SEQ ID NO: 87) GAAAGACTTCGACTTCTGCGTTTGGT AC (SEQ ID NO: 237)
Myostatin-TN12-32 RDDCTFWPEWLWKLC CGTGATGATTGTACTTTTTGGCCAGAA 5 gly
N ERP (SEQ ID NO: 88) TGGCTTTGGAAACTTTGTGAACGTCC A (SEQ ID NO: 238)
Myostatin-TN12-33 YNFCSYLFGVSKEACQ TATAATTTTTGTTCTTATCTTTTTGGTG 5
gly N LP (SEQ ID NO: 89) TTTCTAAAGAAGCTTGTCAACTTCCA (SEQ ID NO:
239) Myostatin-TN12-34 AHWCEQGPWRYGNIC GCTCATTGGTGTGAACAAGGTCCATG 5
gly NC MAY (SEQ ID NO: 90) GCGTTATGGTAATATTTGTATGGCTTA T (SEQ ID
NO: 240) Myostatin-TN12-35 NLVCGKISAWGDEACA
AATCTTGTTTGTGGTAAAATTTCTGCT 5 gly N RA (SEQ ID NO: 91)
TGGGGTGATGAAGCTTGTGCTCGTGC T (SEQ ID NO: 241) Myostatin-TN12-36
HNVCTIMGPSMKWFC CATAATGTTTGTACTATTATGGGTCCA 5 gly NC WND (SEQ ID
NO: 92) TCTATGAAATGGTTTTGTTGGAATGAT (SEQ ID NO: 242)
Myostatin-TN12-37 NDLCAMWGWRNTIWC AATGATCTTTGTGCTATGTGGGGTTGG 5 gly
NC QNS (SEQ ID NO: 93) CGTAATACTATTTGGTGTCAAAATTCT (SEQ ID NO: 243)
Myostatin-TN12-38 PPFCQNDNDMLQSLCK CCACCATTTTGTCAAAATGATAATGA 5 gly
N LL (SEQ ID NO: 94) TATGCTTCAATCTCTTTGTAAACTTCT T (SEQ ID NO: 244)
Myostatin-TN12-39 WYDCNVPNELLSGLCR TGGTATGATTGTAATGTTCCAAATGA 5 gly
N LF (SEQ ID NO: 95) ACTTCTTTCTGGTCTTTGTCGTCTTTTT (SEQ ID NO: 245)
Myostatin-TN12-40 YGDCDQNHWMWPFTC TATGGTGATTGTGATCAAAATCATTG 5 gly
NC LSL (SEQ ID NO: 96) GATGTGGCCATTTACTTGTCTTTCTCT T (SEQ ID NO:
246) Myostatin-TN12-41 GWMCHFDLHDWGAT GGTTGGATGTGTCATTTTGATCTTCAT 5
gly N CQPD (SEQ ID NO: 97) GATTGGGGTGCTACTTGTCAACCAGA T (SEQ ID NO:
247) Myostatin-TN12-42 YFHCMFGGHEFEVHCE TATTTTCATTGTATGTTTGGTGGTCAT
5 gly NC SF (SEQ ID NO: 98) GAATTTGAAGTTCATTGTGAATCTTTT (SEQ ID NO:
248) Myostatin-TN12-43 AYWCWHGQCVRF GCTTATTGGTGTTGGCATGGTCAATGT 5
gly N (SEQ ID NO: 99) GTTCGTTTT (SEQ ID NO: 249) Myostatin-Linear-1
SEHWTFTDWDGNEW TCCGAACACTGGACCTTCACCGACTG 5 gly N WVRPF (SEQ ID NO:
GGACGGTAACGAATGGTGGGTTCGTC 100) CGTTC (SEQ ID NO: 250)
Myostatin-Linear-2 MEMLDSLFELLKDMVP ATGGAAATGCTGGACTCCCTGTTCGA 5
gly N ISKA (SEQ ID NO: 101) ACTGCTGAAAGACATGGTTCCGATCT CCAAAGCT
(SEQ ID NO: 251) Myostatin-Linear-3 SPPEEALMEWLGWQY
TCCCCGCCGGAAGAAGCTCTGATGGA 5 gly N GKFT (SEQ ID NO: 102)
ATGGCTGGGTTGGCAGTACGGTAAAT TCACC (SEQ ID NO: 252)
Myostatin-Linear-4 SPENLLNDLYILMTKQ TCCCCGGAAAACCTGCTGAACGACCT 5
gly N EWYG (SEQ ID NO: 103) GTACATCCTGATGACCAAACAGGAAT GGTACGGT
(SEQ ID NO: 253) Myostatin-Linear-5 FHWEEGIPFHVVTPYS
TTCCACTGGGAAGAAGGTATCCCGTT 5 gly N YDRM (SEQ ID NO:
CCACGTTGTTACCCCGTACTCCTACGA 104) CCGTATG (SEQ ID NO: 254)
Myostatin-Linear-6 KRLLEQFMNDLAELVS AAACGTCTGCTGGAACAGTTCATGAA 5
gly N GHS (SEQ ID NO: 105) CGACCTGGCTGAACTGGTTTCCGGTC ACTCC (SEQ ID
NO: 255) Myostatin-Linear-7 DTRDALFQEFYEFVRS
GACACCCGTGACGCTCTGTTCCAGGA 5 gly N RLVI (SEQ ID NO: 106)
ATTCTACGAATTCGTTCGTTCCCGTCT GGTTATC (SEQ ID NO: 256)
Myostatin-Linear-8 RMSAAPRPLTYRDIMD CGTATGTCCGCTGCTCCGCGTCCGCTG 5
gly N QYWH (SEQ ID NO: ACCTACCGTGACATCATGGACCAGTA 107) CTGGCAC (SEQ
ID NO: 257) Myostatin-Linear-9 NDKAHFFEMFMFDVH
AACGACAAAGCTCACTTCTTCGAAAT 5 gly N NFVES (SEQ ID NO:
GTTCATGTTCGACGTTCACAACTTCGT 108) TGAATCC (SEQ ID NO: 258)
Myostatin-Linear-10 QTQAQKIDGLWELLQS CAGACCCAGGCTCAGAAAATCGACGG 5
gly N IRNQ (SEQ ID NO: 109) TCTGTGGGAACTGCTGCAGTCCATCC GTAACCAG
(SEQ ID NO: 259) Myostatin-Linear-11 MLSEFEEFLGNLVHRQ
ATGCTGTCCGAATTCGAAGAATTCCT 5 gly N EA (SEQ ID NO: 110)
GGGTAACCTGGTTCACCGTCAGGAAG CT (SEQ ID NO: 260) Myostatin-Linear-12
YTPKMGSEWTSFWHN TACACCCCGAAAATGGGTTCCGAATG 5 gly N RIHYL (SEQ ID
NO: 111) GACCTCCTTCTGGCACAACCGTATCC ACTACCTG (SEQ ID NO: 261)
Myostatin-Linear-13 LNDTLLRELKMVLNSL CTGAACGACACCCTGCTGCGTGAACT 5
gly N SDMK (SEQ ID NO: 112) GAAAATGGTTCTGAACTCCCTGTCCG ACATGAAA
(SEQ ID NO: 262) Myostatin-Linear-14 FDVERDLMRWLEGFM
TTCGACGTTGAACGTGACCTGATGCG 5 gly N QSAAT (SEQ ID NO:
TTGGCTGGAAGGTTTCATGCAGTCCG 113) CTGCTACC (SEQ ID NO: 263)
Myostatin-Linear-15 HHGWNYLRKGSAPQW CACCACGGTTGGAACTACCTGCGTAA 5
gly N FEAWV (SEQ ID NO: AGGTTCCGCTCCGCAGTGGTTCGAAG 114) CTTGGGTT
(SEQ ID NO: 264) Myostatin-Linear-16 VESLHQLQMWLDQKL
GTTGAATCCCTGCACCAGCTGCAGAT 5 gly N ASGPH (SEQ ID NO:
GTGGCTGGACCAGAAACTGGCTTCCG 115) GTCCGCAC (SEQ ID NO: 265)
Myostatin-Linear-17 RATLLKDFWQLVEGY CGTGCTACCCTGCTGAAAGACTTCTG 5
gly N GDN (SEQ ID NO: 116) GCAGCTGGTTGAAGGTTACGGTGACA AC (SEQ ID
NO: 266) Myostatin-Linear-18 EELLREFYRFVSAFDY
GAAGAACTGCTGCGTGAATTCTACCG 5 gly N (SEQ ID NO: 117)
TTTCGTTTCCGCTTTCGACTAC (SEQ ID NO: 267) Myostatin-Linear-19
GLLDEFSHFIAEQFYQ GGTCTGCTGGACGAATTCTCCCACTTC 5 gly N MPGG (SEQ ID
NO: 118) ATCGCTGAACAGTTCTACCAGATGCC GGGTGGT (SEQ ID NO: 268)
Myostatin-Linear-20 YREMSMLEGLLDVLER TACCGTGAAATGTCCATGCTGGAAGG 5
gly N LQHY (SEQ ID NO: 119) TCTGCTGGACGTTCTGGAACGTCTGC AGCACTAC
(SEQ ID NO: 269) Myostatin-Linear-21 HNSSQMLLSELIMLVG
CACAACTCCTCCCAGATGCTGCTGTC 5 gly N SMMQ (SEQ ID NO: 120)
CGAACTGATCATGCTGGTTGGTTCCA TGATGCAG (SEQ ID NO: 270)
Myostatin-Linear-22 WREHFLNSDYIRDKLI TGGCGTGAACACTTCCTGAACTCCGA 5
gly N AIDG (SEQ ID NO: 121) CTACATCCGTGACAAACTGATCGCTA TCGACGGT
(SEQ ID NO: 271) Myostatin-Linear-23 QFPFYVFDDLPAQLEY
CAGTTCCCGTTCTACGTTTTCGACGAC 5 gly N WIA (SEQ ID NO: 122)
CTGCCGGCTCAGCTGGAATACTGGAT CGCT (SEQ ID NO: 272)
Myostatin-Linear-24 EFFHWLHNHRSEVNH GAATTCTTCCACTGGCTGCACAACCA 5
gly N
WLDMN (SEQ ID NO: CCGTTCCGAAGTTAACCACTGGCTGG 123) ACATGAAC (SEQ ID
NO: 273) Myostatin-Linear-25 EALFQNFFRDVLTLSER
GAAGCTCTTTTTCAAAATTTTTTTCGT 5 gly NC EY (SEQ ID NO: 124)
GATGTTCTTACTCTTTCTGAACGTGAA TAT (SEQ ID NO: 274) Myostatin-Linear-
QYWEQQWMTYFRENG CAATATTGGGAACAACAATGGATGAC 5 gly N 26 LHVQY (SEQ ID
NO: TTATTTTCGTGAAAATGGTCTTCATGT 125) TCAATAT (SEQ ID NO: 275)
Myostatin-Linear-27 NQRMMLEDLWRIMTP AATCAACGTATGATGCTTGAAGATCT 5
gly NC MFGRS (SEQ ID NO: TTGGCGTATTATGACTCCAATGTTTGG 126) TCGTTCT
(SEQ ID NO: 276) Myostatin-Linear-29 FLDELKAELSRHYALD
TTTCTTGATGAACTTAAAGCTGAACTT 5 gly N DLDE (SEQ ID NO: 127)
TCTCGTCATTATGCTCTTGATGATCTT GATGAA (SEQ ID NO: 277)
Myostatin-Linear-30 GKLIEGLLNELMQLETF GGTAAACTTATTGAAGGTCTTCTTAAT 5
gly NC MPD (SEQ ID NO: 128) GAACTTATGCAACTTGAAACTTTTATG CCAGAT (SEQ
ID NO: 278) Myostatin-Linear-31 ILLLDEYKKDWKSWF
ATTCTTCTTCTTGATGAATATAAAAAA 5 gly N (SEQ ID NO: 129)
GATTGGAAATCTTGGTTT (SEQ ID NO: 279) Myostatin-2XTN8-
QGHCTRWPWMCPPYG CAGGGCCACTGTACTCGCTGGCCGTG 1k N 19 kc
SGSATGGSGSTASSGSG GATGTGCCCGCCGTACGGTTCTGGTT SATGQGHCTRWPWMC
CCGCTACCGGTGGTTCTGGTTCCACTG PPY (SEQ ID NO: 130)
CTTCTTCTGGTTCCGGTTCTGCTACTG GTCAGGGTCACTGCACTCGTTGGCCA
TGGATGTGTCCACCGTAT (SEQ ID NO: 280) Myostatin-2XTN8-
WYPCYEGHFWCYDLG TGGTATCCGTGTTATGAGGGTCACTTC 5 gly C CON6
SGSTASSGSGSATGWY TGGTGCTACGATCTGGGTTCTGGTTCC PCYEGHFWCYDL
ACTGCTTCTTCTGGTTCCGGTTCCGCT (SEQ ID NO: 131)
ACTGGTTGGTACCCGTGCTACGAAGG TCACTTTTGGTGTTATGATCTG (SEQ ID NO: 281)
Myostatin-2XTN8-5 HTPCPWFAPLCVEWGS CACACTCCGTGTCCGTGGTTTGCTCCG 1k C
kc GSATGGSGSTASSGSGS CTGTGCGTTGAATGGGGTTCTGGTTCC ATGHTPCPWFAPLCVE
GCTACTGGTGGTTCCGGTTCCACTGCT W (SEQ ID NO: 132)
TCTTCTGGTTCCGGTTCTGCAACTGGT CACACCCCGTGCCCGTGGTTTGCACC
GCTGTGTGTAGAGTGG (SEQ ID NO: 282) Myostatin-2XTN8- PDWCIDPDWWCKFWG
CCGGATTGGTGTATCGACCCGGACTG 1k C 18 kc SGSATGGSGSTASSGSG
GTGGTGCAAATTCTGGGGTTCTGGTTC SATGPDWCIDPDWWC
CGCTACCGGTGGTTCCGGTTCCACTG KFW (SEQ ID NO: 133)
CTTCTTCTGGTTCCGGTTCTGCAACTG GTCCGGACTGGTGCATCGACCCGGAT
TGGTGGTGTAAATTTTGG (SEQ ID NO: 283) Myostatin-2XTN8- ANWCVSPNWFCMVM
CCGGATTGGTGTATCGACCCGGACTG 1k C 11 kc GSGSATGGSGSTASSGS
GTGGTGCAAATTCTGGGGTTCTGGTTC GSATGANWCVSPNWF
CGCTACCGGTGGTTCCGGTTCCACTG CMVM (SEQ ID NO:
CTTCTTCTGGTTCCGGTTCTGCAACTG 134) GTCCGGACTGGTGCATCGACCCGGAT
TGGTGGTGTAAATTTTGG (SEQ ID NO; 284) Myostatin-2XTN8-
PDWCIDPDWWCKFWG ACCACTTGGTGCATCTCTCCGATGTG 1k C 25 kc
SGSATGGSGSTASSGSG GTTCTGCTCTCAGCAGGGTTCTGGTTC SATGPDWCIDPDWWC
CACTGCTTCTTCTGGTTCCGGTTCTGC KFW (SEQ ID NO: 135)
AACTGGTACTACTTGGTGTATCTCTCC AATGTGGTTTTGTTCTCAGCAA (SEQ ID NO: 285)
Myostatin-2XTN8- HWACGYWPWSCKWV CACTGGGCATGTGGCTATTGGCCGTG 1k C 23
kc GSGSATGGSGSTASSGS GTCCTGCAAATGGGTTGGTTCTGGTTC GSATGHWACGYWPWS
CGCTACCGGTGGTTCCGGTTCCACTG CKWV (SEQ ID NO:
CTTCTTCTGGTTCCGGTTCTGCAACTG 136) GTCACTGGGCTTGCGGTTACTGGCCG
TGGTCTTGTAAATGGGTT (SEQ ID NO: 286) Myostatin-TN8-29-
KKHCQIWTWMCAPKG AAAAAACACTGTCAGATCTGGACTTG 1k C 19 kc
SGSATGGSGSTASSGSG GATGTGCGCTCCGAAAGGTTCTGGTT SATGQGHCTRWPWMC
CCGCTACCGGTGGTTCTGGTTCCACTG PPY (SEQ ID NO: 137)
CTTCTTCTGGTTCCGGTTCCGCTACTG GTCAGGGTCACTGCACTCGTTGGCCA
TGGATGTGTCCGCCGTAT (SEQ ID NO: 287) Myostatin-TN8-19-
QGHCTRWPWMCPPYG CAGGGTCACTGCACCCGTTGGCCGTG 1k C 29 kc
SGSATGGSGSTASSGSG GATGTGCCCGCCGTACGGTTCTGGTT SATGKKHCQIWTWMC
CCGCTACCGGTGGTTCTGGTTCCACTG APK (SEQ ID NO: 138)
CTTCTTCTGGTTCCGGTTCTGCTACTG GTAAAAAACACTGCCAGATCTGGACT
TGGATGTGCGCTCCGAAA (SEQ ID NO: 288) Myostatin-TN8-29-
KKHCQIWTWMCAPKG AAAAAACACTGTCAGATCTGGACTTG 1k N 19 kn
SGSATGGSGSTASSGSG GATGTGCGCTCCGAAAGGTTCTGGTT SATGQGHCTRWPWMC
CCGCTACCGGTGGTTCTGGTTCCACTG PPY (SEQ ID NO: 139)
CTTCTTCTGGTTCCGGTTCCGCTACTG GTCAGGGTCACTGCACTCGTTGGCCA
TGGATGTGTCCGCCGTAT (SEQ ID NO: 289) Myostatin-TN8-29-
KKHCQIWTWMCAPKG AAAAAACACTGCCAGATCTGGACTTG 8 gly C 19-8g
GGGGGGGQGHCTRWP GATGTGCGCTCCGAAAGGTGGTGGTG WMCPPY (SEQ ID NO:
GTGGTGGCGGTGGCCAGGGTCACTGC 140) ACCCGTTGGCCGTGGATGTGTCCGCC GTAT
(SEQ ID NO: 290) Myostatin-TN8-19- QGHCTRWPWMCPPYG
CAGGGTCACTGCACCCGTTGGCCGTG 6 gly C 29-6gc GGGGGKKHCQIWTWM
GATGTGCCCGCCGTACGGTGGTGGTG CAPK (SEQ ID NO: 141)
GTGGTGGCAAAAAACACTGCCAGATC TGGACTTGGATGTGCGCTCCGAAA (SEQ ID NO:
291)
Example 3
In Vitro Assays
C2C12 Cell Based Myostatin Activity Assay
[0372] This assay demonstrates the myostatin neutralizing
capability of the inhibitor being tested by measuring the extent
that binding of myostatin to its receptor is inhibited.
[0373] A myostatin-responsive reporter cell line was generated by
transfection of C2C12 myoblast cells (ATCC No: CRL-1772) with a
pMARE-luc construct. The pMARE-luc construct was made by cloning
twelve repeats of the CAGA sequence, representing the
myostatin/activin response elements (Dennler et al. EMBO 17:
3091-3100 (1998)) into a pLuc-MCS reporter vector (Stratagene cat
#219087) upstream of the TATA box. The myoblast C2C12 cells
naturally express myostatin/activin receptors on its cell surface.
When myostatin binds the cell receptors, the Smad pathway is
activated, and phosphorylated Smad binds to the response element
(Macias-Silva et al. Cell 87:1215 (1996)), resulting in the
expression of the lucerase gene. Luciferase activity is then
measured using a commercial luciferase reporter assay kit (cat
#E4550, Promega, Madison, Wis.) according to manufacturer's
protocol. A stable line of C2C12 cells that had been transfected
with pMARE-luc (C2C12/pMARE clone #44) was used to measure
myostatin activity according to the following procedure.
[0374] Equal numbers of the reporter cells (C2C12/pMARE clone #44)
were plated into 96 well cultures. A first round screening using
two dilutions of peptibodies was performed with the myostatin
concentration fixed at 4 nM. Recombinant mature myostatin was
pre-incubated for 2 hours at room temperature with peptibodies at
40 nM and 400 nM respectively. The reporter cell culture was
treated with the myostatin with or without peptibodies for six
hours. Myostatin activity was measured by determining the
luciferase activity in the treated cultures. This assay was used to
initially identify peptibody hits that inhibited the myostatin
signaling activity in the reporter assay. Subsequently, a nine
point titration curve was generated with the myostatin
concentration fixed at 4 nM. The myostatin was preincubated with
each of the following nine concentrations of peptibodies: 0.04 mM,
0.4 nM, 4 nM, 20 nM, 40 nM, 200 nM, 400 nM, 2 uM and 4 uM for two
hours before adding the mixture to the reporter cell culture. The
IC.sub.50 values for a number of exemplary peptibodies are provided
in Table III, and for affinity matured peptibodies, in Table
VIII.
BIAcore.RTM. Assay
[0375] An affinity analysis of each candidate myostatin peptibody
was performed on a BIAcore.RTM. 3000 (Biacore, Inc., Piscataway,
N.J.), apparatus using sensor chip CM5, and 0.005 percent P20
surfactant (Biacore, Inc.) as running buffer. Recombinant mature
myostatin protein was immobilized to a research grade CM5 sensor
chip (Biacore, Inc.) via primary amine groups using the Amine
Coupling Kit (Biacore, Inc.) according to the manufacturer's
suggested protocol.
[0376] Direct binding assays were used to screen and rank the
peptibodies in order of their ability to bind to immobilized
myostatin. Binding assays were carried by injection of two
concentrations (40 and 400 nM) of each candidate myostatin-binding
peptibody to the immobilized myostatin surface at a flow rate of 50
.mu.l/min for 3 minutes. After a dissociation time of 3 minutes,
the surface was regenerated. Binding curves were compared
qualitatively for binding signal intensity, as well as for
dissociation rates. Peptibody binding kinetic parameters including
k.sub.a (association rate constant), k.sub.d (dissociation rate
constant) and K.sub.D (dissociation equilibrium constant) were
determined using the BIA evaluation 3.1 computer program (Biacore,
Inc.). The lower the dissociation equilibrium constants (expressed
in nM), the greater the affinity of the peptibody for myostatin.
Examples of peptibody K.sub.D values are shown in Table III and
Table VI for affinity-matured peptibodies below.
Blocking Assay on ActRIIB/Fc Surface
[0377] Blocking assays were carried out using immobilized
ActRIIB/Fc (R&D Systems, Minneapolis, Minn.) and myostatin in
the presence and absence of peptibodies with the BIAcore.RTM. assay
system. Assays were used to classify peptibodies as
non-neutralizing (those which did not prevent myostatin binding to
ActRIIB/Fc) or neutralizing (those that prevented myostatin binding
to ActRIIB/Fc). Baseline myostatin-ActRIIB/Fc binding was first
determined in the absence of any peptibody.
[0378] For early screening studies, peptibodies were diluted to 4
nM, 40 nM, and 400 nM in sample buffer and incubated with 4 nM
myostatin (also diluted in sample buffer). The peptibody: ligand
mixtures were allowed to reach equilibrium at room temperature (at
least 5 hours) and then were injected over the immobilized
ActRIIB/Fc surface for 20 to 30 minutes at a flow rate of 10
uL/min. An increased binding response (over control binding with no
peptibody) indicated that peptibody binding to myostatin was
non-neutralizing. A decreased binding response (compared to the
control) indicated that peptibody binding to myostatin blocked the
binding of myostatin to ActRIIB/Fc. Selected peptibodies were
further characterized using the blocking assay of a full
concentration series in order to derive IC.sub.50 values (for
neutralizing peptibodies) or EC.sub.50 (for non-neutralizing
peptibodies). The peptibody samples were serially diluted from 200
nM to 0.05 mM in sample buffer and incubated with 4 mM myostatin at
room temperature to reach equilibrium (minimum of five hours)
before injected over the immobilized ActRIIB/Fc surface for 20 to
30 minutes at a flow rate of 10 uL/min. Following the sample
injection, bound ligand was allowed to dissociate from the receptor
for 3 minutes. Plotting the binding signal vrs. peptibody
concentration, the IC.sub.50 values for each peptibody in the
presence of 4 nM myostatin were calculated. It was found, for
example, that the peptibodies TN8-19, L2 and L17 inhibit myostatin
activity in cell-based assay, but binding of TN-8-19 does not block
myostatin/ActRIIB/Fc interactions, indicating that TN-8-19 binds to
a different epitope than that observed for the other two
peptibodies.
Epitope Binning for Peptibodies
[0379] A purified peptibody was immobilized on a BIAcore chip to
capture myostatin before injection of a second peptibody, and the
amount of secondary peptibody bound to the captured myostatin was
determined Only peptibodies with distinct epitopes will bind to the
captured myostatin, thus enabling the binning of peptibodies with
similar or distinct epitope binding properties. For example, it was
shown that peptibodies TN8-19 and L23 bind to different epitopes on
myostatin.
Selectivity Assays
[0380] These assays were performed using BIAcore.RTM. technology,
to determine the selectivity of binding of the peptibodies to other
TGF.beta. family members. ActRIIB/Fc, TGF.beta.RII/Fc and
BMPR-1A/Fc (all obtained from R & D Systems, Minneapolis,
Minn.) were covalently coupled to research grade sensor chips
according to manufacturer's suggested protocol. Because BIAcore
assays detects changes in the refractive index, the difference
between the response detected with injection over the immobilized
receptor surfaces compared with the response detected with
injection over the control surface in the absence of any peptibody
represents the actual binding of Activin A, TGF.beta.1, TGF.beta.3,
and BMP4 to the receptors, respectively. With pre-incubation of
peptibodies and TGF.beta. molecules, a change (increase or
decrease) in binding response indicates peptibody binding to the
TGF.beta. family of molecules. The peptibodies of the present
invention all bind to myostatin but not to Activin A, TGF.beta.1,
TGF.beta.3, or BMP4.
KinEx A.TM. Equilibrium Assays
[0381] Solution-based equilibrium-binding assays using KinExA.TM.
technology (Sapidyne Instruments, Inc.) were used to determine the
dissociation equilibrium (K.sub.D) of myostatin binding to
peptibody molecules. This solution-based assay is considered to be
more sensitive than the BIAcore assay in some instances.
Reacti-Gel.TM. 6.times. was pre-coated with about 50 ug/ml
myostatin for over-night, and then blocked with BSA. 30 pM and 100
pM of peptibody samples were incubated with various concentrations
(0.5 pM to 5 nM) of myostatin in sample buffer at room temperature
for 8 hours before being run through the myostatin-coated beads.
The amount of the bead-bound peptibody was quantified by
fluorescent (Cy5) labeled goat anti-human-Fc antibody at 1 mg/ml in
superblock. The binding signal is proportional to the concentration
of free peptibody at equilibrium with a given myostatin
concentration. K.sub.D was obtained from the nonlinear regression
of the competition curves using a dual-curve one-site homogeneous
binding model provided in the KinEx A.TM. software (Sapidyne
Instruments, Inc.).
Example 4
Comparison of Myostatin Inhibitors
[0382] The ability of three exemplary first-round peptibodies to
bind to (K.sub.D) and inhibit (IC.sub.50) were compared with the
K.sub.D and IC.sub.50 values obtained for the soluble receptor
fusion protein actRIIB/Fc (R &D Systems, Inc., Minneapolis,
Minn.). The IC.sub.50 values were determined using the pMARE luc
cell-based assay described in Example 3 and the K.sub.D values were
determined using the Biacore.RTM. assay described in Example 3.
TABLE-US-00013 TABLE III Inhibitor IC.sub.50 (nM) K.sub.D (nM)
ActRIIB/Fc ~83 ~7 2xTN8-19-kc ~9 ~2 TN8-19 ~23 ~2 TN8-29 ~26 ~60
TN12-34 ~30 -- Linear-20 ~11 --
[0383] The peptibodies have an IC.sub.50 that is improved over the
receptor/Fc inhibitor and binding affinities which are comparable
in two peptibodies with the receptor/Fc.
Example 5
Comparison of Ability of Peptide and Peptibody to Inhibit
Myostatin
[0384] The following peptide sequence: QGHCTRWPWMCPPY (TN8-19) (SEQ
ID NO: 33) was used to construct the corresponding peptibody
TN8-19(pb) according to the procedure described in Example 2 above.
Both the peptide alone and the peptibody were screened for
myostatin inhibiting activity using the C2C12 based assay described
in Example 3 above. It can be seen from FIG. 1 the IC.sub.50
(effective concentration for fifty percent inhibition of myostatin)
for the peptibody is significantly less than that of the peptide,
and thus the ability of the peptide to inhibit myostatin activity
has been substantially improved by placing it in the peptibody
configuration.
Example 6
Generation of Affinity-Matured Peptides and Peptibodies
[0385] Several of the first round peptides used for peptibody
generation were chosen for affinity maturation. The selected
peptides included the following: the cysteine constrained TN8-19,
QGHCTRWPWMCPPY (SEQ ID NO: 33), and the linear peptides Linear-2
MEMLDSLFELLKDMVPISKA (SEQ ID NO: 104); Linear-15
HHGWNYLRKGSAPQWFEAWV (SEQ. ID NO: 117); Linear-17
RATLLKDFWQLVEGYGDN (SEQ ID NO: 119); Linear-20 YREMSMLEGLLDVLERLQHY
(SEQ ID NO: 122), Linear-21 HNSSQMLLSELIMLVGSMMQ (SEQ ID NO: 123),
Linear-24 EFFHWLHNHRSEVNHWLDMN (SEQ ID NO: 126). Based on a
consensus sequence, directed secondary phage display libraries were
generated in which the "core" amino acids (determined from the
consensus sequence) were either held constant or biased in
frequency of occurrence. Alternatively, an individual peptide
sequence could be used to generate a biased, directed phage display
library. Panning of such libraries under more stringent conditions
can yield peptides with enhanced binding to myostatin, selective
binding to myostatin, or with some additional desired property.
Production of Doped Oligos for Libraries
[0386] Oligonucleotides were synthesized in a DNA synthesizer which
were 91% "doped" at the core sequences, that is, each solution was
91% of the represented base (A, G, C, or T), and 3% of each of the
other 3 nucleotides. For the TN8-19 family, for example, a 91%
doped oligo used for the construction of a secondary phage library
was the following:
TABLE-US-00014 (SEQ ID NO: 634) 5'-CAC AGT GCA CAG GGT NNK NNK NNK
caK ggK caK tgK acK cgK tgKccK tgK atK tgK ccK ccK taK NNK NNK NNK
CAT TCT CTC GAG ATC A-3'
wherein "N" indicates that each of the four nucleotides A, T, C,
and G were equally represented, K indicates that G and T were
equally represented, and the lower case letter represents a mixture
of 91% of the indicated base and 3% of each of the other bases. The
family of oligonucleotides prepared in this manner were PCR
amplified as described above, ligated into a phagemid vectors, for
example, a modified pCES1 plasmid (Dyax), or any available phagemid
vector according to the protocol described above. The secondary
phage libraries generated were all 91% doped and had between 1 and
6.5.times.10.sup.9 independent transformants. The libraries were
panned as described above, but with the following conditions:
Round 1 Panning:
[0387] Input phage number: 10.sup.12-10.sup.13 cfu of phagemid
[0388] Selection method: Nunc Immuno Tube selection [0389] Negative
selection: 2.times. with Nunc Immuno Tubes coated with 2% BSA at 10
min each [0390] Panning coating: Coat with 1 .mu.g of Myostatin
protein in 1 ml of 0.1M Sodium carbonate buffer (pH 9.6) [0391]
Binding time: 3 hours [0392] Washing conditions:
6.times.2%-Milk-PBST; 6.times.PBST; 2.times.PBS [0393] Elution
condition: 100 mM TEA elution
Round 2 Panning:
[0393] [0394] Input phage number: 10.sup.11 cfu of phagemid [0395]
Selection method: Nunc Immuno Tube selection [0396] Negative
selection: 2.times. with Nunc Immuno Tubes coated with 2% BSA at 30
min. each [0397] Panning coating: Coat with 1 .mu.g of Myostatin
protein in 1 ml of 0.1M Sodium carbonate buffer (pH 9.6) [0398]
Binding time: 1 hour [0399] Washing conditions:
15.times.2%-Milk-PBST, 1.times.2%-Milk-PBST for 1 hr.,
10.times.2%-BSA-PBST, 1.times.2%-BSA-PBST for 1 hr., 10.times.PBST
and 3.times.PBS [0400] Elution condition: 100 mM TEA elution
Round 3 Panning:
[0400] [0401] Input phage number: 10.sup.10 cfu of phagemid [0402]
Selection method: Nunc Immuno Tube selection [0403] Negative
selection: 6.times. with Nunc Immuno Tubes coated with 2% BSA at 10
min. each [0404] Panning coating: Coat with 0.1 .mu.g of Myostatin
protein in 1 ml of 0.1M Sodium carbonate buffer (pH 9.6) [0405]
Binding time: 1 hour [0406] Washing conditions:
15.times.2%-Milk-PBST, 1.times.2%-Milk-PBST for 1 hr.,
10.times.2%-BSA-PBST, 1.times.2%-BSA-PBST for 1 hr., 10.times.PBST
and 3.times.PBS [0407] Elution condition: 100 mM TEA elution
[0408] Panning of the secondary libraries yielded peptides with
enhanced binding to myostatin. Individual selected clones were
subjected phage ELISA, as described above, and sequenced.
[0409] The following affinity matured TN8-19 family of peptides are
shown in Table IV below.
TABLE-US-00015 TABLE IV Affinity-matured SEQ ID peptibody NO:
Peptide sequence mTN8-19-1 305 VALHGQCTRWPWMCPPQREG mTN8-19-2 306
YPEQGLCTRWPWMCPPQTLA mTN8-19-3 307 GLNQGHCTRWPWMCPPQDSN mTN8-19-4
308 MITQGQCTRWPWMCPPQPSG mTN8-19-5 309 AGAQEHCTRWPWMCAPNDWI
mTN8-19-6 310 GVNQGQCTRWRWMCPPNGWE mTN8-19-7 311
LADHGQCIRWPWMCPPEGWE mTN8-19-8 312 ILEQAQCTRWPWMCPPQRGG mTN8-19-9
313 TQTHAQCTRWPWMCPPQWEG mTN8-19-10 314 VVTQGHCTLWPWMCPPQRWR
mTN8-19-11 315 IYPHDQCTRWPWMCPPQPYP mTN8-19-12 316
SYWQGQCTRWPWMCPPQWRG mTN8-19-13 317 MWQQGHCTRWPWMCPPQGWG mTN8-19-14
318 EFTQWHCTRWPWMCPPQRSQ mTN8-19-15 319 LDDQWQCTRWPWMCPPQGFS
mTN8-19-16 320 YQTQGLCTRWPWMCPPQSQR mTN8-19-17 321
ESNQGQCTRWPWMCPPQGGW mTN8-19-18 322 WTDRGPCTRWPWMCPPQANG mTN8-19-19
323 VGTQGQCTRWPWMCPPYETG mTN8-19-20 324 PYEQGKCTRWPWMCPPYEVE
mTN8-19-21 325 SEYQGLCTRWPWMCPPQGWK mTN8-19-22 326
TFSQGHCTRWPWMCPPQGWG mTN8-19-23 327 PGAHDHCTRWPWMCPPQSRY mTN8-19-24
328 VAEEWHCRRWPWMCPPQDWR mTN8-19-25 329 VGTQGHCTRWPWMCPPQPAG
mTN8-19-26 330 EEDQAHCRSWPWMCPPQGWV mTN8-19-27 331
ADTQGHCTRWPWMCPPQHWF mTN8-19-28 332 SGPQGHCTRWPWMCAPQGWF mTN8-19-29
333 TLVQGHCTRWPWMCPPQRWV mTN8-19-30 334 GMAHGKCTRWAWMCPPQSWK
mTN8-19-31 335 ELYHGQCTRWPWMCPPQSWA mTN8-19-32 336
VADHGHCTRWPWMCPPQGWG mTN8-19-33 337 PESQGHCTRWPWMCPPQGWG mTN8-19-34
338 IPAHGHCTRWPWMCPPQRWR mTN8-19-35 339 FTVHGHCTRWPWMCPPYGWV
mTN8-19-36 340 PDFPGHCTRWRWMCPPQGWE mTN8-19-37 341
QLWQGPCTQWPWMCPPKGRY mTN8-19-38 342 HANDGHCTRWQWMCPPQWGG mTN8-19-39
343 ETDHGLCTRWPWMCPPYGAR mTN8-19-40 344 GTWQGLCTRWPWMCPPQGWQ
mTN8-19 con1 345 VATQGQCTRWPWMCPPQGWG mTN8-19 con2 346
VATQGQCTRWPWMCPPQRWG mTN8 con6-1 347 QREWYPCYGGHLWCYDLHKA mTN8
con6-2 348 ISAWYSCYAGHFWCWDLKQK mTN8 con6-3 349
WTGWYQCYGGHLWCYDLRRK mTN8 con6-4 350 KTFWYPCYDGHFWCYNLKSS mTN8
con6-5 351 ESRWYPCYEGHLWCFDLTET
[0410] The consensus sequence derived from the affinity-matured
TN-8-19-1 through Con2 (excluding the mTN8 con6 sequences) shown
above is: Ca.sub.1a.sub.2Wa.sub.3WMCPP (SEQ ID NO: 352). All of
these peptides comprise the sequence WMCPP (SEQ ID NO: 633). The
underlined amino acids represent the core amino acids present in
all embodiments, and a.sub.1, a.sub.2 and a.sub.3 are selected from
a neutral hydrophobic, neutral polar, or basic amino acid. In one
embodiment of this consensus sequence, Cb.sub.1b.sub.2Wb.sub.3WMCPP
(SEQ ID NO: 353), b.sub.1 is selected from any one of the amino
acids T, I, or R; b.sub.2 is selected from any one of R, S, Q; and
b.sub.3 is selected from any one of P, R and Q. All of the peptides
comprise the sequence WMCPP (SEQ ID NO: 633). A more detailed
analysis of the affinity matured TN8 sequences comprising SEQ ID
NO: 352 provides the following formula:
c.sub.1c.sub.2c.sub.3c.sub.4c.sub.5c.sub.6Cc.sub.7c.sub.8Wc.sub.9WMCPPc.-
sub.10c.sub.11c.sub.12c.sub.13(SEQ ID NO: 354),
[0411] wherein:
[0412] c.sub.1 is absent or any amino acid;
[0413] c.sub.2 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0414] c.sub.3 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0415] c.sub.4 is absent or any amino acid;
[0416] c.sub.5 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0417] c.sub.6 is absent or a neutral hydrophobic, neutral polar,
or basic amino acid;
[0418] c.sub.7 is a neutral hydrophobic, neutral polar, or basic
amino acid;
[0419] c.sub.8 is a neutral hydrophobic, neutral polar, or basic
amino acid;
[0420] c.sub.9 is a neutral hydrophobic, neutral polar or basic
amino acid; and wherein
[0421] c.sub.10 to c.sub.13 is any amino acid.
[0422] In one embodiment of the above formulation, b.sub.7 is
selected from any one of the amino acids T, I, or R; b.sub.8 is
selected from any one of R, S, Q; and b.sub.9 is selected from any
one of P, R and Q. This provides the following sequence:
d.sub.1d.sub.2d.sub.3d.sub.4d.sub.5d.sub.6Cd.sub.7d.sub.8Wd.sub.9WMCPPd.-
sub.10d.sub.11d.sub.12d.sub.13(SEQ ID NO: 355).
[0423] d.sub.1 is absent or any amino acid;
[0424] d.sub.2 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0425] d.sub.3 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0426] d.sub.4 is absent or any amino acid;
[0427] d.sub.5 is absent or a neutral hydrophobic, neutral polar,
or acidic amino acid;
[0428] d.sub.6 is absent or a neutral hydrophobic, neutral polar,
or basic amino acid;
[0429] d.sub.7 is selected from any one of the amino acids T, I, or
R;
[0430] d.sub.8 is selected from any one of R, S, Q;
[0431] d.sub.9 is selected from any one of P, R and Q
[0432] and d.sub.10 through d.sub.13 are selected from any amino
acid.
[0433] The consensus sequence of the mTN8 con6 series is
WYe.sub.1e.sub.2Ye.sub.3G, (SEQ ID NO: 356) wherein e.sub.1 is P, S
or Y; e.sub.2 is C or Q, and e.sub.3 is G or H.
[0434] In addition to the TN-19 affinity matured family, additional
affinity matured peptides were produced from the linear L-2, L-15,
L-17, L-20, L-21, and L-24 first round peptides. These families are
presented in Table V below.
TABLE-US-00016 TABLE V Affinity matured SEQ ID peptibody NO:
Peptide Sequence L2 104 MEMLDSLFELLKDMVPISKA mL2-Con1 357
RMEMLESLLELLKEIVPMSKAG mL2-Con2 358 RMEMLESLLELLKEIVPMSKAR mL2-1
359 RMEMLESLLELLKDIVPMSKPS mL2-2 360 GMEMLESLFELLQEIVPMSKAP mL2-3
361 RMEMLESLLELLKDIVPISNPP mL2-4 362 RIEMLESLLELLQEIVPISKAE mL2-5
363 RMEMLQSLLELLKDIVPMSNAR mL2-6 364 RMEMLESLLELLKEIVPTSNGT mL2-7
365 RMEMLESLFELLKEIVPMSKAG mL2-8 366 RMEMLGSLLELLKEIVPMSKAR mL2-9
367 QMELLDSLFELLKEIVPKSQPA mL2-10 368 RMEMLDSLLELLKEIVPMSNAR mL2-11
369 RMEMLESLLELLHEIVPMSQAG mL2-12 370 QMEMLESLLQLLKEIVPMSKAS mL2-13
371 RMEMLDSLLELLKDMVPMTTGA mL2-14 372 RIEMLESLLELLKDMVPMANAS mL2-15
373 RMEMLESLLQLLNEIVPMSRAR mL2-16 374 RMEMLESLFDLLKELVPMSKGV mL2-17
375 RIEMLESLLELLKDIVPIQKAR mL2-18 376 RMELLESLFELLKDMVPMSDSS mL2-19
377 RMEMLESLLEVLQEIVPRAKGA mL2-20 378 RMEMLDSLLQLLNEIVPMSHAR mL2-21
379 RMEMLESLLELLKDIVPMSNAG mL2-22 380 RMEMLQSLFELLKGMVPISKAG mL2-23
381 RMEMLESLLELLKEIVPNSTAA mL2-24 382 RMEMLQSLLELLKEIVPISKAG mL2-25
383 RIEMLDSLLELLNELVPMSKAR L-15 117 HHGWNYLRKGSAPQWFEAWV mL15-con1
384 QVESLQQLLMWLDQKLASGPQG mL15-1 385 RMELLESLFELLKEMVPRSKAV mL15-2
386 QAVSLQHLLMWLDQKLASGPQH mL15-3 387 DEDSLQQLLMWLDQKLASGPQL mL15-4
388 PVASLQQLLIWLDQKLAQGPHA mL15-5 389 EVDELQQLLNWLDHKLASGPLQ mL15-6
390 DVESLEQLLMWLDHQLASGPHG mL15-7 391 QVDSLQQVLLWLEHKLALGPQV mL15-8
392 GDESLQHLLMWLEQKLALGPHG mL15-9 393 QIEMLESLLDLLRDMVPMSNAF
mL15-10 394 EVDSLQQLLMWLDQKLASGPQA mL15-11 395
EDESLQQLLIYLDKMLSSGPQV mL15-12 396 AMDQLHQLLIWLDHKLASGPQA mL15-13
397 RIEMLESLLELLDEIALIPKAW mL15-14 398 EVVSLQHLLMWLEHKLASGPDG
mL15-15 399 GGESLQQLLMWLDQQLASGPQR mL15-16 400
GVESLQQLLIFLDHMLVSGPHD mL15-17 401 NVESLEHLMMWLERLLASGPYA mL15-18
402 QVDSLQQLLIWLDHQLASGPKR mL15-19 403 EVESLQQLLMWLEHKLAQGPQG
mL15-20 404 EVDSLQQLLMWLDQKLASGPHA mL15-21 405
EVDSLQQLLMWLDQQLASGPQK mL15-22 406 GVEQLPQLLMWLEQKLASGPQR mL15-23
407 GEDSLQQLLMWLDQQLAAGPQV mL15-24 408 ADDSLQQLLMWLDRKLASGPHV
mL15-25 409 PVDSLQQLLIWLDQKLASGPQG L-17 119 RATLLKDFWQLVEGYGDN
mL17-con1 410 DWRATLLKEFWQLVEGLGDNLV mL17-con2 411
QSRATLLKEFWQLVEGLGDKQA mL17-1 412 DGRATLLTEFWQLVQGLGQKEA mL17-2 413
LARATLLKEFWQLVEGLGEKVV mL17-3 414 GSRDTLLKEFWQLVVGLGDMQT mL17-4 415
DARATLLKEFWQLVDAYGDRMV mL17-5 416 NDRAQLLRDFWQLVDGLGVKSW mL17-6 417
GVRETLLYELWYLLKGLGANQG mL17-7 418 QARATLLKEFCQLVGCQGDKLS mL17-8 419
QERATLLKEFWQLVAGLGQNMR mL17-9 420 SGRATLLKEFWQLVQGLGEYRW mL17-10
421 TMRATLLKEFWLFVDGQREMQW mL17-11 422 GERATLLNDFWQLVDGQGDNTG
mL17-12 423 DERETLLKEFWQLVHGWGDNVA mL17-13 424
GGRATLLKELWQLLEGQGANLV mL17-14 425 TARATLLNELVQLVKGYGDKLV mL17-15
426 GMRATLLQEFWQLVGGQGDNWM mL17-16 427 STRATLLNDLWQLMKGWAEDRG
mL17-17 428 SERATLLKELWQLVGGWGDNFG mL17-18 429
VGRATLLKEFWQLVEGLVGQSR mL17-19 430 EIRATLLKEFWQLVDEWREQPN mL17-20
431 QLRATLLKEFLQLVHGLGETDS mL17-21 432 TQRATLLKEFWQLIEGLGGKHV
mL17-22 433 HYRATLLKEFWQLVDGLREQGV mL17-23 434
QSRVTLLREFWQLVESYRPIVN mL17-24 435 LSRATLLNEFWQFVDGQRDKRM mL17-25
436 WDRATLLNDFWHLMEELSQKPG mL17-26 437 QERATLLKEFWRMVEGLGKNRG
mL17-27 438 NERATLLREFWQLVGGYGVNQR L-20 122 YREMSMLEGLLDVLERLQHY
mL20-1 439 HQRDMSMLWELLDVLDGLRQYS mL20-2 440 TQRDMSMLDGLLEVLDQLRQQR
mL20-3 441 TSRDMSLLWELLEELDRLGHQR mL20-4 442 MQHDMSMLYGLVELLESLGHQI
mL20-5 443 WNRDMRMLESLFEVLDGLRQQV mL20-6 444 GYRDMSMLEGLLAVLDRLGPQL
mL20 con1 445 TQRDMSMLEGLLEVLDRLGQQR mL20 con2 446
WYRDMSMLEGLLEVLDRLGQQR L-21 123 HNSSQMLLSELIMLVGSMMQ mL21-1 447
TQNSRQMLLSDFMMLVGSMIQG mL21-2 448 MQTSRHILLSEFMMLVGSIMHG mL21-3 449
HDNSRQMLLSDLLHLVGTMIQG mL21-4 450 MENSRQNLLRELIMLVGNMSHQ mL21-5 451
QDTSRHMLLREFMMLVGEMIQG mL21 con1 452 DQNSRQMLLSDLMILVGSMIQG L-24
126 EFFHWLHNHRSEVNHWLDMN mL24-1 453 NVFFQWVQKHGRVVYQWLDINV mL24-2
454 FDFLQWLQNHRSEVEHWLVMDV
[0435] The affinity matured peptides provided in Tables IV and V
are then assembed into peptibodies as described above and assayed
using the in vivo assays.
[0436] The affinity matured L2 peptides comprise a consensus
sequence of f.sub.1EMLf.sub.2SLf.sub.3f.sub.4LL, (SEQ ID NO: 455),
wherein f.sub.1 is M or I; f.sub.2 is any amino acid; f.sub.3 is L
or F; and f.sub.4 is E, Q or D.
[0437] The affinity matured L15 peptide family comprise the
sequence Lg.sub.1g.sub.2LLg.sub.3g.sub.4L, (SEQ ID NO: 456),
wherein g.sub.1 is Q, D or E, g.sub.2 is S, Q, D or E, g.sub.3 is
any amino acid, and g.sub.4 is L, W, F, or Y. The affinity matured
L17 family comprises the sequence:
h.sub.1h.sub.2h.sub.3h.sub.4h.sub.5h.sub.6h.sub.7h.sub.8h.sub.9
(SEQ ID NO: 457) wherein h.sub.1 is R or D; h.sub.2 is any amino
acid; h.sub.3 is A, T S or Q; h.sub.4 is L or M; h.sub.5 is L or S;
h.sub.6 is any amino acid; h.sub.7 is F or E; h.sub.8 is W, F or C;
and h.sub.9 is L, F, M or K. Consensus sequences may also be
determined for the mL20, mL21 and mL24 families of peptides shown
above.
[0438] Peptibodies were constructed from these affinity matured
peptides as described above, using a linker attached to the Fc
domain of human IgG1, having SEQ ID NO: 296, at the N-terminus (N
configuration), at the C terminus (C configuration) of the Fc, or
at both the N and C terminals (N,C configurations), as described in
Example 2 above. The peptides named were attached to the C or N
terminals via a 5 glycine (5G), 8 glycine or k linker sequence. In
the 2.times. peptibody version the peptides were linked with
linkers such as 5 gly, 8 gly or k. Affinity matured peptides and
peptibodies are designated with a small "m" such as mTN8-19-22 for
example. Peptibodies of the present invention further contain two
splice sites where the peptides were spliced into the phagemid
vectors. The position of these splice sites are AQ-peptide-LE. The
peptibodies generally include these additional amino acids
(although they are not included in the peptide sequences listed in
the tables). In some peptibodies the LE amino acids were removed
from the peptides sequences. These peptibodies are designated
-LE.
[0439] Exemplary peptibodies, and exemplary polynucleotide
sequences encoding them, are provided in Table VI below. This table
includes examples of peptibody sequences (as opposed to peptide
only), such as the 2.times.mTN8-19-7 (SEQ ID NO: 615) and the
peptibody with the LE sequences deleted (SEQ ID NO: 617). By way of
explanation, the linker sequences in the 2.times. versions refer to
the linker between the tandem peptides. These peptibody sequences
contain the Fc, linkers, AQ and LE sequences. The accompanying
nucleotide sequence encodes the peptide sequence in addition to the
AQ/LE linker sequences, if present, but does not encode the
designated linker.
TABLE-US-00017 TABLE VI Peptibody Name Peptide Nucleotide Sequence
(SEQ ID No) Linker Terminus mL2-Con1 RMEMLESLLELL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N KEIVPMSKAG
TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 357) AATGTCTAAAGCTGGT (SEQ ID
NO: 458) mL2-Con2 RMEMLESLLELL CGTATGGAAATGCTTGAATCTCTTC 5 gly N
KEIVPMSKAR TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 358)
AATGTCTAAAGCTCGT (SEQ ID NO: 459) mL2-1 RMEMLESLLELL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N KDIVPMSKPS
TTGAACTTCTTAAAGATATTGTTCC (SEQ ID NO: 359) AATGTCTAAACCATCT (SEQ ID
NO: 460) mL2-2 GMEMLESLFELL GGTATGGAAATGCTTGAATCTCTTT 5 gly N
QEIVPMSKAP TTGAACTTCTTCAAGAAATTGTTCC (SEQ ID NO: 360)
AATGTCTAAAGCTCCA (SEQ ID NO: 461) mL2-3 RMEMLESLLELL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N KDIVPISNPP (SEQ
TTGAACTTCTTAAAGATATTGTTCC ID NO: 361) AATTTCTAATCCACCA (SEQ ID NO:
462) mL2-4 RIEMLESLLELLQ CGTATTGAAATGCTTGAATCTCTTC 5 gly N
EIVPISKAE (SEQ TTGAACTTCTTCAAGAAATTGTTCC ID NO: 362)
AATTTCTAAAGCTGAA (SEQ ID NO: 463) mL2-5 RMEMLQSLLELL
CGTATGGAAATGCTTCAATCTCTTC 5 gly N KDIVPMSNAR
TTGAACTTCTTAAAGATATTGTTCC (SEQ ID NO: 363) AATGTCTAATGCTCGT (SEQ ID
NO: 464) mL2-6 RMEMLESLLELL CGTATGGAAATGCTTGAATCTCTTC 5 gly N
KEIVPTSNGT TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 364)
AACTTCTAATGGTACT (SEQ ID NO: 465) mL2-7 RMEMLESLFELL
CGTATGGAAATGCTTGAATCTCTTT 5 gly N KEIVPMSKAG
TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 365) AATGTCTAAAGCTGGT (SEQ ID
NO: 466) mL2-8 RMEMLGSLLELL CGTATGGAAATGCTTGGTTCTCTTC 5 gly N
KEIVPMSKAR TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 366)
AATGTCTAAAGCTCGT(SEQ ID NO: 467) mL2-9 QMELLDSLFELL
CAAATGGAACTTCTTGATTCTCTTT 5 gly N KEIVPKSQPA
TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 367) AAAATCTCAACCAGCT (SEQ ID
NO: 468) mL2-10 RMEMLDSLLELL CGTATGGAAATGCTTGATTCTCTTC 5 gly N
KEIVPMSNAR TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 368)
AATGTCTAATGCTCGT (SEQ ID NO: 469) mL2-11 RMEMLESLLELL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N HEIVPMSQAG
TTGAACTTCTTCATGAAATTGTTCC (SEQ ID NO: 369) AATGTCTCAAGCTGGT (SEQ ID
NO: 470) mL2-12 QMEMLESLLQLL CAAATGGAAATGCTTGAATCTCTTC 5 gly N
KEIVPMSKAS TTCAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 370)
AATGTCTAAAGCTTCT (SEQ ID NO: 471) mL2-13 RMEMLDSLLELL
CGTATGGAAATGCTTGATTCTCTTC 5 gly N KDMVPMTTGA
TTGAACTTCTTAAAGATATGGTTCC (SEQ ID NO: 371) AATGACTACTGGTGCT (SEQ ID
NO: 472) mL2-14 RIEMLESLLELLK CGTATTGAAATGCTTGAATCTCTTC 5 gly N
DMVPMANAS TTGAACTTCTTAAAGATATGGTTCC (SEQ ID NO: 372)
AATGGCTAATGCTTCT (SEQ ID NO: 473) mL2-15 RMEMLESLLQLL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N NEIVPMSRAR
TTCAACTTCTTAATGAAATTGTTCC (SEQ ID NO: 373) AATGTCTCGTGCTCGT (SEQ ID
NO: 474) mL2-16 RMEMLESLFDLL CGTATGGAAATGCTTGAATCTCTTT 5 gly N
KELVPMSKGV TTGATCTTCTTAAAGAACTTGTTCC (SEQ ID NO: 374)
AATGTCTAAAGGTGTT (SEQ ID NO: 475) mL2-17 RIEMLESLLELLK
CGTATTGAAATGCTTGAATCTCTTC 5 gly N DIVPIQKAR (SEQ
TTGAACTTCTTAAAGATATTGTTCC ID NO: 375) AATTCAAAAAGCTCGT (SEQ ID NO:
476) mL2-18 RMELLESLFELLK CGTATGGAACTTCTTGAATCTCTTT 5 gly N
DMVPMSDSS TTGAACTTCTTAAAGATATGGTTCC (SEQ ID NO: 376)
AATGTCTGATTCTTCT (SEQ ID NO: 477) mL2-19 RMEMLESLLEVL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N QEIVPRAKGA
TTGAAGTTCTTCAAGAAATTGTTCC (SEQ ID NO: 377) ACGTGCTAAAGGTGCT (SEQ ID
NO: 478) mL2-20 RMEMLDSLLQLL CGTATGGAAATGCTTGATTCTCTTC 5 gly N
NEIVPMSHAR TTCAACTTCTTAATGAAATTGTTCC (SEQ ID NO: 378)
AATGTCTCATGCTCGT (SEQ ID NO: 479) mL2-21 RMEMLESLLELL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N KDIVPMSNAG
TTGAACTTCTTAAAGATATTGTTCC (SEQ ID NO: 379) AATGTCTAATGCTGGT (SEQ ID
NO: 480) mL2-22 RMEMLQSLFELL CGTATGGAAATGCTTCAATCTCTTT 5 gly N
KGMVPISKAG TTGAACTTCTTAAAGGTATGGTTCC (SEQ ID NO: 380)
AATTTCTAAAGCTGGT (SEQ ID NO: 481) mL2-23 RMEMLESLLELL
CGTATGGAAATGCTTGAATCTCTTC 5 gly N KEIVPNSTAA
TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 381) AAATTCTACTGCTGCT (SEQ ID
NO: 482) mL2-24 RMEMLQSLLELL CGTATGGAAATGCTTCAATCTCTTC 5 gly N
KEIVPISKAG TTGAACTTCTTAAAGAAATTGTTCC (SEQ ID NO: 382)
AATTTCTAAAGCTGGT (SEQ ID NO: 483) mL2-25 RIEMLDSLLELLN
CGTATTGAAATGCTTGATTCTCTTC 5 gly N ELVPMSKAR
TTGAACTTCTTAATGAACTTGTTCC (SEQ ID NO: 383) AATGTCTAAAGCTCGT (SEQ ID
NO: 484) mL17-Con1 DWRATLLKEFW GATTGGCGTGCTACTCTTCTTAAAG 5 gly N
QLVEGLGDNLV AATTTTGGCAACTTGTTGAAGGTCT (SEQ ID NO: 384)
TGGTGATAATCTTGTT (SEQ ID NO: 485) mL17-1 DGRATLLTEFWQ
GATGGTCGTGCTACTCTTCTTACTG 5 gly N LVQGLGQKEA
AATTTTGGCAACTTGTTCAAGGTCT (SEQ ID NO: 412) TGGTCAAAAAGAAGCT (SEQ ID
NO: 486) mL17-2 LARATLLKEFWQ CTTGCTCGTGCTACTCTTCTTAAAG 5 gly N
LVEGLGEKVV AATTTTGGCAACTTGTTGAAGGTCT (SEQ ID NO: 413)
TGGTGAAAAAGTTGTT (SEQ ID NO: 487) mL17-3 GSRDTLLKEFWQ
GGTTCTCGTGATACTCTTCTTAAAG 5 gly N LVVGLGDMQT
AATTTTGGCAACTTGTTGTTGGTCT (SEQ ID NO: 414) TGGTGATATGCAAACT (SEQ ID
NO: 488) mL17-4 DARATLLKEFWQ GATGCTCGTGCTACTCTTCTTAAAG 5 gly N
LVDAYGDRMV AATTTTGGCAACTTGTTGATGCTTA (SEQ ID NO: 415)
TGGTGATCGTATGGTT (SEQ ID NO: 489) mL17-5 NDRAQLLRDFWQ
AATGATCGTGCTCAACTTCTTCGTG 5 gly N LVDGLGVKSW
ATTTTTGGCAACTTGTTGATGGTCT (SEQ ID NO: 416) TGGTGTTAAATCTTGG (SEQ ID
NO: 490) mL17-6 GVRETLLYELWY GGTGTTCGTGAAACTCTTCTTTATG 5 gly N
LLKGLGANQG AACTTTGGTATCTTCTTAAAGGTCT (SEQ ID NO: 417)
TGGTGCTAATCAAGGT (SEQ ID NO: 491) mL17-7 QARATLLKEFCQ
CAAGCTCGTGCTACTCTTCTTAAAG 5 gly N LVGCQGDKLS
AATTTTGTCAACTTGTTGGTTGTCA (SEQ ID NO: 418) AGGTGATAAACTTTCT (SEQ ID
NO: 492) mL17-8 QERATLLKEFWQ CAAGAACGTGCTACTCTTCTTAAA 5 gly N
LVAGLGQNMR GAATTTTGGCAACTTGTTGCTGGTC (SEQ ID NO: 419)
TTGGTCAAAATATGCGT (SEQ ID NO: 493) mL17-9 SGRATLLKEFWQ
TCTGGTCGTGCTACTCTTCTTAAAG 5 gly N LVQGLGEYRW
AATTTTGGCAACTTGTTCAAGGTCT (SEQ ID NO: 420) TGGTGAATATCGTTGG (SEQ ID
NO: 494) mL17-10 TMRATLLKEFWL ACTATGCGTGCTACTCTTCTTAAAG 5 gly N
FVDGQREMQW AATTTTGGCTTTTTGTTGATGGTCA (SEQ ID NO: 421)
ACGTGAAATGCAATGG (SEQ ID NO: 495) mL17-11 GERATLLNDFWQ
GGTGAACGTGCTACTCTTCTTAATG 5 gly N LVDGQGDNTG
ATTTTTGGCAACTTGTTGATGGTCA (SEQ ID NO: 422) AGGTGATAATACTGGT (SEQ ID
NO: 496) mL17-12 DERETLLKEFWQ GATGAACGTGAAACTCTTCTTAAA 5 gly N
LVHGWGDNVA GAATTTTGGCAACTTGTTCATGGTT (SEQ ID NO: 423)
GGGGTGATAATGTTGCT (SEQ ID NO: 497) mL17-13 GGRATLLKELWQ
GGTGGTCGTGCTACTCTTCTTAAAG 5 gly N LLEGQGANLV
AACTTTGGCAACTTCTTGAAGGTCA (SEQ ID NO: 424) AGGTGCTAATCTTGTT (SEQ ID
NO: 498) mL17-14 TARATLLNELVQ ACTGCTCGTGCTACTCTTCTTAATG 5 gly N
LVKGYGDKLV AACTTGTTCAACTTGTTAAAGGTTA (SEQ ID NO: 425)
TGGTGATAAACTTGTT (SEQ ID NO: 499) mL17-15 GMRATLLQEFWQ
GGTATGCGTGCTACTCTTCTTCAAG 5 gly N LVGGQGDNWM
AATTTTGGCAACTTGTTGGTGGTCA (SEQ ID NO: 426) AGGTGATAATTGGATG (SEQ ID
NO: 500) mL17-16 STRATLLNDLWQ TCTACTCGTGCTACTCTTCTTAATG 5 gly N
LMKGWAEDRG ATCTTTGGCAACTTATGAAAGGTTG (SEQ ID NO: 427)
GGCTGAAGATCGTGGT (SEQ ID NO: 501) mL17-17 SERATLLKELWQ
TCTGAACGTGCTACTCTTCTTAAAG 5 gly N LVGGWGDNFG
AACTTTGGCAACTTGTTGGTGGTTG (SEQ ID NO: 428) GGGTGATAATTTTGGT (SEQ ID
NO: 502) mL17-18 VGRATLLKEFWQ GTTGGTCGTGCTACTCTTCTTAAAG 5 gly N
LVEGLVGQSR AATTTTGGCAACTTGTTGAAGGTCT (SEQ ID NO: 429)
TGTTGGTCAATCTCGT (SEQ ID NO: 503) 2x mTN8-Con6- M-GAQ-
TGGTATCCGTGTTATGAGGGTCACT 1K N (N)-1K WYPCYEGHFWC
TCTGGTGCTACGATCTGGGTTCTGG YDL- TTCCACTGCTTCTTCTGGTTCCGGT
GSGSATGGSGST TCCGCTACTGGTTGGTACCCGTGCT ASSGSGSATG-
ACGAAGGTCACTTTTGGTGTTATGA WYPCYEGHFWC TCTG (SEQ ID NO: 505)
YDL-LE-5G-FC (SEQ ID NO: 504) 2x mTN8-Con6- FC-5G-AQ-
TGGTATCCGTGTTATGAGGGTCACT 1K C (C)-1K WYPCYEGHFWC
TCTGGTGCTACGATCTGGGTTCTGG YDL- TTCCACTGCTTCTTCTGGTTCCGGT
GSGSATGGSGST TCCGCTACTGGTTGGTACCCGTGCT ASSGSGSATG-
ACGAAGGTCACTTTTGGTGTTATGA WYPCYEGHFWC TCTG (SEQ ID NO: 507) YDL-LE
(SEQ ID
NO: 506) 2x mTN8-Con7- M-GAQ- ATCTTTGGCTGTAAATGGTGGGAC 1K N (N)-1K
IFGCKWWDVQC GTTCAGTGCTACCAGTTCGGTTCTG YQF-
GTTCCACTGCTTCTTCTGGTTCCGG GSGSATGGSGST TTCCGCTACTGGTATCTTCGGTTGC
ASSGSGSATG- AAGTGGTGGGATGTACAGTGTTAT IFGCKWWDVQC CAGTTT (SEQ ID NO:
509) YQF-LE-5G-FC (SEQ ID NO: 508) 2x mTN8-Con7- FC-5G-AQ-
ATCTTTGGCTGTAAATGGTGGGAC 1K C (C)-1K IFGCKWWDVQC
GTTCAGTGCTACCAGTTCGGTTCTG YQF- GTTCCACTGCTTCTTCTGGTTCCGG
GSGSATGGSGST TTCCGCTACTGGTATCTTCGGTTGC ASSGSGSATG-
AAGTGGTGGGATGTACAGTGTTAT IFGCKWWDVQC CAGTTT (SEQ ID NO: 511) YQF-LE
(SEQ ID NO: 510) 2x mTN8-Con8- M-GAQ- ATCTTTGGCTGTAAGTGGTGGGAC 1K N
(N)-1K IFGCKWWDVDC GTTGACTGCTACCAGTTCGGTTCTG YQF-
GTTCCACTGCTTCTTCTGGTTCCGG GSGSATGGSGST TTCCGCTACTGGTATCTTCGGTTGC
ASSGSGSATG- AAATGGTGGGACGTTGATTGTTAT IFGCKWWDVDC CAGTTT (SEQ ID NO:
513) YQF-LE-5G-FC (SEQ ID NO: 512) 2x mTN8-Con8- FC-5G-AQ-
ATCTTTGGCTGTAAGTGGTGGGAC 1K C (C)-1K IFGCKWWDVDC
GTTGACTGCTACCAGTTCGGTTCTG YQF- GTTCCACTGCTTCTTCTGGTTCCGG
GSGSATGGSGST TTCCGCTACTGGTATCTTCGGTTGC ASSGSGSATG-
AAATGGTGGGACGTTGATTGTTAT IFGCKWWDVDC CAGTTT (SEQ ID NO: 515) YQF-LE
(SEQ ID NO: 514) mL15-Con1 QVESLQQLLMWL CAGGTTGAATCCCTGCAGCAGCTG 5
gly C DQKLASGPQG CTGATGTGGCTGGACCAGAAACTG (SEQ ID NO: 384)
GCTTCCGGTCCGCAGGGT (SEQ ID NO: 516) mL15-1 RMELLESLFELLK
CGTATGGAACTGCTGGAATCCCTG 5 gly C EMVPRSKAV TTCGAACTGCTGAAAGAAATGGTT
(SEQ ID NO: 385) CCGCGTTCCAAAGCTGTT (SEQ ID NO: 517) mL15-2
QAVSLQHLLMW CAGGCTGTTTCCCTGCAGCACCTGC 5 gly C LDQKLASGPQH
TGATGTGGCTGGACCAGAAACTGG (SEQ ID NO: 386) CTTCCGGTCCGCAGCAC (SEQ ID
NO: 518) mL15-3 DEDSLQQLLMWL GACGAAGACTCCCTGCAGCAGCTG 5 gly C
DQKLASGPQL CTGATGTGGCTGGACCAGAAACTG (SEQ ID NO: 387)
GCTTCCGGTCCGCAGCTG (SEQ ID NO: 519) mL15-4 PVASLQQLLIWL
CCGGTTGCTTCCCTGCAGCAGCTGC 5 gly C DQKLAQGPHA
TGATCTGGCTGGACCAGAAACTGG (SEQ ID NO: 388) CTCAGGGTCCGCACGCT (SEQ ID
NO: 520) mL15-5 EVDELQQLLNWL GAAGTTGACGAACTGCAGCAGCTG 5 gly C
DHKLASGPLQ CTGAACTGGCTGGACCACAAACTG (SEQ ID NO: 389)
GCTTCCGGTCCGCTGCAG (SEQ ID NO: 521) mL15-6 DVESLEQLLMWL
GACGTTGAATCCCTGGAACAGCTG 5 gly C DHQLASGPHG
CTGATGTGGCTGGACCACCAGCTG (SEQ ID NO: 390) GCTTCCGGTCCGCACGGT (SEQ
ID NO: 522) mL15-7 QVDSLQQVLLWL CAGGTTGACTCCCTGCAGCAGGTT 5 gly C
EHKLALGPQV CTGCTGTGGCTGGAACACAAACTG (SEQ ID NO: 391)
GCTCTGGGTCCGCAGGTT (SEQ ID NO: 523) mL15-8 GDESLQHLLMWL
GGTGACGAATCCCTGCAGCACCTG 5 gly C EQKLALGPHG
CTGATGTGGCTGGAACAGAAACTG (SEQ ID NO: 392) GCTCTGGGTCCGCACGGT (SEQ
ID NO: 524) mL15-9 QIEMLESLLDLLR CAGATCGAAATGCTGGAATCCCTG 5 gly C
DMVPMSNAF CTGGACCTGCTGCGTGACATGGTTC (SEQ ID NO: 393)
CGATGTCCAACGCTTTC (SEQ ID NO: 525) mL15-10 EVDSLQQLLMWL
GAAGTTGACTCCCTGCAGCAGCTG 5 gly C DQKLASGPQA
CTGATGTGGCTGGACCAGAAACTG (SEQ ID NO: 394) GCTTCCGGTCCGCAGGCT (SEQ
ID NO: 526) mL15-11 EDESLQQLLIYLD GAAGACGAATCCCTGCAGCAGCTG 5 gly C
KMLSSGPQV CTGATCTACCTGGACAAAATGCTG (SEQ ID NO: 395)
TCCTCCGGTCCGCAGGTT (SEQ ID NO: 527) mL15-12 AMDQLHQLLIWL
GCTATGGACCAGCTGCACCAGCTG 5 gly C DHKLASGPQA
CTGATCTGGCTGGACCACAAACTG (SEQ ID NO: 396) GCTTCCGGTCCGCAGGCT (SEQ
ID NO: 528) mL15-13 RIEMLESLLELLD CGTATCGAAATGCTGGAATCCCTG 5 gly C
EIALIPKAW (SEQ CTGGAACTGCTGGACGAAATCGCT ID NO: 397)
CTGATCCCGAAAGCTTGG (SEQ ID NO: 529) mL15-14 EVVSLQHLLMWL
GAAGTTGTTTCCCTGCAGCACCTGC 5 gly C EHKLASGPDG
TGATGTGGCTGGAACACAAACTGG (SEQ ID NO: 398) CTTCCGGTCCGGACGGT (SEQ ID
NO: 530) mL15-15 GGESLQQLLMWL GGTGGTGAATCCCTGCAGCAGCTG 5 gly C
DQQLASGPQR CTGATGTGGCTGGACCAGCAGCTG (SEQ ID NO: 399)
GCTTCCGGTCCGCAGCGT (SEQ ID NO: 531) mL15-16 GVESLQQLLIFLD
GGTGTTGAATCCCTGCAGCAGCTG 5 gly C HMLVSGPHD
CTGATCTTCCTGGACCACATGCTGG (SEQ ID NO: 400) TTTCCGGTCCGCACGAC (SEQ
ID NO: 532) mL15-17 NVESLEHLMMW AACGTTGAATCCCTGGAACACCTG 5 gly C
LERLLASGPYA ATGATGTGGCTGGAACGTCTGCTG (SEQ ID NO: 401)
GCTTCCGGTCCGTACGCT (SEQ ID NO: 533) mL15-18 QVDSLQQLLIWL
CAGGTTGACTCCCTGCAGCAGCTG 5 gly C DHQLASGPKR
CTGATCTGGCTGGACCACCAGCTG (SEQ ID NO: 402) GCTTCCGGTCCGAAACGT (SEQ
ID NO: 534) mL15-19 EVESLQQLLMWL GAAGTTGAATCCCTGCAGCAGCTG 5 gly C
EHKLAQGPQG CTGATGTGGCTGGAACACAAACTG (SEQ ID NO: 403)
GCTCAGGGTCCGCAGGGT (SEQ ID NO: 535) mL15-20 EVDSLQQLLMWL
GAAGTTGACTCCCTGCAGCAGCTG 5 gly C DQKLASGPHA
CTGATGTGGCTGGACCAGAAACTG (SEQ ID NO: 404) GCTTCCGGTCCGCACGCT (SEQ
ID NO: 536) mL15-21 EVDSLQQLLMWL GAAGTTGACTCCCTGCAGCAGCTG 5 gly C
DQQLASGPQK CTGATGTGGCTGGACCAGCAGCTG (SEQ ID NO: 405)
GCTTCCGGTCCGCAGAAA (SEQ ID NO: 537) mL15-22 GVEQLPQLLMWL
GGTGTTGAACAGCTGCCGCAGCTG 5 gly C EQKLASGPQR
CTGATGTGGCTGGAACAGAAACTG (SEQ ID NO: 406) GCTTCCGGTCCGCAGCGT (SEQ
ID NO: 538) mL15-23 GEDSLQQLLMWL GGTGAAGACTCCCTGCAGCAGCTG 5 gly C
DQQLAAGPQV CTGATGTGGCTGGACCAGCAGCTG (SEQ ID NO: 407)
GCTGCTGGTCCGCAGGTT (SEQ ID NO: 539) mL15-24 ADDSLQQLLMW
GCTGACGACTCCCTGCAGCAGCTG 5 gly C LDRKLASGPHV
CTGATGTGGCTGGACCGTAAACTG (SEQ ID NO: 408) GCTTCCGGTCCGCACGTT (SEQ
ID NO: 540) mL15-25 PVDSLQQLLIWL CCGGTTGACTCCCTGCAGCAGCTG 5 gly C
DQKLASGPQG CTGATCTGGCTGGACCAGAAACTG (SEQ ID NO: 409)
GCTTCCGGTCCGCAGGGT (SEQ ID NO: 541) mL17-con2 QSRATLLKEFWQ
CAGTCCCGTGCTACCCTGCTGAAA 5 gly C LVEGLGDKQA
GAATTCTGGCAGCTGGTTGAAGGT (SEQ ID NO: 411) CTGGGTGACAAACAGGCT (SEQ
ID NO: 542) mL17-19 EIRATLLKEFWQL GAAATCCGTGCTACCCTGCTGAAA 5 gly C
VDEWREQPN GAATTCTGGCAGCTGGTTGACGAA (SEQ ID NO: 430)
TGGCGTGAACAGCCGAAC (SEQ ID NO: 543) mL17-20 QLRATLLKEFLQL
CAGCTGCGTGCTACCCTGCTGAAA 5 gly C VHGLGETDS
GAATTCCTGCAGCTGGTTCACGGTC (SEQ ID NO: 431) TGGGTGAAACCGACTCC (SEQ
ID NO: 544) mL17-21 TQRATLLKEFWQ ACCCAGCGTGCTACCCTGCTGAAA 5 gly C
LIEGLGGKHV GAATTCTGGCAGCTGATCGAAGGT (SEQ ID NO: 432)
CTGGGTGGTAAACACGTT (SEQ ID NO: 545) mL17-22 HYRATLLKEFWQ
CACTACCGTGCTACCCTGCTGAAA 5 gly C LVDGLREQGV
GAATTCTGGCAGCTGGTTGACGGT (SEQ ID NO: 433) CTGCGTGAACAGGGTGTT (SEQ
ID NO: 546) mL17-23 QSRVTLLREFWQ CAGTCCCGTGTTACCCTGCTGCGTG 5 gly C
LVESYRPIVN AATTCTGGCAGCTGGTTGAATCCTA (SEQ ID NO: 434)
CCGTCCGATCGTTAAC (SEQ ID NO: 547) mL17-24 LSRATLLNEFWQ
CTGTCCCGTGCTACCCTGCTGAACG 5 gly C FVDGQRDKRM
AATTCTGGCAGTTCGTTGACGGTCA (SEQ ID NO: 435) GCGTGACAAACGTATG (SEQ ID
NO: 548) mL17-25 WDRATLLNDFW TGGGACCGTGCTACCCTGCTGAAC 5 gly C
HLMEELSQKPG GACTTCTGGCACCTGATGGAAGAA (SEQ ID NO: 436)
CTGTCCCAGAAACCGGGT (SEQ ID NO: 549) mL17-26 QERATLLKEFWR
CAGGAACGTGCTACCCTGCTGAAA 5 gly C MVEGLGKNRG
GAATTCTGGCGTATGGTTGAAGGT (SEQ ID NO: 437) CTGGGTAAAAACCGTGGT (SEQ
ID NO: 550) mL17-27 NERATLLREFWQ AACGAACGTGCTACCCTGCTGCGT 5 gly C
LVGGYGVNQR GAATTCTGGCAGCTGGTTGGTGGTT (SEQ ID NO: 438)
ACGGTGTTAACCAGCGT (SEQ ID NO: 551) mTN8Con6-1 QREWYPCYGGHL
CAGCGTGAATGGTACCCGTGCTAC 5 gly C WCYDLHKA (SEQ
GGTGGTCACCTGTGGTGCTACGAC ID NO: 347) CTGCACAAAGCT (SEQ ID NO: 552)
mTN8Con6-2 ISAWYSCYAGHF ATCTCCGCTTGGTACTCCTGCTACG 5 gly C WCWDLKQK
CTGGTCACTTCTGGTGCTGGGACCT (SEQ ID NO: 348) GAAACAGAAA (SEQ ID NO:
553) mTN8Con6-3 WTGWYQCYGGH TGGACCGGTTGGTACCAGTGCTAC 5 gly C
LWCYDLRRK GGTGGTCACCTGTGGTGCTACGAC (SEQ ID NO: 349) CTGCGTCGTAAA
(SEQ ID NO: 554) mTN8Con6-4 KTFWYPCYDGHF AAAACCTTCTGGTACCCGTGCTAC 5
gly C WCYNLKSS (SEQ GACGGTCACTTCTGGTGCTACAAC ID NO: 350)
CTGAAATCCTCC (SEQ ID NO: 555) mTN8Con6-5 ESRWYPCYEGHL
GAATCCCGTTGGTACCCGTGCTAC 5 gly C WCFDLTET (SEQ
GAAGGTCACCTGTGGTGCTTCGAC ID NO: 351) CTGACCGAAACC (SEQ ID NO: 556)
mL24-1 NVFFQWVQKHG AATGTTTTTTTTCAATGGGTTCAAA 5 gly C RVVYQWLDINV
AACATGGTCGTGTTGTTTATCAATG (SEQ ID NO: 453) GCTTGATATTAATGTT (SEQ ID
NO: 557) mL24-2 FDFLQWLQNHRS TTTGATTTTCTTCAATGGCTTCAAA 5 gly C
EVEHWLVMDV ATCATCGTTCTGAAGTTGAACATTG (SEQ ID NO: 454)
GCTTGTTATGGATGTT (SEQ ID NO: 558) mL20-1 HQRDMSMLWEL
CATCAACGTGATATGTCTATGCTTT 5 gly C LDVLDGLRQYS
GGGAACTTCTTGATGTTCTTGATGG (SEQ ID NO: 439) TCTTCGTCAATATTCT (SEQ ID
NO:
559) mL20-2 TQRDMSMLDGLL ACTCAACGTGATATGTCTATGCTTG 5 gly C
EVLDQLRQQR ATGGTCTTCTTGAAGTTCTTGATCA (SEQ ID NO: 440)
ACTTCGTCAACAACGT (SEQ ID NO: 560) mL20-3 TSRDMSLLWELL
ACCTCCCGTGACATGTCCCTGCTGT 5 gly C EELDRLGHQR
GGGAACTGCTGGAAGAACTGGACC (SEQ ID NO: 441) GTCTGGGTCACCAGCGT (SEQ ID
NO: 561) mL20-4 MQHDMSMLYGL ATGCAACATGATATGTCTATGCTTT 5 gly C
VELLESLGHQI ATGGTCTTGTTGAACTTCTTGAATC (SEQ ID NO: 442)
TCTTGGTCATCAAATT (SEQ ID NO: 562) mL20-5 WNRDMRMLESL
TGGAATCGTGATATGCGTATGCTTG 5 gly C FEVLDGLRQQV
AATCTCTTTTTGAAGTTCTTGATGG (SEQ ID NO: 443) TCTTCGTCAACAAGTT (SEQ ID
NO: 563) mL20-6 GYRDMSMLEGLL GGTTATCGTGATATGTCTATGCTTG 5 gly C
AVLDRLGPQL AAGGTCTTCTTGCTGTTCTTGATCG (SEQ ID NO: 444)
TCTTGGTCCACAACTT (SEQ ID NO: 564) mL20 Con1 TQRDMSMLEGLL
ACTCAACGTGATATGTCTATGCTTG 5 gly C EVLDRLGQQR
AAGGTCTTCTTGAAGTTCTTGATCG (SEQ ID NO: 445) TCTTGGTCAACAACGT (SEQ ID
NO: 565) mL20 Con2 WYRDMSMLEGL TGGTACCGTGACATGTCCATGCTG 5 gly C
LEVLDRLGQQR GAAGGTCTGCTGGAAGTTCTGGAC (SEQ ID NO: 446)
CGTCTGGGTCAGCAGCGT (SEQ ID NO: 566) mL21-1 TQNSRQMLLSDF
ACTCAAAATTCTCGTCAAATGCTTC 5 gly C MMLVGSMIQG
TTTCTGATTTTATGATGCTTGTTGG (SEQ ID NO: 447) TTCTATGATTCAAGGT (SEQ ID
NO: 567) mL21-2 MQTSRHILLSEFM ATGCAAACTTCTCGTCATATTCTTC 5 gly C
MLVGSIMHG TTTCTGAATTTATGATGCTTGTTGG (SEQ ID NO: 448)
TTCTATTATGCATGGT (SEQ ID NO: 568) mL21-3 HDNSRQMLLSDL
CACGACAACTCCCGTCAGATGCTG 5 gly C LHLVGTMIQG
CTGTCCGACCTGCTGCACCTGGTTG (SEQ ID NO: 449) GTACCATGATCCAGGGT (SEQ
ID NO: 569) mL21-4 MENSRQNLLRELI ATGGAAAACTCCCGTCAGAACCTG 5 gly C
MLVGNMSHQ CTGCGTGAACTGATCATGCTGGTTG (SEQ ID NO: 450)
GTAACATGTCCCACCAG (SEQ ID NO: 570) mL21-5 QDTSRHMLLREF
CAGGACACCTCCCGTCACATGCTG 5 gly C MMLVGEMIQG
CTGCGTGAATTCATGATGCTGGTTG (SEQ ID NO: 451) GTGAAATGATCCAGGGT (SEQ
ID NO: 571) mL21 Con1 DQNSRQMLLSDL GACCAGAACTCCCGTCAGATGCTG 5 gly C
MILVGSMIQG CTGTCCGACCTGATGATCCTGGTTG (SEQ ID NO: 452)
GTTCCATGATCCAGGGT (SEQ ID NO: 572) mTN8-19-1 VALHGQCTRWP
GTTGCTCTTCATGGTCAATGTACTC 5 gly C WMCPPQREG
GTTGGCCATGGATGTGTCCACCAC (SEQ ID NO: 305) AACGTGAAGGT (SEQ ID NO:
573) mTN8-19-2 YPEQGLCTRWPW TATCCAGAACAAGGTCTTTGTACTC 5 gly C
MCPPQTLA (SEQ GTTGGCCATGGATGTGTCCACCAC ID NO: 306) AAACTCTTGCT (SEQ
ID N: 574) mTN8-19-3 GLNQGHCTRWP GGTCTGAACCAGGGTCACTGCACC 5 gly C
WMCPPQDSN CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 307) CAGGACTCCAAC
(SEQ ID NO: 575) mTN8-19-4 MITQGQCTRWPW ATGATTACTCAAGGTCAATGTACTC 5
gly C MCPPQPSG (SEQ GTTGGCCATGGATGTGTCCACCAC ID NO: 308)
AACCATCTGGT (SEQ ID NO: 576) mTN8-19-5 AGAQEHCTRWP
GCTGGTGCTCAGGAACACTGCACC 5 gly C WMCAPNDWI CGTTGGCCGTGGATGTGCGCTCCG
(SEQ ID NO: 309) AACGACTGGATC (SEQ ID NO: 577) mTN8-19-6
GVNQGQCTRWR GGTGTTAACCAGGGTCAGTGCACC 5 gly C WMCPPNGWE
CGTTGGCGTTGGATGTGCCCGCCG (SEQ ID NO: 310) AACGGTTGGGAA (SEQ ID NO:
578) mTN8-19-7 LADHGQCIRWPW CTGGCTGACCACGGTCAGTGCATC 5 gly C
MCPPEGWE (SEQ CGTTGGCCGTGGATGTGCCCGCCG ID NO: 311) GAAGGTTGGGAA
(SEQ ID NO: 579) mTN8-19-8 ILEQAQCTRWPW ATCCTGGAACAGGCTCAGTGCACC 5
gly C MCPPQRGG (SEQ CGTTGGCCGTGGATGTGCCCGCCG ID NO: 312)
CAGCGTGGTGGT (SEQ ID NO: 580) mTN8-19-9 TQTHAQCTRWP
ACTCAAACTCATGCTCAATGTACTC 5 gly C WMCPPQWEG
GTTGGCCATGGATGTGTCCACCAC (SEQ ID NO: 313) AATGGGAAGGT (SEQ ID NO:
581) mTN8-19-10 VVTQGHCTLWP GTTGTTACTCAAGGTCATTGTACTC 5 gly C
WMCPPQRWR TTTGGCCATGGATGTGTCCACCACA (SEQ ID NO: 314) ACGTTGGCGT
(SEQ ID NO: 582) mTN8-19-11 IYPHDQCTRWPW ATTTATCCACATGATCAATGTACTC
5 gly C MCPPQPYP (SEQ GTTGGCCATGGATGTGTCCACCAC ID NO: 315)
AACCATATCCA (SEQ ID NO: 583) mTN8-19-12 SYWQGQCTRWP
TCTTATTGGCAAGGTCAATGTACTC 5 gly C WMCPPQWRG
GTTGGCCATGGATGTGTCCACCAC (SEQ ID NO: 316) AATGGCGTGGT (SEQ ID NO:
584) mTN8-19-13 MWQQGHCTRWP ATGTGGCAACAAGGTCATTGTACT 5 gly C
WMCPPQGWG CGTTGGCCATGGATGTGTCCACCA (SEQ ID NO: 317) CAAGGTTGGGGT
(SEQ ID NO: 585) mTN8-19-14 EFTQWHCTRWP GAATTCACCCAGTGGCACTGCACC 5
gly C WMCPPQRSQ CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 318)
CAGCGTTCCCAG (SEQ ID NO: 586) mTN8-19-15 LDDQWQCTRWP
CTGGACGACCAGTGGCAGTGCACC 5 gly C WMCPPQGFS CGTTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 319) CAGGGTTTCTCC (SEQ ID NO: 587) mTN8-19-16
YQTQGLCTRWP TATCAAACTCAAGGTCTTTGTACTC 5 gly C WMCPPQSQR
GTTGGCCATGGATGTGTCCACCAC (SEQ ID NO: 320) AATCTCAACGT (SEQ ID NO:
588) mTN8-19-17 ESNQGQCTRWP GAATCTAATCAAGGTCAATGTACT 5 gly C
WMCPPQGGW CGTTGGCCATGGATGTGTCCACCA (SEQ ID NO: 321) CAAGGTGGTTGG
(SEQ ID NO: 589) mTN8-19-18 WTDRGPCTRWP TGGACCGACCGTGGTCCGTGCACC 5
gly C WMCPPQANG CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 322)
CAGGCTAACGGT (SEQ ID NO: 590) mTN8-19-19 VGTQGQCTRWP
GTTGGTACCCAGGGTCAGTGCACC 5 gly C WMCPPYETG CGTTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 323) TACGAAACCGGT (SEQ ID NO: 591) mTN8-19-20
PYEQGKCTRWP CCGTACGAACAGGGTAAATGCACC 5 gly C WMCPPYEVE
CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 324) TACGAAGTTGAA (SEQ ID NO:
592) mTN8-19-21 SEYQGLCTRWPW TCCGAATACCAGGGTCTGTGCACC 5 gly C
MCPPQGWK (SEQ CGTTGGCCGTGGATGTGCCCGCCG ID NO: 325) CAGGGTTGGAAA
(SEQ ID NO: 593) mTN8-19-22 TFSQGHCTRWPW ACCTTCTCCCAGGGTCACTGCACCC
5 gly C MCPPQGWG (SEQ GTTGGCCGTGGATGTGCCCGCCGC ID NO: 326)
AGGGTTGGGGT (SEQ ID NO: 594) mTN8-19-23 PGAHDHCTRWP
CCGGGTGCTCACGACCACTGCACC 5 gly C WMCPPQSRY CGTTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 327) CAGTCCCGTTAC (SEQ ID NO: 595) mTN8-19-24
VAEEWHCRRWP GTTGCTGAAGAATGGCACTGCCGT 5 gly C WMCPPQDWR
CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 328) CAGGACTGGCGT (SEQ ID NO:
596) mTN8-19-25 VGTQGHCTRWP GTTGGTACCCAGGGTCACTGCACC 5 gly C
WMCPPQPAG CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 329) CAGCCGGCTGGT
(SEQ ID NO: 597) mTN8-19-26 EEDQAHCRSWP GAAGAAGACCAGGCTCACTGCCGT 5
gly C WMCPPQGWV TCCTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 330)
CAGGGTTGGGTT (SEQ ID NO: 598) mTN8-19-27 ADTQGHCTRWP
GCTGACACCCAGGGTCACTGCACC 5 gly C WMCPPQHWF CGTTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 331) CAGCACTGGTTC (SEQ ID NO: 599) mTN8-19-28
SGPQGHCTRWPW TCCGGTCCGCAGGGTCACTGCACC 5 gly C MCAPQGWF (SEQ
CGTTGGCCGTGGATGTGCGCTCCG ID NO: 332) CAGGGTTGGTTC (SEQ ID NO: 600)
mTN8-19-29 TLVQGHCTRWP ACCCTGGTTCAGGGTCACTGCACC 5 gly C WMCPPQRWV
CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 333) CAGCGTTGGGTT (SEQ ID NO:
601) mTN8-19-30 GMAHGKCTRWA GGTATGGCTCACGGTAAATGCACC 5 gly C
WMCPPQSWK CGTTGGGCTTGGATGTGCCCGCCG (SEQ ID NO: 334) CAGTCCTGGAAA
(SEQ ID NO: 602) mTN8-19-31 ELYHGQCTRWP GAACTGTACCACGGTCAGTGCACC 5
gly C WMCPPQSWA CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 335)
CAGTCCTGGGCT (SEQ ID NO: 603) mTN8-19-32 VADHGHCTRWP
GTTGCTGACCACGGTCACTGCACC 5 gly C WMCPPQGWG CGTTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 336) CAGGGTTGGGGT (SEQ ID NO: 604 mTN8-19-33
PESQGHCTRWPW CCGGAATCCCAGGGTCACTGCACC 5 gly C MCPPQGWG (SEQ
CGTTGGCCGTGGATGTGCCCGCCG ID NO: 337) CAGGGTTGGGGT (SEQ ID NO: 605)
mTN8-19-34 IPAHGHCTRWPW ATCCCGGCTCACGGTCACTGCACC 5 gly C MCPPQRWR
(SEQ CGTTGGCCGTGGATGTGCCCGCCG ID NO: 338) CAGCGTTGGCGT (SEQ ID NO:
606) mTN8-19-35 FTVHGHCTRWP TTCACCGTTCACGGTCACTGCACCC 5 gly C
WMCPPYGWV GTTGGCCGTGGATGTGCCCGCCGT (SEQ ID NO: 339) ACGGTTGGGTT
(SEQ ID NO: 607) mTN8-19-36 PDFPGHCTRWRW CCAGATTTTCCAGGTCATTGTACTC
5 gly C MCPPQGWE (SEQ GTTGGCGTTGGATGTGTCCACCAC ID NO: 340)
AAGGTTGGGAA (SEQ ID NO: 608) mTN8-19-37 QLWQGPCTQWP
CAGCTGTGGCAGGGTCCGTGCACC 5 gly C WMCPPKGRY CAGTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 341) AAAGGTCGTTAC (SEQ ID NO: 609) mTN8-19-38
HANDGHCTRWQ CACGCTAACGACGGTCACTGCACC 5 gly C WMCPPQWGG
CGTTGGCAGTGGATGTGCCCGCCG (SEQ ID NO: 342) CAGTGGGGTGGT (SEQ ID NO:
610) mTN8-19-39 ETDHGLCTRWPW GAAACCGACCACGGTCTGTGCACC 5 gly C
MCPPYGAR (SEQ CGTTGGCCGTGGATGTGCCCGCCG ID NO: 343) TACGGTGCTCGT
(SEQ ID NO: 611) mTN8-19-40 GTWQGLCTRWP GGTACCTGGCAGGGTCTGTGCACC 5
gly C WMCPPQGWQ CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 344)
CAGGGTTGGCAG (SEQ ID NO: 612) mTN8-19 Con1 VATQGQCTRWP
GTTGCTACCCAGGGTCAGTGCACC 5 gly C WMCPPQGWG CGTTGGCCGTGGATGTGCCCGCCG
(SEQ ID NO: 345) CAGGGTTGGGGT (SEQ ID NO: 613) mTN8-19 Con2
VATQGQCTRWP GTTGCTACCCAGGGTCAGTGCACC 5 gly C WMCPPQRWG
CGTTGGCCGTGGATGTGCCCGCCG (SEQ ID NO: 346) CAGCGTTGGGGT (SEQ ID NO:
614) 2X mTN8-19-7 FC-5G-AQ- CTTGCTGATCATGGTCAATGTATTC 1K C
LADHGQCIRWPW GTTGGCCATGGATGTGTCCACCAG MCPPEGWELEGS
AAGGTTGGGAACTCGAGGGTTCCG GSATGGSGSTASS GTTCCGCTACCGGCGGCTCTGGCTC
GSGSATGLADHG CACTGCTTCTTCCGGTTCCGGTTCT QCIRWPWMCPPE
GCTACTGGTCTGGCTGACCACGGT GWE-LE (SEQ ID CAGTGCATCCGTTGGCCGTGGATG
NO: 615) TGCCCGCCGGAAGGTTGGGAACTG GAA (SEQ ID NO: 616) 2X mTN8-19-7
FC-5G-AQ- CTTGCTGATCATGGTCAATGTATTC 1K C ST-GG del2x LADHGQCIRWPW
GTTGGCCATGGATGTGTCCACCAG LE MCPPEGWEGSGS AAGGTTGGGAAGGTTCCGGTTCCG
ATGGSGGGASSG CTACCGGCGGCTCTGGCGGTGGCG SGSATGLADHGQ
CTTCTTCCGGTTCCGGTTCTGCTAC
CIRWPWMCPPEG TGGTCTGGCTGACCACGGTCAGTG WE (SEQ ID NO:
CATCCGTTGGCCGTGGATGTGTCCA 617) CCAGAAGGTTGGGAA (SEQ ID NO: 618) 2X
mTN8-19-21 FC-5G-AQ- TCTGAATATCAAGGTCTTTGTACTC 1K C SEYQGLCTRWPW
GTTGGCCATGGATGTGTCCACCAC MCPPQGWKLEGS AAGGTTGGAAACTCGAGGGTTCCG
GSATGGSGSTASS GTTCCGCTACCGGCGGCTCTGGCTC GSGSATGSEYQG
CACTGCTTCTTCCGGTTCCGGTTCT LCTRWPWMCPPQ GCTACTGGTTCTGAGTATCAAGGC
GWK-LE (SEQ CTCTGTACTCGCTGGCCATGGATGT ID NO: 619)
GTCCACCACAAGGCTGGAAGCTGG AA (SEQ ID NO: 620) 2X mTN8-19-21
FC-5G-AQ- TCTGAATATCAAGGTCTTTGTACTC 1K C ST-GG del2x SEYQGLCTRWPW
GTTGGCCATGGATGTGTCCACCAC LE MCPPQGWKGSGS AAGGTTGGAAAGGTTCCGGTTCCG
ATGGSGGGASSG CTACCGGCGGCTCTGGCGGTGGCG SGSATGSEYQGL
CTTCTTCCGGTTCCGGTTCTGCTAC CTRWPWMCPPQ TGGTTCTGAGTATCAAGGCCTCTGT GWK
(SEQ ID NO: ACTCGCTGGCCATGGATGTGTCCA 621) CCACAAGGTTGGAAA (SEQ ID
NO: 622) 2X mTN8-19-22 FC-5G-AQ- ACTTTTTCTCAAGGTCATTGTACTC 1K C
TFSQGHCTRWPW GTTGGCCATGGATGTGTCCACCAC MCPPQGWGLEGS
AAGGTTGGGGTCTCGAGGGTTCCG GSATGGSGSTASS GTTCCGCTACCGGCGGCTCTGGCTC
GSGSATGTFSQG CACTGCTTCTTCCGGTTCCGGTTCT HCTRWPWMCPP
GCTACTGGTACTTTTTCTCAAGGCC QGWG-LE (SEQ ATTGTACTCGCTGGCCATGGATGTG ID
NO: 623) TCCACCACAAGGCTGGGGCCTGGA A (SEQ ID NO: 624) 2X mTN8-19-32
FC-5G-AQ- GTTGCTGATCATGGTCATTGTACTC 1K C VADHGHCTRWP
GTTGGCCATGGATGTGTCCACCAC WMCPPQGWGLE AAGGTTGGGGTCTCGAGGGTTCCG
GSGSATGGSGST GTTCCGCAACCGGCGGCTCTGGCT ASSGSGSATGVA
CCACTGCTTCTTCCGGTTCCGGTTC DHGHCTRWPWM TGCTACTGGTGTTGCTGACCACGGT
CPPQGWG-LE CACTGCACCCGTTGGCCGTGGATG (SEQ ID NO: 625)
TGCCCGCCGCAGGGTTGGGGTCTG GAA (SEQ ID NO: 626) 2X mTN8-19-32
FC-5G-AQ- GTTGCTGATCATGGTCATTGTACTC 1K C ST-GG del2x VADHGHCTRWP
GTTGGCCATGGATGTGTCCACCAC LE WMCPPQGWGGS AAGGTTGGGGTGGTTCCGGTTCCG
GSATGGSGGGAS CTACCGGCGGCTCTGGCGGTGGTG SGSGSATGVADH
CTTCTTCCGGTTCCGGTTCTGCTAC GHCTRWPWVCPP TGGTGTTGCTGACCACGGTCACTGC
QGWG (SEQ ID ACCCGTTGGCCGTGGGTGTGTCCA NO: 627) CCACAAGGTTGGGGT (SEQ
ID NO: 628) 2X mTN8-19-33 FC-5G-AQ- CCAGAATCTCAAGGTCATTGTACTC 1K C
PESQGHCTRWPW GTTGGCCATGGATGTGTCCACCAC MCPPQGWGLEGS
AAGGTTGGGGTCTCGAGGGTTCCG GSATGGSGSTASS GTTCCGCTACCGGCGGCTCTGGCTC
GSGSATGPESQG CACTGCTTCTTCCGGTTCCGGTTCT HCTRWPWMCPP
GCTACTGGTCCGGAATCCCAGGGT QGWGLE (SEQ CACTGCACCCGTTGGCCGTGGATG ID
NO: 629) TGCCCGCCGCAGGGTTGGGGTCTG GAA (SEQ ID NO: 630) 2X
mTN8-19-33 FC-5G-AQ- CCAGAATCTCAAGGTCATTGTACTC 1K C ST-GG del2x
PESQGHCTRWPW GTTGGCCATGGATGTGTCCACCAC LE MCPPQGWGGSGS
AAGGTTGGGGTGGTTCCGGTTCCG ATGGSGGGASSG CTACCGGCGGCTCTGGCGGTGGTG
SGSATGPESQGH CTTCTTCCGGTTCCGGTTCTGCTAC CTRWPWMCP
TGGTCCGGAATCCCAGGGTCACTG PQGWG (SEQ ID CACCCGTTGGCCGTGGATGTGTCC NO:
631) ACCACAAGGTTGGGGT (SEQ ID NO: 632)
Example 7
In Vitro Screening of Affinity Matured Peptibodies
[0440] The following exemplary peptibodies were screened according
to the protocols set forth above to obtain the following K.sub.D
and IC.sub.50 values. Table VII shows the range of K.sub.D values
for selected affinity matured peptibodies compared with the parent
peptibodies, as determined by KinExA.TM. solution based assays or
BIAcore.RTM. assays. These values demonstrate increased binding
affinity of the affinity matured peptibodies for myostatin compared
with the parent peptibodies. Table VIII shows IC.sub.50 values for
a number of affinity matured peptibodies. A range of values is
given in this table.
TABLE-US-00018 TABLE VII peptibodies K.sub.D TN8-19 (parent) >1
nM 2xmTN8-19 (parent) >1 nM 1x mTN8-19-7 10 pM 2x mTN8-19-7 12
pM 1x mTN8-19-21 6 pM 2x mTN8-19-21 6 pM 1x mTN8-19-32 9 pM 1x
mTN8-19-33 21 pM 2x mTN8-19-33 3 pM 1x mTN8-19-22 4 pM 1x
mTN8-19-con1 20 pM
TABLE-US-00019 TABLE VIII Affinity Matured Peptibody IC.sub.50 (nM)
mTN8-19 Con1 1.0-4.4 mTN8-19-2 7.508-34.39 mTN8-19-4 16.74
mTN8-19-5 7.743-3.495 mTN8-19-6 17.26 mTN8-19-7 1.778 mTN8-19-9
22.96-18.77 mTN8-19-10 5.252-7.4 mTN8-19-11 28.66 mTN8-19-12 980.4
mTN8-19-13 20.04 mTN8-19-14 4.065-6.556 mTN8-19-16 4.654 mTN8-19-21
2.767-3.602 mTN8-19-22 1.927-3.258 mTN8-19-23 6.584 mTN8-19-24
1.673-2.927 mTN8-19-27 4.837-4.925 mTN8-19-28 4.387 mTN8-19-29
6.358 mTN8-19-32 1.842-3.348 mTN8-19-33 2.146-2.745 mTN8-19-34
5.028-5.069 mTN8Con6-3 86.81 mTN8Con6-5 2385 mTN8-19-7(-LE)
1.75-2.677 mTN8-19-21(-LE) 2.49 mTN8-19-33(-LE) 1.808 2xmTN8-19-7
0.8572-2.649 2xmTN8-19-9 1.316-1.228 2xmTN8-19-14 1.18-1.322
2xmTN8-19-16 0.9903-1.451 2xmTN8-19-21 0.828-1.434 2xmTN8-19-22
0.9937-1.22 2xmTN8-19-27 1.601-3.931 2xmTN8-19-7(-LE) 1.077-1.219
2xmTN8-19-21(-LE) 0.8827-1.254 2xmTN8-19-33(-LE) 1.12-1.033 mL2-7
90.24 mL2-9 105.5 mL15-7 32.75 mL15-9 354.2 mL20-2 122.6 mL20-3
157.9 mL20-4 160
Example 8
In Vivo Anabolic Activity of Exemplary Peptibodies
[0441] The CD1 nu/nu mouse model (Charles River Laboratories,
Massachusettes) was used to determine the in vivo efficacy of the
peptibodies of the present invention which included the human Fc
region (huFc). This model responded to the inhibitors of the
present invention with a rapid anabolic response which was
associated with increased dry muscle mass and an increase in
myofibrillar proteins but was not associated with accumulation in
body water content.
[0442] In one example, the efficacy of 1.times. peptibody
mTN8-19-21 in vivo was demonstrated by the following experiment. A
group of 10 8 week old CD1 nu/nu mice were treated twice weekly or
once weekly with dosages of 1 mg/kg, 3 mg/kg and 10 mg/kg
(subcutaneous injection). The control group of 10 8 week old CD1
nu/nu mice received a twice weekly (subcutaneous) injection of huFc
(vehicle) at 10 mg/kg. The animals were weighed every other day and
lean body mass determined by NMR on day 0 and day 13. The animals
are then sacrificed at day 14 and the size of the gastrocnemius
muscle determined. The results are shown in FIGS. 2 and 3. FIG. 2
shows the increase in total body weight of the mice over 14 days
for the various dosages of peptibody compared with the control. As
can be seen from FIG. 2, all of the dosages have show an increase
in body weight compared with the control, with all of the dosages
showing statistically significant increases over the control by day
14. FIG. 3 shows the change in lean body mass on day 0 and day 13
as determined by NMR, as well as the change in weight of the
gastrocnemius muscle dissected from the animals at day 14.
[0443] In another example, the 1.times.mTN8-19-32 peptibody was
administered to CD1 nu/nu mice in a biweekly injection of 1 mg/kg,
3 mg/kg, 10 mg/kg, and 30 mg/kg compared with the huFc control
(vehicle). The peptibody-treated animals show an increase in total
body weight (not shown) as well as lean body mass on day 13
compared with day 0 as determined by NMR measurement. The increase
in lean body mass is shown in FIG. 4.
[0444] In another example, a 1.times. affinity-matured peptibody
was compared with a 2.times. affinity-matured peptibody for in vivo
anabolic efficacy. CD1 nu/nu male mice (10 animals per group) were
treated with twice weekly injections of 1 mg/kg and 3 mg/kg of
1.times.mTN8-19-7 and 2.times.mTN8-19-7 for 35 days, while the
control group (10 animals) received twice weekly injections of huFc
(3 mg/kg). As shown in FIG. 5, treatment with the 2.times.
peptibody resulted in a greater body weight gain and lean carcass
weight at necropsy compared with the 1.times. peptibody or
control.
Example 9
Increase in Muscular Strength
[0445] Normal age-matched 4 month old male C57B/6 mice were treated
for 30 days with 2 injections per week subcutaneous injections 5
mg/kg per week of 2.times.mTN8-19-33, 2.times.mTN8-19-7, and huFc
vehicle control group (10 animals/group). The animals were allowed
to recover without any further injections. Gripping strength was
measured on day 18 of the recovery period. Gripping strength was
measured using a Columbia Instruments meter, model 1027 dsm
(Columbus, Ohio). Peptibody treatment resulted in significant
increase in gripping strength, with 2.times.mTN8-19-33 pretreated
animals showing a 14% increase in gripping strength compared with
the control-treated mice, while 2.times.mTN8-19-7 showed a 15%
increase in gripping strength compared with the control treated
mice.
Example 10
Pharmacokinetics
[0446] In vivo phamacokinetics experiments were performed using
representative peptibodies without the LE sequences. 10 mg/kg and 5
mg/kg dosages were administered to CD1 nu/nu mice and the following
parameters determined. Cmax (ug/mL), area under the curve (AUC)
(ug-hr/mL), and half-life (hr). It was found that the 2.times.
versions of the affinity matured peptibodies have a significantly
longer half-life than the 1.times. versions. For example, 1.times.
affinity matured mTN8-19-22 has a half-life in the animals of about
50.2 hours, whereas 2.times.mTN8-19-22 has a half-life of about
85.2 hours. Affinity matured 1.times.mTN8-7 has a half-life of
about 65 hours, whereas 2.times.mTN8-19-7 has a half-life of about
106 hours.
Example 11
Treatment of Mdx Mice
[0447] The peptibodies of the present invention have been shown to
increase lean muscle mass in an animal and are useful for the
treatment of a variety of disorders which involve muscle wasting.
Muscular dystrophy is one of those disorders. The mouse model for
Duchenne's muscular dystrophy is the Duchenne mdx mouse (Jackson
Laboratories, Bar Harbor, Me.). Aged (10 month old) mdx mice were
injected with either the peptibody 1.times.mTN8-19-33 (n=8/group)
or with the vehicle huFc protein (N=6/group) for a three month
period of time. The dosing schedule was every other day, 10 mg/kg,
by subcutaneous injection. The peptibody treatment had a positive
effect on increasing and maintaining body mass for the aged mdx
mice. Significant increases in body weight were observed in the
peptibody-treated group compared to the hu-Fc-treated control
group, as shown in FIG. 6A. In addition, NMR analysis revealed that
the lean body mass to fat mass ratio was also significantly
increased in the aged mdx mice as a result of the peptibody
treatment compared with the control group, and that the fat
percentage of body weight decreased in the peptibody treated mice
compared with the control group, as shown in FIG. 6B.
[0448] The present invention is not to be limited in scope by the
specific embodiments described herein, which are intended as single
illustrations of individual aspects of the invention, and
functionally equivalent methods and components of the invention.
Indeed, various modifications of the invention, in addition to
those shown and described herein will become apparent to those
skilled in the art from the foregoing description and accompanying
drawings. Such modifications are intended to fall within the scope
of the appended claims.
Sequence CWU 1
1
634114PRTArtificial SequenceMyostatin Binding Peptide 1Lys Asp Lys
Cys Lys Met Trp His Trp Met Cys Lys Pro Pro1 5 10214PRTArtificial
SequenceMyostatin Binding Peptide 2Lys Asp Leu Cys Ala Met Trp His
Trp Met Cys Lys Pro Pro1 5 10313PRTArtificial SequenceMyostatin
Binding Peptide 3Asp Leu Cys Lys Met Trp Lys Trp Met Cys Lys Pro
Pro1 5 10414PRTArtificial SequenceMyostatin Binding Peptide 4Lys
Asp Leu Cys Lys Met Trp His Trp Met Cys Lys Pro Lys1 5
10514PRTArtificial SequenceMyostatin Binding Peptide 5Trp Tyr Pro
Cys Tyr Glu Phe His Phe Trp Cys Tyr Asp Leu1 5 10614PRTArtificial
SequenceMyostatin Binding Peptide 6Trp Tyr Pro Cys Tyr Glu Gly His
Phe Trp Cys Tyr Asp Leu1 5 10714PRTArtificial SequenceMyostatin
Binding Peptide 7Ile Phe Gly Cys Lys Trp Trp Asp Val Gln Cys Tyr
Gln Phe1 5 10814PRTArtificial SequenceMyostatin Binding Peptide
8Ile Phe Gly Cys Lys Trp Trp Asp Val Asp Cys Tyr Gln Phe1 5
10914PRTArtificial SequenceMyostatin Binding Peptide 9Ala Asp Trp
Cys Val Ser Pro Asn Trp Phe Cys Met Val Met1 5 101014PRTArtificial
SequenceMyostatin Binding Peptide 10His Lys Phe Cys Pro Trp Trp Ala
Leu Phe Cys Trp Asp Phe1 5 101114PRTArtificial SequenceMyostatin
Binding Peptide 11Lys Asp Leu Cys Lys Met Trp His Trp Met Cys Lys
Pro Pro1 5 101214PRTArtificial SequenceMyostatin Binding Peptide
12Ile Asp Lys Cys Ala Ile Trp Gly Trp Met Cys Pro Pro Leu1 5
101314PRTArtificial SequenceMyostatin Binding Peptide 13Trp Tyr Pro
Cys Gly Glu Phe Gly Met Trp Cys Leu Asn Val1 5 101411PRTArtificial
SequenceMyostatin Binding Peptide 14Trp Phe Thr Cys Leu Trp Asn Cys
Asp Asn Glu1 5 101514PRTArtificial SequenceMyostatin Binding
Peptide 15His Thr Pro Cys Pro Trp Phe Ala Pro Leu Cys Val Glu Trp1
5 101614PRTArtificial SequenceMyostatin Binding Peptide 16Lys Glu
Trp Cys Trp Arg Trp Lys Trp Met Cys Lys Pro Glu1 5
101714PRTArtificial SequenceMyostatin Binding Peptide 17Phe Glu Thr
Cys Pro Ser Trp Ala Tyr Phe Cys Leu Asp Ile1 5 101814PRTArtificial
SequenceMyostatin Binding Peptide 18Ala Tyr Lys Cys Glu Ala Asn Asp
Trp Gly Cys Trp Trp Leu1 5 101914PRTArtificial SequenceMyostatin
Binding Peptide 19Asn Ser Trp Cys Glu Asp Gln Trp His Arg Cys Trp
Trp Leu1 5 102014PRTArtificial SequenceMyostatin Binding Peptide
20Trp Ser Ala Cys Tyr Ala Gly His Phe Trp Cys Tyr Asp Leu1 5
102114PRTArtificial SequenceMyostatin Binding Peptide 21Ala Asn Trp
Cys Val Ser Pro Asn Trp Phe Cys Met Val Met1 5 102214PRTArtificial
SequenceMyostatin Binding Peptide 22Trp Thr Glu Cys Tyr Gln Gln Glu
Phe Trp Cys Trp Asn Leu1 5 102314PRTArtificial SequenceMyostatin
Binding Peptide 23Glu Asn Thr Cys Glu Arg Trp Lys Trp Met Cys Pro
Pro Lys1 5 102414PRTArtificial SequenceMyostatin Binding Peptide
24Trp Leu Pro Cys His Gln Glu Gly Phe Trp Cys Met Asn Phe1 5
102514PRTArtificial SequenceMyostatin Binding Peptide 25Ser Thr Met
Cys Ser Gln Trp His Trp Met Cys Asn Pro Phe1 5 102614PRTArtificial
SequenceMyostatin Binding Peptide 26Ile Phe Gly Cys His Trp Trp Asp
Val Asp Cys Tyr Gln Phe1 5 102714PRTArtificial SequenceMyostatin
Binding Peptide 27Ile Tyr Gly Cys Lys Trp Trp Asp Ile Gln Cys Tyr
Asp Ile1 5 102814PRTArtificial SequenceMyostatin Binding Peptide
28Pro Asp Trp Cys Ile Asp Pro Asp Trp Trp Cys Lys Phe Trp1 5
102914PRTArtificial SequenceMyostatin Binding Peptide 29Gln Gly His
Cys Thr Arg Trp Pro Trp Met Cys Pro Pro Tyr1 5 103014PRTArtificial
SequenceMyostatin Binding Peptide 30Trp Gln Glu Cys Tyr Arg Glu Gly
Phe Trp Cys Leu Gln Thr1 5 103114PRTArtificial SequenceMyostatin
Binding Peptide 31Trp Phe Asp Cys Tyr Gly Pro Gly Phe Lys Cys Trp
Ser Pro1 5 103214PRTArtificial SequenceMyostatin Binding Peptide
32Gly Val Arg Cys Pro Lys Gly His Leu Trp Cys Leu Tyr Pro1 5
103314PRTArtificial SequenceMyostatin Binding Peptide 33His Trp Ala
Cys Gly Tyr Trp Pro Trp Ser Cys Lys Trp Val1 5 103414PRTArtificial
SequenceMyostatin Binding Peptide 34Gly Pro Ala Cys His Ser Pro Trp
Trp Trp Cys Val Phe Gly1 5 103514PRTArtificial SequenceMyostatin
Binding Peptide 35Thr Thr Trp Cys Ile Ser Pro Met Trp Phe Cys Ser
Gln Gln1 5 103614PRTArtificial SequenceMyostatin Binding Peptide
36His Lys Phe Cys Pro Pro Trp Ala Ile Phe Cys Trp Asp Phe1 5
103714PRTArtificial SequenceMyostatin Binding Peptide 37Pro Asp Trp
Cys Val Ser Pro Arg Trp Tyr Cys Asn Met Trp1 5 103814PRTArtificial
SequenceMyostatin Binding Peptide 38Val Trp Lys Cys His Trp Phe Gly
Met Asp Cys Glu Pro Thr1 5 103914PRTArtificial SequenceMyostatin
Binding Peptide 39Lys Lys His Cys Gln Ile Trp Thr Trp Met Cys Ala
Pro Lys1 5 104014PRTArtificial SequenceMyostatin Binding Peptide
40Trp Phe Gln Cys Gly Ser Thr Leu Phe Trp Cys Tyr Asn Leu1 5
104114PRTArtificial SequenceMyostatin Binding Peptide 41Trp Ser Pro
Cys Tyr Asp His Tyr Phe Tyr Cys Tyr Thr Ile1 5 104214PRTArtificial
SequenceMyostatin Binding Peptide 42Ser Trp Met Cys Gly Phe Phe Lys
Glu Val Cys Met Trp Val1 5 104314PRTArtificial SequenceMyostatin
Binding Peptide 43Glu Met Leu Cys Met Ile His Pro Val Phe Cys Asn
Pro His1 5 104414PRTArtificial SequenceMyostatin Binding Peptide
44Leu Lys Thr Cys Asn Leu Trp Pro Trp Met Cys Pro Pro Leu1 5
104514PRTArtificial SequenceMyostatin Binding Peptide 45Val Val Gly
Cys Lys Trp Tyr Glu Ala Trp Cys Tyr Asn Lys1 5 104614PRTArtificial
SequenceMyostatin Binding Peptide 46Pro Ile His Cys Thr Gln Trp Ala
Trp Met Cys Pro Pro Thr1 5 104714PRTArtificial SequenceMyostatin
Binding Peptide 47Asp Ser Asn Cys Pro Trp Tyr Phe Leu Ser Cys Val
Ile Phe1 5 104814PRTArtificial SequenceMyostatin Binding Peptide
48His Ile Trp Cys Asn Leu Ala Met Met Lys Cys Val Glu Met1 5
104914PRTArtificial SequenceMyostatin Binding Peptide 49Asn Leu Gln
Cys Ile Tyr Phe Leu Gly Lys Cys Ile Tyr Phe1 5 105014PRTArtificial
SequenceMyostatin Binding Peptide 50Ala Trp Arg Cys Met Trp Phe Ser
Asp Val Cys Thr Pro Gly1 5 105114PRTArtificial SequenceMyostatin
Binding Peptide 51Trp Phe Arg Cys Phe Leu Asp Ala Asp Trp Cys Thr
Ser Val1 5 105214PRTArtificial SequenceMyostatin Binding Peptide
52Glu Lys Ile Cys Gln Met Trp Ser Trp Met Cys Ala Pro Pro1 5
105314PRTArtificial SequenceMyostatin Binding Peptide 53Trp Phe Tyr
Cys His Leu Asn Lys Ser Glu Cys Thr Glu Pro1 5 105414PRTArtificial
SequenceMyostatin Binding Peptide 54Phe Trp Arg Cys Ala Ile Gly Ile
Asp Lys Cys Lys Arg Val1 5 105514PRTArtificial SequenceMyostatin
Binding Peptide 55Asn Leu Gly Cys Lys Trp Tyr Glu Val Trp Cys Phe
Thr Tyr1 5 105614PRTArtificial SequenceMyostatin Binding Peptide
56Ile Asp Leu Cys Asn Met Trp Asp Gly Met Cys Tyr Pro Pro1 5
105714PRTArtificial SequenceMyostatin Binding Peptide 57Glu Met Pro
Cys Asn Ile Trp Gly Trp Met Cys Pro Pro Val1 5 105818PRTArtificial
SequenceMyostatin Binding Peptide 58Trp Phe Arg Cys Val Leu Thr Gly
Ile Val Asp Trp Ser Glu Cys Phe1 5 10 15Gly Leu5918PRTArtificial
SequenceMyostatin Binding Peptide 59Trp Phe Arg Cys Val Leu Thr Gly
Ile Val Asp Trp Ser Glu Cys Phe1 5 10 15Gly Leu6018PRTArtificial
SequenceMyostatin Binding Peptide 60Leu Pro Trp Cys His Asp Gln Val
Asn Ala Asp Trp Gly Phe Cys Met1 5 10 15Leu Trp6118PRTArtificial
SequenceMyostatin Binding Peptide 61Tyr Pro Thr Cys Ser Glu Lys Phe
Trp Ile Tyr Gly Gln Thr Cys Val1 5 10 15Leu Trp6218PRTArtificial
SequenceMyostatin Binding Peptide 62Leu Gly Pro Cys Pro Ile His His
Gly Pro Trp Pro Gln Tyr Cys Val1 5 10 15Tyr Trp6318PRTArtificial
SequenceMyostatin Binding Peptide 63Pro Phe Pro Cys Glu Thr His Gln
Ile Ser Trp Leu Gly His Cys Leu1 5 10 15Ser Phe6418PRTArtificial
SequenceMyostatin Binding Peptide 64His Trp Gly Cys Glu Asp Leu Met
Trp Ser Trp His Pro Leu Cys Arg1 5 10 15Arg Pro6518PRTArtificial
SequenceMyostatin Binding Peptide 65Leu Pro Leu Cys Asp Ala Asp Met
Met Pro Thr Ile Gly Phe Cys Val1 5 10 15Ala Tyr6618PRTArtificial
SequenceMyostatin Binding Peptide 66Ser His Trp Cys Glu Thr Thr Phe
Trp Met Asn Tyr Ala Lys Cys Val1 5 10 15His Ala6718PRTArtificial
SequenceMyostatin Binding Peptide 67Leu Pro Lys Cys Thr His Val Pro
Phe Asp Gln Gly Gly Phe Cys Leu1 5 10 15Trp Tyr6818PRTArtificial
SequenceMyostatin Binding Peptide 68Phe Ser Ser Cys Trp Ser Pro Val
Ser Arg Gln Asp Met Phe Cys Val1 5 10 15Phe Tyr6917PRTArtificial
SequenceMyostatin Binding Peptide 69Ser His Lys Cys Glu Tyr Ser Gly
Trp Leu Gln Pro Leu Cys Tyr Arg1 5 10 15Pro7018PRTArtificial
SequenceMyostatin Binding Peptide 70Pro Trp Trp Cys Gln Asp Asn Tyr
Val Gln His Met Leu His Cys Asp1 5 10 15Ser Pro7118PRTArtificial
SequenceMyostatin Binding Peptide 71Trp Phe Arg Cys Met Leu Met Asn
Ser Phe Asp Ala Phe Gln Cys Val1 5 10 15Ser Tyr7218PRTArtificial
SequenceMyostatin Binding Peptide 72Pro Asp Ala Cys Arg Asp Gln Pro
Trp Tyr Met Phe Met Gly Cys Met1 5 10 15Leu Gly7314PRTArtificial
SequenceMyostatin Binding Peptide 73Phe Leu Ala Cys Phe Val Glu Phe
Glu Leu Cys Phe Asp Ser1 5 107418PRTArtificial SequenceMyostatin
Binding Peptide 74Ser Ala Tyr Cys Ile Ile Thr Glu Ser Asp Pro Tyr
Val Leu Cys Val1 5 10 15Pro Leu7518PRTArtificial SequenceMyostatin
Binding Peptide 75Pro Ser Ile Cys Glu Ser Tyr Ser Thr Met Trp Leu
Pro Met Cys Gln1 5 10 15His Asn7618PRTArtificial SequenceMyostatin
Binding Peptide 76Trp Leu Asp Cys His Asp Asp Ser Trp Ala Trp Thr
Lys Met Cys Arg1 5 10 15Ser His7718PRTArtificial SequenceMyostatin
Binding Peptide 77Tyr Leu Asn Cys Val Met Met Asn Thr Ser Pro Phe
Val Glu Cys Val1 5 10 15Phe Asn7818PRTArtificial SequenceMyostatin
Binding Peptide 78Tyr Pro Trp Cys Asp Gly Phe Met Ile Gln Gln Gly
Ile Thr Cys Met1 5 10 15Phe Tyr7918PRTArtificial SequenceMyostatin
Binding Peptide 79Phe Asp Tyr Cys Thr Trp Leu Asn Gly Phe Lys Asp
Trp Lys Cys Trp1 5 10 15Ser Arg8018PRTArtificial SequenceMyostatin
Binding Peptide 80Leu Pro Leu Cys Asn Leu Lys Glu Ile Ser His Val
Gln Ala Cys Val1 5 10 15Leu Phe8118PRTArtificial SequenceMyostatin
Binding Peptide 81Ser Pro Glu Cys Ala Phe Ala Arg Trp Leu Gly Ile
Glu Gln Cys Gln1 5 10 15Arg Asp8218PRTArtificial SequenceMyostatin
Binding Peptide 82Tyr Pro Gln Cys Phe Asn Leu His Leu Leu Glu Trp
Thr Glu Cys Asp1 5 10 15Trp Phe8318PRTArtificial SequenceMyostatin
Binding Peptide 83Arg Trp Arg Cys Glu Ile Tyr Asp Ser Glu Phe Leu
Pro Lys Cys Trp1 5 10 15Phe Phe8414PRTArtificial SequenceMyostatin
Binding Peptide 84Leu Val Gly Cys Asp Asn Val Trp His Arg Cys Lys
Leu Phe1 5 108518PRTArtificial SequenceMyostatin Binding Peptide
85Ala Gly Trp Cys His Val Trp Gly Glu Met Phe Gly Met Gly Cys Ser1
5 10 15Ala Leu8618PRTArtificial SequenceMyostatin Binding Peptide
86His His Glu Cys Glu Trp Met Ala Arg Trp Met Ser Leu Asp Cys Val1
5 10 15Gly Leu8718PRTArtificial SequenceMyostatin Binding Peptide
87Phe Pro Met Cys Gly Ile Ala Gly Met Lys Asp Phe Asp Phe Cys Val1
5 10 15Trp Tyr8818PRTArtificial SequenceMyostatin Binding Peptide
88Arg Asp Asp Cys Thr Phe Trp Pro Glu Trp Leu Trp Lys Leu Cys Glu1
5 10 15Arg Pro8918PRTArtificial SequenceMyostatin Binding Peptide
89Tyr Asn Phe Cys Ser Tyr Leu Phe Gly Val Ser Lys Glu Ala Cys Gln1
5 10 15Leu Pro9018PRTArtificial SequenceMyostatin Binding Peptide
90Ala His Trp Cys Glu Gln Gly Pro Trp Arg Tyr Gly Asn Ile Cys Met1
5 10 15Ala Tyr9118PRTArtificial SequenceMyostatin Binding Peptide
91Asn Leu Val Cys Gly Lys Ile Ser Ala Trp Gly Asp Glu Ala Cys Ala1
5 10 15Arg Ala9218PRTArtificial SequenceMyostatin Binding Peptide
92His Asn Val Cys Thr Ile Met Gly Pro Ser Met Lys Trp Phe Cys Trp1
5 10 15Asn Asp9318PRTArtificial SequenceMyostatin Binding Peptide
93Asn Asp Leu Cys Ala Met Trp Gly Trp Arg Asn Thr Ile Trp Cys Gln1
5 10 15Asn Ser9418PRTArtificial SequenceMyostatin Binding Peptide
94Pro Pro Phe Cys Gln Asn Asp Asn Asp Met Leu Gln Ser Leu Cys Lys1
5 10 15Leu Leu9518PRTArtificial SequenceMyostatin Binding Peptide
95Trp Tyr Asp Cys Asn Val Pro Asn Glu Leu Leu Ser Gly Leu Cys Arg1
5 10 15Leu Phe9618PRTArtificial SequenceMyostatin Binding Peptide
96Tyr Gly Asp Cys Asp Gln Asn His Trp Met Trp Pro Phe Thr Cys Leu1
5 10 15Ser Leu9718PRTArtificial SequenceMyostatin Binding Peptide
97Gly Trp Met Cys His Phe Asp Leu His Asp Trp Gly Ala Thr Cys Gln1
5 10 15Pro Asp9818PRTArtificial SequenceMyostatin Binding Peptide
98Tyr Phe His Cys Met Phe Gly Gly His Glu Phe Glu Val His Cys Glu1
5 10 15Ser Phe9912PRTArtificial SequenceMyostatin Binding Peptide
99Ala Tyr Trp Cys Trp His Gly Gln Cys Val Arg Phe1 5
1010019PRTArtificial SequenceMyostatin Binding Peptide 100Ser Glu
His Trp Thr Phe Thr Asp Trp Asp Gly Asn Glu Trp Trp Val1 5 10 15Arg
Pro Phe10120PRTArtificial SequenceMyostatin Binding Peptide 101Met
Glu Met Leu Asp Ser Leu Phe Glu Leu Leu Lys Asp Met Val Pro1 5 10
15Ile Ser Lys Ala 2010219PRTArtificial SequenceMyostatin Binding
Peptide 102Ser Pro Pro Glu Glu Ala Leu Met Glu Trp Leu Gly Trp Gln
Tyr Gly1 5 10 15Lys Phe Thr10320PRTArtificial SequenceMyostatin
Binding Peptide 103Ser Pro Glu Asn Leu Leu Asn Asp Leu Tyr Ile Leu
Met Thr Lys Gln1 5 10 15Glu Trp Tyr Gly 2010420PRTArtificial
SequenceMyostatin Binding Peptide 104Phe His Trp Glu Glu Gly Ile
Pro Phe His Val Val Thr Pro Tyr Ser1 5 10 15Tyr Asp Arg Met
2010519PRTArtificial SequenceMyostatin Binding Peptide 105Lys Arg
Leu Leu Glu Gln Phe Met Asn Asp Leu Ala Glu Leu Val Ser1 5 10 15Gly
His Ser10620PRTArtificial SequenceMyostatin Binding Peptide 106Asp
Thr Arg Asp Ala Leu Phe Gln Glu Phe Tyr Glu Phe Val Arg Ser1 5 10
15Arg Leu Val Ile 2010720PRTArtificial SequenceMyostatin Binding
Peptide 107Arg Met Ser Ala Ala Pro Arg Pro Leu Thr Tyr Arg Asp Ile
Met Asp1 5 10 15Gln Tyr Trp His 2010820PRTArtificial
SequenceMyostatin Binding Peptide 108Asn Asp Lys Ala His Phe Phe
Glu Met Phe Met Phe Asp Val His Asn1 5 10 15Phe Val Glu Ser
2010920PRTArtificial SequenceMyostatin Binding Peptide 109Gln Thr
Gln Ala Gln Lys Ile Asp Gly Leu Trp Glu Leu Leu Gln Ser1 5 10 15Ile
Arg Asn Gln 2011018PRTArtificial SequenceMyostatin Binding Peptide
110Met Leu Ser Glu Phe Glu Glu Phe Leu Gly Asn Leu Val His Arg Gln1
5 10 15Glu Ala11120PRTArtificial SequenceMyostatin Binding Peptide
111Tyr Thr Pro Lys Met Gly Ser Glu Trp Thr Ser Phe Trp His Asn
Arg1
5 10 15Ile His Tyr Leu 2011220PRTArtificial SequenceMyostatin
Binding Peptide 112Leu Asn Asp Thr Leu Leu Arg Glu Leu Lys Met Val
Leu Asn Ser Leu1 5 10 15Ser Asp Met Lys 2011320PRTArtificial
SequenceMyostatin Binding Peptide 113Phe Asp Val Glu Arg Asp Leu
Met Arg Trp Leu Glu Gly Phe Met Gln1 5 10 15Ser Ala Ala Thr
2011420PRTArtificial SequenceMyostatin Binding Peptide 114His His
Gly Trp Asn Tyr Leu Arg Lys Gly Ser Ala Pro Gln Trp Phe1 5 10 15Glu
Ala Trp Val 2011520PRTArtificial SequenceMyostatin Binding Peptide
115Val Glu Ser Leu His Gln Leu Gln Met Trp Leu Asp Gln Lys Leu Ala1
5 10 15Ser Gly Pro His 2011618PRTArtificial SequenceMyostatin
Binding Peptide 116Arg Ala Thr Leu Leu Lys Asp Phe Trp Gln Leu Val
Glu Gly Tyr Gly1 5 10 15Asp Asn11716PRTArtificial SequenceMyostatin
Binding Peptide 117Glu Glu Leu Leu Arg Glu Phe Tyr Arg Phe Val Ser
Ala Phe Asp Tyr1 5 10 1511820PRTArtificial SequenceMyostatin
Binding Peptide 118Gly Leu Leu Asp Glu Phe Ser His Phe Ile Ala Glu
Gln Phe Tyr Gln1 5 10 15Met Pro Gly Gly 2011920PRTArtificial
SequenceMyostatin Binding Peptide 119Tyr Arg Glu Met Ser Met Leu
Glu Gly Leu Leu Asp Val Leu Glu Arg1 5 10 15Leu Gln His Tyr
2012020PRTArtificial SequenceMyostatin Binding Peptide 120His Asn
Ser Ser Gln Met Leu Leu Ser Glu Leu Ile Met Leu Val Gly1 5 10 15Ser
Met Met Gln 2012120PRTArtificial SequenceMyostatin Binding Peptide
121Trp Arg Glu His Phe Leu Asn Ser Asp Tyr Ile Arg Asp Lys Leu Ile1
5 10 15Ala Ile Asp Gly 2012219PRTArtificial SequenceMyostatin
Binding Peptide 122Gln Phe Pro Phe Tyr Val Phe Asp Asp Leu Pro Ala
Gln Leu Glu Tyr1 5 10 15Trp Ile Ala12320PRTArtificial
SequenceMyostatin Binding Peptide 123Glu Phe Phe His Trp Leu His
Asn His Arg Ser Glu Val Asn His Trp1 5 10 15Leu Asp Met Asn
2012419PRTArtificial SequenceMyostatin Binding Peptide 124Glu Ala
Leu Phe Gln Asn Phe Phe Arg Asp Val Leu Thr Leu Ser Glu1 5 10 15Arg
Glu Tyr12520PRTArtificial SequenceMyostatin Binding Peptide 125Gln
Tyr Trp Glu Gln Gln Trp Met Thr Tyr Phe Arg Glu Asn Gly Leu1 5 10
15His Val Gln Tyr 2012620PRTArtificial SequenceMyostatin Binding
Peptide 126Asn Gln Arg Met Met Leu Glu Asp Leu Trp Arg Ile Met Thr
Pro Met1 5 10 15Phe Gly Arg Ser 2012720PRTArtificial
SequenceMyostatin Binding Peptide 127Phe Leu Asp Glu Leu Lys Ala
Glu Leu Ser Arg His Tyr Ala Leu Asp1 5 10 15Asp Leu Asp Glu
2012820PRTArtificial SequenceMyostatin Binding Peptide 128Gly Lys
Leu Ile Glu Gly Leu Leu Asn Glu Leu Met Gln Leu Glu Thr1 5 10 15Phe
Met Pro Asp 2012915PRTArtificial SequenceMyostatin Binding Peptide
129Ile Leu Leu Leu Asp Glu Tyr Lys Lys Asp Trp Lys Ser Trp Phe1 5
10 1513050PRTArtificial SequenceMyostatin Binding Peptide 130Gln
Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro Tyr Gly Ser1 5 10
15Gly Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly
20 25 30Ser Ala Thr Gly Gln Gly His Cys Thr Arg Trp Pro Trp Met Cys
Pro 35 40 45Pro Tyr 5013143PRTArtificial SequenceMyostatin Binding
Peptide 131Trp Tyr Pro Cys Tyr Glu Gly His Phe Trp Cys Tyr Asp Leu
Gly Ser1 5 10 15Gly Ser Thr Ala Ser Ser Gly Ser Gly Ser Ala Thr Gly
Trp Tyr Pro 20 25 30Cys Tyr Glu Gly His Phe Trp Cys Tyr Asp Leu 35
4013250PRTArtificial SequenceMyostatin Binding Peptide 132His Thr
Pro Cys Pro Trp Phe Ala Pro Leu Cys Val Glu Trp Gly Ser1 5 10 15Gly
Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly 20 25
30Ser Ala Thr Gly His Thr Pro Cys Pro Trp Phe Ala Pro Leu Cys Val
35 40 45Glu Trp 5013350PRTArtificial SequenceMyostatin Binding
Peptide 133Pro Asp Trp Cys Ile Asp Pro Asp Trp Trp Cys Lys Phe Trp
Gly Ser1 5 10 15Gly Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser
Gly Ser Gly 20 25 30Ser Ala Thr Gly Pro Asp Trp Cys Ile Asp Pro Asp
Trp Trp Cys Lys 35 40 45Phe Trp 5013450PRTArtificial
SequenceMyostatin Binding Peptide 134Ala Asn Trp Cys Val Ser Pro
Asn Trp Phe Cys Met Val Met Gly Ser1 5 10 15Gly Ser Ala Thr Gly Gly
Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly 20 25 30Ser Ala Thr Gly Ala
Asn Trp Cys Val Ser Pro Asn Trp Phe Cys Met 35 40 45Val Met
5013550PRTArtificial SequenceMyostatin Binding Peptide 135Pro Asp
Trp Cys Ile Asp Pro Asp Trp Trp Cys Lys Phe Trp Gly Ser1 5 10 15Gly
Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly 20 25
30Ser Ala Thr Gly Pro Asp Trp Cys Ile Asp Pro Asp Trp Trp Cys Lys
35 40 45Phe Trp 5013650PRTArtificial SequenceMyostatin Binding
Peptide 136His Trp Ala Cys Gly Tyr Trp Pro Trp Ser Cys Lys Trp Val
Gly Ser1 5 10 15Gly Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser
Gly Ser Gly 20 25 30Ser Ala Thr Gly His Trp Ala Cys Gly Tyr Trp Pro
Trp Ser Cys Lys 35 40 45Trp Val 5013750PRTArtificial
SequenceMyostatin Binding Peptide 137Lys Lys His Cys Gln Ile Trp
Thr Trp Met Cys Ala Pro Lys Gly Ser1 5 10 15Gly Ser Ala Thr Gly Gly
Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly 20 25 30Ser Ala Thr Gly Gln
Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro 35 40 45Pro Tyr
5013850PRTArtificial SequenceMyostatin Binding Peptide 138Gln Gly
His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro Tyr Gly Ser1 5 10 15Gly
Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly 20 25
30Ser Ala Thr Gly Lys Lys His Cys Gln Ile Trp Thr Trp Met Cys Ala
35 40 45Pro Lys 5013950PRTArtificial SequenceMyostatin Binding
Peptide 139Lys Lys His Cys Gln Ile Trp Thr Trp Met Cys Ala Pro Lys
Gly Ser1 5 10 15Gly Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser Ser
Gly Ser Gly 20 25 30Ser Ala Thr Gly Gln Gly His Cys Thr Arg Trp Pro
Trp Met Cys Pro 35 40 45Pro Tyr 5014036PRTArtificial
SequenceMyostatin Binding Peptide 140Lys Lys His Cys Gln Ile Trp
Thr Trp Met Cys Ala Pro Lys Gly Gly1 5 10 15Gly Gly Gly Gly Gly Gly
Gln Gly His Cys Thr Arg Trp Pro Trp Met 20 25 30Cys Pro Pro Tyr
3514134PRTArtificial SequenceMyostatin Binding Peptide 141Gln Gly
His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro Tyr Gly Gly1 5 10 15Gly
Gly Gly Gly Lys Lys His Cys Gln Ile Trp Thr Trp Met Cys Ala 20 25
30Pro Lys14214PRTArtificial SequenceMyostatin Binding Peptide
142Lys Asp Xaa Cys Xaa Xaa Trp His Trp Met Cys Lys Pro Xaa1 5
1014314PRTArtificial SequenceMyostatin Binding Peptide 143Trp Xaa
Xaa Cys Xaa Xaa Xaa Gly Phe Trp Cys Leu Asn Val1 5
1014414PRTArtificial SequenceMyostatin Binding Peptide 144Ile Xaa
Gly Cys Xaa Trp Trp Asp Xaa Xaa Cys Tyr Xaa Xaa1 5
1014514PRTArtificial SequenceMyostatin Binding Peptide 145Xaa Xaa
Trp Cys Val Ser Pro Xaa Trp Phe Cys Xaa Xaa Xaa1 5
1014614PRTArtificial SequenceMyostatin Binding Peptide 146Xaa Xaa
Xaa Cys Pro Trp Phe Ala Xaa Xaa Cys Val Asp Trp1 5
1014742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 147aaagacaaat gcaaaatgtg gcactggatg tgcaaaccgc cg
4214842DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 148aaagacctgt gcgctatgtg gcactggatg tgcaaaccgc cg
4214942DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 149aaagacctgt gcaaaatgtg gaaatggatg tgcaaaccgc cg
4215042DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 150aaagacctgt gcaaaatgtg gcactggatg tgcaaaccga aa
4215142DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 151tggtacccgt gctacgaatt ccacttctgg tgctacgacc tg
4215242DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 152tggtacccgt gctacgaatt ccacttctgg tgctacgacc tg
4215342DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 153tggtacccgt gctacgaagg tcacttctgg tgctacgacc tg
4215442DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 154tggtacccgt gctacgaagg tcacttctgg tgctacgacc tg
4215542DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 155atcttcggtt gcaaatggtg ggacgttcag tgctaccagt tc
4215642DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 156atcttcggtt gcaaatggtg ggacgttgac tgctaccagt tc
4215742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 157atcttcggtt gcaaatggtg ggacgttgac tgctaccagt tc
4215842DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 158gctgactggt gcgtttcccc gaactggttc tgcatggtta tg
4215942DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 159cacaaattct gcccgtggtg ggctctgttc tgctgggact tc
4216042DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 160aaagacctgt gcaaaatgtg gcactggatg tgcaaaccgc cg
4216142DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 161atcgacaaat gcgctatctg gggttggatg tgcccgccgc tg
4216242DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 162tggtacccgt gcggtgaatt cggtatgtgg tgcctgaacg tt
4216333DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 163tggttcacct gcctgtggaa ctgcgacaac gaa
3316442DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 164cacaccccgt gcccgtggtt cgctccgctg tgcgttgaat gg
4216542DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 165aaagaatggt gctggcgttg gaaatggatg tgcaaaccgg aa
4216642DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 166ttcgaaacct gcccgtcctg ggcttacttc tgcctggaca tc
4216742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 167ttcgaaacct gcccgtcctg ggcttacttc tgcctggaca tc
4216842DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 168gcttacaaat gcgaagctaa cgactggggt tgctggtggc tg
4216942DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 169aactcctggt gcgaagacca gtggcaccgt tgctggtggc tg
4217042DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 170tggtccgctt gctacgctgg tcacttctgg tgctacgacc tg
4217142DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 171gctaactggt gcgtttcccc gaactggttc tgcatggtta tg
4217242DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 172tggaccgaat gctaccagca ggaattctgg tgctggaacc tg
4217342DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 173gaaaacacct gcgaacgttg gaaatggatg tgcccgccga aa
4217442DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 174tggctgccgt gccaccagga aggtttctgg tgcatgaact tc
4217542DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 175tccaccatgt gctcccagtg gcactggatg tgcaacccgt tc
4217642DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 176atcttcggtt gccactggtg ggacgttgac tgctaccagt tc
4217742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 177atctacggtt gcaaatggtg ggacatccag tgctacgaca tc
4217842DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 178ccggactggt gcatcgatcc ggactggtgg tgcaaattct gg
4217942DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 179cagggtcact gcacccgttg gccgtggatg tgcccgccgt ac
4218042DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 180tggcaggaat gctaccgtga aggtttctgg tgcctgcaga cc
4218142DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 181tggttcgact gctacggtcc gggtttcaaa tgctggtccc cg
4218242DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 182ggtgttcgtt gcccgaaagg tcacctgtgg tgcctgtacc cg
4218342DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 183cactgggctt gcggttactg gccgtggtcc tgcaaatggg tt
4218442DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 184ggtccggctt gccactcccc gtggtggtgg tgcgttttcg gt
4218542DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 185accacctggt gcatctcccc gatgtggttc tgctcccagc ag
4218642DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 186cacaaattct gcccgccgtg ggctatcttc tgctgggact tc
4218742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 187ccggactggt gcgtttcccc gcgttggtac tgcaacatgt gg
4218842DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 188gtttggaaat gccactggtt cggtatggac tgcgaaccga cc
4218942DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 189aaaaaacact gccagatctg gacctggatg tgcgctccga aa
4219042DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 190tggttccagt gcggttccac cctgttctgg tgctacaacc tg
4219142DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 191tggtccccgt gctacgacca ctacttctac tgctacacca tc
4219242DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 192tcctggatgt gcggtttctt caaagaagtt tgcatgtggg tt
4219342DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 193gaaatgctgt gcatgatcca cccggttttc tgcaacccgc ac
4219442DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 194ctgaaaacct gcaacctgtg gccgtggatg tgcccgccgc tg
4219542DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 195gttgttggtt gcaaatggta cgaagcttgg tgctacaaca aa
4219642DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 196ccgatccact gcacccagtg ggcttggatg tgcccgccga cc
4219742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 197gactccaact gcccgtggta cttcctgtcc tgcgttatct tc
4219842DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 198gactccaact gcccgtggta cttcctgtcc tgcgttatct tc
4219942DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide
199aacctgcagt gcatctactt cctgggtaaa tgcatctact tc
4220042DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 200gcttggcgtt gcatgtggtt ctccgacgtt tgcaccccgg gt
4220142DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 201tggtttcgtt gttttcttga tgctgattgg tgtacttctg tt
4220242DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 202gaaaaaattt gtcaaatgtg gtcttggatg tgtgctccac ca
4220342DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 203tggttttatt gtcatcttaa taaatctgaa tgtactgaac ca
4220442DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 204ttttggcgtt gtgctattgg tattgataaa tgtaaacgtg tt
4220542DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 205ttttggcgtt gtgctattgg tattgataaa tgtaaacgtg tt
4220642DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 206attgatcttt gtaatatgtg ggatggtatg tgttatccac ca
4220742DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 207gaaatgccat gtaatatttg gggttggatg tgtccaccag tt
4220854DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 208tggttccgtt gcgttctgac cggtatcgtt gactggtccg
aatgcttcgg tctg 5420954DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 209ggtttctcct gcaccttcgg
tctggacgaa ttctacgttg actgctcccc gttc 5421054DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
210ctgccgtggt gccacgacca ggttaacgct gactggggtt tctgcatgct gtgg
5421154DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 211tacccgacct gctccgaaaa attctggatc tacggtcaga
cctgcgttct gtgg 5421254DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 212ctgggtccgt gcccgatcca
ccacggtccg tggccgcagt actgcgttta ctgg 5421354DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
213ccgttcccgt gcgaaaccca ccagatctcc tggctgggtc actgcctgtc cttc
5421454DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 214cactggggtt gcgaagacct gatgtggtcc tggcacccgc
tgtgccgtcg tccg 5421554DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 215ctgccgctgt gcgacgctga
catgatgccg accatcggtt tctgcgttgc ttac 5421654DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
216tcccactggt gcgaaaccac cttctggatg aactacgcta aatgcgttca cgct
5421754DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 217ctgccgaaat gcacccacgt tccgttcgac cagggtggtt
tctgcctgtg gtac 5421854DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 218ttctcctcct gctggtcccc
ggtttcccgt caggacatgt tctgcgtttt ctac 5421951DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
219tcccacaaat gcgaatactc cggttggctg cagccgctgt gctaccgtcc g
5122054DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 220ccgtggtggt gccaggacaa ctacgttcag cacatgctgc
actgcgactc cccg 5422154DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 221tggttccgtt gcatgctgat
gaactccttc gacgctttcc agtgcgtttc ctac 5422254DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
222ccggacgctt gccgtgacca gccgtggtac atgttcatgg gttgcatgct gggt
5422342DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 223ttcctggctt gcttcgttga attcgaactg tgcttcgact cc
4222454DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 224tccgcttact gcatcatcac cgaatccgac ccgtacgttc
tgtgcgttcc gctg 5422554DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 225ccgtccatct gcgaatccta
ctccaccatg tggctgccga tgtgccagca caac 5422654DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
226tggctggact gccacgacga ctcctgggct tggaccaaaa tgtgccgttc ccac
5422754DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 227tacctgaact gcgttatgat gaacacctcc ccgttcgttg
aatgcgtttt caac 5422854DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 228tacccgtggt gcgacggttt
catgatccag cagggtatca cctgcatgtt ctac 5422954DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
229ttcgactact gcacctggct gaacggtttc aaagactgga aatgctggtc ccgt
5423054DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 230ctgccgctgt gcaacctgaa agaaatctcc cacgttcagg
cttgcgttct gttc 5423154DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 231tccccggaat gcgctttcgc
tcgttggctg ggtatcgaac agtgccagcg tgac 5423254DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
232tacccgcagt gcttcaacct gcacctgctg gaatggaccg aatgcgactg gttc
5423354DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 233cgttggcgtt gcgaaatcta cgactccgaa ttcctgccga
aatgctggtt cttc 5423442DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 234ctggttggtt gcgacaacgt
ttggcaccgt tgcaaactgt tc 4223554DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 235gctggttggt
gccacgtttg gggtgaaatg ttcggtatgg gttgctccgc tctg
5423654DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 236caccacgaat gcgaatggat ggctcgttgg atgtccctgg
actgcgttgg tctg 5423754DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 237ttcccgatgt gcggtatcgc
tggtatgaaa gacttcgact tctgcgtttg gtac 5423854DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
238cgtgatgatt gtactttttg gccagaatgg ctttggaaac tttgtgaacg tcca
5423954DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 239tataattttt gttcttatct ttttggtgtt tctaaagaag
cttgtcaact tcca 5424054DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 240gctcattggt gtgaacaagg
tccatggcgt tatggtaata tttgtatggc ttat 5424154DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
241aatcttgttt gtggtaaaat ttctgcttgg ggtgatgaag cttgtgctcg tgct
5424254DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 242cataatgttt gtactattat gggtccatct atgaaatggt
tttgttggaa tgat 5424354DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 243aatgatcttt gtgctatgtg
gggttggcgt aatactattt ggtgtcaaaa ttct 5424454DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
244ccaccatttt gtcaaaatga taatgatatg cttcaatctc tttgtaaact tctt
5424554DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 245tggtatgatt gtaatgttcc aaatgaactt ctttctggtc
tttgtcgtct tttt 5424654DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 246tatggtgatt gtgatcaaaa
tcattggatg tggccattta cttgtctttc tctt 5424754DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
247ggttggatgt gtcattttga tcttcatgat tggggtgcta cttgtcaacc agat
5424854DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 248tattttcatt gtatgtttgg tggtcatgaa tttgaagttc
attgtgaatc tttt 5424936DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 249gcttattggt gttggcatgg
tcaatgtgtt cgtttt 3625057DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 250tccgaacact ggaccttcac
cgactgggac ggtaacgaat ggtgggttcg tccgttc 5725160DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
251atggaaatgc tggactccct gttcgaactg ctgaaagaca tggttccgat
ctccaaagct 6025257DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 252tccccgccgg aagaagctct
gatggaatgg ctgggttggc agtacggtaa attcacc 5725360DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
253tccccggaaa acctgctgaa cgacctgtac atcctgatga ccaaacagga
atggtacggt 6025460DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 254ttccactggg aagaaggtat
cccgttccac gttgttaccc cgtactccta cgaccgtatg 6025557DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
255aaacgtctgc tggaacagtt catgaacgac ctggctgaac tggtttccgg tcactcc
5725660DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 256gacacccgtg acgctctgtt ccaggaattc tacgaattcg
ttcgttcccg tctggttatc 6025760DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 257cgtatgtccg
ctgctccgcg tccgctgacc taccgtgaca tcatggacca gtactggcac
6025860DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 258aacgacaaag ctcacttctt cgaaatgttc atgttcgacg
ttcacaactt cgttgaatcc 6025960DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 259cagacccagg
ctcagaaaat cgacggtctg tgggaactgc tgcagtccat ccgtaaccag
6026054DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 260atgctgtccg aattcgaaga attcctgggt aacctggttc
accgtcagga agct 5426160DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 261tacaccccga aaatgggttc
cgaatggacc tccttctggc acaaccgtat ccactacctg 6026260DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
262ctgaacgaca ccctgctgcg tgaactgaaa atggttctga actccctgtc
cgacatgaaa 6026360DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 263ttcgacgttg aacgtgacct
gatgcgttgg ctggaaggtt tcatgcagtc cgctgctacc 6026460DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
264caccacggtt ggaactacct gcgtaaaggt tccgctccgc agtggttcga
agcttgggtt 6026560DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 265gttgaatccc tgcaccagct
gcagatgtgg ctggaccaga aactggcttc cggtccgcac 6026654DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
266cgtgctaccc tgctgaaaga cttctggcag ctggttgaag gttacggtga caac
5426748DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 267gaagaactgc tgcgtgaatt ctaccgtttc gtttccgctt
tcgactac 4826860DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 268ggtctgctgg acgaattctc ccacttcatc
gctgaacagt tctaccagat gccgggtggt 6026960DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
269taccgtgaaa tgtccatgct ggaaggtctg ctggacgttc tggaacgtct
gcagcactac 6027060DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 270cacaactcct cccagatgct
gctgtccgaa ctgatcatgc tggttggttc catgatgcag 6027160DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
271tggcgtgaac acttcctgaa ctccgactac atccgtgaca aactgatcgc
tatcgacggt 6027257DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 272cagttcccgt tctacgtttt
cgacgacctg ccggctcagc tggaatactg gatcgct 5727360DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
273gaattcttcc actggctgca caaccaccgt tccgaagtta accactggct
ggacatgaac 6027457DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 274gaagctcttt ttcaaaattt
ttttcgtgat gttcttactc tttctgaacg tgaatat 5727560DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
275caatattggg aacaacaatg gatgacttat tttcgtgaaa atggtcttca
tgttcaatat 6027660DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 276aatcaacgta tgatgcttga
agatctttgg cgtattatga ctccaatgtt tggtcgttct 6027760DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
277tttcttgatg aacttaaagc tgaactttct cgtcattatg ctcttgatga
tcttgatgaa 6027860DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 278ggtaaactta ttgaaggtct
tcttaatgaa cttatgcaac ttgaaacttt tatgccagat 6027945DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
279attcttcttc ttgatgaata taaaaaagat tggaaatctt ggttt
45280150DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 280cagggccact gtactcgctg gccgtggatg
tgcccgccgt acggttctgg ttccgctacc 60ggtggttctg gttccactgc ttcttctggt
tccggttctg ctactggtca gggtcactgc 120actcgttggc catggatgtg
tccaccgtat 150281129DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 281tggtatccgt gttatgaggg
tcacttctgg tgctacgatc tgggttctgg ttccactgct 60tcttctggtt ccggttccgc
tactggttgg tacccgtgct acgaaggtca cttttggtgt 120tatgatctg
129282150DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 282cacactccgt gtccgtggtt tgctccgctg
tgcgttgaat ggggttctgg ttccgctact 60ggtggttccg gttccactgc ttcttctggt
tccggttctg caactggtca caccccgtgc 120ccgtggtttg caccgctgtg
tgtagagtgg 150283150DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 283ccggattggt gtatcgaccc
ggactggtgg tgcaaattct ggggttctgg ttccgctacc 60ggtggttccg gttccactgc
ttcttctggt tccggttctg caactggtcc ggactggtgc 120atcgacccgg
attggtggtg taaattttgg 150284150DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 284ccggattggt
gtatcgaccc ggactggtgg tgcaaattct ggggttctgg ttccgctacc 60ggtggttccg
gttccactgc ttcttctggt tccggttctg caactggtcc ggactggtgc
120atcgacccgg attggtggtg taaattttgg 150285129DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
285accacttggt gcatctctcc gatgtggttc tgctctcagc agggttctgg
ttccactgct 60tcttctggtt ccggttctgc aactggtact acttggtgta tctctccaat
gtggttttgt 120tctcagcaa 129286150DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 286cactgggcat
gtggctattg gccgtggtcc tgcaaatggg ttggttctgg ttccgctacc 60ggtggttccg
gttccactgc ttcttctggt tccggttctg caactggtca ctgggcttgc
120ggttactggc cgtggtcttg taaatgggtt 150287150DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
287aaaaaacact gtcagatctg gacttggatg tgcgctccga aaggttctgg
ttccgctacc 60ggtggttctg gttccactgc ttcttctggt tccggttccg ctactggtca
gggtcactgc 120actcgttggc catggatgtg tccgccgtat
150288150DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 288cagggtcact gcacccgttg gccgtggatg
tgcccgccgt acggttctgg ttccgctacc 60ggtggttctg gttccactgc ttcttctggt
tccggttctg ctactggtaa aaaacactgc 120cagatctgga cttggatgtg
cgctccgaaa 150289150DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 289aaaaaacact gtcagatctg
gacttggatg tgcgctccga aaggttctgg ttccgctacc 60ggtggttctg gttccactgc
ttcttctggt tccggttccg ctactggtca gggtcactgc 120actcgttggc
catggatgtg tccgccgtat 150290108DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 290aaaaaacact
gccagatctg gacttggatg tgcgctccga aaggtggtgg tggtggtggc 60ggtggccagg
gtcactgcac ccgttggccg tggatgtgtc cgccgtat 108291102DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
291cagggtcact gcacccgttg gccgtggatg tgcccgccgt acggtggtgg
tggtggtggc 60aaaaaacact gccagatctg gacttggatg tgcgctccga aa
10229237DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 292gagagagagc atatgaatga gaacagtgag
caaaaag 3729334DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 293agagagggat ccattatgag cacccacagc ggtc
3429425DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 294cggcgcaact atcggtatca agctg 2529526DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
295catgtaccgt aacactgagt ttcgtc 26296227PRTArtificial
SequenceMyostatin Binding Peptide 296Asp Lys Thr His Thr Cys Pro
Pro Cys Pro Ala Pro Glu Leu Leu Gly1 5 10 15Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25
30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
Val 50 55 60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr65 70 75 80Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
Trp Leu Asn Gly 85 90 95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala Pro Ile 100 105 110Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 115 120 125Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145 150 155 160Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170
175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met 195 200 205His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser 210 215 220Pro Gly Lys22529767DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
297acaaacaaac atatgggtgc acagaaagcg gccgcaaaaa aactcgaggg
tggaggcggt 60ggggaca 6729820DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 298ggtcattact
ggaccggatc 2029925DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 299cgtacaggtt tacgcaagaa aatgg
2530066DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 300tttgttggat ccattactcg agtttttttg cggccgcttt
ctgtgcacca ccacctccac 60ctttac 66301681DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
301gacaaaactc acacatgtcc accttgccca gcacctgaac tcctgggggg
accgtcagtt 60ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc
tgaggtcaca 120tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca
agttcaactg gtacgtggac 180ggcgtggagg tgcataatgc caagacaaag
ccgcgggagg agcagtacaa cagcacgtac 240cgtgtggtca gcgtcctcac
cgtcctgcac caggactggc tgaatggcaa ggagtacaag 300tgcaaggtct
ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa
360gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga
gctgaccaag 420aaccaggtca gcctgacctg cctggtcaaa ggcttctatc
ccagcgacat cgccgtggag 480tgggagagca atgggcagcc ggagaacaac
tacaagacca cgcctcccgt gctggactcc 540gacggctcct tcttcctcta
cagcaagctc accgtggaca agagcaggtg gcagcagggg 600aacgtcttct
catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
660ctctccctgt ctccgggtaa a 68130215DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 302ggtggaggtg gtggt
1530322PRTArtificial SequencePeptibody 303Met Phe Cys Gly Gly Gly
Gly Gly Lys Asp Lys Cys Lys Met Trp His1 5 10 15Trp Met Cys Lys Pro
Pro20304740DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 304atggacaaaa ctcacacatg tccaccttgc
ccagcacctg aactcctggg gggaccgtca 60gttttcctct tccccccaaa acccaaggac
accctcatga tctcccggac ccctgaggtc 120acatgcgtgg tggtggacgt
gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg 180gacggcgtgg
aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg
240taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg
caaggagtac 300aagtgcaagg tctccaacaa agccctccca gcccccatcg
agaaaaccat ctccaaagcc 360aaagggcagc cccgagaacc acaggtgtac
accctgcccc catcccggga tgagctgacc 420aagaaccagg tcagcctgac
ctgcctggtc aaaggcttct atcccagcga catcgccgtg 480gagtgggaga
gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac
540tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag
gtggcagcag 600gggaacgtct tctcatgctc cgtgatgcat gaggctctgc
acaaccacta cacgcagaag 660agcctctccc tgtctccggg taaaggtgga
ggtggtggta agacaaatgc aaaatgtggc 720actggatgtg caaaccgccg
74030520PRTArtificial SequenceMyostatin Binding Peptide 305Val Ala
Leu His Gly Gln Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Arg Glu Gly 2030620PRTArtificial SequenceMyostatin Binding Peptide
306Tyr Pro Glu Gln Gly Leu Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Thr Leu Ala 2030720PRTArtificial SequenceMyostatin
Binding Peptide 307Gly Leu Asn Gln Gly His Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Gln Asp Ser Asn 2030820PRTArtificial
SequenceMyostatin Binding Peptide 308Met Ile Thr Gln Gly Gln Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Pro Ser Gly
2030920PRTArtificial SequenceMyostatin Binding Peptide 309Ala Gly
Ala Gln Glu His Cys Thr Arg Trp Pro Trp Met Cys Ala Pro1 5 10 15Asn
Asp Trp Ile 2031020PRTArtificial SequenceMyostatin Binding Peptide
310Gly Val Asn Gln Gly Gln Cys Thr Arg Trp Arg Trp Met Cys Pro Pro1
5 10 15Asn Gly Trp Glu 2031120PRTArtificial SequenceMyostatin
Binding Peptide 311Leu Ala Asp His Gly Gln Cys Ile Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Glu Gly Trp Glu 2031220PRTArtificial
SequenceMyostatin Binding Peptide 312Ile Leu Glu Gln Ala Gln Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Arg Gly Gly
2031320PRTArtificial SequenceMyostatin Binding Peptide 313Thr Gln
Thr His Ala Gln Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Trp Glu Gly 2031420PRTArtificial SequenceMyostatin Binding Peptide
314Val Val Thr Gln Gly His Cys Thr Leu Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Arg Trp Arg 2031520PRTArtificial SequenceMyostatin
Binding Peptide 315Ile Tyr Pro His Asp Gln Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Gln Pro Tyr Pro 2031620PRTArtificial
SequenceMyostatin Binding Peptide 316Ser Tyr Trp Gln Gly Gln Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Trp Arg Gly
2031720PRTArtificial SequenceMyostatin Binding Peptide 317Met Trp
Gln Gln Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Gly Trp Gly 2031820PRTArtificial SequenceMyostatin Binding Peptide
318Glu Phe Thr Gln Trp His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Arg Ser Gln 2031920PRTArtificial SequenceMyostatin
Binding Peptide 319Leu Asp Asp Gln Trp Gln Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Gln Gly Phe Ser 2032020PRTArtificial
SequenceMyostatin Binding Peptide 320Tyr Gln Thr Gln Gly Leu Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Ser Gln Arg
2032120PRTArtificial SequenceMyostatin Binding Peptide 321Glu Ser
Asn Gln Gly Gln Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Gly Gly Trp 2032220PRTArtificial SequenceMyostatin Binding Peptide
322Trp Thr Asp Arg Gly Pro Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Ala Asn Gly 2032320PRTArtificial SequenceMyostatin
Binding Peptide 323Val Gly Thr Gln Gly Gln Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Tyr Glu Thr Gly 2032420PRTArtificial
SequenceMyostatin Binding Peptide 324Pro Tyr Glu Gln Gly Lys Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Tyr Glu Val Glu
2032520PRTArtificial SequenceMyostatin Binding Peptide 325Ser Glu
Tyr Gln Gly Leu Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Gly Trp Lys 2032620PRTArtificial SequenceMyostatin Binding Peptide
326Thr Phe Ser Gln Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Gly Trp Gly 2032720PRTArtificial SequenceMyostatin
Binding Peptide 327Pro Gly Ala His Asp His Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Gln Ser Arg Tyr 2032820PRTArtificial
SequenceMyostatin Binding Peptide 328Val Ala Glu Glu Trp His Cys
Arg Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Asp Trp Arg
2032920PRTArtificial SequenceMyostatin Binding Peptide 329Val Gly
Thr Gln Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Pro Ala Gly 2033020PRTArtificial SequenceMyostatin Binding Peptide
330Glu Glu Asp Gln Ala His Cys Arg Ser Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Gly Trp Val 2033120PRTArtificial SequenceMyostatin
Binding Peptide 331Ala Asp Thr Gln Gly His Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Gln His Trp Phe 2033220PRTArtificial
SequenceMyostatin Binding Peptide 332Ser Gly Pro Gln Gly His Cys
Thr Arg Trp Pro Trp Met Cys Ala Pro1 5 10 15Gln Gly Trp Phe
2033320PRTArtificial SequenceMyostatin Binding Peptide 333Thr Leu
Val Gln Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Arg Trp Val 2033420PRTArtificial SequenceMyostatin Binding Peptide
334Gly Met Ala His Gly Lys Cys Thr Arg Trp Ala Trp Met Cys Pro Pro1
5 10 15Gln Ser Trp Lys 2033520PRTArtificial SequenceMyostatin
Binding Peptide 335Glu Leu Tyr His Gly Gln Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Gln Ser Trp Ala 2033620PRTArtificial
SequenceMyostatin Binding Peptide 336Val Ala Asp His Gly His Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Gly Trp Gly
2033720PRTArtificial SequenceMyostatin Binding Peptide 337Pro Glu
Ser Gln Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Gly Trp Gly 2033820PRTArtificial SequenceMyostatin Binding Peptide
338Ile Pro Ala His Gly His Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Arg Trp Arg 2033920PRTArtificial SequenceMyostatin
Binding Peptide 339Phe Thr Val His Gly His Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Tyr Gly Trp Val 2034020PRTArtificial
SequenceMyostatin Binding Peptide 340Pro Asp Phe Pro Gly His Cys
Thr Arg Trp Arg Trp Met Cys Pro Pro1 5 10 15Gln Gly Trp Glu
2034120PRTArtificial SequenceMyostatin Binding Peptide 341Gln Leu
Trp Gln Gly Pro Cys Thr Gln Trp Pro Trp Met Cys Pro Pro1 5 10 15Lys
Gly Arg Tyr 2034220PRTArtificial SequenceMyostatin Binding Peptide
342His Ala Asn Asp Gly His Cys Thr Arg Trp Gln Trp Met Cys Pro Pro1
5 10 15Gln Trp Gly Gly 2034320PRTArtificial SequenceMyostatin
Binding Peptide 343Glu Thr Asp His Gly Leu Cys Thr Arg Trp Pro Trp
Met Cys Pro Pro1 5 10 15Tyr Gly Ala Arg 2034420PRTArtificial
SequenceMyostatin Binding Peptide 344Gly Thr Trp Gln Gly Leu Cys
Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln Gly Trp Gln
2034520PRTArtificial SequenceMyostatin Binding Peptide 345Val Ala
Thr Gln Gly Gln Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1 5 10 15Gln
Gly Trp Gly 2034620PRTArtificial SequenceMyostatin Binding Peptide
346Val Ala Thr Gln Gly Gln Cys Thr Arg Trp Pro Trp Met Cys Pro Pro1
5 10 15Gln Arg Trp Gly 2034720PRTArtificial SequenceMyostatin
Binding Peptide 347Gln Arg Glu Trp Tyr Pro Cys Tyr Gly Gly His Leu
Trp Cys Tyr Asp1 5 10 15Leu His Lys Ala 2034820PRTArtificial
SequenceMyostatin Binding Peptide 348Ile Ser Ala Trp Tyr Ser Cys
Tyr Ala Gly His Phe Trp Cys Trp Asp1 5 10 15Leu Lys Gln Lys
2034920PRTArtificial SequenceMyostatin Binding Peptide 349Trp Thr
Gly Trp Tyr Gln Cys Tyr Gly Gly His Leu Trp Cys Tyr Asp1 5 10 15Leu
Arg Arg Lys 2035020PRTArtificial SequenceMyostatin Binding Peptide
350Lys Thr Phe Trp Tyr Pro Cys Tyr Asp Gly His Phe Trp Cys Tyr Asn1
5 10 15Leu Lys Ser Ser 2035120PRTArtificial SequenceMyostatin
Binding Peptide 351Glu Ser Arg Trp Tyr Pro Cys Tyr Glu Gly His Leu
Trp Cys Phe Asp1 5 10 15Leu Thr Glu Thr 2035210PRTArtificial
SequenceMyostatin Binding Peptide 352Cys Xaa Xaa Trp Xaa Trp Met
Cys Pro Pro1 5 1035310PRTArtificial SequenceMyostatin Binding
Peptide 353Cys Xaa Xaa Trp Xaa Trp Met Cys Pro Pro1 5
1035420PRTArtificial SequenceMyostatin Binding Peptide 354Xaa Xaa
Xaa Xaa Xaa Xaa Cys Xaa Xaa Trp Xaa Trp Met Cys Pro Pro1 5 10 15Xaa
Xaa Xaa Xaa 2035520PRTArtificial SequenceMyostatin Binding Peptide
355Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Trp Xaa Trp Met Cys Pro Pro1
5 10 15Xaa Xaa Xaa Xaa 203567PRTArtificial SequenceMyostatin
Binding Peptide 356Trp Tyr Xaa Xaa Tyr Xaa Gly1 535722PRTArtificial
SequenceMyostatin Binding Peptide 357Arg Met Glu Met Leu Glu Ser
Leu Leu Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro Met Ser Lys Ala Gly
2035822PRTArtificial SequenceMyostatin Binding Peptide 358Arg Met
Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro
Met Ser Lys Ala Arg 2035922PRTArtificial SequenceMyostatin Binding
Peptide 359Arg Met Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Lys Asp
Ile Val1 5 10 15Pro Met Ser Lys Pro Ser 2036022PRTArtificial
SequenceMyostatin Binding Peptide 360Gly Met Glu Met Leu Glu Ser
Leu Phe Glu Leu Leu Gln Glu Ile Val1 5 10 15Pro Met Ser Lys Ala Pro
2036122PRTArtificial SequenceMyostatin Binding Peptide 361Arg Met
Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Lys Asp Ile Val1 5 10 15Pro
Ile Ser Asn Pro Pro 2036222PRTArtificial SequenceMyostatin Binding
Peptide 362Arg Ile Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Gln Glu
Ile Val1 5 10 15Pro Ile Ser Lys Ala Glu 2036322PRTArtificial
SequenceMyostatin Binding Peptide 363Arg Met Glu Met Leu Gln Ser
Leu Leu Glu Leu Leu Lys Asp Ile Val1 5 10 15Pro Met Ser Asn Ala Arg
2036422PRTArtificial SequenceMyostatin Binding Peptide 364Arg Met
Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro
Thr Ser Asn Gly Thr 2036522PRTArtificial SequenceMyostatin Binding
Peptide 365Arg Met Glu Met Leu Glu Ser Leu Phe Glu Leu Leu Lys Glu
Ile Val1 5 10 15Pro Met Ser Lys Ala Gly 2036622PRTArtificial
SequenceMyostatin Binding Peptide 366Arg Met Glu Met Leu Gly Ser
Leu Leu Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro Met Ser Lys Ala Arg
2036722PRTArtificial SequenceMyostatin Binding Peptide 367Gln Met
Glu Leu Leu Asp Ser Leu Phe Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro
Lys Ser Gln Pro Ala 2036822PRTArtificial SequenceMyostatin Binding
Peptide 368Arg Met Glu Met Leu Asp Ser Leu Leu Glu Leu Leu Lys Glu
Ile Val1 5
10 15Pro Met Ser Asn Ala Arg 2036922PRTArtificial SequenceMyostatin
Binding Peptide 369Arg Met Glu Met Leu Glu Ser Leu Leu Glu Leu Leu
His Glu Ile Val1 5 10 15Pro Met Ser Gln Ala Gly
2037022PRTArtificial SequenceMyostatin Binding Peptide 370Gln Met
Glu Met Leu Glu Ser Leu Leu Gln Leu Leu Lys Glu Ile Val1 5 10 15Pro
Met Ser Lys Ala Ser 2037122PRTArtificial SequenceMyostatin Binding
Peptide 371Arg Met Glu Met Leu Asp Ser Leu Leu Glu Leu Leu Lys Asp
Met Val1 5 10 15Pro Met Thr Thr Gly Ala 2037222PRTArtificial
SequenceMyostatin Binding Peptide 372Arg Ile Glu Met Leu Glu Ser
Leu Leu Glu Leu Leu Lys Asp Met Val1 5 10 15Pro Met Ala Asn Ala Ser
2037322PRTArtificial SequenceMyostatin Binding Peptide 373Arg Met
Glu Met Leu Glu Ser Leu Leu Gln Leu Leu Asn Glu Ile Val1 5 10 15Pro
Met Ser Arg Ala Arg 2037422PRTArtificial SequenceMyostatin Binding
Peptide 374Arg Met Glu Met Leu Glu Ser Leu Phe Asp Leu Leu Lys Glu
Leu Val1 5 10 15Pro Met Ser Lys Gly Val 2037522PRTArtificial
SequenceMyostatin Binding Peptide 375Arg Ile Glu Met Leu Glu Ser
Leu Leu Glu Leu Leu Lys Asp Ile Val1 5 10 15Pro Ile Gln Lys Ala Arg
2037622PRTArtificial SequenceMyostatin Binding Peptide 376Arg Met
Glu Leu Leu Glu Ser Leu Phe Glu Leu Leu Lys Asp Met Val1 5 10 15Pro
Met Ser Asp Ser Ser 2037722PRTArtificial SequenceMyostatin Binding
Peptide 377Arg Met Glu Met Leu Glu Ser Leu Leu Glu Val Leu Gln Glu
Ile Val1 5 10 15Pro Arg Ala Lys Gly Ala 2037822PRTArtificial
SequenceMyostatin Binding Peptide 378Arg Met Glu Met Leu Asp Ser
Leu Leu Gln Leu Leu Asn Glu Ile Val1 5 10 15Pro Met Ser His Ala Arg
2037922PRTArtificial SequenceMyostatin Binding Peptide 379Arg Met
Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Lys Asp Ile Val1 5 10 15Pro
Met Ser Asn Ala Gly 2038022PRTArtificial SequenceMyostatin Binding
Peptide 380Arg Met Glu Met Leu Gln Ser Leu Phe Glu Leu Leu Lys Gly
Met Val1 5 10 15Pro Ile Ser Lys Ala Gly 2038122PRTArtificial
SequenceMyostatin Binding Peptide 381Arg Met Glu Met Leu Glu Ser
Leu Leu Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro Asn Ser Thr Ala Ala
2038222PRTArtificial SequenceMyostatin Binding Peptide 382Arg Met
Glu Met Leu Gln Ser Leu Leu Glu Leu Leu Lys Glu Ile Val1 5 10 15Pro
Ile Ser Lys Ala Gly 2038322PRTArtificial SequenceMyostatin Binding
Peptide 383Arg Ile Glu Met Leu Asp Ser Leu Leu Glu Leu Leu Asn Glu
Leu Val1 5 10 15Pro Met Ser Lys Ala Arg 2038422PRTArtificial
SequenceMyostatin Binding Peptide 384Gln Val Glu Ser Leu Gln Gln
Leu Leu Met Trp Leu Asp Gln Lys Leu1 5 10 15Ala Ser Gly Pro Gln Gly
2038522PRTArtificial SequenceMyostatin Binding Peptide 385Arg Met
Glu Leu Leu Glu Ser Leu Phe Glu Leu Leu Lys Glu Met Val1 5 10 15Pro
Arg Ser Lys Ala Val 2038622PRTArtificial SequenceMyostatin Binding
Peptide 386Gln Ala Val Ser Leu Gln His Leu Leu Met Trp Leu Asp Gln
Lys Leu1 5 10 15Ala Ser Gly Pro Gln His 2038722PRTArtificial
SequenceMyostatin Binding Peptide 387Asp Glu Asp Ser Leu Gln Gln
Leu Leu Met Trp Leu Asp Gln Lys Leu1 5 10 15Ala Ser Gly Pro Gln Leu
2038822PRTArtificial SequenceMyostatin Binding Peptide 388Pro Val
Ala Ser Leu Gln Gln Leu Leu Ile Trp Leu Asp Gln Lys Leu1 5 10 15Ala
Gln Gly Pro His Ala 2038922PRTArtificial SequenceMyostatin Binding
Peptide 389Glu Val Asp Glu Leu Gln Gln Leu Leu Asn Trp Leu Asp His
Lys Leu1 5 10 15Ala Ser Gly Pro Leu Gln 2039022PRTArtificial
SequenceMyostatin Binding Peptide 390Asp Val Glu Ser Leu Glu Gln
Leu Leu Met Trp Leu Asp His Gln Leu1 5 10 15Ala Ser Gly Pro His Gly
2039122PRTArtificial SequenceMyostatin Binding Peptide 391Gln Val
Asp Ser Leu Gln Gln Val Leu Leu Trp Leu Glu His Lys Leu1 5 10 15Ala
Leu Gly Pro Gln Val 2039222PRTArtificial SequenceMyostatin Binding
Peptide 392Gly Asp Glu Ser Leu Gln His Leu Leu Met Trp Leu Glu Gln
Lys Leu1 5 10 15Ala Leu Gly Pro His Gly 2039322PRTArtificial
SequenceMyostatin Binding Peptide 393Gln Ile Glu Met Leu Glu Ser
Leu Leu Asp Leu Leu Arg Asp Met Val1 5 10 15Pro Met Ser Asn Ala Phe
2039422PRTArtificial SequenceMyostatin Binding Peptide 394Glu Val
Asp Ser Leu Gln Gln Leu Leu Met Trp Leu Asp Gln Lys Leu1 5 10 15Ala
Ser Gly Pro Gln Ala 2039522PRTArtificial SequenceMyostatin Binding
Peptide 395Glu Asp Glu Ser Leu Gln Gln Leu Leu Ile Tyr Leu Asp Lys
Met Leu1 5 10 15Ser Ser Gly Pro Gln Val 2039622PRTArtificial
SequenceMyostatin Binding Peptide 396Ala Met Asp Gln Leu His Gln
Leu Leu Ile Trp Leu Asp His Lys Leu1 5 10 15Ala Ser Gly Pro Gln Ala
2039722PRTArtificial SequenceMyostatin Binding Peptide 397Arg Ile
Glu Met Leu Glu Ser Leu Leu Glu Leu Leu Asp Glu Ile Ala1 5 10 15Leu
Ile Pro Lys Ala Trp 2039822PRTArtificial SequenceMyostatin Binding
Peptide 398Glu Val Val Ser Leu Gln His Leu Leu Met Trp Leu Glu His
Lys Leu1 5 10 15Ala Ser Gly Pro Asp Gly 2039922PRTArtificial
SequenceMyostatin Binding Peptide 399Gly Gly Glu Ser Leu Gln Gln
Leu Leu Met Trp Leu Asp Gln Gln Leu1 5 10 15Ala Ser Gly Pro Gln Arg
2040022PRTArtificial SequenceMyostatin Binding Peptide 400Gly Val
Glu Ser Leu Gln Gln Leu Leu Ile Phe Leu Asp His Met Leu1 5 10 15Val
Ser Gly Pro His Asp 2040122PRTArtificial SequenceMyostatin Binding
Peptide 401Asn Val Glu Ser Leu Glu His Leu Met Met Trp Leu Glu Arg
Leu Leu1 5 10 15Ala Ser Gly Pro Tyr Ala 2040222PRTArtificial
SequenceMyostatin Binding Peptide 402Gln Val Asp Ser Leu Gln Gln
Leu Leu Ile Trp Leu Asp His Gln Leu1 5 10 15Ala Ser Gly Pro Lys Arg
2040322PRTArtificial SequenceMyostatin Binding Peptide 403Glu Val
Glu Ser Leu Gln Gln Leu Leu Met Trp Leu Glu His Lys Leu1 5 10 15Ala
Gln Gly Pro Gln Gly 2040422PRTArtificial SequenceMyostatin Binding
Peptide 404Glu Val Asp Ser Leu Gln Gln Leu Leu Met Trp Leu Asp Gln
Lys Leu1 5 10 15Ala Ser Gly Pro His Ala 2040522PRTArtificial
SequenceMyostatin Binding Peptide 405Glu Val Asp Ser Leu Gln Gln
Leu Leu Met Trp Leu Asp Gln Gln Leu1 5 10 15Ala Ser Gly Pro Gln Lys
2040622PRTArtificial SequenceMyostatin Binding Peptide 406Gly Val
Glu Gln Leu Pro Gln Leu Leu Met Trp Leu Glu Gln Lys Leu1 5 10 15Ala
Ser Gly Pro Gln Arg 2040722PRTArtificial SequenceMyostatin Binding
Peptide 407Gly Glu Asp Ser Leu Gln Gln Leu Leu Met Trp Leu Asp Gln
Gln Leu1 5 10 15Ala Ala Gly Pro Gln Val 2040822PRTArtificial
SequenceMyostatin Binding Peptide 408Ala Asp Asp Ser Leu Gln Gln
Leu Leu Met Trp Leu Asp Arg Lys Leu1 5 10 15Ala Ser Gly Pro His Val
2040922PRTArtificial SequenceMyostatin Binding Peptide 409Pro Val
Asp Ser Leu Gln Gln Leu Leu Ile Trp Leu Asp Gln Lys Leu1 5 10 15Ala
Ser Gly Pro Gln Gly 2041022PRTArtificial SequenceMyostatin Binding
Peptide 410Asp Trp Arg Ala Thr Leu Leu Lys Glu Phe Trp Gln Leu Val
Glu Gly1 5 10 15Leu Gly Asp Asn Leu Val 2041122PRTArtificial
SequenceMyostatin Binding Peptide 411Gln Ser Arg Ala Thr Leu Leu
Lys Glu Phe Trp Gln Leu Val Glu Gly1 5 10 15Leu Gly Asp Lys Gln Ala
2041222PRTArtificial SequenceMyostatin Binding Peptide 412Asp Gly
Arg Ala Thr Leu Leu Thr Glu Phe Trp Gln Leu Val Gln Gly1 5 10 15Leu
Gly Gln Lys Glu Ala 2041322PRTArtificial SequenceMyostatin Binding
Peptide 413Leu Ala Arg Ala Thr Leu Leu Lys Glu Phe Trp Gln Leu Val
Glu Gly1 5 10 15Leu Gly Glu Lys Val Val 2041422PRTArtificial
SequenceMyostatin Binding Peptide 414Gly Ser Arg Asp Thr Leu Leu
Lys Glu Phe Trp Gln Leu Val Val Gly1 5 10 15Leu Gly Asp Met Gln Thr
2041522PRTArtificial SequenceMyostatin Binding Peptide 415Asp Ala
Arg Ala Thr Leu Leu Lys Glu Phe Trp Gln Leu Val Asp Ala1 5 10 15Tyr
Gly Asp Arg Met Val 2041622PRTArtificial SequenceMyostatin Binding
Peptide 416Asn Asp Arg Ala Gln Leu Leu Arg Asp Phe Trp Gln Leu Val
Asp Gly1 5 10 15Leu Gly Val Lys Ser Trp 2041722PRTArtificial
SequenceMyostatin Binding Peptide 417Gly Val Arg Glu Thr Leu Leu
Tyr Glu Leu Trp Tyr Leu Leu Lys Gly1 5 10 15Leu Gly Ala Asn Gln Gly
2041822PRTArtificial SequenceMyostatin Binding Peptide 418Gln Ala
Arg Ala Thr Leu Leu Lys Glu Phe Cys Gln Leu Val Gly Cys1 5 10 15Gln
Gly Asp Lys Leu Ser 2041922PRTArtificial SequenceMyostatin Binding
Peptide 419Gln Glu Arg Ala Thr Leu Leu Lys Glu Phe Trp Gln Leu Val
Ala Gly1 5 10 15Leu Gly Gln Asn Met Arg 2042022PRTArtificial
SequenceMyostatin Binding Peptide 420Ser Gly Arg Ala Thr Leu Leu
Lys Glu Phe Trp Gln Leu Val Gln Gly1 5 10 15Leu Gly Glu Tyr Arg Trp
2042122PRTArtificial SequenceMyostatin Binding Peptide 421Thr Met
Arg Ala Thr Leu Leu Lys Glu Phe Trp Leu Phe Val Asp Gly1 5 10 15Gln
Arg Glu Met Gln Trp 2042222PRTArtificial SequenceMyostatin Binding
Peptide 422Gly Glu Arg Ala Thr Leu Leu Asn Asp Phe Trp Gln Leu Val
Asp Gly1 5 10 15Gln Gly Asp Asn Thr Gly 2042322PRTArtificial
SequenceMyostatin Binding Peptide 423Asp Glu Arg Glu Thr Leu Leu
Lys Glu Phe Trp Gln Leu Val His Gly1 5 10 15Trp Gly Asp Asn Val Ala
2042422PRTArtificial SequenceMyostatin Binding Peptide 424Gly Gly
Arg Ala Thr Leu Leu Lys Glu Leu Trp Gln Leu Leu Glu Gly1 5 10 15Gln
Gly Ala Asn Leu Val 2042522PRTArtificial SequenceMyostatin Binding
Peptide 425Thr Ala Arg Ala Thr Leu Leu Asn Glu Leu Val Gln Leu Val
Lys Gly1 5 10 15Tyr Gly Asp Lys Leu Val 2042622PRTArtificial
SequenceMyostatin Binding Peptide 426Gly Met Arg Ala Thr Leu Leu
Gln Glu Phe Trp Gln Leu Val Gly Gly1 5 10 15Gln Gly Asp Asn Trp Met
2042722PRTArtificial SequenceMyostatin Binding Peptide 427Ser Thr
Arg Ala Thr Leu Leu Asn Asp Leu Trp Gln Leu Met Lys Gly1 5 10 15Trp
Ala Glu Asp Arg Gly 2042822PRTArtificial SequenceMyostatin Binding
Peptide 428Ser Glu Arg Ala Thr Leu Leu Lys Glu Leu Trp Gln Leu Val
Gly Gly1 5 10 15Trp Gly Asp Asn Phe Gly 2042922PRTArtificial
SequenceMyostatin Binding Peptide 429Val Gly Arg Ala Thr Leu Leu
Lys Glu Phe Trp Gln Leu Val Glu Gly1 5 10 15Leu Val Gly Gln Ser Arg
2043022PRTArtificial SequenceMyostatin Binding Peptide 430Glu Ile
Arg Ala Thr Leu Leu Lys Glu Phe Trp Gln Leu Val Asp Glu1 5 10 15Trp
Arg Glu Gln Pro Asn 2043122PRTArtificial SequenceMyostatin Binding
Peptide 431Gln Leu Arg Ala Thr Leu Leu Lys Glu Phe Leu Gln Leu Val
His Gly1 5 10 15Leu Gly Glu Thr Asp Ser 2043222PRTArtificial
SequenceMyostatin Binding Peptide 432Thr Gln Arg Ala Thr Leu Leu
Lys Glu Phe Trp Gln Leu Ile Glu Gly1 5 10 15Leu Gly Gly Lys His Val
2043322PRTArtificial SequenceMyostatin Binding Peptide 433His Tyr
Arg Ala Thr Leu Leu Lys Glu Phe Trp Gln Leu Val Asp Gly1 5 10 15Leu
Arg Glu Gln Gly Val 2043422PRTArtificial SequenceMyostatin Binding
Peptide 434Gln Ser Arg Val Thr Leu Leu Arg Glu Phe Trp Gln Leu Val
Glu Ser1 5 10 15Tyr Arg Pro Ile Val Asn 2043522PRTArtificial
SequenceMyostatin Binding Peptide 435Leu Ser Arg Ala Thr Leu Leu
Asn Glu Phe Trp Gln Phe Val Asp Gly1 5 10 15Gln Arg Asp Lys Arg Met
2043622PRTArtificial SequenceMyostatin Binding Peptide 436Trp Asp
Arg Ala Thr Leu Leu Asn Asp Phe Trp His Leu Met Glu Glu1 5 10 15Leu
Ser Gln Lys Pro Gly 2043722PRTArtificial SequenceMyostatin Binding
Peptide 437Gln Glu Arg Ala Thr Leu Leu Lys Glu Phe Trp Arg Met Val
Glu Gly1 5 10 15Leu Gly Lys Asn Arg Gly 2043822PRTArtificial
SequenceMyostatin Binding Peptide 438Asn Glu Arg Ala Thr Leu Leu
Arg Glu Phe Trp Gln Leu Val Gly Gly1 5 10 15Tyr Gly Val Asn Gln Arg
2043922PRTArtificial SequenceMyostatin Binding Peptide 439His Gln
Arg Asp Met Ser Met Leu Trp Glu Leu Leu Asp Val Leu Asp1 5 10 15Gly
Leu Arg Gln Tyr Ser 2044022PRTArtificial SequenceMyostatin Binding
Peptide 440Thr Gln Arg Asp Met Ser Met Leu Asp Gly Leu Leu Glu Val
Leu Asp1 5 10 15Gln Leu Arg Gln Gln Arg 2044122PRTArtificial
SequenceMyostatin Binding Peptide 441Thr Ser Arg Asp Met Ser Leu
Leu Trp Glu Leu Leu Glu Glu Leu Asp1 5 10 15Arg Leu Gly His Gln Arg
2044222PRTArtificial SequenceMyostatin Binding Peptide 442Met Gln
His Asp Met Ser Met Leu Tyr Gly Leu Val Glu Leu Leu Glu1 5 10 15Ser
Leu Gly His Gln Ile 2044322PRTArtificial SequenceMyostatin Binding
Peptide 443Trp Asn Arg Asp Met Arg Met Leu Glu Ser Leu Phe Glu Val
Leu Asp1 5 10 15Gly Leu Arg Gln Gln Val 2044422PRTArtificial
SequenceMyostatin Binding Peptide 444Gly Tyr Arg Asp Met Ser Met
Leu Glu Gly Leu Leu Ala Val Leu Asp1 5 10 15Arg Leu Gly Pro Gln Leu
2044522PRTArtificial SequenceMyostatin Binding Peptide 445Thr Gln
Arg Asp Met Ser Met Leu Glu Gly Leu Leu Glu Val Leu Asp1 5 10 15Arg
Leu Gly Gln Gln Arg 2044622PRTArtificial SequenceMyostatin Binding
Peptide 446Trp Tyr Arg Asp Met Ser Met Leu Glu Gly Leu Leu Glu Val
Leu Asp1 5 10 15Arg Leu Gly Gln Gln Arg 2044722PRTArtificial
SequenceMyostatin Binding Peptide 447Thr Gln Asn Ser Arg Gln Met
Leu Leu Ser Asp Phe Met Met Leu Val1 5 10 15Gly Ser Met Ile Gln Gly
2044822PRTArtificial SequenceMyostatin Binding Peptide 448Met Gln
Thr Ser Arg His Ile Leu Leu Ser Glu Phe Met Met Leu Val1 5 10 15Gly
Ser Ile Met His Gly 2044922PRTArtificial SequenceMyostatin Binding
Peptide 449His Asp Asn Ser Arg Gln Met Leu Leu Ser Asp Leu Leu His
Leu Val1 5 10 15Gly Thr Met Ile Gln Gly 2045022PRTArtificial
SequenceMyostatin Binding Peptide 450Met Glu Asn Ser Arg Gln Asn
Leu Leu Arg Glu Leu Ile Met Leu Val1 5 10 15Gly Asn Met Ser His Gln
2045122PRTArtificial SequenceMyostatin Binding Peptide 451Gln Asp
Thr Ser Arg His Met Leu Leu Arg Glu Phe Met Met Leu Val1 5 10 15Gly
Glu Met Ile Gln Gly 2045222PRTArtificial SequenceMyostatin Binding
Peptide 452Asp Gln Asn Ser
Arg Gln Met Leu Leu Ser Asp Leu Met Ile Leu Val1 5 10 15Gly Ser Met
Ile Gln Gly 2045322PRTArtificial SequenceMyostatin Binding Peptide
453Asn Val Phe Phe Gln Trp Val Gln Lys His Gly Arg Val Val Tyr Gln1
5 10 15Trp Leu Asp Ile Asn Val 2045422PRTArtificial
SequenceMyostatin Binding Peptide 454Phe Asp Phe Leu Gln Trp Leu
Gln Asn His Arg Ser Glu Val Glu His1 5 10 15Trp Leu Val Met Asp Val
2045511PRTArtificial SequenceMyostatin Binding Peptide 455Xaa Glu
Met Leu Xaa Ser Leu Xaa Xaa Leu Leu1 5 104568PRTArtificial
SequenceMyostatin Binding Peptide 456Leu Xaa Xaa Leu Leu Xaa Xaa
Leu1 54579PRTArtificial SequenceMyostatin Binding Peptide 457Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 545866DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
458cgtatggaaa tgcttgaatc tcttcttgaa cttcttaaag aaattgttcc
aatgtctaaa 60gctggt 6645966DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 459cgtatggaaa
tgcttgaatc tcttcttgaa cttcttaaag aaattgttcc aatgtctaaa 60gctcgt
6646066DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 460cgtatggaaa tgcttgaatc tcttcttgaa cttcttaaag
atattgttcc aatgtctaaa 60ccatct 6646166DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
461ggtatggaaa tgcttgaatc tctttttgaa cttcttcaag aaattgttcc
aatgtctaaa 60gctcca 6646266DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 462cgtatggaaa
tgcttgaatc tcttcttgaa cttcttaaag atattgttcc aatttctaat 60ccacca
6646366DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 463cgtattgaaa tgcttgaatc tcttcttgaa cttcttcaag
aaattgttcc aatttctaaa 60gctgaa 6646466DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
464cgtatggaaa tgcttcaatc tcttcttgaa cttcttaaag atattgttcc
aatgtctaat 60gctcgt 6646566DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 465cgtatggaaa
tgcttgaatc tcttcttgaa cttcttaaag aaattgttcc aacttctaat 60ggtact
6646666DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 466cgtatggaaa tgcttgaatc tctttttgaa cttcttaaag
aaattgttcc aatgtctaaa 60gctggt 6646766DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
467cgtatggaaa tgcttggttc tcttcttgaa cttcttaaag aaattgttcc
aatgtctaaa 60gctcgt 6646866DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 468caaatggaac
ttcttgattc tctttttgaa cttcttaaag aaattgttcc aaaatctcaa 60ccagct
6646966DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 469cgtatggaaa tgcttgattc tcttcttgaa cttcttaaag
aaattgttcc aatgtctaat 60gctcgt 6647066DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
470cgtatggaaa tgcttgaatc tcttcttgaa cttcttcatg aaattgttcc
aatgtctcaa 60gctggt 6647166DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 471caaatggaaa
tgcttgaatc tcttcttcaa cttcttaaag aaattgttcc aatgtctaaa 60gcttct
6647266DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 472cgtatggaaa tgcttgattc tcttcttgaa cttcttaaag
atatggttcc aatgactact 60ggtgct 6647366DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
473cgtattgaaa tgcttgaatc tcttcttgaa cttcttaaag atatggttcc
aatggctaat 60gcttct 6647466DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 474cgtatggaaa
tgcttgaatc tcttcttcaa cttcttaatg aaattgttcc aatgtctcgt 60gctcgt
6647566DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 475cgtatggaaa tgcttgaatc tctttttgat cttcttaaag
aacttgttcc aatgtctaaa 60ggtgtt 6647666DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
476cgtattgaaa tgcttgaatc tcttcttgaa cttcttaaag atattgttcc
aattcaaaaa 60gctcgt 6647766DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 477cgtatggaac
ttcttgaatc tctttttgaa cttcttaaag atatggttcc aatgtctgat 60tcttct
6647866DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 478cgtatggaaa tgcttgaatc tcttcttgaa gttcttcaag
aaattgttcc acgtgctaaa 60ggtgct 6647966DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
479cgtatggaaa tgcttgattc tcttcttcaa cttcttaatg aaattgttcc
aatgtctcat 60gctcgt 6648066DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 480cgtatggaaa
tgcttgaatc tcttcttgaa cttcttaaag atattgttcc aatgtctaat 60gctggt
6648166DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 481cgtatggaaa tgcttcaatc tctttttgaa cttcttaaag
gtatggttcc aatttctaaa 60gctggt 6648266DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
482cgtatggaaa tgcttgaatc tcttcttgaa cttcttaaag aaattgttcc
aaattctact 60gctgct 6648366DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 483cgtatggaaa
tgcttcaatc tcttcttgaa cttcttaaag aaattgttcc aatttctaaa 60gctggt
6648466DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 484cgtattgaaa tgcttgattc tcttcttgaa cttcttaatg
aacttgttcc aatgtctaaa 60gctcgt 6648566DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
485gattggcgtg ctactcttct taaagaattt tggcaacttg ttgaaggtct
tggtgataat 60cttgtt 6648666DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 486gatggtcgtg
ctactcttct tactgaattt tggcaacttg ttcaaggtct tggtcaaaaa 60gaagct
6648766DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 487cttgctcgtg ctactcttct taaagaattt tggcaacttg
ttgaaggtct tggtgaaaaa 60gttgtt 6648866DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
488ggttctcgtg atactcttct taaagaattt tggcaacttg ttgttggtct
tggtgatatg 60caaact 6648966DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 489gatgctcgtg
ctactcttct taaagaattt tggcaacttg ttgatgctta tggtgatcgt 60atggtt
6649066DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 490aatgatcgtg ctcaacttct tcgtgatttt tggcaacttg
ttgatggtct tggtgttaaa 60tcttgg 6649166DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
491ggtgttcgtg aaactcttct ttatgaactt tggtatcttc ttaaaggtct
tggtgctaat 60caaggt 6649266DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 492caagctcgtg
ctactcttct taaagaattt tgtcaacttg ttggttgtca aggtgataaa 60ctttct
6649366DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 493caagaacgtg ctactcttct taaagaattt tggcaacttg
ttgctggtct tggtcaaaat 60atgcgt 6649466DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
494tctggtcgtg ctactcttct taaagaattt tggcaacttg ttcaaggtct
tggtgaatat 60cgttgg 6649566DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 495actatgcgtg
ctactcttct taaagaattt tggctttttg ttgatggtca acgtgaaatg 60caatgg
6649666DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 496ggtgaacgtg ctactcttct taatgatttt tggcaacttg
ttgatggtca aggtgataat 60actggt 6649766DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
497gatgaacgtg aaactcttct taaagaattt tggcaacttg ttcatggttg
gggtgataat 60gttgct 6649866DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 498ggtggtcgtg
ctactcttct taaagaactt tggcaacttc ttgaaggtca aggtgctaat 60cttgtt
6649966DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 499actgctcgtg ctactcttct taatgaactt gttcaacttg
ttaaaggtta tggtgataaa 60cttgtt 6650066DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
500ggtatgcgtg ctactcttct tcaagaattt tggcaacttg ttggtggtca
aggtgataat 60tggatg 6650166DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 501tctactcgtg
ctactcttct taatgatctt tggcaactta tgaaaggttg ggctgaagat 60cgtggt
6650266DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 502tctgaacgtg ctactcttct taaagaactt tggcaacttg
ttggtggttg gggtgataat 60tttggt 6650366DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
503gttggtcgtg ctactcttct taaagaattt tggcaacttg ttgaaggtct
tgttggtcaa 60tctcgt 6650461PRTArtificial SequencePeptibody 504Met
Gly Ala Gln Trp Tyr Pro Cys Tyr Glu Gly His Phe Trp Cys Tyr1 5 10
15Asp Leu Gly Ser Gly Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser
20 25 30Ser Gly Ser Gly Ser Ala Thr Gly Trp Tyr Pro Cys Tyr Glu Gly
His 35 40 45Phe Trp Cys Tyr Asp Leu Leu Glu Gly Gly Gly Gly Gly 50
55 60505129DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 505tggtatccgt gttatgaggg tcacttctgg
tgctacgatc tgggttctgg ttccactgct 60tcttctggtt ccggttccgc tactggttgg
tacccgtgct acgaaggtca cttttggtgt 120tatgatctg 12950659PRTArtificial
SequencePeptibody 506Gly Gly Gly Gly Gly Ala Gln Trp Tyr Pro Cys
Tyr Glu Gly His Phe1 5 10 15Trp Cys Tyr Asp Leu Gly Ser Gly Ser Ala
Thr Gly Gly Ser Gly Ser 20 25 30Thr Ala Ser Ser Gly Ser Gly Ser Ala
Thr Gly Trp Tyr Pro Cys Tyr 35 40 45Glu Gly His Phe Trp Cys Tyr Asp
Leu Leu Glu 50 55507129DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 507tggtatccgt gttatgaggg
tcacttctgg tgctacgatc tgggttctgg ttccactgct 60tcttctggtt ccggttccgc
tactggttgg tacccgtgct acgaaggtca cttttggtgt 120tatgatctg
12950861PRTArtificial SequencePeptibody 508Met Gly Ala Gln Ile Phe
Gly Cys Lys Trp Trp Asp Val Gln Cys Tyr1 5 10 15Gln Phe Gly Ser Gly
Ser Ala Thr Gly Gly Ser Gly Ser Thr Ala Ser 20 25 30Ser Gly Ser Gly
Ser Ala Thr Gly Ile Phe Gly Cys Lys Trp Trp Asp 35 40 45Val Gln Cys
Tyr Gln Phe Leu Glu Gly Gly Gly Gly Gly 50 55 60509129DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
509atctttggct gtaaatggtg ggacgttcag tgctaccagt tcggttctgg
ttccactgct 60tcttctggtt ccggttccgc tactggtatc ttcggttgca agtggtggga
tgtacagtgt 120tatcagttt 12951059PRTArtificial SequencePeptibody
510Gly Gly Gly Gly Gly Ala Gln Ile Phe Gly Cys Lys Trp Trp Asp Val1
5 10 15Gln Cys Tyr Gln Phe Gly Ser Gly Ser Ala Thr Gly Gly Ser Gly
Ser 20 25 30Thr Ala Ser Ser Gly Ser Gly Ser Ala Thr Gly Ile Phe Gly
Cys Lys 35 40 45Trp Trp Asp Val Gln Cys Tyr Gln Phe Leu Glu 50
55511129DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 511atctttggct gtaaatggtg ggacgttcag
tgctaccagt tcggttctgg ttccactgct 60tcttctggtt ccggttccgc tactggtatc
ttcggttgca agtggtggga tgtacagtgt 120tatcagttt 12951261PRTArtificial
SequencePeptibody 512Met Gly Ala Gln Ile Phe Gly Cys Lys Trp Trp
Asp Val Asp Cys Tyr1 5 10 15Gln Phe Gly Ser Gly Ser Ala Thr Gly Gly
Ser Gly Ser Thr Ala Ser 20 25 30Ser Gly Ser Gly Ser Ala Thr Gly Ile
Phe Gly Cys Lys Trp Trp Asp 35 40 45Val Asp Cys Tyr Gln Phe Leu Glu
Gly Gly Gly Gly Gly 50 55 60513129DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 513atctttggct
gtaagtggtg ggacgttgac tgctaccagt tcggttctgg ttccactgct 60tcttctggtt
ccggttccgc tactggtatc ttcggttgca aatggtggga cgttgattgt 120tatcagttt
12951459PRTArtificial SequencePeptibody 514Gly Gly Gly Gly Gly Ala
Gln Ile Phe Gly Cys Lys Trp Trp Asp Val1 5 10 15Asp Cys Tyr Gln Phe
Gly Ser Gly Ser Ala Thr Gly Gly Ser Gly Ser 20 25 30Thr Ala Ser Ser
Gly Ser Gly Ser Ala Thr Gly Ile Phe Gly Cys Lys 35 40 45Trp Trp Asp
Val Asp Cys Tyr Gln Phe Leu Glu 50 55515129DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
515atctttggct gtaagtggtg ggacgttgac tgctaccagt tcggttctgg
ttccactgct 60tcttctggtt ccggttccgc tactggtatc ttcggttgca aatggtggga
cgttgattgt 120tatcagttt 12951666DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 516caggttgaat
ccctgcagca gctgctgatg tggctggacc agaaactggc ttccggtccg 60cagggt
6651766DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 517cgtatggaac tgctggaatc cctgttcgaa ctgctgaaag
aaatggttcc gcgttccaaa 60gctgtt 6651866DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
518caggctgttt ccctgcagca cctgctgatg tggctggacc agaaactggc
ttccggtccg 60cagcac 6651966DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 519gacgaagact
ccctgcagca gctgctgatg tggctggacc agaaactggc ttccggtccg 60cagctg
6652066DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 520ccggttgctt ccctgcagca gctgctgatc tggctggacc
agaaactggc tcagggtccg 60cacgct 6652166DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
521gaagttgacg aactgcagca gctgctgaac tggctggacc acaaactggc
ttccggtccg
60ctgcag 6652266DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 522gacgttgaat ccctggaaca gctgctgatg
tggctggacc accagctggc ttccggtccg 60cacggt 6652366DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
523caggttgact ccctgcagca ggttctgctg tggctggaac acaaactggc
tctgggtccg 60caggtt 6652466DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 524ggtgacgaat
ccctgcagca cctgctgatg tggctggaac agaaactggc tctgggtccg 60cacggt
6652566DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 525cagatcgaaa tgctggaatc cctgctggac ctgctgcgtg
acatggttcc gatgtccaac 60gctttc 6652666DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
526gaagttgact ccctgcagca gctgctgatg tggctggacc agaaactggc
ttccggtccg 60caggct 6652766DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 527gaagacgaat
ccctgcagca gctgctgatc tacctggaca aaatgctgtc ctccggtccg 60caggtt
6652866DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 528gctatggacc agctgcacca gctgctgatc tggctggacc
acaaactggc ttccggtccg 60caggct 6652966DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
529cgtatcgaaa tgctggaatc cctgctggaa ctgctggacg aaatcgctct
gatcccgaaa 60gcttgg 6653066DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 530gaagttgttt
ccctgcagca cctgctgatg tggctggaac acaaactggc ttccggtccg 60gacggt
6653166DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 531ggtggtgaat ccctgcagca gctgctgatg tggctggacc
agcagctggc ttccggtccg 60cagcgt 6653266DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
532ggtgttgaat ccctgcagca gctgctgatc ttcctggacc acatgctggt
ttccggtccg 60cacgac 6653366DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 533aacgttgaat
ccctggaaca cctgatgatg tggctggaac gtctgctggc ttccggtccg 60tacgct
6653466DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 534caggttgact ccctgcagca gctgctgatc tggctggacc
accagctggc ttccggtccg 60aaacgt 6653566DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
535gaagttgaat ccctgcagca gctgctgatg tggctggaac acaaactggc
tcagggtccg 60cagggt 6653666DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 536gaagttgact
ccctgcagca gctgctgatg tggctggacc agaaactggc ttccggtccg 60cacgct
6653766DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 537gaagttgact ccctgcagca gctgctgatg tggctggacc
agcagctggc ttccggtccg 60cagaaa 6653866DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
538ggtgttgaac agctgccgca gctgctgatg tggctggaac agaaactggc
ttccggtccg 60cagcgt 6653966DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 539ggtgaagact
ccctgcagca gctgctgatg tggctggacc agcagctggc tgctggtccg 60caggtt
6654066DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 540gctgacgact ccctgcagca gctgctgatg tggctggacc
gtaaactggc ttccggtccg 60cacgtt 6654166DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
541ccggttgact ccctgcagca gctgctgatc tggctggacc agaaactggc
ttccggtccg 60cagggt 6654266DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 542cagtcccgtg
ctaccctgct gaaagaattc tggcagctgg ttgaaggtct gggtgacaaa 60caggct
6654366DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 543gaaatccgtg ctaccctgct gaaagaattc tggcagctgg
ttgacgaatg gcgtgaacag 60ccgaac 6654466DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
544cagctgcgtg ctaccctgct gaaagaattc ctgcagctgg ttcacggtct
gggtgaaacc 60gactcc 6654566DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 545acccagcgtg
ctaccctgct gaaagaattc tggcagctga tcgaaggtct gggtggtaaa 60cacgtt
6654666DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 546cactaccgtg ctaccctgct gaaagaattc tggcagctgg
ttgacggtct gcgtgaacag 60ggtgtt 6654766DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
547cagtcccgtg ttaccctgct gcgtgaattc tggcagctgg ttgaatccta
ccgtccgatc 60gttaac 6654866DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 548ctgtcccgtg
ctaccctgct gaacgaattc tggcagttcg ttgacggtca gcgtgacaaa 60cgtatg
6654966DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 549tgggaccgtg ctaccctgct gaacgacttc tggcacctga
tggaagaact gtcccagaaa 60ccgggt 6655066DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
550caggaacgtg ctaccctgct gaaagaattc tggcgtatgg ttgaaggtct
gggtaaaaac 60cgtggt 6655166DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 551aacgaacgtg
ctaccctgct gcgtgaattc tggcagctgg ttggtggtta cggtgttaac 60cagcgt
6655260DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 552cagcgtgaat ggtacccgtg ctacggtggt cacctgtggt
gctacgacct gcacaaagct 6055360DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 553atctccgctt
ggtactcctg ctacgctggt cacttctggt gctgggacct gaaacagaaa
6055460DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 554tggaccggtt ggtaccagtg ctacggtggt cacctgtggt
gctacgacct gcgtcgtaaa 6055560DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 555aaaaccttct
ggtacccgtg ctacgacggt cacttctggt gctacaacct gaaatcctcc
6055660DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 556gaatcccgtt ggtacccgtg ctacgaaggt cacctgtggt
gcttcgacct gaccgaaacc 6055766DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 557aatgtttttt
ttcaatgggt tcaaaaacat ggtcgtgttg tttatcaatg gcttgatatt 60aatgtt
6655866DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 558tttgattttc ttcaatggct tcaaaatcat cgttctgaag
ttgaacattg gcttgttatg 60gatgtt 6655966DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
559catcaacgtg atatgtctat gctttgggaa cttcttgatg ttcttgatgg
tcttcgtcaa 60tattct 6656066DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 560actcaacgtg
atatgtctat gcttgatggt cttcttgaag ttcttgatca acttcgtcaa 60caacgt
6656166DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 561acctcccgtg acatgtccct gctgtgggaa ctgctggaag
aactggaccg tctgggtcac 60cagcgt 6656266DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
562atgcaacatg atatgtctat gctttatggt cttgttgaac ttcttgaatc
tcttggtcat 60caaatt 6656366DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 563tggaatcgtg
atatgcgtat gcttgaatct ctttttgaag ttcttgatgg tcttcgtcaa 60caagtt
6656466DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 564ggttatcgtg atatgtctat gcttgaaggt cttcttgctg
ttcttgatcg tcttggtcca 60caactt 6656566DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
565actcaacgtg atatgtctat gcttgaaggt cttcttgaag ttcttgatcg
tcttggtcaa 60caacgt 6656666DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 566tggtaccgtg
acatgtccat gctggaaggt ctgctggaag ttctggaccg tctgggtcag 60cagcgt
6656766DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 567actcaaaatt ctcgtcaaat gcttctttct gattttatga
tgcttgttgg ttctatgatt 60caaggt 6656866DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
568atgcaaactt ctcgtcatat tcttctttct gaatttatga tgcttgttgg
ttctattatg 60catggt 6656966DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 569cacgacaact
cccgtcagat gctgctgtcc gacctgctgc acctggttgg taccatgatc 60cagggt
6657066DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 570atggaaaact cccgtcagaa cctgctgcgt gaactgatca
tgctggttgg taacatgtcc 60caccag 6657166DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
571caggacacct cccgtcacat gctgctgcgt gaattcatga tgctggttgg
tgaaatgatc 60cagggt 6657266DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 572gaccagaact
cccgtcagat gctgctgtcc gacctgatga tcctggttgg ttccatgatc 60cagggt
6657360DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 573gttgctcttc atggtcaatg tactcgttgg ccatggatgt
gtccaccaca acgtgaaggt 6057460DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 574tatccagaac
aaggtctttg tactcgttgg ccatggatgt gtccaccaca aactcttgct
6057560DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 575ggtctgaacc agggtcactg cacccgttgg ccgtggatgt
gcccgccgca ggactccaac 6057660DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 576atgattactc
aaggtcaatg tactcgttgg ccatggatgt gtccaccaca accatctggt
6057760DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 577gctggtgctc aggaacactg cacccgttgg ccgtggatgt
gcgctccgaa cgactggatc 6057860DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 578ggtgttaacc
agggtcagtg cacccgttgg cgttggatgt gcccgccgaa cggttgggaa
6057960DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 579ctggctgacc acggtcagtg catccgttgg ccgtggatgt
gcccgccgga aggttgggaa 6058060DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 580atcctggaac
aggctcagtg cacccgttgg ccgtggatgt gcccgccgca gcgtggtggt
6058160DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 581actcaaactc atgctcaatg tactcgttgg ccatggatgt
gtccaccaca atgggaaggt 6058260DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 582gttgttactc
aaggtcattg tactctttgg ccatggatgt gtccaccaca acgttggcgt
6058360DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 583atttatccac atgatcaatg tactcgttgg ccatggatgt
gtccaccaca accatatcca 6058460DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 584tcttattggc
aaggtcaatg tactcgttgg ccatggatgt gtccaccaca atggcgtggt
6058560DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 585atgtggcaac aaggtcattg tactcgttgg ccatggatgt
gtccaccaca aggttggggt 6058660DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 586gaattcaccc
agtggcactg cacccgttgg ccgtggatgt gcccgccgca gcgttcccag
6058760DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 587ctggacgacc agtggcagtg cacccgttgg ccgtggatgt
gcccgccgca gggtttctcc 6058860DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 588tatcaaactc
aaggtctttg tactcgttgg ccatggatgt gtccaccaca atctcaacgt
6058960DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 589gaatctaatc aaggtcaatg tactcgttgg ccatggatgt
gtccaccaca aggtggttgg 6059060DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 590tggaccgacc
gtggtccgtg cacccgttgg ccgtggatgt gcccgccgca ggctaacggt
6059160DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 591gttggtaccc agggtcagtg cacccgttgg ccgtggatgt
gcccgccgta cgaaaccggt 6059260DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 592ccgtacgaac
agggtaaatg cacccgttgg ccgtggatgt gcccgccgta cgaagttgaa
6059360DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 593tccgaatacc agggtctgtg cacccgttgg ccgtggatgt
gcccgccgca gggttggaaa 6059460DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 594accttctccc
agggtcactg cacccgttgg ccgtggatgt gcccgccgca gggttggggt
6059560DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 595ccgggtgctc acgaccactg cacccgttgg ccgtggatgt
gcccgccgca gtcccgttac 6059660DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 596gttgctgaag
aatggcactg ccgtcgttgg ccgtggatgt gcccgccgca ggactggcgt
6059760DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 597gttggtaccc agggtcactg cacccgttgg ccgtggatgt
gcccgccgca gccggctggt 6059860DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 598gaagaagacc
aggctcactg ccgttcctgg ccgtggatgt gcccgccgca gggttgggtt
6059960DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 599gctgacaccc agggtcactg cacccgttgg ccgtggatgt
gcccgccgca gcactggttc 6060060DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 600tccggtccgc
agggtcactg cacccgttgg ccgtggatgt gcgctccgca gggttggttc
6060160DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 601accctggttc agggtcactg cacccgttgg ccgtggatgt
gcccgccgca gcgttgggtt 6060260DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 602ggtatggctc
acggtaaatg cacccgttgg gcttggatgt gcccgccgca gtcctggaaa
6060360DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 603gaactgtacc acggtcagtg cacccgttgg ccgtggatgt
gcccgccgca gtcctgggct 6060460DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 604gttgctgacc
acggtcactg cacccgttgg ccgtggatgt gcccgccgca gggttggggt
6060560DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 605ccggaatccc agggtcactg cacccgttgg ccgtggatgt
gcccgccgca gggttggggt 6060660DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 606atcccggctc
acggtcactg cacccgttgg ccgtggatgt gcccgccgca gcgttggcgt
6060760DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 607ttcaccgttc acggtcactg cacccgttgg ccgtggatgt
gcccgccgta cggttgggtt 6060860DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 608ccagattttc
caggtcattg tactcgttgg cgttggatgt gtccaccaca aggttgggaa
6060960DNAArtificial SequenceNucleotide sequence encoding
Myostatin
Binding Peptide 609cagctgtggc agggtccgtg cacccagtgg ccgtggatgt
gcccgccgaa aggtcgttac 6061060DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 610cacgctaacg
acggtcactg cacccgttgg cagtggatgt gcccgccgca gtggggtggt
6061160DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 611gaaaccgacc acggtctgtg cacccgttgg ccgtggatgt
gcccgccgta cggtgctcgt 6061260DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 612ggtacctggc
agggtctgtg cacccgttgg ccgtggatgt gcccgccgca gggttggcag
6061360DNAArtificial SequenceNucleotide sequence encoding Myostatin
Binding Peptide 613gttgctaccc agggtcagtg cacccgttgg ccgtggatgt
gcccgccgca gggttggggt 6061460DNAArtificial SequenceNucleotide
sequence encoding Myostatin Binding Peptide 614gttgctaccc
agggtcagtg cacccgttgg ccgtggatgt gcccgccgca gcgttggggt
6061573PRTArtificial SequencePeptibody 615Gly Gly Gly Gly Gly Ala
Gln Leu Ala Asp His Gly Gln Cys Ile Arg1 5 10 15Trp Pro Trp Met Cys
Pro Pro Glu Gly Trp Glu Leu Glu Gly Ser Gly 20 25 30Ser Ala Thr Gly
Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly Ser 35 40 45Ala Thr Gly
Leu Ala Asp His Gly Gln Cys Ile Arg Trp Pro Trp Met 50 55 60Cys Pro
Pro Glu Gly Trp Glu Leu Glu65 70616198DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
616cttgctgatc atggtcaatg tattcgttgg ccatggatgt gtccaccaga
aggttgggaa 60ctcgagggtt ccggttccgc taccggcggc tctggctcca ctgcttcttc
cggttccggt 120tctgctactg gtctggctga ccacggtcag tgcatccgtt
ggccgtggat gtgcccgccg 180gaaggttggg aactggaa 19861769PRTArtificial
SequencePeptibody 617Gly Gly Gly Gly Gly Ala Gln Leu Ala Asp His
Gly Gln Cys Ile Arg1 5 10 15Trp Pro Trp Met Cys Pro Pro Glu Gly Trp
Glu Gly Ser Gly Ser Ala 20 25 30Thr Gly Gly Ser Gly Gly Gly Ala Ser
Ser Gly Ser Gly Ser Ala Thr 35 40 45Gly Leu Ala Asp His Gly Gln Cys
Ile Arg Trp Pro Trp Met Cys Pro 50 55 60Pro Glu Gly Trp
Glu65618186DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 618cttgctgatc atggtcaatg tattcgttgg
ccatggatgt gtccaccaga aggttgggaa 60ggttccggtt ccgctaccgg cggctctggc
ggtggcgctt cttccggttc cggttctgct 120actggtctgg ctgaccacgg
tcagtgcatc cgttggccgt ggatgtgtcc accagaaggt 180tgggaa
18661973PRTArtificial SequencePeptibody 619Gly Gly Gly Gly Gly Ala
Gln Ser Glu Tyr Gln Gly Leu Cys Thr Arg1 5 10 15Trp Pro Trp Met Cys
Pro Pro Gln Gly Trp Lys Leu Glu Gly Ser Gly 20 25 30Ser Ala Thr Gly
Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly Ser 35 40 45Ala Thr Gly
Ser Glu Tyr Gln Gly Leu Cys Thr Arg Trp Pro Trp Met 50 55 60Cys Pro
Pro Gln Gly Trp Lys Leu Glu65 70620198DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
620tctgaatatc aaggtctttg tactcgttgg ccatggatgt gtccaccaca
aggttggaaa 60ctcgagggtt ccggttccgc taccggcggc tctggctcca ctgcttcttc
cggttccggt 120tctgctactg gttctgagta tcaaggcctc tgtactcgct
ggccatggat gtgtccacca 180caaggctgga agctggaa 19862169PRTArtificial
SequencePeptibody 621Gly Gly Gly Gly Gly Ala Gln Ser Glu Tyr Gln
Gly Leu Cys Thr Arg1 5 10 15Trp Pro Trp Met Cys Pro Pro Gln Gly Trp
Lys Gly Ser Gly Ser Ala 20 25 30Thr Gly Gly Ser Gly Gly Gly Ala Ser
Ser Gly Ser Gly Ser Ala Thr 35 40 45Gly Ser Glu Tyr Gln Gly Leu Cys
Thr Arg Trp Pro Trp Met Cys Pro 50 55 60Pro Gln Gly Trp
Lys65622186DNAArtificial SequenceNucleotide sequence encoding
Myostatin Binding Peptide 622tctgaatatc aaggtctttg tactcgttgg
ccatggatgt gtccaccaca aggttggaaa 60ggttccggtt ccgctaccgg cggctctggc
ggtggcgctt cttccggttc cggttctgct 120actggttctg agtatcaagg
cctctgtact cgctggccat ggatgtgtcc accacaaggt 180tggaaa
18662373PRTArtificial SequencePeptibody 623Gly Gly Gly Gly Gly Ala
Gln Thr Phe Ser Gln Gly His Cys Thr Arg1 5 10 15Trp Pro Trp Met Cys
Pro Pro Gln Gly Trp Gly Leu Glu Gly Ser Gly 20 25 30Ser Ala Thr Gly
Gly Ser Gly Ser Thr Ala Ser Ser Gly Ser Gly Ser 35 40 45Ala Thr Gly
Thr Phe Ser Gln Gly His Cys Thr Arg Trp Pro Trp Met 50 55 60Cys Pro
Pro Gln Gly Trp Gly Leu Glu65 70624198DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
624actttttctc aaggtcattg tactcgttgg ccatggatgt gtccaccaca
aggttggggt 60ctcgagggtt ccggttccgc taccggcggc tctggctcca ctgcttcttc
cggttccggt 120tctgctactg gtactttttc tcaaggccat tgtactcgct
ggccatggat gtgtccacca 180caaggctggg gcctggaa 19862573PRTArtificial
SequencePeptibody 625Gly Gly Gly Gly Gly Ala Gln Val Ala Asp His
Gly His Cys Thr Arg1 5 10 15Trp Pro Trp Met Cys Pro Pro Gln Gly Trp
Gly Leu Glu Gly Ser Gly 20 25 30Ser Ala Thr Gly Gly Ser Gly Ser Thr
Ala Ser Ser Gly Ser Gly Ser 35 40 45Ala Thr Gly Val Ala Asp His Gly
His Cys Thr Arg Trp Pro Trp Met 50 55 60Cys Pro Pro Gln Gly Trp Gly
Leu Glu65 70626198DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 626gttgctgatc atggtcattg
tactcgttgg ccatggatgt gtccaccaca aggttggggt 60ctcgagggtt ccggttccgc
aaccggcggc tctggctcca ctgcttcttc cggttccggt 120tctgctactg
gtgttgctga ccacggtcac tgcacccgtt ggccgtggat gtgcccgccg
180cagggttggg gtctggaa 19862769PRTArtificial SequencePeptibody
627Gly Gly Gly Gly Gly Ala Gln Val Ala Asp His Gly His Cys Thr Arg1
5 10 15Trp Pro Trp Met Cys Pro Pro Gln Gly Trp Gly Gly Ser Gly Ser
Ala 20 25 30Thr Gly Gly Ser Gly Gly Gly Ala Ser Ser Gly Ser Gly Ser
Ala Thr 35 40 45Gly Val Ala Asp His Gly His Cys Thr Arg Trp Pro Trp
Val Cys Pro 50 55 60Pro Gln Gly Trp Gly65628186DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
628gttgctgatc atggtcattg tactcgttgg ccatggatgt gtccaccaca
aggttggggt 60ggttccggtt ccgctaccgg cggctctggc ggtggtgctt cttccggttc
cggttctgct 120actggtgttg ctgaccacgg tcactgcacc cgttggccgt
gggtgtgtcc accacaaggt 180tggggt 18662973PRTArtificial
SequencePeptibody 629Gly Gly Gly Gly Gly Ala Gln Pro Glu Ser Gln
Gly His Cys Thr Arg1 5 10 15Trp Pro Trp Met Cys Pro Pro Gln Gly Trp
Gly Leu Glu Gly Ser Gly 20 25 30Ser Ala Thr Gly Gly Ser Gly Ser Thr
Ala Ser Ser Gly Ser Gly Ser 35 40 45Ala Thr Gly Pro Glu Ser Gln Gly
His Cys Thr Arg Trp Pro Trp Met 50 55 60Cys Pro Pro Gln Gly Trp Gly
Leu Glu65 70630198DNAArtificial SequenceNucleotide sequence
encoding Myostatin Binding Peptide 630ccagaatctc aaggtcattg
tactcgttgg ccatggatgt gtccaccaca aggttggggt 60ctcgagggtt ccggttccgc
taccggcggc tctggctcca ctgcttcttc cggttccggt 120tctgctactg
gtccggaatc ccagggtcac tgcacccgtt ggccgtggat gtgcccgccg
180cagggttggg gtctggaa 19863169PRTArtificial SequencePeptibody
631Gly Gly Gly Gly Gly Ala Gln Pro Glu Ser Gln Gly His Cys Thr Arg1
5 10 15Trp Pro Trp Met Cys Pro Pro Gln Gly Trp Gly Gly Ser Gly Ser
Ala 20 25 30Thr Gly Gly Ser Gly Gly Gly Ala Ser Ser Gly Ser Gly Ser
Ala Thr 35 40 45Gly Pro Glu Ser Gln Gly His Cys Thr Arg Trp Pro Trp
Met Cys Pro 50 55 60Pro Gln Gly Trp Gly65632186DNAArtificial
SequenceNucleotide sequence encoding Myostatin Binding Peptide
632ccagaatctc aaggtcattg tactcgttgg ccatggatgt gtccaccaca
aggttggggt 60ggttccggtt ccgctaccgg cggctctggc ggtggtgctt cttccggttc
cggttctgct 120actggtccgg aatcccaggg tcactgcacc cgttggccgt
ggatgtgtcc accacaaggt 180tggggt 1866335PRTArtificial
SequenceMyostatin Binding Peptide 633Trp Met Cys Pro Pro1
563490DNAArtificial SequenceRandomly generated nucleotide sequence
634cacagtgcac agggtnnknn knnkcakggk caktgkackc gktgkccktg
katktgkcck 60ccktaknnkn nknnkcattc tctcgagatc 90
* * * * *